CPDD 70th ANNUAL SCIENTIFIC MEETING
The Caribe Hilton, San Juan, Puerto Rico
June 14-19, 2008

PROGRAM BOOK
BOARD OF DIRECTORS

Stephen T. Higgins, PhD, President
Thomas R. Kosten, MD, Past-President
Sharon Walsh, PhD, President-Elect
Stephen G. Holtzman, PhD, Treasurer
James C. Anthony, PhD
Patrick M. Beardsley, PhD
Steven R. Childers, PhD
Theodore J. Cicero, PhD
William L. Dewey, PhD

Toby K. Eisenstein, PhD
A. Thomas McLellan, PhD
Michael A. Nader, PhD
Edward V. Nunes, PhD
Alison Oliveto-Beaudoin, PhD
Linda J. Porrino, PhD
Richard A. Rawson, PhD
Maxine L. Stitzer, PhD
Dace S. Svikis, PhD

EXECUTIVE OFFICER

Martin W. Adler, PhD

SCIENTIFIC PROGRAM COMMITTEE

Sari Izenwasser, PhD, Chair
Sharon Walsh, PhD, Past-Chair
Martin W. Adler, PhD, ex officio
Ellen B. Geller, MA, ex officio
Anna Rose Childress, PhD
Sandra Comer, PhD
Mark Greenwald, PhD
Scott Hemby, PhD
Kathleen Kantak, PhD
Jennifer Tidey, PhD
Ellen Unterwald, PhD
Friedbert Weiss, PhD
Sandra Welch, PhD
## Pre-Meeting Satellites

*The International Study Group Investigating Drugs as Reinforcers (ISGIDAR)*  
Chaired by Elise Weerts  
San Cristobal E/G

*8th Annual Meeting Center for Substance Abuse Treatment (CSAT)*  
Science to Services and Services to Science: The Identification and Adoption of Effective Practices for Substance Abuse Treatment  
Chaired by Laura House  
San Cristobal A/D

*The 13th Annual NIDA International Forum on Building International Research on Drug Abuse: Progress through Collaboration*  
Chaired by Steven Gust  
San Geronimo A/C

## CPDD Registration

**Tropical**

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, June 14</td>
<td>1:30 PM - 5:30 PM</td>
</tr>
<tr>
<td>Sunday, June 15</td>
<td>8:00 AM - 12:00 PM</td>
</tr>
<tr>
<td></td>
<td>2:00 PM - 5:30 PM</td>
</tr>
<tr>
<td>Monday, June 16</td>
<td>8:00 AM - 12:00 PM</td>
</tr>
<tr>
<td></td>
<td>1:30 PM - 5:00 PM</td>
</tr>
<tr>
<td>Tuesday, June 17</td>
<td>8:00 AM - 1:00 PM</td>
</tr>
<tr>
<td>Wednesday, June 18</td>
<td>8:00 AM - 12:00 PM</td>
</tr>
<tr>
<td></td>
<td>1:15 PM - 5:00 PM</td>
</tr>
<tr>
<td>Thursday, June 19</td>
<td>8:00 AM - 1:00 PM</td>
</tr>
</tbody>
</table>

**Opening Reception**  
(Cash Bar)  
7:00 – 9:00 PM  
Pool Area
Sunday, June 15, 2008

CSAT Travel Awards Breakfast
(Salon del Mar)
(7:00 - 8:00 AM)

Plenary Session
(San Geronimo Ballroom)
(8:30 - 11:00 AM)

8:30  Stephen T. Higgins
     Welcome, CPDD President

8:45  Report from the National Institute on Drug Abuse
     Nora D. Volkow, Director, NIDA

9:15  Presentation of the Distinguished Service Award to Geoffrey K. Mumford
     Introduction by William L. Dewey and Stephen T. Higgins

9:20  Presentation of the Media Award to William Cope Moyers
     Introduction by Marc Kaufman

9:40  Presentation of the J. Michael Morrison Award to Betty Tai and Rita Liu
     Introduction by Martin W. Adler

9:45  Presentation of the Joseph Cochin Young Investigator Award to Hendree Jones
     Introduction by Karol Kaltenbach

9:50  Presentation of the Mentorship Award to Joseph V. Brady
     Introduction by Jack E. Henningfield

9:55  Presentation of the Nathan B. Eddy Award to Billy R. Martin
     Introduction by William L. Dewey

10:00 Nathan B. Eddy Award Lecture by Billy R. Martin:
The journey from marijuana to the endocannabinoid system

Art and Addiction Exhibition
(Flamingo)
(9:00 AM - 6:00 PM)
# Public Policy Forum
(Brown Bag Lunch)

Chairs: William Dewey and Martin Iguchi

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30</td>
<td>Introduction</td>
<td>Martin Iguchi</td>
</tr>
<tr>
<td>11:40</td>
<td>Current status on Capitol Hill</td>
<td>Ed Long</td>
</tr>
<tr>
<td>12:00</td>
<td>Friends of NIDA and CPDD Public Policy activities</td>
<td>William Dewey</td>
</tr>
<tr>
<td>12:20</td>
<td>Need for increased public understanding of drug abuse illness</td>
<td>William Cope Moyers</td>
</tr>
</tbody>
</table>

## President’s Lecture

**CAN FOOD BE ADDICTIVE AND WHY?**

Kelly D. Brownell, Director, Rudd Center for Food Policy and Obesity, Yale University, New Haven, CT

## Symposium I

**OF VICE AND MEN: SHARED BRAIN VULNERABILITIES FOR DRUG AND NON-DRUG (FOOD, SEX, GAMBLING) REWARDS**

Chairs: Anna Rose Childress and Marc Potenza

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:30</td>
<td>Shared brain vulnerabilities in obesity and drug addiction</td>
<td>Joseph Frascella, NIDA, Bethesda, MD</td>
</tr>
<tr>
<td>2:55</td>
<td>Brain activation in obsessive, early romantic infatuation</td>
<td>Lucy Brown, Albert Einstein College of Medicine, Bronx, NY</td>
</tr>
<tr>
<td>3:20</td>
<td>Shared brain, behavioral, and genetic vulnerabilities in pathological gambling and in drug addictions</td>
<td>Marc Potenza, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT</td>
</tr>
<tr>
<td>3:45</td>
<td>Emergence of problematic addiction-relevant behaviors in Parkinsons patients on dopamine replacement therapy</td>
<td>Dan Weintraub, University of Pennsylvania School of Medicine, Philadelphia, PA</td>
</tr>
<tr>
<td>4:10</td>
<td>If it walks like a duck: Theoretical, treatment and nosologic implications of overlapping brain vulnerabilities in the compulsive pursuit of drug and non-drug rewards</td>
<td>Anna Rose Childress, University of Pennsylvania School of Medicine, Philadelphia, PA</td>
</tr>
</tbody>
</table>
Symposium II

COCAINE DEPENDENCE AND SOCIAL DISADVANTAGE:
EVIDENCE FROM THE LABORATORY, CLINIC, AND
COMMUNITY

Chair: Stephen T. Higgins

2:30  The changing relationship between cocaine use and social class over time
      Howard D. Chilcoat, GlaxoSmithKline, Research Triangle Park, NC

2:55  Social dominance in monkeys: Dopamine D2 receptors and the reinforcing effects of cocaine
      Michael A. Nader, Wake Forest University School of Medicine, Winston-Salem, NC

3:20  Do gestational cocaine exposure and/or socioeconomic status affect child neurocognitive outcome?
      Hallam Hurt, The Children’s Hospital of Philadelphia, Philadelphia, PA

3:45  Operant interventions to address the interrelated problems of poverty and cocaine addiction
      Kenneth Silverman, Johns Hopkins University School of Medicine, Baltimore, MD

4:10  Discussant
      Charles R. Schuster, Loyola University-Chicago, Stritch School of Medicine, Maywood, IL

Oral Communications 1

HIV/HCV/STD

San Geronimo C

2:30 - 4:30 PM

Chairs: Gayle Baldwin and Leah Floyd

2:30  Cocaine modulates human dendritic cell differentiation and T-cell activation with downstream effects on HIV replication
      G.C. Baldwin, S. Kiertscher, J. Zhuo, A. Harui, D.P. Tashkin and M.D. Roth, Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA

2:45  Cocaine use is associated with all-cause mortality among drug users engaged in HIV care
      A.A. Chaudhry1, R.E. Thompson2 and R.D. Moore1,2,1 Johns Hopkins University School of Medicine, and 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

3:00  HCV treatment in patients on opioid therapy for narcotic addiction looking at compliance, safety, virological response and effect on drug usage
      I.J. Kronborg1, M. Weltman2, J. Sasadeusz3, G. Dore4, D. Barton5 and M. Yoshihara6,
      1DASWest, Western Health, Footscray, VIC, 2Gastroenterology, Nepean Hospital, Nepean, NSW, 3VIDS, Royal Melbourne Hosp., and 5Alfred Hosp., Melbourne, VIC, 4Nat’l Centre in HIV Epidemiology and Clinical Research, and 6Roche, Sydney, NSW, Australia

3:15  Methamphetamine use as a predictor of a sexually transmitted disease co-infection among HIV positive men who have sex with men
      E.T. Rudy1, P. Kerndt1, S. Shoptaw2,3, B. Bolan4 and S. Tilekar4,1 Los Angeles County STD Program, 2Family Medicine-University of California-Los Angeles, 3Integrated Substance Abuse Program, University of California-Los Angeles, and 4Los Angeles Gay & Lesbian Center, Los Angeles, CA
Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City
D.C. Des Jarlais, K. Arasteh, C. McKnight, H. Hagan, D. Perlman and S.R. Friedman,
Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center
and National Development and Research Institutes, Inc., New York, NY

Compound RANTES and CCR2 genetic polymorphisms affect risk of HCV infection among injecting drug users in China
H. Liu, S. Yu, J. Du, H. Chen, C. Fan, C. Yuan, D. Wang, M. Comerford, C. McCoy and M. Zhao,
University of Miami Miller School of Medicine, Miami, FL and Shanghai Mental Health Center, Shanghai, China

Substance use and sex trade among South Africans
L.J. Floyd, C. Salama, A. Lawson and W. Latimer, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD

Injecting equipment sharing among Russian drug-injecting dyads
V. Gyarmathy, N. Li, K.E. Tobin, I.F. Hoffman, A.P. Kozlov, H.D. Chilcoat and C.A. Latkin,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, University of North Carolina at Chapel Hill, and GlaxoSmithKline, Research Triangle Park, NC

Oral Communications 2
San Geronimo A
2:30- 4:30 PM

OPIOID BEHAVIORAL PHARMACOLOGY

Effects of pain and analgesia on intracranial self-stimulation in rats
G. Pereira Do Carmo, K. Schrode, W.A. Carlezon and S.S. Negus,
Department of Psychology, Marist College, Poughkeepsie, NY, Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA and Behavioral Genetics Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA

Involvement of endogenous β-endorphin in the suppression of the morphine-induced rewarding effect under a neuropathic pain-like state in rodents
K. Niikura, M. Narita, M. Narita, A. Nakamura, D. Okutsu, K. Kurahashi, Y. Kobayashi, M. Suzuki and T. Suzuki, Toxicology, Hoshi University, Tokyo, Japan

Metabotropic glutamate receptor antagonists increase the antinociceptive efficacy of µ-opioid agonists
B.D. Fischer, L.L. Miller, F.E. Henry, M.J. Picker and L.A. Dykstra, Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC

Involvement of ifenprodil in the addiction memory vs. the spatial learning and memory in rats
Y. Ma, J.S. Han, D.Y. Lee and C.L. Cui,
Neurobiology, Neuroscience Research Institute, Beijing, China and Psychiatry, McLean Hospital, Belmont, MA

Chronic fentanyl administration in aging rats: Body composition, thermoregulation, and behavioral outcomes
D. Morgan, J. DuPree, S. DePaolo, G. Foremny, D. Seo and C.S. Carter,
University of Florida, Geriatric Research, Education, Clinical Center, and Institute on Aging, Gainesville, FL
Sunday, June 15, 2008

3:45  *Interactions between direct- and indirect-acting 5-HT2 receptor agonists and the discriminative stimulus effects of morphine in rhesus monkeys: Perceptual masking?*  
J. Li¹ and C.P. France¹², ¹Pharmacology, and ²Psychiatry, University of Texas Health Science Center, San Antonio, TX

4:00  *Compromised endogenous opioid activity results in habitual behavior*  
K. Wassum¹, I.C. Cely¹, B.W. Balleine² and N.T. Maidment¹, ¹Semel Institute and ²Psychology, University of California-Los Angeles, Los Angeles, CA

4:15  *Orexin neurons that project to the ventral tegmental area are activated by morphine preference during protracted forced abstinence*  
K.A. Richardson, P.T. Knackstedt and G. Aston-Jones, Neurosciences, Medical University of South Carolina, Charleston, SC

**Forum**

**A ROADMAP TO NIH AND NIDA FUNDING OPPORTUNITIES AND RESEARCH RESOURCES**

Chairs: Timothy P. Condon and David Shurtleff

- *Genetic resources and initiatives at NIH and NIDA*
  Joni Rutter, NIDA, Bethesda, MD

- *Taking advantage of the NIH KOMP GENSAT and collaborative cross projects for drug abuse research*
  Jonathan Pollock, NIDA, Bethesda, MD

- *Using the NIH-Roadmap and NIDA funding opportunities to advance drug abuse research*
  Timothy P. Condon, NIDA, Bethesda, MD

**ASPET Mixer**

**Las Olas**

6:00 - 8:00 PM

**Primm-Singleton Travel Awardees Meeting**

**Salon del Mar**

6:30 - 8:00 PM

**Workshop I**

**San Geronimo A**

8:00 - 10:00 PM

**ORGANIZING A SPECIAL INTEREST GROUP ON STRESS AND ADDICTION**

Chairs: Rajita Sinha and Helen Wu

*Panelists: Nicholas E. Goeders, Rajita Sinha, Byron Adinoff, Friedbert Weiss, and Helen Wu*
Workshop II  
San Geronimo B  
8:00 - 10:00 PM

DEA’S DRUG AND CHEMICAL EVALUATION SECTION:  
THE SCIENTISTS BEHIND THE BADGE. THE ROLE OF  
THE SCIENTIFIC STAFF WITHIN DEA AND  
RESOURCES FOR CPDD

Chairs: Christine A. Sannerud and Srihari R. Tella

- *DEA’s Drug and Chemical Evaluation section overview: Who we are and what we do domestically and internationally*  
  Christine A. Sannerud, Office of Diversion Control, Drug Enforcement Administration, Washington, DC

- *Gathering the data necessary to support drug control: DEA databases and cooperation with other agencies*  
  Srihari R. Tella, Office of Diversion Control, Drug Enforcement Administration, Washington, DC

- *Ongoing drug-scheduling actions and Schedule I researcher registrations*  
  Sandy G. Ghozland, Office of Diversion Control, Drug Enforcement Administration, Washington, DC

- *Precursor chemical control, analogue determinations, and drug exemptions*  
  Terrence L. Boos, Office of Diversion Control, Drug Enforcement Administration, Washington, DC

Workshop III  
San Geronimo C  
8:00 - 10:00 PM

FROM AN ACUTE CARE MODEL TO A RECOVERY MANAGED CARE MODEL: WHAT DO WE KNOW AND WHERE DO WE GO FROM HERE?

Chairs: Ken Winters and Anne Helene Skinstad

- *A summary of the status of existing research on long-term care for substance use disorders*  
  Peter Nathan, College of Public Health, University of Iowa, Iowa City, IA

- *Recovery support services and client outcomes: Results of two interim evaluations in Texas*  
  Laurel M. Mangrum, University of Texas-Austin, Austin, TX

- *Recovery management in recovery high schools*  
  Paul Moberg, Population Health Institute, University of Wisconsin School of Medicine and Public Health, Madison, WI

- *From a passive to an active recovery environment*  
  Gary Olson, Center for Alcohol and Drug Treatment, Duluth, MN

- *Building an agenda in research and practice to support recovery in America: What’s the difference?*  
  Michael Flaherty, IRETA, Pittsburgh, PA

Movie: **THE PANIC IN NEEDLE PARK** featuring Al Pacino  
Auditorium  8:00 PM
POSTER SESSION I (Breakfast)  

Odd-numbered posters manned first hour;  
Even-numbered, second hour  

Set-up time begins Sunday 1:00 PM  
Must be removed by Monday 12:00 NOON  

OPIOIDS: ANIMAL STUDIES

1 Studies on the determination of the pharmacophoric elements of the naturally occurring opioid receptor agonist, mitragynine and related alkaloids from Mitragyna speciosa  
   J. Cui¹, J.F. Leon¹, C. Mesangeau¹, B. Peres¹, J.E. Adkins¹, E.B. Furr¹, M. Arribas¹,  
   T.L. Nolan¹, S.J. Cutler¹, W.E. Polgar², L. Toll² and C.R. McCurdy¹,  
   ¹Medicinal Chemistry, University of Mississippi, University, MS and ²Pharmacology, SRI, Inc., Menlo Park, CA

2 Comparison of amphibian and human mu opioid receptors: Differences in receptor internalization and inhibition of cAMP in stable cell lines  
   C.W. Stevens, C.M. Brasel and G.W. Sawyer, Pharmacology, OSU-CHS, Tulsa, OK

3 Buprenorphine and naltrexone are partial kappa agonists  
   J.M. Bidlack and B.I. Knapp, Pharmacology and Physiology, University of Rochester, Rochester, NY

4 Identification of a "neutral" mu opioid receptor antagonist, LTC-274, for pharmacological analyses  
   E.J. Sally, H. Xu, C.M. Dersch, L.T. Chang, L.W. Hsin, T.E. Prisinzano, D. Simpson,  
   K.C. Rice, A.E. Jacobson, J. Zezula, K.J. Cheng and R.B. Rothman, Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, MD

5 Pre-treatment with PKC and PKA inhibitors prevents the development of morphine tolerance but not physical dependence in mice  
   B.H. Gabra¹, F.L. Smith² and W.L. Dewey¹, ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA and ²Pharmaceutical Sciences, Harding University College of Pharmacy, Searcy, AR

6 Role of delta receptor efficacy as a determinant of delta/mu opioid interactions in rhesus monkeys  
   S.S. Negus¹ and K.C. Rice², ¹Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA and ²Chemical Biology Research Branch, NIDA/NIAAA, Rockville, MD

7 Anxiolytic behavior induced by delta opioid receptor activation within the central nucleus of the amygdala  
   J.F. Randall-Thompson and E.M. Unterwald, Pharmacology, Temple University School of Medicine, Philadelphia, PA

8 SNC80-induced taste aversions in F344 and LEW rat strains  
   C.M. Davis¹, K.C. Rice² and A.L. Riley¹, ¹Psychology, American University, Washington, DC, and ²Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD
9 Naloxone as a stimulus in drug discrimination learning
A.L. Riley¹, G.W. Stevenson⁷, C.M. Davis¹, F. Cañadas¹, T. Ullrich³ and K.C. Rice³,
¹Psychology, American University, Washington, DC, ²Psychology, University of New
England, Biddeford, ME and ³Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD

10 Synaptic localization of hippocampal AMPA receptors is altered upon the extinction of
morphine-dependent conditioned behavior
S. Billa, N. Sinha and J. Moron Concepcion, Center for Addiction Research, University of
Texas Medical Branch, Galveston, TX

11 Oxycodone-induced conditioned place preference in adolescent and adult mice
A. Wells, R. Raugei, Y. Zhang, S.D. Schlussman, E.R. Butelman, A. Ho and M.J. Kreek,
The Laboratory of the Biology of the Addictive Diseases, The Rockefeller University,
New York, NY

12 Oxycodone self-administration in adolescent and adult C57BL/6J mice
Y. Zhang, R. Picetti, E.R. Butelman, A. Ho and M.J. Kreek, The Laboratory of the Biology of
the Addictive Diseases, The Rockefeller University, New York, NY

13 The specific Ih channel blocker ZD7288 potentiates acquisition of morphine CPP and increases
the firing rate of putative dopaminergic neurons in the VTA
J.M. Mitchell, E.B. Margolis, Y.F. Xia, G.O. Hjelmstad and H.L. Fields, Ernest Gallo Clinic
and Research Center, Neurology, UCSF, San Francisco, CA

14 Usefulness of aripiprazole for reducing morphine-induced nausea and rewarding effect
T. Suzuki¹, D. Takei¹, M. Shiokawa¹₂, Y. Tsurukawa¹, A. Nakamura¹, K. Hashimoto¹,
N. Kuzumaki¹, M. Suzuki¹, T. Inoue² and M. Narita¹,¹ Toxicology, Hoshi University, and
²Pharmacy, St. Luke's International Hospital, Tokyo, Japan

15 Blockade of D1-family dopamine receptors in the dorsolateral striatum attenuates context-
induced reinstatement of heroin seeking
J.M. Bossert, K.A. Wihbey and Y. Shaham, Behavioral Neuroscience,
IRP/NIDA/NIH/DHHS, Baltimore, MD

16 Individual differences in stress-induced heroin-seeking behavior and neuroendocrine responses
in rats: Involvement of arginine vasopressin and V1b receptor
Y. Zhou¹, F. Leri², E. Cummins², R. Raugei¹ and M.J. Kreek¹,¹ Rockefeller University,
New York, NY and ²University of Guelph, Guelph, ONT, Canada

17 Effects of herkinorin, a salvinorin analog with μ-opioid effects, in a neuroendocrine biomarker
assay
E. Butelman¹, S. Rus¹, D.S. Simpson³, K. Tidgewell³, T.E. Prisinzano²³ and M.J. Kreek¹,
¹The Rockefeller University, New York, NY, ²Medicinal Chemistry, University of Kansas,
Lawrence, KS and ³University of Iowa College of Pharmacy, Iowa City, IA

18 The effect of estrogen on cytokine production during inflammatory pain in ovariectomized
female rats
K.Y. Shivers¹², N.J. Amador¹², L. Abrams¹², D. Hunter¹², S. Jenab¹² and V. Quinones-
Jenab¹²,¹ Psychology, The Graduate School and University Center, and ²Biopsychology and
Behavioral Neuroscience Subprogram, Hunter College, CUNY, New York, NY

19 Inflammatory pain alters levels of prostaglandin E2 and D2 during the female reproductive
cycle
N.J. Amador¹², K.Y. Shivers¹², D. Hunter¹², V. Quinones-Jenab¹² and S. Jenab¹²,
¹BioPsychology, CUNY Graduate School and University Center, and ²BioPsychology, Hunter
College, New York, NY
20 The NMDA antagonists LY235959 and dextromethorphan enhance morphine’s effectiveness in a test of capsaicin-induced hyperalgesia

21 Opioid-induced antinociception: Alteration by pharmacological and genetic manipulations of the \(\text{N}-\text{methyl-D-aspartate (NMDA)}\) system
L.A. Dykstra, F.E. Henry and B.D. Fischer, Psychology, University of North Carolina at Chapel Hill, Chapel Hill, NC

22 The antinociceptive effect induced by DAMGO in chemokine CCR5 receptor knockout mice
X. Chen, E.B. Geller and M.W. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA

23 Morphine sensitizes to systemic infection with \(\text{Acinetobacter baumannii}\) in a murine model
J. Breslow\(^1\), J.J. Meissler\(^1\), P.B. Spence\(^1\), J.P. Gaughan\(^4\), M.W. Adler\(^1\), M.A. Monroy\(^5\) and T.K. Eisenstein\(^1\), \(^1\)Center for Substance Abuse Research, \(^2\)Microbiology and Immunology, \(^3\)Pharmacology, \(^4\)Physiology, and \(^5\)Surgery, Temple University School of Medicine, Philadelphia, PA

HIV/HCV I

24 Increased exposure to an HIV risk-reduction protocol associated with a reduction in substance abuse
L. Haynes\(^1\), R.E. Carter\(^1\), A.E. Herrin\(^1\) and D.A. Calsyn\(^2\), \(^1\)Medical University of South Carolina, Charleston, SC and \(^2\)University of Washington, Seattle, WA

25 Effect of women's HIV safer sex skills groups on sex-with-drug occasions: NIDA Clinical Trials Network Trial results
S. Tross\(^1\), A. Campbell\(^2\), M. Pavlicova\(^2\), M. Hu\(^1\), L. Cohen\(^2\), G. Miele\(^1\) and E. Nunes\(^1\), \(^1\)HIV Center, NYS Psychiatric Institute, New York, NY and \(^2\)Columbia University, NY, NY

26 Changes in HIV and HCV risk-taking behavior and seroprevalence among treatment admissions of opiate users: Possible link with French harm reduction policy from 1994 to 2004
M. Fatseas\(^1\), C. Denis\(^1\), E. Lavie\(^1\), J. Daulouede\(^2\) and M. Auriacombe\(^1\), \(^1\)Addiction Psychiatry EA4139/INSERM-IFR99, Université Victor Segalen, Bordeaux, and \(^2\)Bizia Center, Bayonne, France

27 Puerto Rican injection drug users in Massachusetts and Puerto Rico: HIV, HCV, and other STDs
L.M. Lopez, L. Zerden, T. Fitzgerald and L. Lundgren, School of Social Work, Boston University, Boston, MA

28 Specific joint hepatology-addiction medicine follow-up of hepatitis C treatment for intravenous drug users (IDU) or ex-IDU: Is there any benefit?
L. Gourarier\(^1\), A. Gervais\(^2\), V. Bourseul\(^3\), C. Berdah\(^4\), M. Sananes\(^4\) and J. Jungman\(^1\), \(^1\)“La Terrasse”, Hôpital Maison Blanche, \(^2\)Tropical and Infectious Diseases, Hôpital Bichat, AP-HP., \(^3\)Réseau de Santé Paris Nord, and \(^4\)ECIMUD, Hopital Bichat, AP-HP, Paris, France

29 FibroScan used in street-based outreach for drug users can improve HCV screening, management and treatment: A prospective study
J. Foucher\(^1\), B. Reiller\(^2\), V. Jullien\(^3\), F. Léal\(^3\), E. Scotto di Cesare\(^2\), S. Villars\(^1\), W. Merrouche\(^1\), J.M. Delille\(^2\) and V. de Lédinghen\(^1\), \(^1\)Centre d'Investigation de la Fibrose hépatique, Hopital Haut Leveque, \(^2\)Centre Planterose, CEID, \(^3\)La Case, Medecins du Monde, and \(^4\)INSERM U889, Université Victor Segalen, Bordeaux, France
30 Minor fibrosis in patients infected by hepatitis C virus while sharing drug-injection material: A minor problem?
A. Gervais\textsuperscript{3}, I. Gourarier\textsuperscript{2}, M. Pascal\textsuperscript{1}, A. Gauchet\textsuperscript{4} and A. Hij\textsuperscript{1}, \textsuperscript{1}General Hospital, Saint Dizier, \textsuperscript{2}La Terrasse, APHP, Paris, \textsuperscript{3}Hopital Bichat, APHP, Paris, and \textsuperscript{4}Faculte de Psychologie, Grenoble, France

31 The effect of cognitive ability on hepatitis C infection prevalence among injection drug users in Baltimore, Maryland
C.M. Graham, D.E. Whitaker, S.L. Hedden and W.W. Latimer, Mental Health, Johns Hopkins University, Baltimore, MD

32 Effects of medical/psychiatric comorbidity on HCV treatment eligibility in methadone maintenance
S.L. Batki\textsuperscript{1,2,3}, K.M. Canfield\textsuperscript{2}, E. Smyth\textsuperscript{2}, K. Amodio\textsuperscript{2}, K. Manser\textsuperscript{2} and R.A. Levine\textsuperscript{2}, \textsuperscript{1}Psychiatry, University of California, San Francisco, San Francisco, CA, \textsuperscript{2}Psychiatry, SUNY Upstate Medical University, Syracuse, NY and \textsuperscript{3}San Francisco VAMC, SF, CA

33 Health-related quality of life after 12 months in treatment with methadone or buprenorphine: Outcome and predictive factors of improvement
E. Lavie\textsuperscript{1,2}, C. Denis\textsuperscript{1,2}, M. Fatseas\textsuperscript{1,2}, J. Daulouede\textsuperscript{3,2} and M. Auriacombe\textsuperscript{1,2,3}, \textsuperscript{1}Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux, and \textsuperscript{2}Addiction Treatment Center, CHCP, CHU, Bordeaux, and \textsuperscript{3}BIZIA Addiction Center, Bayonne, France

34 Prevalence of chronic health conditions among drug users
M.E. Mino, S. Deren and S. Kang, Center for Drug Use and HIV Research, National Development and Research Institutes, New York, NY

35 Personality differences among cocaine consumers varies by HIV/HCV status
C. Morales-Manrique\textsuperscript{1}, E. Gómez\textsuperscript{1}, V. Agulló\textsuperscript{1}, J.C. Valderrama-Zurián\textsuperscript{1}, M. Castellano\textsuperscript{1,2}, S.R. Friedman\textsuperscript{3}, M. Mateu-Gelabert\textsuperscript{1}, M. Sandoval\textsuperscript{3}, J.C. Perez de los Cobos\textsuperscript{1} and G. Staying Safe Valencia\textsuperscript{2}, \textsuperscript{1}U. of Valencia, and \textsuperscript{2}Dirección General de Drogodependencias, Conselleria de Sanitat, Valencia, \textsuperscript{3}Hosp. de la Santa Creu i Sant Pau., Barcelona, Spain, \textsuperscript{4}NDRI, NY, NY

COCAINE: HUMAN STUDIES I

36 Laboratory model of a cocaine binge

37 Follow-up drug use of cocaine-dependent humans given cocaine in experimental studies
C.L. Wallace\textsuperscript{1}, W.L. Murff\textsuperscript{1}, R.J. Lamb\textsuperscript{1}, J. Mojsiak\textsuperscript{2}, A. Elkashef\textsuperscript{3} and J.D. Roache\textsuperscript{1}, \textsuperscript{1}University of Texas Health Science Center, San Antonio, TX and \textsuperscript{2}NIDA, Washington, DC

38 Impact of primary drug of abuse on BMI: Status and at end of treatment

39 Self-reports of interoceptive responses during stress and drug cue-related experiences in cocaine-dependent individuals
K.L. Bergquist, H.C. Fox and R. Sinha, Psychiatry, Yale University, New York, CT

40 Effects of written emotional expression on craving during recovery from cocaine dependence
K.W. Grasing\textsuperscript{1,2}, D. Mathur\textsuperscript{1} and C. DeSouza\textsuperscript{1}, \textsuperscript{1}Substance Abuse Research Laboratory, Kansas City VA Medical Center, Kansas City, MO and \textsuperscript{2}Division of Clinical Pharmacology, Medicine, University of Kansas School of Medicine, Kansas City, KS
41 Correlates of changing psychological stress over six months among rural stimulant users from Arkansas and Kentucky
   T.F. Garrity¹, J.M. Webster¹, C.G. Leukefeld¹ and B.M. Booth², ¹Behavioral Science, University of Kentucky, Lexington, KY and ²Psychiatry, University of Arkansas, Little Rock, AR

42 Early life trauma and enhanced sensitivity to current life stressors among cocaine-dependent individuals
   S.E. Back, A.E. Waldrop, S.D. Yeatts and K.T. Brady, Psychiatry, Medical University of South Carolina, Charleston, SC

43 Motivations for cocaine use among urban young adults
   B. Wells¹, V. Andersen¹² and J.T. Parsons¹³, ¹The Center for HIV Educational Studies and Training, ²City College of the City University of New York, and ³Psychology, Hunter College of the City University of New York, New York, NY

44 Internalizing and externalizing behavior of children of mothers who misuse drugs versus fathers who misuse drugs
   M.L. Kelley¹, K. Lam² and W. Fals-Stewart², ¹Psychology, Old Dominion University, Norfolk, VA and ²School of Nursing, University of Rochester, Rochester, NY

45 Anxiety sensitivity as a predictor of treatment dropout among inner-city crack/cocaine and heroin users in a residential substance use treatment center
   S.M. Gorka, C.W. Lejuez and S.B. Daughters, Psychology, University of Maryland, College Park, MD

46 Atomoxetine affects responses to psychological and physical stress in humans
   K.P. Hill¹², J. Poling³⁴, T.R. Kosten² and M. Sofuoglu³⁴, ¹McLean Hospital, Belmont, and ²Psychiatry, Harvard Medical School, Boston, MA, ³Psychiatry, Yale University, New Haven, and ⁴VA Healthcare System, West Haven, CT and ⁵Psychiatry, Baylor College of Medicine, Houston, TX

47 A safety review of dermatologic conditions in two double-blind placebo-controlled trials: A comparison of modafinil and N-acetylcysteine for cocaine dependence
   R.J. Malcolm¹, K.R. Huebner¹, S.L. Hedden², A. Mountford¹ and K. Hartwell¹, ¹Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC and ²Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

48 Temperament and Character Inventory dimensions change during a placebo-controlled trial of mirtazapine for patients with cocaine dependence and depression
   L.C. Sanfilippo¹², W.N. Raby¹² and E.V. Nunes¹², ¹Columbia University, and ²New York State Psychiatric Institute, New York, NY

49 Anticonvulsive drugs in cocaine dependence: A systematic review and meta-analysis
   M. Farre¹³, Y. Alvarez¹³, F. Fonseca²⁴, J. Cami¹⁴ and M. Torrens²³, ¹Pharmacology, IMIM-Hospital del Mar, ²Drug Abuse Unit, IAPS-Hospital del Mar, ³Universitat Autonoma Barcelona, UAB, and ⁴Universitat Pompeu Fabra, UPF, Barcelona, Spain

50 Sequential agonist medication strategies for cocaine dependence: Bayesian analysis
   D.V. Herin¹, C.M. Green¹, N.J. Moukaddam¹, J.M. Schmitz¹ and J. Grabowski², ¹Psychiatry, University of Texas Health Science Center, Houston, TX and ²Psychiatry/Behavioral Science, University of Minnesota and SMDC, Minneapolis/Duluth, MN

51 Cocaine vaccine: 6-month follow-up during drop in antibody levels
   T. Kosten¹³, B. Martell², J. Poling¹² and T. Gardner¹³, ¹Psychiatry, Baylor College of Medicine, and ²Veterans Administration, Houston, TX, ³Psychiatry, Yale University, New Haven, CT

11
52 Cannabis dimensionality: Dependence, abuse and consumption
C. Beseler¹, H. Katz¹ and D.S. Hasin¹², ¹Psychiatry, New York State Psychiatric Institute and
²College of Physicians and Surgeons, Columbia University, NY, NY

53 Clinical features of DSM-IV cannabis abuse in a cross-national context
F.A. Fiestas¹, M.E. Radovanovic¹, M. Medina-Mora², J. Posada-Villa³, J.C. Anthony¹ and
World Mental Health Survey Consortium¹, ¹Epidemiology, Michigan State University, East
Lansing, MI, ²Institute of Psychiatry, Mexico, Mexico, ³Saldarriaga Concha Foundation,
Bogota, Colombia and ⁴WHMS Consortium, Boston, MA

54 The reliability of self-report cannabis abuse and dependence criteria: Multisite study of
differences between general population and treatment groups
C.E. Mennes, A. Ben Abdallah and L.B. Cottler, Washington University School of Medicine,
Saint Louis, MO

55 Treatment-seeking characteristics of potential participants for substance use disorder clinical
trials
J.J. Mariani, K.A. Murray and F.R. Levin, Psychiatry/Division on Substance Abuse, Columbia
University/New York State Psychiatric Institute, New York, NY

56 Drug abuse and HIV risk among IDUs near downtown Kathmandu
M.B. Poudyal Chhetri, Planning, CIAA, Kathmandu, Nepal

57 Curls and beginners: Use, abuse and representations of cannabis amongst health educators in
training
P. Courty¹², C. Auclair³, L. Gerbaud¹² and D. Berger², ¹CMP B, CSST SATIS, Clermont
Ferrand Cedex 1, ³JE n°;2432 PAEDI, IUFM d’Auvergne, F- 63407 Chamalieres, and
²Epidemiology and Public Health, CHU G.MONTPIED, F-63003 Clermont Ferrand Cedex 1, 
France

58 Within-session satisfaction and state motivation as predictors of marijuana use at follow-up:
An illustrative analysis
E.R. Grekin² and S.J. Ondersma¹, ¹Psychiatry and OB/GYN, and ²Psychology, Wayne State
University, Detroit, MI

59 Reliability and validity of a short form of the Marijuana Craving Questionnaire
R.J. Evans¹, D.A. Gorelick¹, E.G. Singleton¹, K.H. Levin¹, M.L. Copersino² and
S.J. Heishman¹, ¹National Institute on Drug Abuse, Intramural Research Program, Baltimore,
MD and ²McLean Hospital, Harvard Medical School, Belmont, MA

60 Cognitive performance in a population-based sample of young cannabis, ecstasy or alcohol
users and controls
C.G. Schütz¹², F. Indlekofer², M. Piechatzek², M. Daamen¹, C. Glasmacher¹, R. Lieb³, 
H. Pfister³ and H.U. Wittchen⁴, ¹Psychiatry, Wilhelms-Friedrich-University, Bonn,
²Psychiatry, Munich University, Munich, ³Psychiatry, Max-Planck -Institut, Munich, and
⁴Psychology, TU Dresden, Dresden, Germany

61 Cognitive impairment and treatment retention among cannabis-dependent patients
D.J. Brooks¹, E. Aharonovich¹ and F.R. Levin¹², ¹Substance Abuse, NYSPI, and ²Psychiatry,
Columbia University, New York, NY

62 Smoked marijuana affects risk taking but not decision making in a lab study of adult marijuana
smokers
E. Aharonovich¹, T. Crowley² and M. Haney¹, ¹Columbia University, New York, NY and
²University of Colorado, Denver, CO
63 Comparison of the effects of marijuana smoked in cigarette paper (joints) versus cigar paper (blunts)
Z.D. Cooper and M. Haney, Psychiatry, Columbia University, New York, NY

64 Oral THC (dronabinol) effects on sleep parameters in rested and sleep-deprived adults
D.M. Penetar, G.H. Trksak, W. Tartarini and S.E. Lukas, Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA

65 A placebo-controlled trial of buspirone in marijuana-dependent individuals
A. McRae, R.E. Carter, T.K. Killeen, M.J. Carpenter, S.A. Simpson and K.T. Brady, Medical University of South Carolina, Charleston, SC

66 Relationship between cannabinoid agonist efficacy, tolerance, and cross-tolerance in Δ9-tetrahydrocannabinol-treated monkeys
L. McMahon, Pharmacology, UTHSCSA, San Antonio, TX

67 Effects of THC on reversal learning and extradimensional shifts in rhesus monkeys
M.A. Taffe, Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA

68 Marked differences between cannabinoid receptor agonists revealed by their behavioral effects
P. Terry1,2, J. Grey2 and S. Higgs3, 1Psychology Research Unit, Kingston University, Kingston-upon-Thames and 2School of Psychology, University of Birmingham, Birmingham, UK

69 First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain
K. Benamar, S. Addou, E.B. Geller and M.W. Adler, Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA

70 Conformational constrained analogs of SR141716: Design, synthesis, computational analysis and biological evaluations

NICOTINE: ANIMAL STUDIES

71 Role of CB1 receptors on the reinstatement of nicotine seeking in rats
I.H. Gamal Eddin, Pharmacology, University of Toronto, and Translational Addiction Laboratory, CAMH, Toronto, ON, Canada

72 Effects of varenicline and cytisine on the discriminative stimulus effects of nicotine in rats
W.A. Corrigall1,3, M.G. LeSage1,2, D. Shelley1, J.T. Ross1 and F.I. Carroll4, 1Medicine, Minneapolis Medical Research Foundation, 2Medicine, and 3Psychiatry, University of Minnesota, Minneapolis, MN and 4Organic and Medicinal Chemistry, Research Triangle Institute, Research Triangle Park, NC

73 Nicotine, but not varenicline, pretreatment synergistically enhanced amphetamine-stimulated locomotor activity in rats
M.E. Gnegy and E.M. Jutkiewicz, Pharmacology, University of Michigan, Ann Arbor, MI

74 The nicotinic receptor partial agonist cytisine attenuated some, but not all, behavioral effects of nicotine in rodents
E.M. Jutkiewicz and J.H. Woods, Pharmacology, University of Michigan, Ann Arbor, MI

75 Effects of the nicotinic acetylcholine receptor antagonist, N,N'-decane-1,10-diyl-bis-3-picolinium diiodide, on nicotine self-administration and food-maintained responding in rats
T. Wooters1, J.T. Ross1, Z. Zhang2, P.A. Crooks2, L.P. Dwoskin2 and M.T. Bardo1,
1Psychology, and 2Pharmacy, University of Kentucky, Lexington, KY
76 Bupropion blocks acquisition, but not expression, of nicotine-conditioned taste aversion in CD-1 mice
   A.S. Rauhut\textsuperscript{1,2} and S.K. Mardekian\textsuperscript{2}, \textsuperscript{1}Psychology, and \textsuperscript{2}Neuroscience Program, Dickinson College, Carlisle, PA

77 The effects of environmental enrichment on nicotine-induced conditioned hyperactivity and sensitization
   R.A. Coolon, S.T. Pittenger and M.E. Cain, Psychology, Kansas State University, Manhattan, KS

78 Nicotine enhances responding for conditioned and unconditioned reinforcing stimuli under a second-order schedule of food reinforcement in rats
   V.C. Wing and M. Shoaib, Psychobiology Laboratories, Newcastle University, Newcastle, UK

79 Additional support for the reinforcement-enhancing effects of nicotine in rats
   B.R. Raiff and J. Dallery, University of Florida, Gainesville, FL

80 Nicotine effects on the behavioral mechanisms of impulsive choice in rats
   M. Locey and J. Dallery, Psychology, University of Florida, Gainesville, FL

81 Individual differences in delay discounting and nicotine self-administration in rats
   M.M. Sweitzer\textsuperscript{1,2} and E.C. Donny\textsuperscript{1}, \textsuperscript{1}Psychology, and \textsuperscript{2}Center for Neural Basis of Cognition, University of Pittsburgh, Pittsburgh, PA

82 Acquisition and maintenance of nicotine self-administration in adolescent male and female rats
   W.J. Lynch, Psychiatry and Neurobehavioral Sciences, University of VA, Charlottesville, VA

83 Enhanced nicotine-taking behavior in a glutamatergic model of schizophrenia in rats
   K. Farid Araki\textsuperscript{1}, K. Coen\textsuperscript{1}, U. Busto\textsuperscript{2} and B. Le Foll\textsuperscript{1}, \textsuperscript{1}Translational Addiction Research Laboratory, and \textsuperscript{2}Clinical Neuroscience Laboratory, Camh, University of Toronto, Toronto, ON, Canada

84 Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats
   S.A. Roiko\textsuperscript{1,2}, A.C. Harris\textsuperscript{2}, M.G. LeSage\textsuperscript{2}, D.E. Keyler\textsuperscript{2} and P.R. Pentel\textsuperscript{1,2}, \textsuperscript{1}Pharmacology, University of Minnesota, and \textsuperscript{2}Minneapolis Medical Research Foundation, Minneapolis, MN

85 Diminished neurochemical effects of nicotine withdrawal in adolescent versus adult rats
   L.A. Natividad, H.A. Tejeda, O.V. Torres and L.E. O'Dell, Psychology, University of Texas at El Paso, El Paso, TX

PROGRAM DESCRIPTION I

86 Indolizidine 235B\textsuperscript{1} potently inhibits nicotine-evoked dopamine release from superfused rat striatal slices
   L.P. Dwoskin\textsuperscript{1}, M. Pivavarchyk\textsuperscript{1}, H. Tsuneki\textsuperscript{2}, N. Toyooka\textsuperscript{2}, Z. Zhang\textsuperscript{1} and P.A. Crooks\textsuperscript{1}, \textsuperscript{1}Pharmaceutical Sciences, University of Kentucky, Lexington, KY and \textsuperscript{2}Clinical Pharmacology, Toyama Medical and Pharmaceutical University, Toyama, Japan

87 Inhibition of nicotine-evoked dopamine release from superfused rat striatal slices by novel quaternary ammonium salts containing an N-5-(3-biphenyl)pentyl-1-yl substituent
   P.A. Crooks, G. Zheng, M. Pivavarchyk and L.P. Dwoskin, Pharmaceutical Sciences, University of Kentucky, Lexington, KY

88 Online enhancements of smoking cessation: Peru, 2007
   G.F. Alvarado\textsuperscript{1,2}, O.J. Santiago\textsuperscript{2}, C.F. Rios-Bedoya\textsuperscript{2} and J.C. Anthony\textsuperscript{1,2}, \textsuperscript{1}Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru and \textsuperscript{2}Epidemiology, Michigan State University, East Lansing, MI
Feasibility of conducting genetics research at community treatment programs
S.C. Sonne, S. Gentilin, C.L. DeVane, C. Thomas, M. Hatch-Maillette, A. Saxon, W. Berrettini and W. Ling, 1 Medical University of SC, Charleston, SC, 2 University of CA, Los Angeles, CA, 3 University of WA, and 4 VA Puget Sound Health Care System, Seattle, WA and 5 University of Pennsylvania, Philadelphia, PA

Hepatitis C treatment among methadone-maintained patients: Directly observed therapy compared with standard-of-care
R.D. Bruce, A. Acosta, J. Lim, M. Copenhaver and F. Altice, 1 Medicine, Yale University AIDS Program, New Haven 2 Medicine, Yale Viral Hepatitis Program, New Haven, and 3 University of Connecticut Center for Health, Intervention, and Prevention, Storrs, CT

A brief behavioral intervention to enhance medication adherence among HIV-infected injection drug users
O. Amaechi, I. Lee and M. Copenhaver, 1 Allied Health Sciences, and 3 Psychology, University of Connecticut, Storrs, CT 2 Psychology, National Chengchi University, Taipei, Taiwan

Access to HIV and hepatitis screening and treatment among ethnic minority drug users
C.L. Masson, D.C. Perlman, N. Pepper, C. McKnight and J.L. Sorensen, 1 Psychiatry, University of California, San Francisco, San Francisco, CA, 2 Beth Israel Medical Center, and 3 National Development and Research Institutes, Inc., New York, NY

Modified directly observed therapy for HIV in substance-abusing minorities

Successful implementation of an office-based opiate treatment pilot program using buprenorphine in a marginalized population
S. Little, D. Hersh and A. Gleichorn, Community Behavioral Health, San Francisco Department of Public Health, San Francisco, CA

Buprenorphine and methadone in a VA narcotic treatment program in New York City: Retention in treatment and response
P.P. Casadonte, 1 Mental Health, Veterans Affairs Medical Center, and 2 Psychiatry, New York University School of Medicine, New York, NY

Methadone maintenance in Michigan: Five years of data using a contingency management approach
G.L. Rhodes, G.K. Tzilos and M.K. Greenwald, Psychiatry and Behavioral Neuroscience, Wayne State University, Detroit, MI

Acceptance-based behavior therapy for methadone detoxification
A.L. Stotts, A. Masuda, K. Wilson and J. Schmitz, 1 University of Texas Medical School at Houston, Houston, TX, 2 Georgia State University, Atlanta, GA and 3 University of Mississippi, Oxford, MS

The Opioid Renewal Clinic: Can urine drug screens predict treatment outcome?
K. Barth, W.C. Becker, N. Wiedemer, R.M. Gallagher and D.W. Oslin, 1 University of Pennsylvania, and 2 Philadelphia VA Medical Center, Philadelphia, PA

Survey analysis for implementing an electronic information system to enhance practice at an opiate treatment program
100 Collecting daily self-reports of injection drug use via automated telephone interviewing
B.C. Leigh¹, D.D. Brewer² and E.L. Seddig¹, ¹Alcohol and Drug Abuse Institute, University of
Washington, and ²Interdisciplinary Scientific Research, Seattle, WA

101 Technology transfer in a community treatment program: Evidence-based practices from the
training room into the therapy room
D.R. Hall, K. Shuster, C. Street, T. Odell, K. Raymond, G. Soto, C. Chapman, M. Barker and
S. Reiner, Psychiatry, Virginia Commonwealth University, Richmond, VA

102 An assessment of substance abuse training and technical assistance needs in frontier states:
Implications for the adoption of evidence-based practices
N.A. Roget¹, J.A. Hartje¹, E. Gifford¹, W.L. Woods¹, J. Brosh¹ and A.H. Skinstad², ¹CASAT,
University of Nevada, Reno, Reno, NV and ²School of Public Health, University of Iowa,
Iowa City, IA

103 Implementation of a technology-based, quality improvement system at outpatient substance
abuse treatment programs: A qualitative analysis
B. McClure¹, A. Kulaga¹, J. Rotrosen¹, P. Crits-Christoph², S. Ring-Kurtz², C. Temes² and
R. Forman³, ¹Psychiatry, NYU School of Medicine, New York, NY, ²University of
Pennsylvania, Philadelphia, PA and ³Alkermes, Inc., Boston, MA

104 Outcomes of a Native American cultural educational program for non-native counselors
D. Mackey², F. Zavadil², A.H. Skinstad¹, C. Peters¹ and K.M. Summers¹, ¹Community and
Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA and
²University of South Dakota, Vermillion, SD

105 Developing a data resource center for international substance abuse researchers
H. Wong, S. Libretto, R. Oser and M. Barahona, Public Health Research,
Danya International, Inc., Silver Spring, MD

106 A new approach to the community reduction of cannabis use: The Australian National Cannabis
Prevention and Information Centre
J. Copeland, National Cannabis Prevention and Information Centre, University of NSW,
Sydney, NSW, Australia

107 Developing a Computerized Assisted Training protocol for community-based therapists:
Contingency Management with adolescents and their families
A.J. Sheidow, J.E. Chapman and S.W. Henggeler, Psychiatry and Behavioral Sciences,
Medical University of South Carolina, Charleston, SC

108 The development of a survey instrument for the problem gambling workforce
and Behavioral Health, University of Iowa, College of Public Health, Iowa City, IA

109 Internet survey of prescription opioid abuse among college-aged individuals
T. Cassidy, K. Lioy, J. Dickinson, A. Licari, S.H. Budman, S. Lord and S.F. Butler,
Inflexxion, Inc, Newton, MA

110 Project Lazarus: Prescription opioid overdose prevention and responsible pain management
N. Dasgupta¹², F.W. Brason III³⁵, S. Albert³⁴ and J. Graham³, ¹Epidemiology, University of
NC School of Public Health, Chapel Hill, ²NC Harm Reduction Coalition, Jamestown, and
³Northwest Community Care Network, ⁴Wilkes County Health Department, and ⁵Wilkes
Community Health Council, Healthy Carolinians, North Wilkesboro, NC
111 Improvement of pain assessment and pain management in patients on opioid maintenance therapy: A new French clinical research program
N.A. Authier1,2, C. Auclair3, C. Le Blanc1, P. Viguie1, A. Boye1, A. Harrand1, C. Dubray2, A. Eschalier2, P. Llorca4 and P. Courty1, 1Pôle de Psychiatrie - CMP B, CHU G Monpied, 2CIC 501, CHU, and 3Dept Santé Publique, CHU, Clermont Ferrand, France

POLYDRUG ABUSE

112 The effects of daily treatment with citicoline on polydrug abuse in cocaine-dependent volunteers
S.C. Licata1, D. Penetar1, J. Rodolico1, C. Palmer1, J. Berko1, T. Geaghan1, A. Looby1, E. Peters1, E. Ryan1, P. Renshaw2 and S. Lukas1, 1Behavioral Psychopharmacology Research Laboratory, and 2Brain Imaging Center, McLean Hospital/Harvard Medical School, Belmont, MA

113 The association between executive functioning and readiness to change drug use behavior among injection and non-injection drug users in Baltimore, MD
S.G. Severtson, S. von Thomsen, S.L. Hedden and W.W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

114 Drug problems, sex trading, and sex-related attitudes among women entering substance abuse treatment
D.L. Homish, K.H. Derment, J.R. Koutsky and D.K. Augustino, Research Institute on Addictions, The State University of New York at Buffalo, Buffalo, NY

115 The association of state programs with individual risk of drug use disorder
M.H. Yang, M.J. Larson and A.M. Stoddard, New England Research Institutes, Watertown, MA

116 Reliability and validity of the BASIS-24 in drug-dependent patients
L. Madden1,2, R. Freeman1, K. Burne1, C. Doebright1,2, S. Farnum1 and S. Ball1,2, 1The APT Foundation, and 2Psychiatry, Yale School of Medicine, New Haven, CT

117 Latent class growth trajectories of neuropsychological dysfunction in drug users
S.L. Hedden, S.G. Severtson and W.W. Latimer, Mental Health, Johns Hopkins School of Public Health, Baltimore, MD

118 Hospitalization for substance use disorder in a psychiatric emergency service
D.C. Martinez, J.M. Gines, F. Fonseca, C. Garnier, D. Berge, M.A. Malagon, R. Cortizo and A. Bulbena, Hospital del Mar, Barcelona, Spain

119 Predicting the relative risk of death over a 9-year period taking into account baseline risk, substance abuse treatment history and duration of abstinence
C.K. Scott1 and M.L. Dennis2, 1Chestnut Health Systems, Chicago, IL and 2Chestnut Health Systems, Bloomington, IL

120 Overdose within 12 months of treatment for substance use disorders
P.C. Britton1,2, J.D. Wines3 and K.R. Conner2,1, 1Psychiatry, Canandaigua VA Medical Center, Canandaigua, NY, 2Psychiatry, Center for the Study and Prevention of Suicide-University of Rochester School of Medicine and Dentistry, Rochester, NY and 3Psychiatry, McLean Hospital-Harvard Medical School, Belmont, MA

121 Dual substance-abusing parents vs. mother-only substance-abusing parents in treatment: Behavioral functioning of children
W.K. Lam1, W. Fals-Stewart1 and M.L. Kelley2, 1School of Nursing, University of Rochester, Rochester, NY and 2Old Dominion University, Norfolk, VA
122 Parental substance abuse and long-term coping in a sample of adult domestic violence survivors
S. Griffing¹, R.E. Sage², T. Jospitre¹ and M. Chu¹,¹ Urban Resource Institute, and ²Addiction Research and Treatment Corporation, Brooklyn, NY

123 The relations among moral conscience, parental support, and substance use in young adults
J. Wilkinson, G. Carlo and J. Roy, Psychology, University of Nebraska-Lincoln, Lincoln, NE

124 Evaluating a parent workshop to prevent children's access to prescription narcotics on the Internet
N.S. Patapis, D.S. Festinger, C.L. McDonald, K.L. Dugosh, D.B. Marlowe and P.L. Arabia, Law and Ethics, Treatment Research Institute, Philadelphia, PA

125 Exploring metacognition, relapse, and stress as an integrated outcome measure
J. Cilente, Psychology and Education, Middlesex County College, Edison, NJ

126 Deconstructing 12-step involvement as predictor of sustained abstinence from polydrug use
A.B. Laudet¹ and W.L. White²,¹ NDRI, New York City, NY and ²Chestnut, Bloomington, IL

127 Contextual differences in substance use among treatment-seeking women
L.M. Shannon, R. Walker, J.R. Havens, A. Mateyoke-Scriven and C. Leukefeld, Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY

128 Prevalence of violence and substance use among female victims of intimate-partner violence
P. Wupperman, P. Amble, S. Devine, H. Zonana, S. Ciskowski and C. Easton, Yale University School of Medicine, New Haven, CT

129 Dimensions of change instrument and retention in therapeutic communities: The moderating effect of time
J. Miles¹, W. Mandell² and S.L. Wenzel¹, ¹Behavioral and Social Sciences, RAND Corporation, Santa Monica, CA and ²Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

130 Will I stay or will I go? Role of early treatment experiences in predicting attrition
V. Stanick¹, A.B. Laudet¹ and B. Sands²,¹ NDRI, and ²Woodhull Medical Center, New York City, NY

131 Three-year outcomes from the Early Re-Intervention Experiment with Recovery Management Checkups
M.L. Dennis¹ and C.K. Scott²,¹ Chestnut Health Systems, Bloomington, IL and ²Chestnut Health Systems, Chicago, IL

132 Treatment history and job-seeking behaviors among Native Americans
K. Foley², D. Pallas³, M.P. Bogenschutz¹, A.A. Forcehimes¹, D. Svikis³ and J.S. Tonigan¹, ¹CASAA, University of New Mexico, Albuquerque, ²The Na'Nizhoozi Center, Gallup, NM and ³Psychology, Virginia Commonwealth University, Richmond, VA

133 Predictors of social stability among drug users and non-drug users in Baltimore City, Maryland
D. German and C.A. Latkin, Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

134 Outcomes of substance abuse treatment from the California Outcomes Measurement System
R. Gonzales, M. Brecht, R. Rawson and J. Hunter, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA

135 Resource utilization by drug users presenting to an emergency department
B. Khazan¹, A. Sheer¹, J. Hirshon³ and D. Gorelick¹,¹ National Institute on Drug Abuse, NIH, and ²University of Maryland School of Medicine, Baltimore, MD
136 Investigating the active ingredients of motivational interviewing
    K.L. Venner¹, S.J. Erickson², M.P. Bogenschutz¹ and J.S. Tonigan¹, ¹CASAA, and
    ²Psychology, University of New Mexico, Albuquerque, NM

137 A meta-analysis of motivational interviewing to enhance engagement and adherence to
    substance use treatment
    J.E. Hettema, Psychiatry, University of California San Francisco, San Francisco, CA

138 Preliminary findings from an ecological momentary assessment study with polydrug users at a
    methadone clinic
    Section, NIDA, Baltimore, MD

139 Clinician knowledge of Cognitive Behavioral Therapy strategies: Room for improvement
    M. Larson¹, M. Amodeo², E. Gerstenberger¹ and J.S. LoCastro³, ¹New England Research
    Institutes, Watertown, ²School of Social Work, and ³School of Medicine, Boston University,
    and ⁴VA Boston Healthcare, Boston, MA

140 Feasibility and utility of a concurrent recovery monitoring system in Delaware State
    A. Brooks¹, D. Carise¹, A. Camilleri¹, M. Love¹, A. Pecorarro¹, K. Tassini¹ and J. Kemp²,
    ¹Treatment Research Institute, Philadelphia, PA and ²Delaware Division of Mental Health and
    Substance Abuse, New Castle, DE

141 Predictive validity of Nonparametric-Item-Response-Theory-derived ASI scores
    A. Pecora, J.S. Cacciola, K.G. Lynch and A.I. Alterman, University of Pennsylvania School of
    Medicine and Treatment Research Institute, Mays Landing, NJ

142 Who seeks help for a substance use disorder and who does not in the NESARC?
    C. Grella¹, M. Karno¹, U. Warda¹, N. Niv¹ and A. Moore¹, ¹Integrated Substance Abuse
    Programs, and ²Division of Geriatrics, UCLA, Los Angeles, CA

143 Do active addictions contribute to mortality among urban African Americans with poorly
    controlled blood pressure?
    J.H. Young¹, ², K. Weeks¹, ², J. Tilburt³ and S. Dy¹, ², ¹Medicine, Johns Hopkins University and
    ²Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD and
    ³Medicine, Mayo Clinic, Rochester, MN

144 Lifestyle mobility in a cohort of injection drug users
    B. Pieper¹, T.N. Templin¹, R.S. Kirsner² and T.J. Birk¹, ¹College of Nursing, Wayne State
    University, Detroit, MI and ²Miler School of Medicine, University of Miami, Miami, FL

145 Medical co-occurring disorders in a substance-abusing Medicaid population
    D.A. Tompkins¹, K. Stoller¹, A. Schuster², ³, P. Fagan² and R. Brooner¹, ¹Psychiatry, The
    Johns Hopkins University School of Medicine, Baltimore, ²Johns Hopkins Healthcare, LLC,
    Glen Burnie, and ³Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

146 Will patients initiate chronic disease management care for substance dependence?
    T.W. Kim, R. Saitz, D. Cheng, M. Winter and J.H. Samet, Boston University School of
    Medicine and Public Health, Boston, MA

147 Ethnic disparities in health and health-related behaviors among homeless people
    L. Gelberg¹, E. Austin¹ and R.M. Andersen², ¹Family Medicine, David Geffen School of
    Medicine, UCLA and ²Health Services, University of California-Los Angeles School of Public
    Health, Los Angeles, CA and ³Sociology, University of Alabama at Birmingham,
    Birmingham, AL
CRIMINAL JUSTICE

148 A different kind of hustle: A qualitative study of the process of long-term abstinence from heroin use among female ex-offenders
   N.J. Tiburcio, Institute for Treatment Services Research, National Development and Research Institutes, New York, NY

149 Longitudinal changes in attachment, social support, parenting attitudes, and psychological functioning among women drug offenders
   E. Hall, M. Prendergast and U. Warda, Psychiatry, University of California, Los Angeles, Los Angeles, CA

150 Gender differences in chronic medical conditions, psychiatric disorders and substance dependence among U.S. jail inmates
   I.A. Binswanger1, J.O. Merrill2, P.M. Krueger3, M.C. White4, R.E. Booth5, J.G. Elmore2,
   1Medicine, Aurora, and 3Psychiatry, University of Colorado Denver, Denver, CO, 2Medicine, University of Washington, Seattle, WA, 4Public Health, University of Texas, Houston, TX, 5Community Health, University of California San Francisco, San Francisco, CA

151 The impact of race and HIV/AIDS discussion strategies on unprotected sex among female drug-abusing criminal offenders
   C.B. Oser, J. Havens, J. Mooney, M. Staton-Tindall, J. Duvall and C. Leukefeld, University of Kentucky, Lexington, KY

152 Juvenile arrest as an indicator of HIV-related sexual risk behaviors and adult criminal involvement in a community sample of substance-using African American women
   C. Welch, C.L. Callahan and L.B. Cottler, Psychiatry, Washington University in St. Louis, St. Louis, MO

153 Differences in rates and length of incarceration for minority vs. non-minority women: A drug diversion study
   M.C. Scott, P. Wupperman and C.J. Easton, Psychiatry, School of Medicine, Yale University, New Haven, CT

154 Differential success rates in racial groups: Results of a clinical trial of smoking cessation among female prisoners
   K.L. Cropsey1, M.F. Weaver2, G.D. Eldridge5, G.C. Villalobos5, A.M. Best4, M.L. Stitzer3,
   1Psychiatry, University of Alabama at Birmingham, Birmingham, AL, 2Internal Medicine, and 5Biostatistics, Virginia Commonwealth University, Richmond, VA, 3Psychiatry, Johns Hopkins University, Baltimore, MD and 4Psychology, University of Alaska, Anchorage, AK

155 Transitioning from buprenorphine maintenance in jail to the community
   S. Magura1,2, J. Hershberger3, A. Rosenblum2, H. Joseph2, N. Santana2, L. Marsch2, J.D. Lee4, C. Shropshire5, A. Glick5 and J. Liautaud5, 1Western Michigan University, Kalamazoo, MI, 2NDRI, 3DOHMH, 4NY University, and 5Prison Health Services, New York, NY

156 Acute effects of topiramate on aggressive responding in individuals on parole/probation with a history of substance use disorders
   S.D. Lane1,2, F.G. Moeller1,2, J.L. Gowin2, J.L. Steinberg1 and D.R. Cherek1, 1Psychiatry and Behavioral Sciences and 2Graduate School of Biomedical Sciences, University of Texas Health Science Center-Houston, Houston, TX

157 Limited access to Narcotic Replacement Therapy undermines outcomes of treatment diversion
   A. Hawken1,2 and D.M. Anglin1, 1Integrated Substance Abuse Program, University of California-Los Angeles, Los Angeles, and 2School of Public Policy, Pepperdine University, Malibu, CA
Methadone maintenance for prisoners: Findings at 12 months post-release
M.S. Gordon, T.W. Kinlock and R.P. Schwartz, Social Research Center, Friends Research Institute, Baltimore, MD

Impact of interim methadone treatment vs. waiting list on arrests
R.P. Schwartz1, J.H. Jaffe1, D. Highfield1, M. Wilson1, S. Kelly1, A. Ahmed2 and K.E. O'Grady3, 1Friends Research Institute, and 2Morgan State University, Baltimore, MD and 3University of Maryland, College Park, MD

Evaluation of California’s Proposition 36: An initiative offering treatment to non-violent drug offenders
D. Urada, E. Evans, A. Hawken, B.T. Conner and D. Longshore, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA

Employment intervention for offenders
D.M. Coviello1, D.A. Zanis1,2, S.A. Wesnoski1, S.M. Lopacinski1 and L.A. Riley1, 1Psychiatry/Addictions, University of Pennsylvania, and 2Social Administration, Temple University, Philadelphia, PA

Correlates of age of first criminal activity, crime severity, and first heroin use of male prisoners in a randomized clinical trial of methadone maintenance
T. Kinlock1,2, M. Gordon1 and R. Schwartz1, 1Friends Research Institute, 2University of Baltimore, and 3Open Society Institute, Baltimore, MD

Racial differences in psychosocial functioning among youth in juvenile detention
C. Henderson1,2, G.A. Dakof3, C. Gillkin3, H. Li3, C.S. Lederman3 and H.A. Liddle3, 1Psychology, Sam Houston State University, Huntsville, TX, 2Center for Treatment Research on Adolescent Drug Abuse, Miller School of Medicine at the University of Miami, and 3Juvenile Division, 11th Judicial Court, Miami, FL

Illicit drug prevalence among inmates and juvenile offenders in Puerto Rico
J.L. Gonzalez-Perez1, E. Lopez Vargas1, A. Segarra3, J. Bloom Oquendo2 and J. Rodriguez Orengo1,2,3, 1Doping and Drug Detection Division, and 2Criminalistic Laboratory Division, Institute of Forensic Sciences, and 3School of Medicine, University of PR, San Juan, PR

Marijuana abuse in incarcerated adolescents
R. Lebeau, L. Stein and K. Quina, Cancer Prevention Research Center, URI, Kingston, RI

Validity and reliability of the Marijuana Withdrawal Checklist for incarcerated youth
M. Clair1,2, L. Stein2,3, R. Martin1, R. Lebeau2 and M. Gingras3, 1Center for Alcohol and Addictions Studies, Brown University, Providence, 2University of Rhode Island, Kingston, and 3Rhode Island Training School, Cranston, RI

Evaluating a research-based HIV prevention program adapted for use with incarcerated juvenile offenders
W.J. McCuller1, D.W. Watson1,2, F.G. Castro2 and C. Reiber3, 1Friends Research Institute, Torrance, 2Integrated Substance Abuse Programs, University of California, Los Angeles, CA, 3Binghamton University, Binghamton, NY and 4Psychology, Arizona State U., Tempe, AZ

Outcomes of a substance use and HIV prevention program for incarcerated adolescents
D.W. Watson1,2, W.J. McCuller1, F.G. Castro2, C. Reiber3 and J. Herting4, 1Friends Research Institute, Torrance, and 2Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA, 3Psychology, Arizona State University, Tempe, AZ, 4Binghamton University, Binghamton, NY, 4School of Nursing, University of Washington, Seattle, WA

Long-term health outcomes of adjudicated adolescent offenders
R. Ramchand and A. Morral, RAND, Arlington, VA
Monday, June 16, 2008

Art and Addiction Exhibition

Flamingo
9:00 AM - 6:00 PM

Symposium III

San Cristobal
10:00 AM - 12:00 PM

ADDITION LIABILITY AND PAIN RELIEF MEDICATION:
RAYMOND HOUDE MEMORIAL SYMPOSIUM

Chairs: Charles P. O’Brien and Charles Inturrisi

10:00  The pharmacological basis of analgesic rotation in the treatment of pain
       Charles Inturrisi, Cornell University Medical College, New York, NY

10:25  How analgesic studies have contributed to an understanding of opiate receptors
       Gavril Pasternak, Memorial Sloan Kettering Cancer Center, New York, NY

10:50  Pain measurement in the design of modern analgesic clinical trials
       John Farrar, University of Pennsylvania, Philadelphia, PA

11:15  The impact of Houde’s work on analgesic medication development
       William L. Dewey, Virginia Commonwealth University, Richmond, VA

11:40  Discussant
       Charles P. O’Brien, University of Pennsylvania, Philadelphia, PA

Symposium IV

San Geronimo B
10:00 AM - 12:00 PM

UNDERSTANDING EXTINCTION LEARNING AND
ITS TRANSLATION TO DRUG ADDICTION

Chairs: Paul Schnur and David Shurtleff

10:00  Neural substrates of drug-seeking after abstinence vs. extinction training in an animal model of relapse
       Ronald E. See, Medical University of South Carolina, Charleston, SC

10:25  Cognitive enhancement as a therapeutic strategy for drug addiction
       Kathleen M. Kantak, Boston University, Boston, MA

10:50  Environments and people: The challenge smoking-related cues pose for extinction-based treatments
       Cynthia A. Conklin, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA

11:15  Extinction-based smoking cessation treatment attenuates event-related brain responses to smoking cues: Results of a preliminary fMRI study
       Joseph Mcclernon, Duke University Medical Center, Durham, NC

11:40  Discussant
       Gregory Quirk, University of Puerto Rico School of Medicine, San Juan, PR
Oral Communications 3

San Geronimo C
10:00 AM - 12:00 PM

CLUB DRUGS: WHAT’S IN?

Chairs: Jillian Broadbear and Wouter Koek

10:00  Psychedelic-like effects of dextromethorphan
       C.J. Reissig¹, L.P. Carter², M.Z. Mintzer¹ and R.R. Griffiths¹, ¹Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD and ²Medical Affairs Department, Jazz Pharmaceuticals Inc., Bloomington, IN

10:15  Psychomotor, subjective, and cognitive effects of ketamine and triazolam in healthy volunteers
       L.P. Carter¹, R.R. Griffiths²,³ and M.Z. Mintzer², ¹Medical Affairs, Jazz Pharmaceuticals Inc., Bloomington, IN ²Psychiatry and Behavioral Sciences, and ³Neuroscience, Johns Hopkins University, Baltimore, MD

10:30  Self-administration of the gamma-hydroxybutyrate (GHB) prodrug gamma-butyrolactone (GBL) in baboons
       E.M. Weerts, A.K. Goodwin, B.J. Kaminski, R.R. Griffiths and N.A. Ator, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD

10:45  CGP7930, a positive modulator of GABA-B receptors, enhances catalepsy induced by the GABA-B receptor agonist baclofen and by gamma-hydroxybutyrate (GHB)
       W. Koek¹,², K. Cheng³, K.C. Rice³ and C.P. France²,¹, ¹Psychiatry, and ²Pharmacology, University of Texas Health Science Campus San Antonio, San Antonio, TX and ³Chemical Biology Research Branch, NIDA, Bethesda, MD

11:00  The acute effects of trifluoromethylphenylpiperazine (TFMPP) administration on the Poffenberger Paradigm of Interhemispheric Transfer Time
       B.R. Russell¹, H. Lee¹ and I.J. Kirk², ¹School of Pharmacy, and ²Research Centre for Cognitive Neuroscience, Psychology, The University of Auckland, Auckland, New Zealand

11:15  Long-term repeated exposure to MDMA in rats: Effects on thermoregulation and neurotoxicity
       E.J. Jaehne, A. Salem and R.J. Irvine, Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, SA, Australia

11:30  Assessing the role of oxytocin in the interoceptive cues of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") using a drug discrimination paradigm
       J.H. Broadbear and K. Beringer, SPPPM, Monash University, Clayton, VIC, Australia

11:45  Comparison of effects produced by methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans under controlled conditions
TREATING FOR TWO: DRUGS AND PREGNANCY

Chairs: Oriana Vesga and Hendree Jones

10:00 Twelve-month prevalence of substance use and substance use disorders in pregnant and postpartum women
O. Vesga¹, C. Blanco², K. Keyes³, M. Olfson⁴, B. Grant⁴ and D. Hasin¹, ¹²Psychiatry, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, ³Epidemiology, Mailman School of Public Health, Columbia University, NYC, NY and ⁴Laboratory of Epidemiology and Biometry, NIAA, NIH, Bethesda, MD

10:15 Characterizing methadone dose during late pregnancy and postpartum
S.H. Heil¹², T. Scott¹, S. Sigmon¹² and S. Higgins¹², ¹Psychiatry and ²Psychology, University of Vermont, Burlington, VT

10:30 Methamphetamine use among white pregnant women
W. Tompkins and W. Clark, SAMHSA, Rockville, MD

10:45 Pregnancy and race/ethnicity as predictors of readiness for drug treatment
M.M. Mitchell, S.G. Severtson, S.L. Hedden and W.W. Latimer, Mental Health, Johns Hopkins University, Baltimore, MD

11:00 Binge drinking and not heavy regular drinking relates to pregnancy risk due to ineffective contraception
S. Fabbri, L. Farrell, T. Ly, C.D. Ceperich, J.K. Penberthy, J.E. Wartella and K.S. Ingersoll, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA

11:15 Does tobacco use identify post-partum women at risk for alcohol problems and depression?
L. Islam¹, L. Keyser-Marcus¹, S. Ondersma² and D.S. Svikis¹, ¹Psychology, Virginia Commonwealth University, Richmond, VA and ²Wayne State University, Detroit, MI

11:30 Smoking in pregnant patients screened for an agonist medication study: Comparisons to other pregnant and/or drug-dependent female patients
H.E. Jones¹, K. O’Grady¹, K. Kaltenbach², G. Fischer³, S. Heil⁴, P. Martin⁵, S. Stine⁶, M. Coyle⁷, P. Selby¹ and A. Arria¹, ¹Johns Hopkins U., Baltimore, MD, ²Thomas Jefferson U., Philadelphia, PA, ³Medical U. Vienna, Vienna, Austria, ⁴U. of Vermont, Burlington, VT, ⁵Vanderbilt U, Nashville, TN, ⁶Wayne State U., Detroit, MI and ⁷Brown U., Providence, RI

11:45 Nicotine replacement treatment for pregnant smokers
C. Oncken¹, E. Dornelas¹, J. Greene², H. Sankey³, A. Glasmann⁴ and H.R. Kranzler¹, ¹University of Connecticut School of Medicine, Farmington, ²Hartford Hospital, Hartford, and ³Hospital of Central Connecticut, New Britain, CT and ⁴Baystate Medical Center, Baystate, MA

Early Career Investigator Awards Luncheon
(Las Olas 12:00 - 1:30 PM)
Monday, June 16, 2008

Art and Addiction Exhibition
THE NARCOTIC FARM: FACTS AND FICTIONS
Nancy D. Campbell

Symposium V
ADULTS MAY BE FROM MARS, BUT ADOLESCENTS ARE FROM VENUS
Chairs: Minda R. Lynch and James Bjork

1:30 Social interactions during adolescence: Giving a boost to drug reward
Janet L. Neisewander, Arizona State University, Tempe, AZ

1:55 The social and physical environment differentially alters drug reward in adults and adolescents: Are adolescents more sensitive to the world around them?
Sari Izenwasser, University of Miami School of Medicine, Miami, FL

2:20 Adolescent phenotypes: Stress and emotional reactivity in the vulnerability to addiction
Nicole Schramm Sapyta, Duke University Medical Center, Durham, NC

2:45 Adolescent THC exposure: Genetic and neurobiological mechanisms of adult addiction
Yasmin L. Hurd, Mount Sinai School of Medicine, New York, NY

3:10 Risk and reward in human adolescence: A framework for translation
James Bjork, NIDA, Bethesda, MD

Oral Communications 5
PAIN RELIEF, ADDICTION GRIEF:
OPiATE ANALGESIC ABUSE
Chairs: Marc Auriacombe and Stacey Sigmon

1:30 Methodological issues in designing a clinical trial for opioid analgesic dependence:
Defining the population
R.D. Weiss, J.S. Potter, K. Prather, S. Provost, J. Selzer and W. Ling,
Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, and Psychiatry, Harvard Medical School, Boston, MA,
Psychiatry, Hillside Hospital, Glen Oaks, NY and Psychiatry, University of California-Los Angeles School of Medicine, Los Angeles, CA

1:45 A descriptive profile of opioid-dependent patients with chronic pain attending the Columbia University Buprenorphine Program
J.M. Manubay, S.K. Vosburg, E. Gunderson, E. Yango and H.D. Kleber,
Psychiatry, Columbia University, and NYSPI, New York, NY
Monday, June 16, 2008

2:00  A protocol to use buprenorphine for chronic pain in patients at risk for drug abuse
      A. Rosenblum¹, R. Cruciani², H. Joseph¹, L.F. McNicholas⁴, S. Magura⁵, L. Marsch¹,
      S.R. Savage⁶, E.C. Strain¹ and R.K. Portenoy², ¹NDRI, and ²Beth Israel Medical Center, NY, NY,
      ³Johns Hopkins University, Baltimore, MD, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Western MI University, Kalamazoo, MI and ⁶Dartmouth Medical School, Hanover, NH

2:15  Discontinuation of chronic opioids for pain: Addiction concerns
      J.O. Merrill¹, C. Banta-Green¹, D. Boudreau², S. Doyle¹ and D. Calsyn¹, ¹University of
      Washington and ²Center for Health Studies, Seattle, WA

2:30  Self-perceived pain and physical condition after 1 year in maintenance treatment for opiate
dependency: Comparison between methadone and buprenorphine patients
      M. Auriacombe¹, E. Lavie¹, C. Denis¹, M. Fatseas¹, R. Ali³ and W. Ling², ¹Addiction
      Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen, Bordeaux, France, ²ISAP,
      University of California-LA, Los Angeles, CA and ³University, Adelaide, NSW, Australia

2:45  Opioid abuse and pain: Does dose matter?
      D.L. Haller¹² and M.C. Acosta¹², ¹St. Luke's Roosevelt Hospital, and ²Columbia University,
      New York, NY

3:00  Treatment outcomes of MMT patients with and without chronic pain
      D.T. Barry¹, M. Beitel¹, B. Garnet², D. Joshi³ and R.S. Schottenfeld¹, ¹Yale University and
      ²The APT Foundation, Inc., New Haven, CT

3:15  Developing a treatment for prescription opioid abuse
      S.C. Sigmon, K. Dunn, S. Heil and S. Higgins, Psychiatry, University of Vermont,
      Burlington, VT

Oral Communications 6

DECISION IMPRECISION: COGNITIVE DEFICITS

San Geronimo C
1:30 - 3:30 PM

Chair: F. Gerard Moeller and Jesse Suh

1:30  Differential effects of cocaine on neurocognitive functioning of the orbitofrontal cortex in
      adolescent vs. adult rats
      R.C. Harvey, K.A. Dembro, K. Rajagopalan, M.M. Mutebi and K.M. Kantak, Psychology,
      Boston University, Boston, MA

1:45  Escalating dose of methamphetamine induces deficits in response inhibition in non-human
      primates
      S. Groman¹, B. Lee², E. Seu¹, E.D. London²³ and J.D. Jentsch³, ¹Psychology ²Psychiatry and
     Behavioral Sciences and ³Molecular and Medical Pharmacology, University of California Los
      Angeles, Los Angeles, CA

2:00  fMRI of response inhibition in cocaine-dependent subjects and controls: Effect of amphetamine
      F. Moeller¹, J.L. Steinberg¹, S.D. Lane¹, L.A. Kramer³, P.A. Narayana⁴ and T.R. Kosten³,
      ¹Psychiatry and Behavioral Sciences and ²Diagenostic and Interventional Imaging, University
      of Texas Health Science Center at Houston, and ³Menninger Department of Psychiatry and
     Behavioral Sciences, Baylor College of Medicine, Houston, TX

2:15  A novel Affect-Congruent Go NoGo task demonstrates limbic prepotency in cocaine-dependent
      patients
      M. Goldman¹, R. Ehrman², Z. Wang¹, Y. Li¹, J. Hakun¹, W. Jens¹, J. Suh¹, C.P. O'Brien¹,
      J. Detre¹ and A.R. Childress¹, ¹University of Pennsylvania, and ²VAMC, Philadelphia, PA
2:30  Are cocaine-dependent patients less able to predict errors—an fMRI study of the stop signal task?
      C. Li, P. Yan, K. Bergquist and R. Sinha, Psychiatry, Yale University, New Haven, CT

2:45  Decision-making in cocaine abusers: Contingencies and gambling task performance

3:00  Poor fronto-limbic connectivity during both "seen" and "unseen" aversive cues in cocaine patients
      J.J. Suh\textsuperscript{1,2}, R. Ehrman\textsuperscript{1,2}, Y. Li\textsuperscript{1,2}, Z. Wang\textsuperscript{1}, W. Jens\textsuperscript{1}, J. Hakun\textsuperscript{1}, M. Goldman\textsuperscript{1}, C.P. O’Brien\textsuperscript{1,2} and A.R. Childress\textsuperscript{1,2}, \textsuperscript{1}University of Pennsylvania and \textsuperscript{2}VAMC, Philadelphia, PA

3:15  Sensorimotor integration deficits in chronic cocaine users: An fMRI and DTI study

Symposium VI

San Geronimo B
1:30 - 2:30 PM

SEXUAL ACQUISITION AND TRANSMISSION OF HIV FROM AND AMONG DRUG-USING POPULATIONS

Chairs: Martin Y. Iguchi and Richard Jenkins

1:30  Behavioral and biological indicators of risk for HIV transmission in homeless drug users in Los Angeles
      Steven Shoptaw, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA

1:45  Comparison of risks for HIV transmission in rural and urban settings
      Bill Zule, RTI International, Research Triangle Park, NC

2:00  Geographic, recruitment network, and behavioral indices of bridging: Implications for HIV diffusion
      Larry Ouellet, University of Illinois, School of Public Health, Chicago, IL

2:15  Discussant
      Robert Heimer, Epidemiology and Public Health, Yale University, New Haven, CT

Symposium VII

San Geronimo B
2:45 - 3:45 PM

THE TWIN DESIGN: STUDYING GENES AND ENVIRONMENT ON SUBSTANCE USE BEHAVIORS

Chairs: Arpana Agrawal and Michael T. Lynskey

2:45  A longitudinal twin study of vulnerability to substance dependence: The Colorado twins
      Soo Hyun Rhee, University of Colorado, Boulder, CO

3:05  Predictors of cannabis use initiation in Finnish adolescent twins
      Anja C. Huizink, Erasmus Medical Center, Rotterdam, Netherlands

3:25  The role of peer group deviancy in the genetic and environmental pathways to cannabis use in male twins
      Nathan Gillespie, Virginia Commonwealth University, Richmond, VA
Monday, June 16, 2008

Marian W. Fischman Memorial
Award Lecture
San Cristobal
3:45 - 4:45 PM

Presentation of the Marian W. Fischman Memorial Award to
Edythe D. London

Introduction by Jerome H. Jaffe

*Lecture: Studying addiction in the age of neuroimaging*
Edythe D. London

Pre- and Post-Doc Mixer
Las Olas
5:00 - 6:30 PM

Workshop IV
San Geronimo A
8:00 - 10:00 PM

**CHALLENGES FOR ABUSE LIABILITY TESTING FROM**
**DRUG DEVELOPMENT TO FDA APPROVAL**

Chairs: Michael A. Nader and Beatriz Rocha

*Challenges for abuse liability testing of compounds in development for non-CNS indications— Industry perspective: Case scenario 1*
Beatriz Rocha, Merck & Co., Inc., Rahway, NJ

*Challenges for abuse liability testing of compounds in development for non-CNS indications— Industry perspective: Case scenario 2*
Mark A. Ammann, Regulatory Affairs United BioSource Corporation

*Challenges for abuse liability testing of compounds in development for non-CNS indications— FDA perspective*
Silvia N. Calderon, Center for Drug Evaluation and Research, FDA, Rockville, MD

Workshop V
San Geronimo B
8:00 - 10:00 PM

**ACADEMIC SUCCESS AND TENURE IN TIGHT TIMES**

Chairs: Kristen Huntley, Nadine Rogers, Eliane Lazar-Wesley and Mark Swieter

Workshop VI

ADOLESCENT SUBSTANCE ABUSE TREATMENT:
CURRENT FINDINGS AND IMPLICATIONS FOR
JUVENILE JUSTICE SETTINGS

Chairs: Lyn Stein and Michael Dennis

- Empirical support for adolescent substance abuse treatments: A meta-analytic study
  Charles Turner, Oregon Research Institute, Eugene, OR

- Partner-specific HIV risk reduction in substance-using juvenile delinquents
  Cynthia Rosengard, The Warren Alpert Medical School of Brown University, Providence, RI

- Multidimensional family therapy for adolescents in the justice system
  Howard Liddle, University of Miami Miller School of Medicine, Miami, FL

- Treatment outcomes in drug court studies, including evidence for juvenile drug courts
  Douglas B. Marlowe, TRI, University of Pennsylvania, Philadelphia, PA

- Implications of presentations, followed by the Society for Adolescent Substance Abuse Treatment
  Effectiveness (SASATE) Business Meeting
  Michael L. Dennis, Chestnut Health System, Bloomington, IL

Workshop VII

A STEP-BY-STEP GUIDE TO ANALYSIS OF
EPIDEMIOLOGICAL FIELD SURVEY DATA
ON MINORITY HEALTH DISPARITIES AND MALE-
FEMALE DIFFERENCES IN NIDA-RELATED OUTCOMES

Chairs: James Anthony and Silvia S. Martins

- It’s about the basics: Estimating differences and sub-group variation; 95% CI; P-Values
  James Anthony, College of Human Medicine, Michigan State University, East Lansing, MI

- It’s about the basics: Using a generalized linear model to control covariates
  Silvia S. Martins, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD

- It’s about time: The basic life-table, plus event history analysis
  Fernando Wagner, School of Public Health and Policy, Morgan State University, Baltimore, MD

- It’s about Eta: Bias detection via IRT and MIMIC
  Mirjana Radovanovic, Michigan State University, East Lansing, MI

- It’s about online analysis: Buyer beware, you get what you pay for!
  German Alvarado, Universidad Peruana Cayetano Heredia, Lima, Peru

- It’s about hot spots: Sizing up epidemiological clusters of drug use
  Carlos Rios-Bedoya, College of Human Medicine, Michigan State University, East Lansing, MI
NIDA INTERNATIONAL RESEARCH POSTERS

Chair: Steven W. Gust

Peacock Alley
8:00 - 10:00 PM

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
POSTER SESSION II (Breakfast)  
Expo Center  
8:00 - 10:00 AM

Odd-numbered posters manned first hour;  
Even-numbered, second hour

Set-up time begins Monday 1:00 PM  
Must be removed by Tuesday 12:00 NOON

HALLUCINOGENS

1 Serotonin vs. hallucinogen actions at the 5-HT2A receptor: A determining role for beta-arrestins in vivo  
   C.L. Schmid, K.M. Raehal and L.M. Bohn, Pharmacology and Psychiatry, The Ohio State University, Columbus, OH

2 Novel PCP analogs with high inhibitory potency at α7 nAChRs  
   G. Abdurakhmanova1, F.I. Carroll2, B. Blough2, M. Thiruvazhi2, R.B. Rothman3, M.I. Damaj1  
   and B.R. Martin1, 1Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 2Research Triangle Institute, Research Triangle Park, NC and 3National Institute of Drug Abuse, Baltimore, MD

3 The role of NMDAR 2A and 2B in PCP-induced neurotoxicity and development of locomotor sensitization  
   N. Anastasio and K.M. Johnson, UTMB Galveston, Galveston, TX

4 The street drugs 2C-I and 2C-T-2 share discriminative stimulus effects with abused hallucinogens  
   M.B. Gatch, T. Carbonaro, M. Rutledge, C. Elsken and M.J. Forster, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX

5 Cross-substitution between LSD and commonly co-abused drugs  
   T. Carbonaro and M.B. Gatch, Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX

6 Linguistic analysis of psilocybin session narratives  
   M.W. Johnson and R.R. Griffiths, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD

7 Psilocybin occasions mystical-type experiences: Dose effects  
   R.R. Griffiths1, M.W. Johnson2, W.A. Richards2, U.D. McCann2 and B.D. Richards2,  
   1Psychiatry and Neuroscience and 2Psychiatry, Johns Hopkins, Baltimore, MD

8 Use of a hallucinogenic sacrament by American members of the Santo Daime Church: Evidence of safety  
   J.H. Halpern1, A.R. Sherwood2 and A.J. Ruttenber3, 1Alcohol and Drug Abuse Research Center, McLean Hospital/HMS, Belmont, MA, 2Center for Neuropsychological Services, University of New Mexico School of Medicine, Albuquerque, NM and 3University of Colorado Health Science Center, Denver, CO
SEDATIVE-HYPNOTICS, INHALANTS

9 Youth's inhalant drug use in Bogotá, Colombia
   Y. Neumark and C. Lopez, School of Public Health, Hebrew University of Jerusalem, Jerusalem, Israel

10 Anxiety and depressive symptoms among crack and inhalant users in Southern Brazil
   C. Zubaran, K. Foresti-Zubaran, M. Thorell and P. Franceschini, Biomedical Sciences, University of Caxias do Sul, Caxias do Sul, Brazil

11 Factors predicting the onset and discontinuity of prescribed benzodiazepine long-term use
   S. Fang1, C. Chen1, K. Lin1, I. Chang1, E. Wu2 and C. Chang3, 1National Health Research Institute, and 2Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan and 3Chang Gung Memorial Hospital, Taoyuan County, Taiwan

12 Tolerance develops differentially to the sedative effects of alprazolam following chronic treatment in rhesus monkeys

13 Flumazenil selectively attenuates the discriminative stimulus effects of benzodiazepines, and not pregnanolone, in rats discriminating pregnanolone
   L.R. Gerak, Pharmacology, University of Texas Health Science Center, San Antonio, TX

14 Discriminative stimulus effects of toluene vapor: Effect of exposure duration and route of administration
   K.L. Shelton, Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA

15 Development of a dynamic exposure system allowing for self-administration of abused inhalants in mice
   S. Irtenkauf and S. Bowen, Psychology, Wayne State University, Detroit, MI

16 Increased sensitivity in adolescent versus adult rats to the locomotor activating effects of toluene
   S. Bowen and J. Batis, Psychology, Wayne State University, Detroit, MI

17 Alterations in skeletal development following gestational toluene exposure
   A. Stefanski1, S. Irtenkauf1, J. Hannigan12 and S. Bowen1,2, 1Psychology, and 2Obstetrics and Gynecology, Wayne State University, Detroit, MI

PHARMACOKINETICS

18 Identification of the enzymes metabolizing buprenorphine in preterm human placentas
   V. Fokina, O. Zharikova, T.N. Nanovskaya, G. Hankins and M.S. Ahmed, OB/GYN Maternal Fetal Medicine, University of Texas Medical Branch, Galveston, TX

19 Pharmacodynamic and pharmacokinetic evaluations of immediate release morphine in combination with ethanol in healthy subjects
   B. Setnik1, M. Miguelez1, G. Leowen2, A. Negro-Vilar2 and E. Sellers1, 1Research Consulting, DecisionLine Clinical Research Corporation, Toronto, ON, Canada and 2Ligand Pharmaceuticals Inc., San Diego, CA

20 Relative abuse potential of ALO-01, extended-release morphine sulfate plus sequestered naltrexone
   J.B. Jones1, F. Johnson1, G. Wagner1, J. Stauffer1 and E. Sellers2, 1Alpharma Pharmaceuticals LLC, Piscataway, NJ and 2DecisionLine CRC, Toronto, ON, Canada

21 Local blockade of cocaine actions in brain by local gene transfer of cocaine hydrolase
   S. Brimijoin and Y. Gao, Molecular Pharmacology, Mayo Clinic, Rochester, MN
22 Blood levels and dopamine transporter occupancy of orally administered methylphenidate in juvenile rhesus monkeys measured by high resolution PET
K.M. Wilcox1, D.F. Wong1,2, Y. Zhou2, M. Alexander2, A. Rahmim2 and M.R. Weed1,
1Psychiatry and Behavioral Sciences, and 2Radiology, Johns Hopkins University School of Medicine, Baltimore, MD

23 Abuse potential of a slow-onset, long-duration methylphenidate analog with selectivity for the dopamine transporter
M. Froimowitz1,2, Y. Gu2, L.A. Dakin2, C.J. Kelley2, X. Li3, J. Li3, Z.X. Xi3 and E.L. Gardner3,
1DNAPrint Pharmaceuticals, Sarasota, FL, 2Massachusetts College of Pharmacy and Health Sciences, Boston, MA and 3Neuropsychopharmacology Section, Intramural Research Program, NIDA, Baltimore, MD

24 Enhanced immunogenicity of bivalent nicotine vaccine
D. Keyler1,2, S.A. Roiko2, C.A. Ross1, M.P. Murtaugh2 and P.R. Pentel1,2, 1Minneapolis Medical Research Foundation, and 2University of Minnesota, Minneapolis, MN

COCAINE: ANIMAL STUDIES

25 Improving conjugate vaccines against cocaine and methamphetamine
B.M. Kinsey2,1, F.M. Orson2,1, Y. Wu1, R.A. Singh1, W. Huang3 and T.A. Kosten3,
1Internal Medicine, and 2Psychiatry, Baylor College of Medicine, Houston, 3Medical Service, Veterans Affairs Medical Center, Houston, TX

26 Prolonged durations of protection of thermal stabilizing cocaine esterase mutants against cocaine-induced toxicity in mice
M.C. Ko1,2, D. Narasimhan1, J.H. Woods1 and R.K. Sunahara1, 1Pharmacology, University of Michigan, Ann Arbor, MI and 2Psychology, National Cheng-Chi University, Taipei City, Taiwan

27 Novel substituted piperazines with high affinity and selectivity for sigma receptors attenuate cocaine-induced behaviors in mice: Role for sigma-1 and sigma-2 subtypes
N. Kaushal1, J. Shaikh1, C. Croom1, C. Mesangeau1, S. Narayanan1, J.H. Poupaert2, C.R. McCurdy1 and R.R. Matsumoto1, 1University of Mississippi, University, MS and 2Universite Catholique de Louvain, Brussels, Belgium

28 Predictive pharmacophore models for novel sigma-1 and sigma-2 ligands
T.L. Nolan1, N. Singh1, C. Mesangeau1, S. Narayanan1, J. Shaikh2, R.R. Matsumoto2 and C.R. McCurdy1, 1Medicinal Chemistry, and 2Pharmacology, University of Mississippi, University, MS

29 Regulation of serotonin 5-HT2C receptor (5-HT2CR) in models of addiction: Measurement of 5-HT2CR protein expression at cortical synaptic membranes
M.F. Lanfranco, J. Moron-Concepcion and K.A. Cunningham, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX

30 Molecular mechanisms underlying the conditioned association made to a single injection of cocaine
A.M. dela Cruz, J. Moron-Concepcion and K.A. Cunningham, Center for Addiction Research, University of Texas Medical Branch, Galveston, TX

31 Effects of acute cocaine on ERK and DARPPP-32 phosphorylation pathways in the caudate-putamen of Fischer rats
W. Sun1, L. Zhou2, R. Hazim1, V. Quinones-Jenab1 and S. Jenab1, 1Psychology, and 2Biological Sciences, Hunter College and Graduate Center of CUNY, New York, NY
Nucleus accumbens shell and core involvement in drug context-induced cocaine-seeking behavior in rats
R.A. Fuchs, D.R. Ramirez, G.H. Bell, Z. Su and J.L. Eaddy, Psychology, University of North Carolina, Chapel Hill, NC

Cocaine-induced increases in limbic and basal ganglia met-enkephalin content are mediated by a dopaminergic mechanism
M.E. Alburges and G.R. Hanson, Pharmacology and Toxicology, University of Utah, Salt Lake City, UT

Effect of amygdala inactivation on conditioned hyperactivity and sensitization in high-responder and low-responder rats
M.J. Gill, R.A. Coolon and M.E. Cain, Kansas State University, Manhattan, KS

Tolerance to decreases in pigeon locomotion following repeated cocaine administration
M.T. Weaver, G.M. Sizemore and M.N. Branch, Psychology, University of Florida, Gainesville, FL

Effects of chronic cocaine in the presence of an operant contingency in Long-Evans rats: Tolerance to lever pressing and locomotion and no sensitization
J.A. Marusich, M.N. Branch and J. Dallery, University of Florida, Gainesville, FL

Chronic exercise decreases the reinforcing efficacy of cocaine
M.A. Smith, K.T. Schmidt, J.C. Iordanou and M.L. Mustroph, Psychology and Program in Neuroscience, Davidson College, Davidson, NC

Estrogen interacts with mu opioid peptides to modulate behavioral sensitization to cocaine in female rats
A.C. Segarra¹, G. Diaz¹, P. Hernandez¹, G. Santiago¹, M. Febo² and C. Ferris², ¹Physiology, U. of Puerto Rico, San Juan, PR and ²Psychology, Northeastern University, Boston, MA

Progesterone attenuates acute locomotor responses but does not alter cocaine-induced behavioral sensitization in female rats
S.E. Diaz¹², G. Seidman², I. Tulloch¹², S. Jenab²¹ and V. Quinones-Jenab²¹, ¹Psychology, Graduate Center of New York, CUNY, and ²Psychology, Hunter College, New York, NY

Progesterone treatment of the escalation of i.v. cocaine self-administration in rats differing in vulnerability
J.L. Pawlik, J.J. Anker and M.E. Carroll, Psychiatry, University of Minnesota, Minneapolis, MN

Effects of the vasopressin V1b blockade on cocaine self-administration
R. Picetti and M.J. Kreek, Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY

Chronic unpredictable stress alters cocaine conditioned place preference in CB1 knockout mice but not their wildtype littermates
L.L. Miller¹, F. Henry¹, B.D. Fischer¹, S.J. Ward² and L.A. Dykstra¹, ¹Psychology, University of North Carolina, Chapel Hill, NC and ²Pharmaceutical Sciences, Temple University, Philadelphia, PA

Prenatal and neonatal exposure to bisphenol-A affects the central dopaminergic systems in mice: Implications of the functional changes in dopamine D3 receptors
K. Mizuo¹², M. Narita¹, K. Miyagawa¹, M. Miyatake¹, Y. Tsurukawa¹, K. Takeda² and T. Suzuki¹, ¹Toxicology, Hoshi University of Pharmacy and Pharmaceutical Sciences, Tokyo, and ²Research Center for Health Science of Nanoparticles, Tokyo University of Science, Chiba, Japan
PERINATAL SUBSTANCE ABUSE

44 Prenatal cocaine exposure alters default mode and emotional network brain activity: Functional and resting state MRI evidence
P. Santhanam\textsuperscript{1}, Z. Li\textsuperscript{1}, X. Hu\textsuperscript{1}, S. Hamann\textsuperscript{3}, M.E. Lynch\textsuperscript{2} and C.D. Coles\textsuperscript{2}, \textsuperscript{1}Biomedical Engineering, \textsuperscript{3}Psychiatry and Behavioral Sciences, and \textsuperscript{2}Psychology, Emory University, Atlanta, GA

45 Prenatal cocaine exposure and infant stress reactivity
R.D. Eiden\textsuperscript{1}, Y. Veira\textsuperscript{1}, D. Granger\textsuperscript{2} and P. Schuetze\textsuperscript{3}, \textsuperscript{1}Research Institute on Addictions, University at Buffalo, SUNY, Buffalo, NY \textsuperscript{2}Biobehavioral Health, Pennsylvania State University, University Park, PA and \textsuperscript{3}Psychology, Buffalo State College, Buffalo, NY

46 Effects of prenatal cocaine exposure on toddlers' emotional arousal and regulation: Implications for behavior problems across a three-year follow-up
T.M. Chaplin\textsuperscript{1}, L.C. Mayes\textsuperscript{2}, R. Sinha\textsuperscript{1} and T. Fahy\textsuperscript{3}, \textsuperscript{1}Psychiatry, and \textsuperscript{3}Yale Child Study Center, Yale University, and \textsuperscript{4}Social Sciences, Gateway Community College, New Haven, CT

47 The effects of prenatal cocaine exposure and lead on language at age 10
S. Minnes, B. Lewis, E. Short, S. Satayathum and L. Singer, Case Western Reserve University, Cleveland, OH

48 Prenatal cocaine exposure, childhood maltreatment, and adolescent marijuana use
C. Larkby\textsuperscript{1}, S.L. Leech\textsuperscript{2}, M.D. Cornelius\textsuperscript{1} and G.A. Richardson\textsuperscript{1}, \textsuperscript{1}Psychiatry, University of Pittsburgh School of Medicine, and \textsuperscript{2}Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA

49 MET for pregnant substance-abusing women (NIDA CTN 0013): Does baseline motivation moderate efficacy?
S.J. Ondersma\textsuperscript{1}, T. Winhusen\textsuperscript{2} and Y. Wang\textsuperscript{3}, \textsuperscript{1}Psychiatry and Ob/Gyn, and \textsuperscript{3}Family Medicine, Wayne State University, Detroit, MI, \textsuperscript{2}Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH

50 Therapist effects in the treatment of pregnant substance abusers: Clinical Trials Network #13
S.J. Erickson\textsuperscript{1}, J.S. Tonigan\textsuperscript{2} and M.P. Bogenschutz\textsuperscript{2}, \textsuperscript{1}Psychology, and \textsuperscript{2}CASAA, University of New Mexico, Albuquerque, NM

51 Technological innovations in adapting an evidenced-based HIV intervention for pregnant African American women in substance abuse treatment
W. Wechsberg, RTI International, Durham, NC and University of North Carolina School of Public Health, Chapel Hill, NC

52 Licit substance use, depression and trauma in pregnant women at high and low risk for prenatal illicit drug
C. Smith, A. Alvanzo, K. Reid-Quinones, D. Langhorst and D. Svikis, Psychology, Virginia Commonwealth University, Richmond, VA

53 Pregnant women in methadone maintenance: Treatment engagement and illicit drug use
L.M. Sander and L.H. Lundahl, Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI

54 Characteristics of opioid-dependent pregnant women who accept or refuse participation in a clinical trial
S. Stine\textsuperscript{1}, S. Heil\textsuperscript{2}, A. Arria\textsuperscript{3}, K. O’Grady\textsuperscript{3}, K. Kaltenbach\textsuperscript{4}, G. Fischer\textsuperscript{5}, P. Martin\textsuperscript{6}, M. Coyle\textsuperscript{7}, P. Selby\textsuperscript{8} and H. Jones\textsuperscript{3}, \textsuperscript{1}Wayne State U., \textsuperscript{2}University of VT, \textsuperscript{3}Johns Hopkins U., \textsuperscript{4}Thomas Jefferson U., \textsuperscript{5}Med. U. Vienna, Austria, \textsuperscript{6}Vanderbilt U., \textsuperscript{7}Brown U., RI, and \textsuperscript{8}of Toronto, Canada
55 Infant mortality among drug-dependent women
L. Burns and R.P. Mattick, NDARC, UNSW, Sydney, NSW, Australia

56 Maternal methadone dosing schedule and fetal neurobehavior
L.M. Jansson¹, J.A. DiPietro², M. Velez¹, A. Elko¹, H. Knauer¹ and K.T. Kivlighan²,
¹Pediatrics, Johns Hopkins School of Medicine, and ²Population and Family Health Sciences,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

57 Examination of withdrawal symptoms in methadone- or buprenorphine-exposed neonates
T. Linares Scott¹, S.H. Heil¹, S.T. Higgins¹, S.C. Sigmon¹ and H.E. Jones², ¹University of
Vermont, Burlington, VT and ²Johns Hopkins University, Baltimore, MD

58 An examination of physiological regulation in cocaine-exposed infants across the first 7 months
of life
P. Schuetze¹²³, E.P. Edwards² and R.D. Eiden²²³, ¹Psychology, Buffalo State College,
²Research Institute on Addictions, University at Buffalo, and ³Pediatrics, University at
Buffalo, Buffalo, NY

59 Brief, universal intervention for child maltreatment prevention among high-risk parents: Effects
on substance use, mental health, and intimate partner violence
A. Loree², S.J. Ondersma¹, J.R. Beatty³, G. Tzilos³, S.K. Chase³ and C.R. Schuster⁴,
¹Psychiatry and Ob/Gyn, ²Psychiatry, and ³Psychology, Wayne State University, Detroit, MI
and ⁴Neuroscience Institute, Loyola University, Chicago, IL

OPIOIDS: HUMAN STUDIES I

60 Codeine effects in sleepy versus alert healthy normal subjects
T. Roehrs¹², E. Harris¹, M. Hyde¹, M. Greenwald³ and T. Roth¹², ¹Sleep Disorders and
Research Center, Henry Ford Hospital, and ²Psychiatry and Behavioral Neuroscience, Wayne
State University, Detroit, MI

61 Assessment of the level of physical dependence and blockade efficacy produced by tramadol
Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD

62 Effects of repeated tramadol and morphine administration on psychomotor and cognitive
performance in opioid-dependent volunteers
M.Z. Mintzer¹, G.E. Bigelow¹, R.K. Lanier¹, M.R. Lofwall² and E.C. Strain¹, ¹Johns Hopkins
University School of Medicine, Baltimore, MD and ²University of Kentucky College of
Medicine, Lexington, KY

63 Within-subject comparison of the psychopharmacological profile of hydrocodone/
acetaminophen and oxycodone/acetaminophen in healthy volunteers
J.P. Zacny and S. Gutierrez, Anesthesia and Critical Care, University of Chicago, Chicago, IL

64 A preliminary examination of tolerance to oxycodone in humans
W.J. Kowalczyk, S.L. Stephens, M.A. Sullivan, S.K. Vosburg, S.M. Evans, R.W. Foltin and
S.D. Comer, SURC, New York State Psychiatric Institute, Columbia University,
New York, NY

65 Effects of cold pressor pain on cortisol stress response and abuse liability of intranasal
Oxycontin® in non-dependent prescription opioid abusers
M. Lofwall¹², P.A. Nuzzo³, J.P. Tuttle¹ and S.L. Walsh¹²¹, ¹Psychiatry, and ²Behavioral
Science, University of Kentucky, Lexington, KY
66 Validation of assessments for abuse liability trials
M. Sokolowska1, B. Setnik1, J. Jones2, F. Johnson2, M. Romach1 and E. Sellers1,3,
1DecisionLine Clinical Research Corporation, Toronto, ON, Canada, 2Alpharma
Pharmaceuticals LLC, Piscataway, NJ and 3University of Toronto, Toronto, ON, Canada

67 An exploratory profile of illicit prescription opiate users by route of administration
E. McNees1, M. Staton-Tindall1, C. Leukefeld1, R. Walker1 and J. Rees2, 1University of
Kentucky, Lexington, and 2Kentucky Department of Corrections, Frankfort, KY

68 Modeling transitions in behavior during naltrexone-based interventions for opioid dependence
K.M. Carpenter1,2, H. Jiang2,1, M.A. Sullivan2,1, A. Bisaga2,1, W.N. Raby2,1, A.C. Brooks3 and
E.V. Nunes2,1, 1Columbia University, and 2Division on Substance Abuse, New York State
Psychiatric Institute, New York, NY and 3Treatment Research Institute, Philadelphia, PA

69 Behavioral naltrexone therapy for heroin dependence: A randomized controlled trial
M.A. Sullivan, K.M. Carpenter, Y. Elkus, S.J. Anen, E. Leimsider and E.V. Nunes, Columbia
University, New York State Psychiatric Institute, New York, NY

70 Reinforcement-based treatment: A randomized clinical trial
M. Tuten, H. Jones and M. Stitzer, Johns Hopkins University, Baltimore, MD

71 Employment-based reinforcement of acceptance of depot naltrexone injections in opioid-
dependent adults
J.J. Everly, A. Umbracht, M. Fingerhood, G. Bigelow and K. Silverman, Johns Hopkins
University School of Medicine, Baltimore, MD

72 A stress-coping profile of opioid-dependent individuals entering naltrexone treatment
S.M. Hyman, K.A. Hong, D. Comegys, Z. Dabre and R. Sinha, Psychiatry, Yale University
School of Medicine, Substance Abuse Treatment Unit, New Haven, CT

73 A double-blind, placebo-controlled trial of long-acting implantable formulation of naltrexone
for heroin dependence: Results of interim analysis
E. Krupitsky2, E. Zvartau3, V. Egorova3, D. Masalov3, M. Tsoi2, A. Burakov2, N. Bushara2,
T. Romanova2, E. Verbitskaya3, T. Slavina2, A. Grinenko2 and G.E. Woody1, 1Psychiatry,
University of Pennsylvania, Philadelphia, PA and 2Pharmacology, St. Peters, State Pavlov
Medical University, St. Petersburg, Russian Federation

74 Buprenorphine medication contingency efficacious in promoting abstinence from opioids and
cocaine
M.P. Chopra1, R.D. Landes1, M. Mancino1, C. Cargile1, L. Jackson1, K.M. Gatchalian1,
A. Buchhalter4, L. Marsch13 and W.K. Bickel1, 1Psychiatry, University of Arkansas for
Medical Sciences, Little Rock, AR, 2National Development and Research Institutes, and 3St.
Luke's-Roosevelt Hospital Center, New York, NY and 4Pinney Associates, Bethesda, MD

75 "Feeling normal again": Patient perspectives on buprenorphine treatment
J.E. Egan, J. Gass, J. Netherland and L. Weiss, New York Academy of Medicine,
New York, NY

76 Sexual risk and physician screening practices in office-based buprenorphine
L.E. Sullivan1, D.A. Fiellin1, B.A. Moore2 and R.S. Schottenfeld2, 1Internal Medicine, and
2Psychiatry, Yale University, New Haven, CT

77 Automated clinical history database for office management of the individual buprenorphine
J. Listerud1,2, L. McNicholas1,2, D. Osln1,2, C. Burke2 and J. McKay1,2, 1Psychiatry, University
of Pennsylvania, and 2Psychiatry, VAMC, Philadelphia, PA
78 Treatment considerations of physicians prescribing buprenorphine
T.J. Grosheider1, J. Luther1,2, R. Ramgopal2 and A.J. Gordon1,2, 1University of Pittsburgh, and
2VA Pittsburgh Healthcare System, Pittsburgh, PA

79 Factors associated to buprenorphine treatment adoption by Puerto Rican physicians in private
practice
G. Caraballo and C.E. Albizu, Graduate School of Public Health, University of Puerto Rico,
San Juan, PR

80 Opioid abstinence reinforcement delays heroin lapse during buprenorphine dose tapering
C. Steinmiller and M. Greenwald, Psychiatry and Behavioral Neurosciences, Wayne State
University, Detroit, MI

81 Semi-quantitative buprenorphine testing in an ongoing study with prescription opioid abusers

82 Primary care buprenorphine treatment among persons released from jail
J.D. Lee1,2, E. Grossman1,2, D. DiRocco1,2, H. Joseph3, A. Rosenblum3, S. Magura4 and
M.N. Gourevitch1,2, 1New York University School of Medicine, 2Bellevue Hospital Center,
and 3University of Maryland, Baltimore, MD

83 Predictors of successful treatment outcomes in a 30-day buprenorphine detoxification
S. King1, E.C. Katz2,1, B. Brown1,2, R. Schwartz1, D. Gandhi4 and W. Barksdale4, 1Friends
Research Institute, Baltimore, MD, 2Towson University, Towson, MD, 3University of N.
Carolina, Wilmington, NC and 4Western Michigan University, Kalamazoo, MI

84 Examination of a brief adjunctive interoceptive-based intervention for heroin users with high
anxiety sensitivity
J.M. Richards, M.T. Tull, S. Gorka, M.J. McDermott, S.B. Daughters and C.W. Lejuez,
Psychology, Center for Addictions, Personality, and Emotion Research [CAPER], University
of Maryland, College Park, MD

85 Katrina and Rita: Two years later
J.C. Maxwell1 and D. Podus2, 1University of Texas Austin, Austin, TX and 2University of
California-Los Angeles, Los Angeles, CA

EPIDEMIOLOGY, ETHNIC DIFFERENCES

86 Scientific collaboration between the United States and the European union in substance abuse
(2002-2006)
R. Aleixandre-Benavent1, J.C. Valderrama1, G. González1, A. Alonso1, V. Agulló1, N.
Llorens1, F. Bueno2 and J.C. Pérez de los Cobos3, 1IHCD López Piñero, and 2Plan Municipal
Drogodependencias, Ayuntamiento de Valencia, València, and 3Hospital de la Santa Creu i
Sant Pau, Barcelona, Spain

87 Polydrug use and implications for longitudinal research: Ten-year trajectories for heroin,
cocaine, and methamphetamine users
M. Brecht, D. Huang, E. Evans and Y. Hser, Integrated Substance Abuse Programs,
University of California-Los Angeles, Los Angeles, CA

88 Family attention and coca paste use in northern Chile, 1999 and 2005
L.H. Caris1 and J.C. Anthony2, 1Medicine Faculty, University of Chile, Santiago, Chile and
2Epidemiology, Michigan State University, East Lansing, MI

89 Demographic characteristics of cocaine-related decedents in Gainesville, FL
N.A. Graham1, L. Merlo1, S. Win1, C. Hammond1, M. Burt1,2, W. Hamilton2, B. Goldberger1
and M. Gold1, 1Psychiatry and Pathology, University of Florida, and 2District Eight, Medical
Examiners Office, Gainesville, FL
90 The relationship of substance abuse to dependence in the U.S. general population
D. Hasin¹ and T. Harford², ¹Columbia University, College of Physicians and Surgeons,
New York City, NY and ²Boston University, Boston, MA

91 Substance use in patients with STDs: Results from a national survey
J.M. Tetrault, D.A. Fiellin and L.E. Sullivan, Yale University School of Medicine,
New Haven, CT

92 Natural history of opioid addiction: The relationship between time using opioids, patterns of
use, and problem severity in clients in treatment
S.H. Budman and S.F. Butler, Inflexxion, Inc, Newton, MA

93 Age-related drug use patterns in Central Ukraine
O. Zezyulin¹, J.E. Schumacher², K. Dumchev², P. Slobodyanyuk² and L. Moroz³, ¹Vinnitsa
Regional Narcological Dispensary, Vinnitsya, Ukraine, ²University of Alabama at
Birmingham, Birmingham, AL and ³Vinnitsya National Pirogov Medical University,
Vinnitsya, Ukraine

94 Correlates of substance use and related problems in Nigeria and Uganda: Findings from
general population surveys
I.S. Obot, M.B. Hossain and K. Sydnor, Morgan State University, Baltimore, MD

95 Characteristics of a sample female injection drug users in Malaysia
V.B. Kasinather¹, M.C. Chawarski², R.S. Schottenfeld² and M. Mazlan³, ¹Centre for Drug
Research, University Sains Malaysia, Penang, and ³SARC, Muar, Malaysia and ²Yale
University School of Medicine, New Haven, CT

96 Substance use in inner city minority MSM and WSW
S.R. Chappin¹, J.P. Sanchez² and S. Tross³, ¹Psychiatry, New York University, New York,
²Emergency Medicine, Jacobi Medical Center, Bronx, and ³Psychiatry, Beth Israel,
New York, NY

97 Psychosocial correlates of sex trade among drug-abusing women by race/ethnicity
Bloomberg School of Public Health, Baltimore, MD

98 Intra-ethnic differences on the lifetime risk for alcohol, cannabis, and cocaine use among
Latinos
C.F. Ríos-Bedoya, Family Medicine, Michigan State University, East Lansing, MI

99 Using racial admixture to delineate genetic and environmental risk factors of illicit drug use
and dependence
R.K. Price¹, N. Risk¹, G. Widner¹ and J. Sakai², ¹Psychiatry, Washington University School of
Medicine, St. Louis, MO and ²Psychiatry, University of Colorado School of Medicine,
Denver, CO

100 Classism, racism, and expectations of drug use prevalence among low-income African
Americans in the National Survey on Drug Use and Health
L. Windsor, ¹Special Populations Office, National Development and Research Institutes, Inc.,
New York, NY and ²School of Social Work, The University of Texas at Austin, Austin, TX

101 Describing differences between never smokers, current smokers, and former smokers in a low
SES community sample
P. Sheikhattari¹², H. Klein¹², S. Zhu⁴ and F.A. Wagner¹², ¹Center for the Study and
Prevention of Drug Use, ²Center for Health Disparities Solutions, and ³School of Community
Health and Policy, Morgan State University, and ⁴School of Medicine, University of
Maryland, Baltimore, MD
102 Racial differences in the effect of family formation on smoking cessation by middle age among women
A. Thompson, ¹Columbia University, and ²National Development and Research Institute, New York, NY

103 Predicting changes in smoking: Individual, partner and relationship influences
G.G. Homish¹², K.E. Leonard³⁴ and J.R. Cornelius⁴, ¹Health Behavior, ²Research Institute on Addictions, and ³Psychiatry, The State University of New York at Buffalo, Buffalo, NY and ⁴Psychiatry, University of Pittsburgh, Pittsburgh, PA

104 Association of prior tobacco dependence with recent posttraumatic stress disorder in a general population sample: Peru, 2007
V.O. Cruz¹², C. Cachay² and J. Saavedra², ¹Epidemiology, Michigan State University, East Lansing, MI and ²Office of Epidemiology, Peruvian National Institute of Mental Health, Lima, Peru

PSYCHIATRIC COMORBIDITY I

105 Validation and comparison of screening tools for mental disorders in substance abusers
B.R. Rush¹, S. Castel², B. Brands³ and T. Toneatto¹, ¹Health Systems Research and Consulting Unit, Centre for Addiction and Mental Health, Toronto, ²Whitby Mental Health Centre, Oshawa, and ³Health Canada, Ottawa, ON, Canada

106 Personality disorder diagnoses and psychotherapy outcome in a residential therapeutic community
S. Ball¹², L. Maccarelli²³¹, D. LaPaglia² and M. Ostrowski², ¹The APT Foundation, and ²Psychiatry, Yale School of Medicine, New Haven, CT

107 Psychiatric diagnosis, inner resources, and their relations to patients' outcome in methadone maintenance treatment
Y. Abramsohn, D. Potik, E. Peles, S. Schreiber and M. Adelson, Adelson Clinic, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

108 Appropriately identifying mental health services needs among minority substance abuse clients
C.N. Martin, A.A. Mericle and D. Carise, Treatment Research Institute, Philadelphia, PA

109 Comorbidity among drug users presenting to an emergency department
A.J. Sheer¹, J. Hirshon² and D. Gorelick¹, ¹NIDA, NIH, and ²University of Maryland School of Medicine, Baltimore, MD

110 Referenced-EEG guided pharmacotherapy of dual diagnosis patients
M.J. Schiller¹, J.H. Shaffer² and J.E. Milner², ¹University of California, San Francisco, San Francisco, and ²Rancho L'Abri, Dulzura, CA

111 ASPD and distress tolerance: The role of psychopathic traits in a substance use treatment-seeking sample
M.N. Sargeant, S.B. Daughters, R. Schuster, S. Gorka and C.W. Lejuez, Psychology, University of Maryland, College Park, College Park, MD

112 Stress, health-related quality of life and DSM-IV substance abuse and dependence in young, low-income women
H. Wu, C. Holzer, J.J. Grady and A.B. Berenson, University of Texas Medical Branch, Galveston, TX

113 Treatment outcomes for women and men offenders with comorbid mental disorders
D. Jiang¹, Y.Y. Hser² and D. Huang², ¹Shanghai Mental Health Center, Shanghai, China and ²ISAP, Los Angeles, CA
114 Social and mental health correlates of female inmates in the Puerto Rico prison system with lifetime drug use disorder and likely post traumatic stress disorder
   A. Hernandez and C.E. Albizu-Garcia, Center for Evaluation and Sociomedical Research, UPR-Medical Sciences Campus, San Juan, PR

115 Trauma, health problems and depression in drug-dependent women
   S. Meshberg-Cohen, D. Nilson, C. Smith and D. Svikis, Psychology, Virginia Commonwealth University, Richmond, VA

116 Co-morbid psychiatric and substance use disorders among African American women at high risk for HIV
   H.L. Surratt and J.A. Inciardi, Center for Drug & Alcohol Studies, University of Delaware, Coral Gables, FL

117 HIV risk behaviors and PTSD: Secondary findings from a NIDA Clinical Trials Network randomized controlled trial of women in community-based substance abuse treatment
   D. Hien¹, T. Killeen², A. Campbell¹ and E. Nunes³, ¹Columbia University School of Social Work, Columbia University, New York, NY ²Psychiatry, Medical University of South Carolina, Charleston, SC and ³Columbia University and New York State Psychiatry Institute, New York, NY

118 Client's drug treatment satisfaction: Posttraumatic stress disorder and perceived health
   J. Astone-Twerell¹, K. Morgen², T. Hermitche¹, J. Montbach³, T. Varela⁴ and E. Friedman⁴, ¹Research Division, Samaritan Village, Inc., Briarwood, ³Palladia Inc., Bronx, and ⁴Project Samaritan Inc., Bronx, NY ²and Psychology, Monmouth University, Monmouth, NJ

119 A randomized controlled trial of an integrated treatment for substance use and PTSD incorporating exposure therapy: Preliminary findings
   K.L. Mills¹, M. Teesson¹, S. Back⁴, A. Baker², S. Hopwood³, K. Brady⁴ and C. Sannibale¹, ¹National Drug and Alcohol Research Centre, U. of New South Wales, Sydney, ²Centre for Mental Health Studies, U. of Newcastle, Newcastle, ³Centre for Traumatic Stress, Westmead Hospital, Sydney, NSW, Australia and ⁴Psychiatry, Medical U. of SC, Charleston, SC

120 Substance use disorders, chronic pain, and specific depressive symptoms predict suicidality in individuals with major depression
   J.S. Potter¹, L.B. Potter², K. Prather¹ and R.D. Weiss¹, ¹McLean Hospital, Belmont, MA and ²Education Development Center, Newton, MA

121 Trust in social network and risk of suicidality among drug users with depressive symptoms
   P. Chatterjee, S.G. Severtson and C. Latkin, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

122 Recent marijuana, ecstasy and methamphetamine use not associated with depressive symptoms in a community-based urban population
   I. Kuo³, M. Magnus¹, A.L. Rawls¹, J.A. Peterson¹, K.D. Shelley¹, T. West-Ojo², S. Hader², F. Hamilton³ and A.E. Greenberg¹, ¹Epidemiology and Biostatistics, George Washington University School of Public Health, ²HIV/AIDS Administration, District of Columbia Department of Health, and ³Family and Medical Counseling Services, Inc., Washington, DC
HIV/HCV II

123 Development of a novel behavioral activation intervention for depressed, HIV positive, African American substance users—ACT HEALTHY
J. Magidson, R. Schuster and S.B. Daughters, Psychology, University of Maryland, College Park, College Park, MD

124 Adherence during an HIV vaccine clinical trial: High risk drug-using women
J. Becher, S. Chhatre, M. Eisenberg, D. Fiore, D. Dunbar, I. Frank, G. Woody and D. Metzger, University of Pennsylvania, Philadelphia, PA

125 Methamphetamine-related immune system changes in methamphetamine-dependent participants
J. Zhuo, K. Whittaker, R. De La Garza, T.F. Newton and G.C. Baldwin, Psychiatry, and Medicine-Hematology & Oncology, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA

126 Differential incidence of HIV and syphilis between male and female drug users in southwest China
C. Hao, G.M. Qin, H.Z. Qian, Y.H. Ruan, J.L. Zhu, L. Yin, K.L. Chen, S. Liang, H. Xing, K.X. Hong and Y.M. Shao, China CDC, Beijing, The Chinese University of Hong Kong, Hong Kong, Sichuan CDC, Chengdu, and Xichang Center for STD and Leprosy Control, Xichang, China and Vanderbilt University School of Medicine, Nashville, TN

127 Longitudinal trajectories of HIV risk behaviors among methamphetamine users
D. Murphy, M. Brecht, D. Herbeck, E. Evans, L. Li and M. Hillhouse, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA

128 A comparison of two intervention modalities to reduce HIV risk behavior among chronic drug users
C.B. McCoy, V. DeGruttola and M. Comerford, Epidemiology and Public Health, University of Miami, Miami, FL and Harvard University, Cambridge, MA

129 Use of a peer leader intervention model to reduce needle-related risk behaviors among drug injectors in Ukraine

130 WHO collaborative study on substitution therapy of opioid dependence and HIV/AIDS
R. Ali and W. WHO Opioid Substitution Therapy Study Group, WHO Collaborating Centre for Research in the Treatment of Drug and Alcohol Problems, University of Adelaide, Adelaide, SA, Australia

131 Mixed drug use influences HIV risk in Ukrainian IDUs
K. Dumchev, J.E. Schumacher, O. Zezyulin, P. Slobodyanyuk and L. Moroz, Vinnitsya Regional Narcological Dispensary, Vinnitsya, Ukraine, University of Alabama at Birmingham, Birmingham, AL and Vinnitsya National Pirogov Medical University, Vinnitsya, Ukraine

132 Risk behaviors of HIV + and HIV - out-of-treatment IDUs in Malaysia
M.C. Chawarski, M. Mazlan, B. Vicknasingam and R. Schottenfeld, Psychiatry, Yale University School of Medicine, New Haven, CT, Substance Abuse Research Centre, Muar, Malaysia and Centre for Drug Research, University Sains Malaysia, Penang, Malaysia
A comparison of social networks and injection risk behaviors among injection drug users in St. Petersburg, Russia and the Ukraine
C. Latkin, A. Gyarmathy, R. Booth, A. Kozlov, HBS, Johns Hopkins University, Baltimore, MD, Biomedical Institute, St. Petersburg, Russian Federation and Psychiatry, School of Medicine, Denver, CO

Concurrency of sexual and injection risk among new heroin injectors
L.A. Goldsamt and M.C. Clatts, IIRYAR, NDRI, New York, NY and School of Public Health, University of Puerto Rico, San Juan, PR

Feasibility of expanded services for pharmacy IDU syringe customers
N.D. Crawford, K. Standish, D. Vlahov and C.M. Fuller, Center for Urban Epidemiologic Studies, New York Academy of Medicine, and Mailman School of Public Health, Columbia University, New York, NY

Developmental epidemiology and prevention of drug disorders and HIV sexual risk behavior
A.M. Windham, S. Kellam, J. Poduska, C.H. Brown and N. Ialongo, American Institutes for Research, Baltimore, MD, University of South Florida, Tampa, FL and Johns Hopkins University, Baltimore, MD

Teaching condom use skills: Practice is superior to observation

Predictors of condom use among drug-abusing women involved in sex trade in Baltimore, MD
C.H. Salama, A. Nandi, A. Lawson, L. Floyd and W. Latimer, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Drug use, sex, and women's risky relationships

Sex trade behavior among injection and non-injection drug users in Baltimore, MD
B.E. Mancha, D.E. Whitaker and W.W. Latimer, Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

HIV risk among treatment-seeking marijuana, cocaine and opioid users
B.R. Bryan, D.J. Brooks, J.J. Mariani and F.R. Levin, Division on Substance Abuse, Columbia University, and New York State Psychiatric Institute, New York, NY

Alcohol and substance use among persons engaged in HIV prevention in a community mental health center
M.B. Blank, D.S. Metzger, S. Eachus, J. Tennille, T. Ten Have, P. Solomon and M.M. Eisenberg, Psychiatry, University of Pennsylvania, Philadelphia, PA

Methods for estimating dynamical risk factors for HIV spread on sexual and drug-injecting networks
G. Bobashev, R.J. Morris, E. Costenbader and W. Zule, RTI International, Durham, NC

Sexual risk factors: Rates and reliability among ecstasy users
E. Shacham and L.B. Cottler, Psychiatry, Washington University School of Medicine, St. Louis, MO
A comparison of HIV prevalence among MSM and MSMW within a sample of drug users in Los Angeles
C. Hucks-Ortiz¹, J. Wang¹, S. Larkins¹, P. Gorbach² and S. Shoptaw¹, ¹Family Medicine, University of California-Los Angeles and ²Epidemiology, University of California-Los Angeles School of Public Health, Los Angeles, CA

Factors associated with stimulant use during sex in a low-income sample of men who have sex with men
A. Ober¹², S. Shoptaw³, J. Wang³ and P. Gorbach⁴, ¹Social Welfare, University of California-Los Angeles School of Public Affairs, Los Angeles, ²RAND Corporation, Santa Monica, ³Family Medicine, David Geffen School of Medicine and ⁴Epidemiology, University of California-Los Angeles School of Public Health, Los Angeles, CA

Women who have sex with women: HIV risk behaviors and perceived HIV risk
J. Mooney¹, J. Havens¹, C. Oser¹, J. Duvall¹, M. Staton-Tindall¹, C. Leukefeld¹, J. Inciardi², J. Clarke³ and L. Frisman⁴, ¹University of Kentucky, Lexington, KY, ²University of Delaware, Newark, DE, ³Brown University, Providence, RI and ⁴University of Connecticut, Storrs, CT

SUBSTANCE ABUSE IN ADOLESCENTS I

Gender differences in HIV risk behaviors among adolescents in substance abuse treatment
Y. Chan¹, L.L. Passetti¹, J. Lloyd², B.R. Garner¹ and M.L. Dennis¹, ¹Chestnut Health Systems, Bloomington, IL and ²School of Social Administration, Temple University, Philadelphia, PA

Gender differences in risky behaviors among inpatient adolescents
A. Clark, N. Johnson, C. Merritt and D. Deas, Psychiatry, Medical University of South Carolina, Charleston, SC

Perceived harmfulness of drugs and its association with drug use: Young men and women in Bogotá, Colombia see and do things differently
C. Lopez and Y. Neumark, School of Public Health, Hebrew University of Jerusalem, Jerusalem, Israel

Risk behaviors and risk trajectories among young injection drug users
S.E. Lankenau¹², K. Wagner², J. Jackson Bloom², B. Sanders¹² and D. Hathazi², ¹Pediatrics, University of Southern California, and ²Saban Research Institute, Childrens Hospital Los Angeles, Los Angeles, CA

Availability of HIV-related services in adolescent substance abuse treatment programs
H. Knudsen, Behavioral Science, University of Kentucky, Lexington, KY

Relationship between HIV risk behaviors and suicide risk among youth in substance abuse treatment
J.J. Lloyd¹, M.L. Dennis², M. Ives², J. Blanchette² and Y.F. Chan², ¹School of Social Administration, Temple University, Philadelphia, PA and ²Chestnut Health Systems, Bloomington, IL

The intranasal heroin epidemic among Latino adolescents in Texas: They're calling it "cheese"
C.F. Tirado¹, J.C. Maxwell² and B.A. Adinoff³, ¹Psychiatry, UT-Southwestern, Dallas, TX and ²UT-Austin, Austin, TX

Prevalence of muscle-building substances among students
V. Agulló¹, S. Tomás², E. Gómez¹, M.J. Torrijos², A. Vidal², C. Morales¹, R. Aleixandre¹, J.C. Valderrama¹ and J.C. Pérez de los Cobos³, ¹IHCD López Piñero, and ²Fundació per a l'Estudi, Prevenció i Assistència Drogues, FEPAD, València, and ³Hospital Santa Creu i Sant Pau, Barcelona, Spain
Efficacy of an online substance use prevention program for early adolescents
S.E. Lord\textsuperscript{1}, D. D'Amante\textsuperscript{1}, K. Clements\textsuperscript{2} and K. Trudeau\textsuperscript{1}, \textsuperscript{1}Inflexxion, Newton, MA and \textsuperscript{2}Department of Public Health, Boston, MA

Adolescent substance use and condom use in first and recent sexual encounters
B. Beadnell\textsuperscript{2}, D.M. Morrison\textsuperscript{2}, M.J. Hoppe\textsuperscript{2} and B.C. Leigh\textsuperscript{1}, \textsuperscript{1}Alcohol and Drug Abuse Institute, and \textsuperscript{2}School of Social Work, University of Washington, Seattle, WA

Substance use and sexually transmitted infection among young adults in the United States
M.R. Khan, National Development and Research Institutes, New York, NY

Family health and neighborhood satisfaction as a context for motivated learning among urban African American adolescents at risk for drug use
D. Whitaker, G.S. Severtson and W. Latimer, Mental Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD

The relationship between emotional abuse, disinhibition, and substance use and risk-taking behavior in a community sample of young adolescents
F.L. Wang, E.K. Reynolds, M.S. Duplinsky, M. Bornovalova, L. MacPherson and C.W. Lejuez, University of Maryland, College Park, College Park, MD

Sexual maturation, peer delinquency, and drug use in daughters of substance use disorder fathers from childhood to adolescence
A.C. Mezzich, L. Kirisci, M. Vanyukov, G. Kirillova and T. Ridenour, Pharmacy, University of Pittsburgh, Pittsburgh, PA

Does childhood abuse history impact outcomes among homeless youth receiving substance abuse treatment?
N. Slesnick, S. Bartle-Haring, A. Khurana and D. Bantchevska, The Ohio State University, Columbus, OH

Psychobiological correlates of childhood neglect and parental care perception in cocaine addicts
G. Gerra\textsuperscript{123}, C. Leonardi\textsuperscript{2}, M.A. Raggi\textsuperscript{2}, A. Busse\textsuperscript{1}, J. Tomás-Rosselló\textsuperscript{1}, E. Saen-Miranda\textsuperscript{1}, S. Berterame\textsuperscript{1} C. Donnini\textsuperscript{4}, \textsuperscript{1}Global Challenges Sect., UNODC, Vienna, Austria, \textsuperscript{2}Dipendenze, ASL Roma C, Rome, \textsuperscript{3}Scienze Farmaceutiche, U. degli Studi di Bologna, Rome, \textsuperscript{4}Genetica Biologia dei Microorganismi Antropologia Evoluzione, U. degli Studi di Parma, Parma, Italy

Adolescent patients with conduct and substance problems and adolescent controls: Examining perpetrator type and physical and sexual abuse
E.F. Upwood, S.K. Mikulich-Gilbertson and T.J. Crowley, Division of Substance Dependence, Psychiatry, University of Colorado School of Medicine, Denver, CO

Adolescent patients with serious substance and conduct problems and siblings: Directives for retained DNA
M.E. Coors\textsuperscript{1}, K.M. Raymond\textsuperscript{2}, S.K. Mikulich-Gilbertson\textsuperscript{2}, S.K. Stover\textsuperscript{2} and T.J. Crowley\textsuperscript{2}, \textsuperscript{1}Center for Bioethics, University of Colorado at Denver School of Medicine, and \textsuperscript{2}Division of Substance Dependence, Psychiatry, University of Colorado at Denver, Denver, CO

Adolescents with attention deficit disorder and co-occurring substance use disorders: Referral sources and recruitment in a multi-site clinical trial
G. Bailey\textsuperscript{3}, W. Jaffee\textsuperscript{1}, R. Weiss\textsuperscript{1}, M. Lohman\textsuperscript{2} and P. Riggs\textsuperscript{3}, \textsuperscript{1}ADATP, Harvard Medical School, McLean Hospital, Belmont, MA, \textsuperscript{2}Psychiatry, University of Colorado School of Medicine, Denver, CO and \textsuperscript{3}Stanley Street Treatment and Resources, Fall River, MA

One-year post-treatment follow-up in adolescents treated for depression and substance abuse
P. Riggs, S.K. Mikulich-Gilbertson, M. Lohman, C. Klein, R. Davies and S. Stover, Psychiatry, University of Colorado School of Medicine, Denver, CO
The effectiveness of an integrated CBT intervention for co-occurring depression and substance misuse in young people
L. Hides¹, D.I. Lubman¹, S. Carroll¹, L. Catania¹, N. Allen¹, F. Kay-Lambkin² and A. Baker²,
¹ORYGEN Research Centre, Psychiatry, University of Melbourne, Melbourne, VIC, and
²Centre for Mental Health Studies, University of Newcastle, Newcastle, NSW, Australia

Self-efficacy mediates the relationship between depression and length of abstinence after treatment in youth but not adults
D. Ramo¹² and S.A. Brown³⁴, ¹Psychiatry, UCSF, San Francisco, ²SDSU/UCSD Joint Doctoral Program in Clinical Psychology, San Diego, ³Psychology & Psychiatry, UCSD, and
⁴VASDHS, La Jolla, CA

Brief intervention for drug-abusing adolescents
K. Winters, ¹Psychiatry, University of Minnesota, Minneapolis, MN and ²Treatment Research Institute, Philadelphia, PA

Effective thresholds of adolescent self-help meeting attendance and their predictors
L. Passetti, M.L. Dennis, R. Funk, S.H. Godley and M.D. Godley, Chestnut Health Systems, Bloomington, IL

Findings from the Strengthening Communities for Youth initiative: A cluster analysis of services received, their correlates, and how they are associated with outcomes
M.K. White, M.L. Dennis and M. Ives, Chestnut Health Systems, Bloomington, IL

Exposure to A-CRA treatment procedures as a mediator of the relationship between adolescent substance abuse treatment retention and outcome
B. Garner, S.H. Godley, R. Funk, M. Dennis and M.D. Godley, Chestnut Health Systems, Bloomington, IL

Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults
M.P. Bogenschutz¹², R. Kushner¹², J.S. Tonigan² and G.E. Woody³, ¹Psychiatry, and
²CASAA, University of New Mexico, Albuquerque, NM and ³TRI, University of Pennsylvania, Philadelphia, PA

Impact of therapeutic alliance on treatment outcome in opioid-dependent adolescents and young adults treated with buprenorphine
A.A. Forcehimes¹, M.P. Bogenschutz¹, J.S. Tonigan¹ and G.E. Woody², ¹CASAA, University of New Mexico, Albuquerque, NM and ²University of Pennsylvania, Philadelphia, PA

Changes in 12-step cognitions and practices among treatment-seeking adolescents
J.S. Tonigan, A.A. Forcehimes and M.P. Bogenschutz, CASAA, University of New Mexico, Albuquerque, NM

Art and Addiction Exhibition
Flamingo
9:00 AM - 6:00 PM
Symposium VIII

THE CONSEQUENCES OF CHRONIC CANNABIS ABUSE: FROM NEUROCHEMISTRY TO TREATMENT

Chair: Philip Terry

10:00  Cognitive and neural consequences of chronic cannabinoid exposure: Evidence from animal studies
       Paul Mallet, Wilfrid Laurier University, Waterloo, Ontario, Canada

10:25  The effects of chronic cannabis use on cognition, and the brain changes associated with altered psychological function
       Deborah Yurgelun-Todd, McLean Hospital, Belmont, MA

10:50  Long-term cannabis use and the risk of psychosis and other mental health problems
       Louisa Degenhardt, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia

11:15  The impacts of long-term cannabis use on the everyday lives of recreational users
       Philip Terry, Kingston University, Surrey, UK

11:40  Cannabis use, addiction, and treatment
       Alan J. Budney, University of Arkansas, Center for Addiction Research, Little Rock, AR

Symposium IX

NEONATAL RESPONSES TO MATERNAL SUBSTANCE USE

Chairs: Karol Kaltenbach and Loretta Finnegan

10:00  Neonatal abstinence resulting from in-utero exposure to opioids/opiates: Assessment and determination of treatment
       Karol Kaltenbach, Thomas Jefferson University, Philadelphia, PA

10:20  Effects of in-utero cocaine exposure on growth and neurobehavior of the neonate
       Emmalee Bandstra, University of Miami School of Medicine, Miller School of Medicine, Miami, FL

10:40  Adverse effects on gestational and neonatal outcomes: Contributions from depression and antidepressant drugs
       Katherine Wisner, Western Psychiatric Institute and Clinic, Pittsburgh, PA
Oral Communications 7

ALL BOTTLED UP: TREATMENTS FOR ALCOHOL DEPENDENCE AND PSYCHIATRIC COMORBIDITY

Chairs: Kyle Kampman and Ihsan Salloum

11:15 Initiating acamprosate within versus post-detoxification in the treatment of alcohol dependence

11:30 Safety of atomoxetine in ADHD patients with or without comorbid alcohol abuse and dependence
L. Adler¹, T. Wilens², S. Zhang³, T. Durell¹, D. Walker³, L. Schuh³ and P. Trzepacz³,
¹New York University School of Medicine, New York City, NY, ²Harvard Medical School, Boston, MA and ³Eli Lilly and Company, Indianapolis, IN

11:45 Does alcohol use precipitate depression among patients with co-occurring bipolar and substance use disorders?
W. Jaffee¹, M. Griffin¹, R. Gallop², C. Meade¹, F. Graff³, R. Bender³, R. Weiss¹, ¹ADATP, Harvard Medical School, McLean Hosp., Belmont, MA, ²Math and Statistics, West Chester U. of PA, West Chester, and ³Psychology, Temple University, Philadelphia, PA, and ⁴Grad. School of Applied and Professional Psychology, Rutgers University, New Brunswick, NJ

12:00 Advantage of an integrated individual psychotherapy over treatment-as-usual for comorbid bipolar and addictive disorders: Results from a randomized pilot study
I.M. Salloum¹, A.B. Douaihy², T.M. Kelly², J.R. Cornelius² and L. Kirisci³, ¹Psychiatry, University of Miami Leonard M. Miller School of Medicine, Miami, FL, ²Psychiatry, University of Pittsburgh School of Medicine, and ³Pharmacy, University of Pittsburgh, Pittsburgh, PA

Symposium X

FUNCTIONAL AND CLINICAL RELEVANCE OF OPIOID RECEPTOR HETERODIMERS

Chair: Philip S. Portoghese

10:00 Opioid receptor heterooligomers: Distinct pharmacological signaling units
Susan R. George, University of Toronto, Toronto, ON, Canada

10:20 Behavioral studies in rodents on analgesics that mediate their effects via heterodimeric opioid receptors
Sandra Roerig, Louisiana State University Health Sciences Center, Shreveport, LA

10:40 Identification of clinically employed analgesics whose pharmacology is mediated through putative heterodimeric opioid receptors
Ajay Yekkirala, University of Minnesota, Minneapolis, MN
Oral Communications 8

BONDING WITH CHEMISTRY

Chairs: Herbert Seltzman and Fred Nyberg

11:15 Atropisomers as conformational probes of the human hCB1 cannabinoid receptor
   H.H. Seltzman, M.F. Brackeen, D.J. Watkins, J.P. Burgess, A.F. Gilliam, Y. Zhang,
   B.F. Thomas, T.L. Langston and H.A. Navarro, Center for Organic and Medicinal Chemistry,
   RTI International, Research Triangle Park, NC

11:30 Molecular modeling-guided elucidation of dopamine transporter ligand binding sites:
   Development of an in silico "cocaine antagonist" screening tool
   C.K. Surratt1, M. Indarte1, J.D. Madura2, Y. Liu1 and Y. Huang1, 1Pharmaceutical Sciences,
   and 2Chemistry and Biochemistry, Duquesne University, Pittsburgh, PA

11:45 Discovery of a selective sigma-2 receptor ligand and the potential involvement of sigma-2
   receptors in cocaine toxicity
   C.R. McCurdy1,2, C. Mesangeau1, S. Narayanan1, J. Shaikh2, N. Kaushal2, R.R. Matsumoto3
   and J.H. Poupaert3, 1Medicinal Chemistry, and 2Pharmacology, University of Mississippi,
   University, MS and 3Catholic University of Louvain, Brussels, Belgium

12:00 The Substance P system as a target in the development of peptidomimetics acting as drugs for
   treatment of opioid addiction
   F.J. Nyberg, Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

Oral Communications 9

SEX DIFFERENCES WITH COCAINE

Chairs: Steve Kohut and Michael Mancino

10:00 Sex and rearing condition affect generalization to direct and indirect dopamine agonists in adult
   rats discriminating cocaine
   S.J. Kohut1, K.C. Rice2 and A.L. Riley1, 1American University, Washington, DC, and
   2NIDDK, Bethesda, MD

10:15 Sex differences in non-reinforced responding for cocaine
   T.A. Kosten and X.Y. Zhang, Psychiatry, Baylor College of Medicine, Houston, TX

10:30 Age and sex alter sensitivity to cocaine-conditioned reward in rats
   E. Zakharova, I. Kichko, G. Leoni and S. Izenwasser, Psychiatry, University of Miami Miller
   School of Medicine, Miami, FL

10:45 Differential effect of estrous cycle on cocaine-primed reinstatement to food- and cocaine-
   seeking
   K.A. Kerstetter, V.R. Aguilar, A.B. Parrish and T.E. Kippin, Psychology, UCSB, Goleta, CA

11:00 Neural correlates of stress-induced and cue-induced craving: Effects of gender and cocaine
   dependence
   M.N. Potenza1, K.A. Hong1, C.M. Lacadie2, R.K. Fulbright2, C.R. Li1, K.L. Bergquist1 and
   R. Sinha1, 1Psychiatry, and 2Diagnostic Radiology, Yale School of Medicine, New Haven, CT
**Tuesday, June 17, 2008**

11:15  *HPA axis responding in cocaine-dependent males and females*  
M. Moran-Santa Maria, A.L. McRae, S.E. Back, A.E. Waldrop, S.M. DeSantis, 
H.P. Upadhyaya, M.E. Saladin and K.T. Brady, Psychiatry and Behavioral Neurosciences, 
Medical University of South Carolina, Charleston, SC

11:30  *Early and later abstinence in cocaine pharmacotherapy trials: Importance of gender in predicting treatment outcome*  
J.G. Plebani, K.M. Kampman, K.G. Lynch, H.M. Pettinati and C.P. O'Brien, Psychiatry, 
University of Pennsylvania, Philadelphia, PA

11:45  *Gender differences in response to disulfiram treatment for cocaine dependence in methadone-stabilized opioid- and cocaine-dependent individuals*  
M.J. Mancino, Z. Feldman and A. Oliveto, Psychiatry, University of Arkansas for Medical 
Sciences, Little Rock, AR

**Late-Breaking Research News**

San Cristobal  
12:15 - 1:30 PM

Chair: Sari Izenwasser

**Art and Addiction Exhibition**

Flamingo  
1:15 - 2:45 PM

**THE NARCOTIC FARM: FACTS AND FICTIONS**

Nancy D. Campbell

**Grant-Writing Workshop**

Las Olas  
1:15 - 5:00 PM

(Pre-Registrants Only)

**Workshop VIII**

San Geronimo A  
8:00 - 10:00 PM

**14TH ANNUAL CONTINGENCY MANAGEMENT WORKING GROUP**

Chairs: Stacey Sigmon and Kelly Dunn
Workshop IX

WHAT'S NEW AT NIDA AND NIH: A PEEK INTO THE BLACK BOX

Chairs: Nadine Rogers, Eliane Lazar-Wesley, Kristen Huntley and Mark Swieter

Workshop X

INNOVATIVE TECHNOLOGY TRANSFER AND INFORMATION DISSEMINATION STRATEGIES: RESULTS FROM FIVE ATTC-SPONSORED INITIATIVES

Chairs: Anne Helene Skinstad and Paula K. Horvatich

The Native American cultural education program for non-native counselors: An innovative project that examines the impact of training on counselors and their Native American clients
Duane H. Mackey, University of South Dakota, Vermillion, SD

The United Nations project: Utilizing the TOT model and continuing consultation to promote the adoption of EBPs internationally
Thomas Freese, Pacific Southwest ATTC, University of California Los Angeles, Los Angeles, CA

Where’s the neuroscience in our undergraduate and graduate programs? A survey of addiction educators across the United States
Nancy A. Roget, University of Nevada-Reno, Reno, NV

Training tips and lessons learned from the toolbox training programs: Promoting the adoption of EBPs in Iowa’s community-based treatment provider system
Anne-Helene Skinstad, Prairelands ATTC, Iowa City, IA

Implementing motivational interviewing utilizing clinical supervisors in community treatment agencies: A review of performance implementation/integration, resources and associated costs
Paula K. Horvatich, Mid-Atlantic ATTC, Virginia Commonwealth University, Richmond, VA
Workshop XI

San Cristobal
8:00 - 10:00 P.M.

CLINICAL TRIALS OF DRUG ABUSE
PHARMACOTHERAPIES: TOOLS AND STRATEGIES TO ENSURE COMPLIANCE WITH CURRENT REGULATIONS

Chairs: Robert L. Walsh and Ivan D. Montoya

What's coming down the pike from the FDA?
Robert Walsh, NIDA, Bethesda, MD

How to comply with NIH policies for grants involving clinical trials
Ivan D. Montoya, NIDA, Bethesda, MD

Investigator's strategies to cope with clinical trial requirements
Frances Levin, Columbia University, New York, NY

Regulatory pitfalls observed in pharmacotherapy grant applications and how to avoid them
Eric C. Strain, Johns Hopkins University School of Medicine, Baltimore, MD

A Web-based tool for collecting and reporting serious adverse events
Robert L. Walsh and Ivan D. Montoya, NIDA, Bethesda, MD

Discussion

Movie
Auditorium
8:00 PM

DAYS OF WINE AND ROSES
featuring Jack Lemmon and Lee Remick
POSTER SESSION III

Odd-numbered posters manned first hour;
Even-numbered, second hour

Set-up time begins Tuesday 1:00 PM
Must be removed by Wednesday 12:00 NOON

GENETICS

1. Prospective study of genetics informed consent rates for local study and also sharing with a national repository
   B. Ray¹, C. Jackson¹, R. Raugei¹, E. Ducate¹, D. Melia¹, P. Casadonte²,³, J. Rotrosen²,³, S. Linzy⁴, M. Adelson¹,⁴, and M.J. Kreek¹, ¹Biology of Addictive Diseases, Rockefeller University, ²VA Medical Center, NY Harbor Healthcare Sys, and ³NYU Sch. of Med., NY, NY and ⁴Adelson Clinic for Drug Abuse, Treatment and Research, Las Vegas, NV

2. Genetic variations affecting susceptibility to develop heroin addiction
   O. Levran¹, D. Londono², K. O’Hara¹, D.A. Nielsen¹, E. Peles³, J. Rotrosen⁴,⁵, P. Casadonte⁴,⁵, S. Linzy⁴, M. Randesi¹, J. Ott², M. Adelson³, M. Kreek¹, ¹Biol. of Addictive Dis., and ²Stat. Gen. Labs, Rockefeller U., ³VA NY Harbor Healthcare System, and ⁴Sch. Med., NYU, NY, NY, ³,⁶Adelson Clinic, Sourasky Med. Ctr, Tel Aviv, Israel and Las Vegas, NV

3. Pharmacogenomic study of opioid addicts non-responders to methadone treatment: Preliminary results
   F. Fonseca¹, A. Pastor², K. Langohr³, R. Martín-Santos¹,², M. Farre²,⁴, R. de la Torre²,³ and M. Torrens¹,², ¹Drug Addiction Unit, IAPS and, ²Pharmacology Unit, IMIM-Hospital del Mar, ³Experimental and Health Sciences, Pompeu Fabra U., ⁴Pharmacology and Psychiatry, Universitat Autònoma de Barcelona, ⁵Universitat Autònoma de Barcelona, Barcelona, Spain

4. A haplotype implicated in cocaine dependence susceptibility is associated with reduced PDYN expression in human brain
   V. Yuferov¹, F. Ji¹, S. Morgello², A. Ho¹, J. Ott¹ and M.J. Kreek¹, ¹The Rockefeller University, and ²Mount Sinai Medical Center, New York, NY

5. Citalopram and 5HT TC102: A Bayesian analysis
   C.E. Green³, F.G. Moeller¹, J.M. Schmitz¹ and D. Guo², ¹Psychiatry, ²Internal Medicine, and ³Pediatrics, University of Texas, Houston, TX

6. Sexual dimorphism in the effects of Homer 1a deletion upon the behavioral response to acute, but not repeated, cocaine
   A.W. Ary¹, M.C. Datko¹, P.F. Worley² and K.K. Szumlinski¹, ¹Psychology, University of California at Santa Barbara, Santa Barbara, CA and ²Neurosciences, The Johns Hopkins University School of Medicine, Baltimore, MD

7. Effect of matrix metalloproteinase 9 gene expression on methamphetamine neurotoxicity
   Y. Liu¹, S. Brown², J. Shaikh², J.A. Fishback² and R.R. Matsumoto¹,², ¹University of Oklahoma HSC, Oklahoma City, OK and ²University of Mississippi, University, MS
8 Genetic vulnerability in alcohol intake relates to accumbens Homer expression and alcohol-induced neurochemical sensitization
Z. Kapasova\textsuperscript{1}, S.P. Goulding\textsuperscript{2}, I. Obara\textsuperscript{2} and K.K. Szumlinski\textsuperscript{2}, \textsuperscript{1}Behavioral Neuroscience, Oregon Health and Science University, Portland, OR and \textsuperscript{2}Psychology, University of California at Santa Barbara, Santa Barbara, CA

9 Altered pharmacokinetics of delta-9-tetrahydrocannabinol in CF-1 mice deficient in mdr1a P-glycoprotein
A. Benyamina\textsuperscript{1}, L. Bonhomme-Faivre\textsuperscript{2}, M. Reynaud\textsuperscript{1}, R. Farinotti\textsuperscript{3} and C. Abbara\textsuperscript{2}, \textsuperscript{1}Psychiatry, and \textsuperscript{2}Pharmacology, Paul Brousse Hospital, Villejuif, and \textsuperscript{3}Faculty of Pharmacy, University of Paris XI, Chatenay-Malabry, France

10 Detection of significant association of ANKK1 and of a functional polymorphism with nicotine dependence in African American population
M.D. Li\textsuperscript{1}, W. Huang\textsuperscript{1}, J.Z. Ma\textsuperscript{2} and T.J. Payne\textsuperscript{3}, \textsuperscript{1}Psychiatry and Neurobehavioral Sciences, and \textsuperscript{2}Public Health Sciences, University of Virginia, Charlottesville, VA and \textsuperscript{3}ACT Center, University of Mississippi Medical Center, Jackson, MS

IMAGING

11 Imaging of GABA-A benzodiazepine receptor availability in men and women smokers and nonsmokers: Relationship with subsyndromal anxiety and depression
J. Batis\textsuperscript{1}, I. Esterlis\textsuperscript{1}, K.P. Cosgrove\textsuperscript{1}, F. Bois\textsuperscript{1}, S. Stiklus\textsuperscript{1}, T.A. Kloczynski\textsuperscript{1}, E. Perry\textsuperscript{1}, G.D. Tamagnan\textsuperscript{2}, J.P. Seibuyl\textsuperscript{3}, S. Krishnan-Sarin\textsuperscript{1}, S. O'Malley\textsuperscript{1} and J.K. Staley\textsuperscript{1}, \textsuperscript{1}Psychiatry, Yale School of Medicine, West Haven, CT and \textsuperscript{2}Molecular Neuroimaging, New Haven, CT

12 Arterial spin labeling imaging study of IV nicotine administration: Evidence of neurovascular decoupling?
D. Olson, M. Rohan, N. Goletiani, E. Habecker, D. Keith, P. Renshaw and N. Mello, Brain Imaging Center, McLean Hospital, Belmont, MA

13 The correlation between cue-induced craving for Internet video game play and brain activation
D. Han\textsuperscript{1,2}, M.A. Daniels\textsuperscript{1}, N. Bolo\textsuperscript{1}, L. Arenella\textsuperscript{3}, I. Lyoo\textsuperscript{4,1} and P.F. Renshaw\textsuperscript{1}, \textsuperscript{1}Brain Imaging Center, McLean Hospital, Belmont, and \textsuperscript{2}Natural Science, Bentley College, Waltham, MA, \textsuperscript{3}Chung Ang University Hospital, Seoul, and \textsuperscript{4}Psychiatry, Seoul National University Hospital, Seoul, South Korea

14 Brain activation in preadolescent with low vs. high risk for subsequent substance abuse
I. Ivanov, S. Clerkin, K. Schulz, J. Fan, J. Halperin and J. Newcorn, Mt. Sinai School of Medicine, New York, NY

15 Addictive behavior is associated with changes in putamen dopaminergic function
C.E. Wilcox\textsuperscript{3}, M.N. Braskie\textsuperscript{1}, J.T. Kluth\textsuperscript{1}, J. Mitchell\textsuperscript{2}, H.L. Fields\textsuperscript{2,1} and W.J. Jagust\textsuperscript{13}, \textsuperscript{1}UC Berkeley, Berkeley, \textsuperscript{2}EGCRC, Emeryville, and \textsuperscript{3}UCSF, San Francisco, CA

16 Volumetric analysis of the striatum in methamphetamine abusers in early abstinence
B. Lee\textsuperscript{1}, M. Tobias\textsuperscript{1}, S. Chakrapani\textsuperscript{1}, A.V. Bakuris\textsuperscript{1}, J. O'Neil\textsuperscript{1}, J. Monterosso\textsuperscript{1}, R.A. Poldrack\textsuperscript{24} and E.D. London\textsuperscript{13,4}, \textsuperscript{1}Psychiatry and Biobehavioral Sciences, \textsuperscript{2}Psychology, \textsuperscript{3}Molecular and Medical, Pharmacology, and \textsuperscript{4}Brain Research Institute, University of California, Los Angeles, CA

17 Proton MRSI of the human brain in early abstinence from methamphetamine
J. O'Neil\textsuperscript{1}, M. Tobias\textsuperscript{2}, A. Bejjan\textsuperscript{2}, S. Tafazoli\textsuperscript{2}, B. Lee\textsuperscript{3}, M. Walker\textsuperscript{2} and E.D. London\textsuperscript{2}, \textsuperscript{1}Child Psychiatry, and \textsuperscript{2}Laboratory of Molecular Neuroimaging, University of California-Los Angeles Semel Institute for Neurosciences, Los Angeles, CA
18  *The influences of dopamine receptor D4 polymorphism on the brain structures and activity in methamphetamine-dependent subjects*

J. Hwang¹, D.H. Han², I. Lyoo¹ and P.F. Renshaw², ¹Psychiatry, Seoul National University Hospital, Seoul, South Korea and ²Brain Imaging Center, Mclean Hospital, Belmont, MA

19  *Brain activation in a cognitive control task correlates with outcome measures after cognitive behavioral treatment in cocaine-dependent individuals*

J. Brewer, P. Worhunsky, K.M. Carroll, B.J. Rounsaville and M.N. Potenza, Psychiatry, Yale University School of Medicine, New Haven, CT

20  *Prefrontal cortical changes in gray matter associated with cocaine addiction*

A. Straub, G. Pagnoni and C. Kilts, Emory University, Atlanta, GA

21  *Cocaine abstainers have greater gray and white matter densities than current cocaine users*

D.L. Dufault, C.A. Hanlon, M.J. Wesley and L.J. Porrino, Physiology and Pharmacology, Wake Forest University, Winston-Salem, NC

22  *Prolonged exposure to cocaine self-administration in rhesus monkeys induces a significant decrease in functional activity in the prefrontal cortex*

T.J. Beveridge, H.R. Smith, M.A. Nader and L.J. Porrino, Physiology and Pharmacology, Wake Forest University School of Medicine, Winston Salem, NC

23  *The effects of prolonged exposure to cocaine self-administration on functional activity in monkey striatum*

H.R. Smith, T.J. Beveridge, M.A. Nader and L.J. Porrino, Wake Forest University Health Sciences, Winston-Salem, NC

24  *Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy*

S.A. Perrine, M.S. Michaels, E.M. Hyde, F. Ghoddoussi, M.E. Tancer and M.P. Galloway, Psychiatry and Behavioral Neuroscience, Wayne State University School of Medicine, Detroit, MI

**AMPHETAMINES: HUMAN STUDIES**

25  *Behavioral and cardiovascular effects of intranasal d-amphetamine in humans*


26  *Differential effects of repeated intranasal methamphetamine administration*

M.G. Kirkpatrick¹², A.Y. Perez¹², E. Gunderson¹², R.W. Foltin¹² and C.L. Hart¹², ¹College of Physicians and Surgeons of Columbia University, and ²The New York State Psychiatric Institute, New York, NY

27  *Effects of repeated intranasal methamphetamine on sleep*


28  *The effects of inhaled l-methamphetamine on athletic performance while riding a stationary bicycle*

F. Dufka², G. Galloway¹, M. Baggott¹ and J. Mendelson¹, ¹Addiction Pharmacology, California Pacific Medical Center Research Institute, San Francisco, CA and ²French American International School, San Francisco, CA

29  *Discriminative-stimulus effects of methamphetamine, d-amphetamine, methylphenidate and triazolam in humans*

R. Sevak¹, W.W. Stoops¹, L.R. Hays² and C.R. Rush¹²³, ¹Behavioral Science, ²Psychiatry, and ³Psychology, University of Kentucky, Lexington, KY
30 *d*-Amphetamine modifies the discriminative-stimulus effects of methamphetamine in humans
A.R. Vansickle1,2, W.W. Stoops1, P.E. Glaser1 and C.R. Rush1,2,3, 1Behavioral Science, 2Psychology, and 3Psychiatry, University of Kentucky, Lexington, KY

31 Factors associated with cognitive dysfunction among methamphetamine users
K.G. Heinzerling, S. Shoptaw, A. Swanson and E. Rotheram-Fuller, Family Medicine, University of California-Los Angeles, Los Angeles, CA

32 Developing and testing of a novel virtual reality device in methamphetamine-dependent humans
C. Culbertson1, I. Zaharovits2, R. De La Garza, II1 and T. Newton1, 1Psychiatry and Biobehavioral Sciences, and 2Experimental Technology Center, University of California, Los Angeles, CA

33 An examination of drug craving over time in abstinent methamphetamine users
G. Galloway1, E.G. Singleton2, R.M. Dickerhoof3, M.J. Baggott1 and J.E. Mendelson1, 1Research Institute, California Pacific Medical Center, San Francisco, CA and 2The MayaTech Corporation, Silver Spring, MD

34 Modafinil attenuates subjective effects of methamphetamine in methamphetamine-dependent research subjects
R. De La Garza, T.F. Newton, T.S. Zorick and E.D. London, Psychiatry, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA

35 Open label modafinil for methamphetamine dependence: Safety and tolerability
J.D. McGaugh, M. Mancino, W. Gentry, M. Chopra, C. Cargile and A. Oliveto, Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR

36 Changes in addiction severity in an open trial of long-acting injectable risperidone for methamphetamine dependence
A.J. Saxon1,2, C.W. Meredith1,2, C. Jaffe2, M. Cherrier2,1, J. Robinson1, E. Yanasak1, A. Kennedy1, L. Ferguson1,2, C.A. Malte1 and A. Tapp1,1, 1Mental Health, VA Puget Sound Health Care System, and 2Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA

37 A controlled trial of flumazenil, gabapentin and hydroxyzine in treatment of methamphetamine dependence
H.C. Urschel1, L.L. Hanselka2 and M. Baron3, 1Urschel Recovery Science Institute, 2Research Across America, and 3University of Texas at Dallas, Dallas, TX

38 Naltrexone for the treatment of amphetamine dependence: A randomized placebo-controlled trial
N. Jayaram-Lindstrom1, A. Hammarberg1, O. Beck2 and J. Franck1, 1Clinical Neuroscience, and 2Clinical Chemistry, Karolinska Institutet, Stockholm, Sweden

39 Impact of change in incentives on retention and outcomes in a controlled trial of a medication regimen for treating methamphetamine dependence
L.L. Hanselka1, H.C. Urschel2 and M. Baron3, 1Research Across America, 2Urschel Recovery Science Institute, and 3University of Texas at Dallas, Dallas, TX

40 Assessing paranoia in methamphetamine users: The Methamphetamine Experience Questionnaire
M.H. Leamon1, K. Flower2, R.E. Salo1, T.E. Nordahl1, H.R. Kranzler3 and G.P. Galloway2, 1University of California, Davis, and 2California Pacific Medical Center, San Francisco, CA, and 3University of Connecticut, Farmington, CT

41 Women methamphetamine users' narratives of maternal blame
A.H. Brown and R.A. Rawson, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA
42 Sexual behaviors among female methamphetamine users
S.J. Cousins, A. Brown, J. Brummer, R. Gonzales, V. Pearce and R. Rawson, ISAP,
University of California-Los Angeles, Los Angeles, CA

43 Relationship between trauma histories and sexual behaviors among methamphetamine users
J. Brummer, A. Brown, S. Cousins, R. Gonzales, V. Pearce and R. Rawson, ISAP, University
of California-Los Angeles, Los Angeles, CA

44 Stimulant treatment programs in New South Wales, Australia
A. Dunlop\textsuperscript{1,3}, A. Wodak\textsuperscript{2}, T. Adam\textsuperscript{2}, A. Baker\textsuperscript{3}, B. Tulloch\textsuperscript{1} and R. McKetin\textsuperscript{4}, \textsuperscript{1}Drug &
Alcohol Clinical Ser, Hunter New England Area Health Ser, Newcastle East, \textsuperscript{2}Drug & Alcohol
Ser, St. Vincents Hospital, Sydney, \textsuperscript{3}Mental Health Studies, U. of Newcastle, and \textsuperscript{4}National
Drug & Alcohol Research Centre, U. of New South Wales, Sydney, NSW, Australia

TREATMENT

45 Relational discord at conclusion of treatment predicts future substance use for partnered
patients
W.H. Denton\textsuperscript{1}, P.A. Nakonezny\textsuperscript{1}, B.H. Adinoff\textsuperscript{3} and K.M. Carroll\textsuperscript{2}, \textsuperscript{1}University of Texas
Southwestern Medical Center, Dallas, TX and \textsuperscript{2}Yale University School of Medicine,
New Haven, CT

46 Recovery-oriented systems of care: An examination of recovery support service types and client
outcomes
L. Mangrum, Addiction Research Institute, University of Texas, Austin, TX

47 Patient and staff satisfaction in outpatient substance abuse treatment programs
A. Kulaga\textsuperscript{1}, B. McClure\textsuperscript{1}, J. Rotrosen\textsuperscript{1}, P. Crits-Christoph\textsuperscript{2}, S. Ring-Kurtz\textsuperscript{2}, C. Temes\textsuperscript{2} and
R. Forman\textsuperscript{1}, \textsuperscript{1}Psychiatry, NYU School of Medicine, New York, NY, \textsuperscript{2}University of
Pennsylvania, Philadelphia, PA and \textsuperscript{3}Alkermes, Inc., Boston, MA

48 MMTP staff attitudes toward provision of medical and harm reduction services
S. Deren\textsuperscript{1}, S.Y. Kang\textsuperscript{1}, M. Mino\textsuperscript{1} and R. Seewald\textsuperscript{1}, \textsuperscript{1}Center for Drug Use and HIV Research,
NDRI, and \textsuperscript{2}Office of MMTP Administration, Beth Israel Medical Center, New York, NY

49 Feedback and performance-based incentives for counselors: Response to a brief intervention for
improving group attendance
R. Vandrey and M.L. Stitzer, Johns Hopkins University, Baltimore, MD

50 Preliminary description of South African substance abuse counseling workforce, their training
background, and experience
S. Rataemane\textsuperscript{1}, D.W. Watson\textsuperscript{2,4}, L. Rataemane\textsuperscript{3}, R. Rawson\textsuperscript{2} and W.J. McCuller\textsuperscript{4}, \textsuperscript{1}University of
Limpopo, Pretoria, and \textsuperscript{3}Mental Health and Addiction Centre, Pretoria, South Africa and
\textsuperscript{2}Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles,
and \textsuperscript{4}Friends Research Institute, Torrance, CA

51 What do addiction clinicians untrained in Cognitive Behavioral Therapy (CBT) report about
their use of and interest in CBT practices?
M. Amodeo\textsuperscript{1}, J. Muroff\textsuperscript{1}, M.J. Larson\textsuperscript{2} and E. Gerstenberger\textsuperscript{2}, \textsuperscript{1}Boston University, Boston, MA
and \textsuperscript{2}New England Research Institutes, Inc., Watertown, MA

52 The addiction treatment roundtable
S. Kellogg\textsuperscript{1} and A. Tatarsky\textsuperscript{2}, \textsuperscript{1}Psychology, New York University, and \textsuperscript{2}Harm Reduction
Psychotherapy and Training Associates, New York, NY

57
53 Drug treatment and data management: An analysis of information technology infrastructure
J.P. Wisdom¹, J.H. Ford², D.L. Mackey³ and M.E. Wise², ¹Columbia University, New York, NY, ²University of Wisconsin, Madison, WI and ³Oregon Health and Science University, Portland, OR

54 Measuring dissemination of evidenced-based practices: The creation and validation of the Survey of Practiced Research Efforts to Aid in Dissemination
A.O. Wente, J.E. Hettema and J.L. Sorensen, Psychiatry, University of California, San Francisco, San Francisco, CA

55 Construct and predictive validity of the URICA
C. Field¹, B.A. Adinoff², T.R. Harris³, S.A. Ball⁴ and K.M. Carroll⁴, ¹Health Promotion and Behavioral Sciences, UT School of Public Health, ²Psychiatry, UT Southwestern Medical Center at Dallas and VA North Texas Healthcare System, ³Biostatistics, UT School of Public Health, Dallas, TX and ⁴Psychiatry, Yale University School of Medicine, New Haven, CT

SUBSTANCE ABUSE IN ADOLESCENTS II

56 Examining the severity of alcohol use problems associated with DSM-IV abuse and dependence diagnostic categories using Item Response Theory
H.L. Gelhorn¹, C. Hartman¹, J. Sakai¹, M. Stallings²³, S. Young², S.H. Rhee²³, R. Corley², J. Hewitt²³, C. Hopfer¹ and T.J. Crowley¹, ¹Psychiatry, University of Colorado School of Medicine, Denver, and ²Institute for Behavioral Genetics, and ³Psychology, University of Colorado, Boulder, Boulder, CO

57 A latent class analysis of substance use patterns and mental health problems among youth in mental health treatment

58 Expectancy, subjective response and alcohol involvement in childhood
C. Chen¹, C.L. Storr², S.L. Huang¹, C.Y. Liu¹ and W.J. Chen⁴, ¹Division of Mental Health and Substance Abuse Research, NHRI, Taipei, Taiwan, ²Mental Health, Johns Hopkins University, Baltimore, MD, ³Nursing, National Taipei College of Nursing, and ⁴Institute of Epidemiology, National Taiwan University, Taipei, Taiwan

59 Trends in adolescent substance use, abuse, dependence, and treatment need between 1998 and 2005 in Kentucky
M. Webster¹², D.B. Clark² and T.F. Garrity¹, ¹Behavioral Science, and ²Center on Drug and Alcohol Research, University of Kentucky, Lexington, KY

60 Cross-cultural sex differences in adolescent substance use: Germany and the United States
T.C. Link, Sociology, University of Kentucky, Lexington, KY

61 Examination of ethnicity differences in risk-taking behavior within a community sample of youth
E.K. Reynolds, F.L. Wang, L. MacPherson, M.S. Duplicinsky and C.W. Lejuez, Center for Addictions, Personality, and Emotion Research, University of Maryland, College Park, MD

62 Predicting sexual debut
P. Cavazos-Rehg, M. Krauss, E. Spitznagel, L. Cottler and L. Bierut, Washington University School of Medicine, St. Louis, MO

63 Impulsivity and delay discounting in drug-using and non-drug using adolescents
S.K. Moore¹, L.A. Marsch¹, W.K. Bickel², G.J. Badger³ and A.J. Budney², ¹National Development and Research Institutes, NY, NY, ²University of Arkansas for Medical Sciences, Little Rock, AR, and ³Medical Biostatistics, University of Vermont, Burlington, VT
Marijuana use, impulsivity, coping and gender in adolescents
T.S. Schepis, A.E. Smith, D.A. Cavallo, A. McFetridge, T. Liss and S. Krishnan-Sarin,
Psychiatry, Yale University School of Medicine, New Haven, CT

Adolescent coping and self-efficacy to resist marijuana use in the presence of negative emotion
A.E. Smith, D.A. Cavallo, T. Schepis, A. McFetridge, T. Liss and S. Krishnan-Sarin,
Psychiatry, Yale University School of Medicine, New Haven, CT

Parent monitoring at age 11 and subsequent onset of cannabis use: Results from a prospective study in two socially disparate communities
K.M. Bohnert and N. Breslau, Epidemiology, Michigan State University, East Lansing, MI

Nobody asked me: Substance use screening and HIV risk among high school students in Trinidad and Tobago
M. Pantin, School of Public Health, Columbia University/NDRI/MHRA, Brooklyn, NY

Tobacco and drug use across the transition from high school to college
A.P. Anokhin, Psychiatry, Washington University School of Medicine, St. Louis, MO

Incidence and persistence of cannabis dependence among college students
A. Arria, K.M. Caldeira, K.B. Vincent, K.E. O'Grady and E.D. Wish, Center for Substance Abuse Research, and Psychology, University of Maryland, College Park, MD

Withdrawn

Neighborhood conditions and the first chance to try cannabis
Y.G. Flores-Ortega, J.C. Anthony and the PACARDO research consortium, Epidemiology, Michigan State University, East Lansing, MI

Predictors of early marijuana use and sex in the offspring of teenage mothers
N.M. De Genna and M. Cornelius, Psychiatry, University of Pittsburgh, Pittsburgh, PA

Subjective reactions to cannabis remain associated with heaviness of use and cannabis abuse/dependence in adolescents/young adults after controlling for covariates
J.D. Grant, J.F. Scherrer, A.E. Duncan, J.R. Haber, T. Jacob and K.K. Bucholz, Psychiatry, Washington University School of Medicine, and St. Louis VAMC, St. Louis, MO and Palo Alto VAHCS, Menlo Park, CA

Efficacy of brief image-based interventions for emerging adults
C.C. Werch, H. Bian, M. Moore, S. Ames, C. DiClemente, D. Thombs, S. Porkorny and A. Mendez, University of Florida, University of North Florida, and Mayo Clinic, Jacksonville, FL and University of Maryland, Baltimore County, Baltimore, MD

Trajectories of adolescent cannabis use to problematic use in young adulthood
W. Swift, C. Coffey, J.B. Carlin, L. Degenhardt and G.C. Patton, National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, Australia and Murdoch Children's Research Institute, Melbourne, VIC, Australia

Contingency management for community treatment-seeking adolescents with marijuana use disorders
T.K. Killeen, H. Upadhyaya, A. Mrcaoe, A. Waldrop, C. Brown and K. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

Disruptive behavior disorders influence response to contingency management among adolescent marijuana abusers
J. VanScoyoc, C. Stanger, A. Budney and J. Thostenson, Center for Addiction Research, University of Arkansas, Little Rock, AR
78 Interest in marijuana quit programs among adolescents seeking tobacco cessation treatment: Gender and ethnic differences
E.T. Moolchan, C.C. Collins, C.S. Parzynski, S.J. Heishman and M.K. Leff, TTATRC, NIDA IRP, Baltimore, MD

79 Multidimensional family therapy for severely impaired, dually diagnosed youth: A randomized controlled trial comparing outpatient and residential treatment
H.A. Liddle1, C.E. Henderson2,1, G.A. Dakol1, C.L. Rowe1 and P.E. Greenbaum3, 1Center for Treatment Research on Adolescent Drug Abuse, Miller School of Medicine at the University of Miami, Miami, FL, 2Psychology, Sam Houston State University, Huntsville, TX and 3Florida Mental Health Institute, University of South Florida, Tampa, FL

80 Academic performance trajectories in college students: Relationships with alcohol and marijuana use, depression, anxiety, and behavioral dysregulation
K. O'Grady1, A. Arria2, K. Caldeira2, K. Vincent2 and E. Wish2, 1Psychology, and 2Center for Substance Abuse Research, University of Colorado Denver School of Medicine, Denver, CO

81 Use of quantitative THC/creatinine ratio to refine urinalysis results in teen drug abuse studies
R. Davies, S. Mikulich-Gilbertson, S. Stover and P. Riggs, Psychiatry, University of Colorado Denver School of Medicine, Denver, CO

82 Double-blind fluoxetine in comorbid MDD-AUD adolescents
J.R. Cornelius1, O.G. Bukstein1, I.M. Salloum2, D.S. Wood1 and D.B. Clark1, 1Psychiatry, University of Pittsburgh, Pittsburgh, PA and 2Psychiatry, University of Miami, Miami, FL

ALCOHOL
83 Plasma, serum, and whole-blood ethanol concentrations: Effects of storage conditions and collection tubes
J.F. McNeil, D.M. Penetar, E.T. Ryan and S.E. Lukas, Behavioral Psychopharmacology Research Laboratory, McLean Hospital/ Harvard Medical School, Belmont, MA

84 Alpha-5/GABA(A) receptor mechanisms and the reinforcing effects of ethanol in monkeys
D. Ruedi-Bettschen1, S. Harper-Castle1, T. Clayton2, S. Rallapalli2, J.M. Cook2 and D.M. Platt1, 1New England Primate Research Center, Harvard Medical School, Southborough, MA and 2U. of Wisconsin, Milwaukee, WI

85 Effects of naltrexone on the oral self-administration of ethanol+milk or milk alone in rats trained under a two-lever "choice" procedure
C.A. Paronis, J. Bergman and N.S. Shaller, McLean Hospital, Harvard Medical School, Belmont, MA

86 Extended-release naltrexone injectable suspension for treatment of alcohol dependence in urban primary care: A feasibility study, preliminary analysis
E. Grossman, J.D. Lee, D. DiRocco, J. Rotrosen, L. Chuang, K. Hanley, D. Stevens and M.N. Gourevitch, New York University School of Medicine, New York, NY

87 Ondansetron with olanzapine for the treatment of alcohol dependence: Preliminary clinical trial
B.A. Johnson and N. Ait-Daoud, Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA

88 Use of dietary supplements by regular and non-regular female users of tobacco, alcohol, and caffeine
L.B. Phipps, N. Karjane, L. Anderson, D. Stovall, D. Miles and D.S. Svikis, Institute for Women's Health, AWHARE Program, Virginia Commonwealth University, Richmond, VA

89 Alcohol alters stance stability longer than subjective effects in healthy volunteers
S.E. Lukas, D.M. Penetar and E.T. Ryan, Behavioral Psychopharmacology Research Laboratory, McLean Hospital/Harvard Medical School, Belmont, MA
90 Alcohol affects anxiety but not fear
C.A. Moberg and J.J. Curtin, Psychology, University of Wisconsin, Madison, WI

91 Are samples of subjects in clinical trials of pharmacotherapies for alcohol dependence representative of the general population of alcohol-dependent individuals?
A.C. Andorn and H.D. Chilcoat, Research and Development, GlaxoSmithKline, Durham, NC

92 Measurement properties of the WHOQOL-BREF in alcoholics using the Rasch model
F.H. Kessler, N.S. Rocha, S. Faller, D. Benzano and F. Pechansky, Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

93 The Neuropsychological Assessment Battery - Screening Module: Utility at treatment entry
K. Grohman and E. Edwards, The Research Institute on Addictions, University at Buffalo, Buffalo, NY

94 SBIRT outcomes in Houston: Initial report on a hospital-district program
R.T. Spence1, T. Bohman1, K. Von Sternberg1, M.M. Velasquez1, V. Waters2, K. McQueen2, L. Wallisch1, A. Yeung1, A. Pittman4 and M. Cook1, 1University of Texas, Austin, TX and 2Baylor College of Medicine, Houston, TX

95 Expectancies of alcohol consumption among alcohol-dependent patients: Validation of the French version of the VAV questionnaire
S. Balester Mouret, E. Languerand and P. Batel, UTAMA, APHP, Clichy, France

96 Early outcomes of a 1-session intervention to prevent alcohol-exposed pregnancy in preconception women
S. Ceperich, K. Ingersoll, M. Karakashian, J.K. Penberthy, L. Farrell, S. Fabbri, T. Ly, A. Kracen and C. Detrick, University of Virginia, Charlottesville, VA

97 Mechanisms of a motivational interviewing intervention that reduced drinking and improved contraception
K.S. Ingersoll1, C.C. Wagner2, S.D. Ceperich1, K. von Sternberg4, M.B. Sobell3, M.M. Velasquez4, L.C. Sobell3, S. Agrawal1 and A.C. Fansler1, 1Psychiatry, U. of Virginia, Charlottesville, and 4Rehabilitation Counseling, VCU, Richmond, VA. 3Psychology, Nova Southeastern U., Ft. Lauderdale, FL, and 4Social Work, U. of Texas, Austin, TX

98 Treatment engagement as a mediator of outcome in the women's Recovery Group Study
S.F. Greenfield1,2, M.F. Lincoln1, R. Popuch1, L. Kuper1, A. Cummings3 and R. Gallop3, 1Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, and 3Psychiatry, Harvard Medical School, Boston, MA, and 3Mathematics, Applied Statistics Program, West Chester University, West Chester, PA

99 Hepatitis C among heavy alcohol consumers: Does it require treatment?
E. Peyret2, M. Pascal1, A. Gauchet4, L. Gourarier3 and A. Hij1, 1GEneral HOspital, Saint Dizier, 2APHP, and 3LA TErrasse, APHP, PARis, aNd 4Faculte DE PSychologie, GReenoble, FRance

100 Interest of Fibroscan in the cohort of alcohol consumers with cirrhosis
P. Melin1, A. Gauchet1 and A. Hij1, 1Internal Medicine, General Hospital, Saint Dizier, aNd 2Universite de Psychologie, Grenoble, France

101 Understanding the latent structure of alcohol and cannabis problems in a community sample: A taxometric exploration
T. Slade1, M. Teesson1 and A. Baillie2, 1National Drug and Alcohol Research Centre, University of New South Wales, and 2Psychology, Macquarie University, Sydney, NSW, Australia
102 Risk factors associated with drinking and driving in Brazil
F. Pechansky¹, L. Von Diemen¹, R. DeBoni¹, D. Bumaguín¹, I. Pinsky², M. Zaleski³,
R. Caetano⁴ and R. Laranjeira², ¹Psychiatry, Center for Drug and Alcohol Res, Federal U. of
Rio Grande do Sul, Porto Alegre, and ²Psychiatry, U. of São Paulo, São Paulo, ³Psychiatry, U. of
Santa Catarina, Florianópolis, Brazil and ⁴Epidemiology, U. of Texas SPH, Dallas, TX

103 Gender and the alcohol-violence association in two cities of Peru
M. Piazza, School of Public Health, Universidad Peruana Cayetano Heredia, Barranco, Peru

104 Oppression among poor drug-using African American women in New York: Implications for
practice and policy
E. Benoit, L. Windsor and E. Dunlap, Special Populations Office, National Development and
Research Institutes, Inc., New York, NY

105 Religiosity and substance use in a community sample of adults
C. Walker, T.A. Wills, M. Ainette and C. Isasi, Epidemiology and Population Health, Albert
Einstein College of Medicine, Bronx, NY

NICOTINE: HUMAN STUDIES

106 A pilot study of topiramate for smoking cessation
A. Hulbert¹², K. Drexler¹², J. Casarella², S. Salles², M. Vaughn¹² and T. Carter², ¹Psychiatry
and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA and ²Addiction
Medicine, Veterans Affairs Medical Center, Decatur, GA

107 The effects of acute varenicline administration on eating and smoking behavior
W.W. Stoops¹, A.R. Vansickel¹² and C.R. Rush¹², ¹Behavioral Science, ²Psychology, and
³Psychiatry, University of Kentucky, Lexington, KY

108 N-Acetylcysteine for smoking reduction: A pilot study
S. LaRowe¹², P.N. Mardikian¹, H. Upadhyaya¹, M. Corley¹ and R.J. Malcolm¹, ¹Psychiatry
and Behavioral Sciences, Medical University of South Carolina, and ²Mental Health Service
Line, Ralph H. Johnson VAMC, Charleston, SC

109 A control trial of the feasibility of remote real-time monitoring of smoking
P.A. Nuzzo¹, J. Dallery², S. McQueary¹, C.A. Martin¹, T.H. Kelly¹ and C.J. Wong¹,
¹Behavioral Science and Psychiatry, University of Kentucky, Lexington, KY and ²Psychology,
University of Florida, Gainesville, FL

110 A single dose of nicotine enhances reward responsiveness in non-smokers: Implications for
development of dependence
A.E. Evins, Psychiatry, Massachusetts General Hospital, Boston, MA

111 Subliminal processing of smoking and affective stimuli in tobacco dependence
A.M. Leventhal¹, A.J. Waters², B.G. Breitmeyer³, E.K. Miller⁴, E. Tapia³ and Y. Li⁴, ¹Center
for Alcohol and Addiction Studies, Brown U., Providence, RI, ²Medical and Clinical
Psychology, Uniformed Services U. of the Health Sciences, Bethesda, MD, ³Psychology, U. of
Houston, and ⁴The University of Texas-M.D. Anderson Cancer Center, Houston, TX

112 Current tobacco use and other health risk behaviors in a primary care sample of women
A. Alvanzo, D. Langhorst and D. Svikis, Virginia Commonwealth University, Richmond, VA

113 An experimental investigation of a self-control mechanism underlying the detrimental effects of
dieting on concurrent smoking cessation
D. Shmueli and J.J. Prochaska, Psychiatry, UCSF, San Francisco, CA
114 Standard versus stringent CO cutoffs: Implications for smoking cessation outcomes
D.O. Jackson¹, K.L. Cropsey², M.F. Weaver³, G.C. Villalobos³ and M.L. Stitzer⁴, ¹Psychology, and ²Psychiatry, University of Alabama at Birmingham, Birmingham, AL, ³Internal Medicine, Virginia Commonwealth University, Richmond, VA and ⁴Psychiatry, Johns Hopkins University, Baltimore, MD

115 Effectiveness of a community pharmacist-based smoking cessation intervention: The STOP Study Phase IV
B. Sproule¹, M.J. Costello¹, R. Dragonetti¹, L. Zawertailo¹² and P. Selby¹, ¹Centre for Addiction and Mental Health, and ²University of Toronto, Toronto, ON, Canada

116 Smokers know what they want, but do they know what they need?
S. Hussain, L. Zawertailo, R. Dragonetti and P. Selby, Centre for Addiction and Mental Health, Toronto, ON, Canada

117 A meta-analysis of the use of Motivational Interviewing for smoking cessation
C. Heckman, B.L. Egleston and M. Hofmann, Population Science, Fox Chase Cancer Center, Philadelphia, PA

118 Internet-based contingency management for smoking cessation
C.J. Wong¹, C.A. Martin¹, J. Dallery², T. Helmbrecht¹, G. Guenther¹, P.A. Nuzzo¹, M. Grabinski¹ and T.H. Kelly¹, ¹Behavioral Science, University of Kentucky, Lexington, KY, ²Psychology, University of Florida, Gainesville, FL and ³Red5Group, New York, NY

119 An organizational change intervention to address smoking in drug abuse treatment
J.R. Guydish¹, B. Tajima¹, D. Ziedonis² and L. Zammarelli³, ¹University of California, San Francisco, San Francisco, CA, ²University of Massachusetts Medical School, Worcester, MA and ³Willamette Family Inc., Eugene, OR

120 Does participation in clinical trials research affect clinical practices related to smoking?
B. Tajima, J.R. Guydish, K. Delucchi and E. Passalacqua, University of California, San Francisco, San Francisco, CA

121 Lung cancer in the family: A teachable moment
C.A. Martin¹, V. Luftman¹, T. Helmbrecht¹, G. Guenther¹, S. Arnold² and T. Mullett³, ¹Psychiatry, ²Internal Medicine, and ³Surgery, University of Kentucky, Lexington, KY

122 Assessing stigma toward nicotine-dependent clients among social workers
B.K. Ahmedani¹, S.P. Kubiak¹ and J. Anthony², ¹School of Social Work, and ²Epidemiology, Michigan State University, East Lansing, MI

123 Smoking cessation and self-efficacy in methadone-maintained individuals: Brief computer-delivered motivation, with and without concomitant contingency management
H. Durdle¹, S.J. Ondersma² and D.M. Ledgerwood², ¹Psychology, University of Windsor, Windsor, ON, Canada and ²Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI

124 Prize reinforcement for smoking cessation in methadone patients: Preliminary analysis
D.M. Ledgerwood and M.K. Greenwald, Psychiatry, Wayne State School of Medicine, Detroit, MI

125 Cigarette smoking among opioid-dependent clients in a therapeutic community
PRESCRIPTION DRUG ABUSE

126  Training medical residents to recognize and manage prescription opioid abuse among chronic pain patients
E.W. Gunderson\textsuperscript{1,2}, P. Coffin\textsuperscript{1}, S. Polydorou\textsuperscript{1}, N. Chang\textsuperscript{1} and F.R. Levin\textsuperscript{1,2}, \textsuperscript{1}Columbia University, and \textsuperscript{2}NYS Psychiatric Institute, New York, NY

127  Gender differences in prescription opioid use and misuse among chronic pain patients in an outpatient pain management clinic
R. Payne, Medical University of South Carolina, Charleston, SC

128  Opioid misuse, abuse, and dependence: Prevalence, measurement and factor structure among chronic pain patients in a large HMO
C.J. Banta-Green\textsuperscript{1}, J.O. Merrill\textsuperscript{1}, S. Doyle\textsuperscript{1}, D.M. Boudreau\textsuperscript{2} and D. Calsyn\textsuperscript{1}, \textsuperscript{1}University of Washington, and \textsuperscript{2}Center for Health Studies, Seattle, WA

129  Association between chronic pain and prescription drug abuse—cross-sectional analysis of a VA cohort
W. Becker, R. Gallagher, J. Ross and D. Oslin, VISN 4 MIRECC, Philadelphia Veterans Affairs Medical Center, Philadelphia, PA

130  Epidemiological trends in prescription drug misuse and abuse
H.A. Spiller\textsuperscript{1}, D.J. Lorenz\textsuperscript{2}, J.E. Bailey\textsuperscript{1} and R.C. Dart\textsuperscript{3,4}, \textsuperscript{1}KY Regional Poison Center, and \textsuperscript{2}U. of Louisville, Louisville, KY, \textsuperscript{3}Rocky Mountain Poison and Drug Center, Denver, CO and \textsuperscript{4}U. of Colorado Health Sciences Center, Denver, CO

131  Prescription forgery of OxyContin® tablets in the USA
J.D. Haddox and M.Y. Smith, Risk Management & Health Policy, Purdue Pharma L.P., Stamford, CT

132  Detection of prescription opioid abuse/diversion using Research Abuse Diversion and Addiction-Related Surveillance (RADARS®) System data
E.J. Campagna\textsuperscript{1}, J.E. Bailey\textsuperscript{1} and R.C. Dart\textsuperscript{1,2}, \textsuperscript{1}Denver Health-Rocky Mountain Poison and Drug Center, and \textsuperscript{2}University of Colorado Health Sciences Center, Denver, CO

133  Demographic variables associated with prescription opioid-abuse and diversion detected by the RADARS® System
A.E. Zosel\textsuperscript{1,2}, E. Campagna\textsuperscript{1}, J. Bailey\textsuperscript{1} and R. Dart\textsuperscript{1,2}, \textsuperscript{1}Rocky Mountain Poison & Drug Center, Denver Health, and \textsuperscript{2}University of Colorado Health Sciences Center, Denver, CO

134  Spatial analysis of RADARS® System data to identify geographic hot spots of prescription opioid-abuse
A.M. Montoya\textsuperscript{1}, S.L. Heltshoe\textsuperscript{1} and R.C. Dart\textsuperscript{1,2}, \textsuperscript{1}Rocky Mountain Poison and Drug Center-Denver Health, and \textsuperscript{2}University of Colorado Health Sciences Center, Denver, CO

135  Empirical validation of spatial cluster detection for monitoring local patterns of prescription opioid abuse
S.F. Butler\textsuperscript{1} and J.S. Brownstein\textsuperscript{2}, \textsuperscript{1}Inflexxion, Inc, Newton, MA and \textsuperscript{2}Epidemico, LLC, Boston, MA

136  Diversion of medically prescribed stimulants and analgesics by college students
L. Garnier\textsuperscript{1}, A. Arria\textsuperscript{1}, K.M. Caldeira\textsuperscript{1}, K.B. Vincent\textsuperscript{1}, K.E. O’Grady\textsuperscript{2} and E.D. Wish\textsuperscript{1}, \textsuperscript{1}Center for Substance Abuse Research, and \textsuperscript{2}Psychology, University of Maryland, College Park, MD

137  Drug abuse problems among medical and nonmedical users of prescription opioids
C.J. Boyd and S.E. McCabe, UM Substance Abuse Research Center, University of Michigan, Ann Arbor, MI
138 **Non-medical use of pharmaceutical opioids among MDMA users in Ohio**
   R. Daniulaityte, R. Carlson, R. Falck and J. Wang, Wright State University, Dayton, OH

139 **Heavy opioid and benzodiazepine abusers in Miami's club scene: Overlapping groups with drug-specific health markers**
   S.P. Kurtz, J. Inciardi, H. Surratt and J. Kish, Center for Drug and Alcohol Studies, University of Delaware, Coral Gables, FL

140 **Misuse of prescribed stimulant medication for ADHD and associated patterns of substance use: A preliminary analysis among college students**
   D.R. Sepulveda, L.M. Thomas, S.E. McCabe, J.A. Cranford, C.J. Boyd and C.J. Teter, Pharmacy, Northeastern U., Boston, and Alcohol & Drug Abuse Treatment Program, McLean Hospital, Belmont, MA, Substance Abuse Research Center, and Institute for Research on Women and Gender, U. of Michigan, Ann Arbor, MI

141 **Diversion of prescribed stimulant medication for ADHD and its association with specific stimulant formulations: A preliminary analysis among college students**
   L.M. Thomas, D.R. Sepulveda, S.E. McCabe, J.A. Cranford, C.J. Boyd and C.J. Teter, School of Pharmacy, Northeastern U., Boston, and Alcohol & Drug Abuse Treatment Program, McLean Hospital, Belmont, MA, Substance Abuse Research Center, and Institute for Research on Women and Gender, U. of Michigan, Ann Arbor, MI

**LITERATURE REVIEW**

142 **Routes of nonmedical use/abuse of Oxycontin® (oxycodone HCl controlled-release tablets)**
   M.Y. Smith, Risk Management & Health Policy, Purdue Pharma LP, Stamford, CT

143 **Impact of methadone and buprenorphine on mortality rate. A systematic review**
   C. Denis, N. Roscop, E. Lavie, M. Fatseas and M. Auriacombe, Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, Bordeaux, France

144 **Fentanyl-related deaths: Abuse and off-label use of licit and illicit sources of fentanyl**

145 **Adult women's alcohol abuse: Barriers to detection in primary healthcare settings**
   V. Osborne, Social Work, and Psychiatric Epidemiology, Washington University in St. Louis, St. Louis, MO

146 **Herpes simplex virus type 2 infection in drug and alcohol users in low- and middle-income countries**
   A.M. Newberry, L. Sherbin Coffin, H. Hagan, D.C. Des Jarlais, D.C. Perlman, Division of Infectious Diseases, Medicine, and Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, and Center for Drug Use and HIV Research, National Development and Research Institutes, Inc, New York, NY

147 **Drug use and syphilis in low- and middle-income countries: A systematic review**
   L.S. Coffin, A. Newberry, H. Hagan, D.C. Des Jarlais, D. Perlman, Medicine, and Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, and Center for Drug Use & HIV Research, NDRI, Inc, New York, NY

148 **The relationship between stress, coping, substance abuse and HIV-risk behaviors among African American women**
   L. Ruglass, Social Intervention Group, Columbia University, New York, NY
THEORETICAL/COMMENTARY

149 Common principles imbedded in effective adolescent HIV prevention
D. Flannery¹, M.J. Rotheram-Borus¹, B.L. Ingram² and A. Elkavich¹, ¹Semel Institute for Neuroscience and Behavior, Center for Community Health, University of California, and ²Graduate School of Education and Psychology, Pepperdine University, Los Angeles, CA

150 HIV/AIDS among injecting drug users in Indonesia: The role of drug treatment
A. Nurhidayat, G.E. Woody and D.S. Metzger, Psychiatry, University of Pennsylvania, Philadelphia, PA

151 Systems dynamic modeling as an approach to understanding the abuse and diversion of opioid analgesic products: Implications for risk management systems
J.P. Fitzgerald, M.Y. Smith, A.T. Kline and J.D. Haddox, Risk Management, Purdue Pharma L.P., Stamford, CT

152 Withdrawn

153 Accuracy of media reports concerning the abuse and diversion of OxyContin® (oxycodone HCl controlled-release) tablets
A.T. Kline, M.A. Philbrook, M.Y. Smith and J.D. Haddox, Risk Management & Health Policy, Purdue Pharma LP, Stamford, CT

154 Monitoring of federal surveys as a risk minimization action plan component: Applications and limitations

155 Implosion of the criminal justice system and reformulation of illicit drug markets in New Orleans following Hurricane Katrina
B.D. Johnson and E. Dunlap, Special Populations Research, National Development and Research Institutes, New York, NY

156 Key components of a critical race theory approach to the study of drug abuse disparities
C.L. Ford, Epidemiology, Columbia University, New York, NY

157 WHO guidelines for the psychosocially assisted pharmacological treatment of opioid dependence
N. Clark and V. Poznyak, Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland

158 Past, present and predictions in the history of cocaine dependence treatments
T. Llosa, Coca Medica, Lima, Peru

159 Allá en Nueva York todo es mejor: A study on the movement of injecting drug users from Puerto Rico to the United States
R. Torruella, ¹Social-Personality Psych., CUNY, and ²Behavioral Science Training, NDRI, New York, NY

160 Application of principal stratification to control for institutionalization at follow-up in studies of substance abuse treatment programs
B. Griffin, D.F. McCaffrey and A.R. Morral, RAND Corporation, Arlington, VA

161 Public health system structure and activities as barriers to prenatal care for pregnant women who use drugs and alcohol
S.C. Roberts, ¹DrPH Program, University California, Berkeley School of Public Health, Berkeley, CA and ²Alcohol Research Group, Emeryville, CA
162  Barriers to the implementation of an integrated co-occurring disorders treatment model
A.M. Williams¹, M.L. Smith², F. Lorenzi¹ and T.G. Durham¹, ¹The Danya Institute, Inc., Silver Spring, MD and ²District of Columbia, Department of Mental Health, Washington, DC

163  Substance use disorder treatment in an era of integrated behavioral health care
E. Lopez and H.W. Clark, SAMHSA, U.S. Department of Health and Human Services, Rockville, MD

164  An alternative framework for measuring the economic cost of drug abuse
R. Pacula¹, J. Ringel¹, S. Paddock¹, J. Arkes², C. Eibner¹, B. Kilmer¹, T. Bentley¹ and M. Suttrop¹, ¹Drug Policy Research Center, RAND Corporation, Santa Monica, CA and ²Naval Postgraduate School, Monterey, CA

165  The business case for process improvement: Linking treatment access and retention to financial performance among substance abuse providers
A. Quanbeck¹, L. Madden², J. Ford¹, J. McConnell³, D. Gustafson¹, E. Edmundson³ and D. McCarty³, ¹University of Wisconsin, Madison, WI, ²APT Foundation, New Haven, CT and ³Oregon Health Sciences University, Portland, OR

166  Analytic approach for counselor training project with a successive cohort design
C. Barrick and G. Homish, RIA, University at Buffalo, Buffalo, NY

167  The effect of educational background and individual learning styles on substance abuse clinician training
L. Slawiak and C. Barrick, RIA, University at Buffalo, Buffalo, NY

168  Turning k on its head: Comments on use of an ED50 in delay discounting
J.H. Yoon¹ and S.T. Higgins¹², ¹Psychiatry, and ²Psychology, University of Vermont, Burlington, VT

169  Executive functioning and the treatment of drug addiction: A commentary
A.M. Horton¹ and C.R. Reynolds², ¹Neuropsychology Laboratory, Psych Associates of Maryland, Towson, MD and ²Educational Psychology, Texas A&M University, College Station, TX

170  Cannabis potency and contamination: Views of key experts
P. Gates¹, W. Swift¹, J.A. McLaren¹, P. Dillon¹ and S. Allsop², ¹National Drug and Alcohol Research Centre, University of NSW, Sydney, NSW, and ²National Drug Research Institute, Curtin University, Perth, WA, Australia

171  Using microsimulation modeling to capture heterogeneity in marijuana use
S. Paddock¹, J. Arkes², T. Bentley¹, J. Caulkins³, C. Eibner¹, B. Kilmer¹, J. Ringel¹, M. Suttrop¹ and R. Pacula¹, ¹Drug Policy Research Center, RAND Corporation, Santa Monica, and ²Naval Postgraduate School, Monterey, CA and ³Carnegie Mellon University, Pittsburgh, PA

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSIONS
Symposium XI

TRAFFICKING SIGNALS AND ADDICTIVE PROCESSES

Chairs: Kathryn A. Cunningham and Toni S. Shippenberg

10:00  Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors
       Toni S. Shippenberg, NIDA, Intramural Research Program, Baltimore, MD

10:25  Repeated exposure of methamphetamine or morphine differentially regulates AMPA receptor trafficking in limbic brain regions
       T. Celeste Napier, Rush University Medical Center, Chicago, IL

10:50  Morphine-induced neuroplasticity at hippocampal synapses
       Jose Moron-Concepcion, University of Texas Medical Branch, Center for Addiction Research, Galveston, TX

11:15  Plasticity of AMPA receptor transmission during cocaine withdrawal
       Marina E. Wolf, Chicago Medical School, Rosalind Franklin University, North Chicago, IL

11:40  Discussant
       Kathryn A. Cunningham, University of Texas Medical Branch, Center for Addiction Research, Galveston, TX

Symposium XII

ADVANCES IN THE DEVELOPMENT OF MEDICATIONS FOR COMORBID ADHD AND SUBSTANCE USE DISORDERS

Chairs: Petra Jacobs and Frances R. Levin

10:00  Substance use and abuse in the MTA study sample
       Brooke S. Molina, University of Pittsburgh, Pittsburgh, PA

10:25  Smoking cessation in adolescents with ADHD
       Himanshu P. Upadhyaya, Medical University of South Carolina, Charleston, SC

10:50  Pharmacotherapies for ADHD in adolescents with SUD
       Paula Riggs, University of Colorado at Denver, Denver, CO

11:15  Medication to treat adults with comorbid ADHD and SUD
       Frances R. Levin, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY

11:40  Development of treatments for comorbid ADHD and SUD - Future directions
       Timothy E. Wilens, Harvard Medical School, Boston, MA
RAISING THE BAR: STIMULANT EFFECTS ON BEHAVIOR

Chairs: Paul Czoty and Summee Wee

10:00  Bupropion differentially impacts responding for appetitive stimuli
       C.M. Reichel¹, J.E. Murray¹, A.W. Walker¹, K.M. Grant² and R.A. Bevins¹, ¹Psychology,
       University of Nebraska-Lincoln, Lincoln, NE and ²University of Nebraska Medical Center,
       Omaha, NE

10:15  Some behavioral effects of modafinil in monkeys
       J. Bergman¹, J. Frasca¹, N. Shaller¹ and T.E. Prisinzano², ¹Psychiatry, Harvard Medical
       School/McLean Hospital, Belmont, MA and ²Medicinal Chemistry, University of Kansas,
       Lawrence, KS

10:30  Effects of acute social stressors and enrichment on the reinforcing strength of cocaine in
       socially housed male monkeys
       P.W. Czoty¹, M. Icenhower¹, N.R. Garrett¹, J.E. Campbell¹, R.W. Gould¹ and M.A. Nader¹,²,
       ¹Physiology and Pharmacology, and ²Radiology, Wake Forest University School of Medicine,
       Winston-Salem, NC

10:45  History of escalation of cocaine intake with extended access facilitates subsequent escalation of
       cocaine intake after prolonged drug withdrawal in rats
       S. Wee and G.F. Koob, The Scripps Research Institute, La Jolla, CA

11:00  Cocaine esterase prevents ongoing intravenous cocaine self-administration in rats
       G.T. Collins¹, R.L. Brim¹, D. Narasimhan¹, R.K. Sunahara¹, C.G. Zhan² and J.H. Woods¹,
       ¹University of Michigan Medical School, Ann Arbor, MI and ²University of Kentucky,
       Lexington, KY

11:15  Stress-induced potentiation of cued reinstatement of cocaine-seeking in an animal model of
       relapse
       D. Buffalari and R.E. See, Medical University of South Carolina, Charleston, SC

11:30  Relationship between extinction responding and cue-induced reinstatement in cocaine self-
       administration in "low-anxiety" and "high-anxiety" rats
       B. Nic Dhonchadha, S.J. Stutz and K.A. Cunningham, Center for Addiction Research,
       UTMB, Galveston, TX

11:45  Comorbidity between mood and substance dependence disorders; behavioral Phenotyping In
       laboratory rats
       F. Leri, S. Djazayeri, C. Allen, A.M. Levy and M. Sticht, Psychology, University of Guelph,
       Guelph, ON, Canada
Oral Communications 11
San Geronimo C
10:00 AM - 12:00 PM

DRUG INTERACTIONS

Chairs: Margaret Haney and William Fantegrossi

10:00 Pharmacodynamic interactions of alprazolam in methadone and buprenorphine-naloxone patients
S. Nielsen\textsuperscript{1,2,4}, N. Lintzeris\textsuperscript{3,4}, N.K. Lee\textsuperscript{1}, A.J. Bond\textsuperscript{4} and D.A. Taylor\textsuperscript{2}, \textsuperscript{1}Turning Point Alcohol and Drug Centre, Fitzroy, \textsuperscript{2}Monash University, Melbourne, and \textsuperscript{3}Sydney South West Area Health Service, Sydney, VIC, Australia and \textsuperscript{4}Kings College, London, UK

10:15 Smoking in methadone maintenance patients: Nicotine and methadone relationships
A. Elkader\textsuperscript{1,2}, B. Sproule\textsuperscript{1,2}, B. Brands\textsuperscript{1,2} and P. Selby\textsuperscript{1,2}, \textsuperscript{1}Centre for Addiction and Mental Health, and \textsuperscript{2}University of Toronto, Toronto, ON, Canada

10:30 Naltrexone increases marijuana intoxication in humans
M. Haney and Z.D. Cooper, Psychiatry, Columbia University, New York, NY

10:45 Do cannabis users require less opioids to treat pain?
M.C. Acosta\textsuperscript{1,2} and D.L. Haller\textsuperscript{1,2}, \textsuperscript{1}St. Luke's-Roosevelt Hospital, and \textsuperscript{2}Columbia University, New York, NY

11:00 Cocaine effects during d-amphetamine maintenance
C.R. Rush\textsuperscript{1,2,3}, W.W. Stoops\textsuperscript{1}, P.E. Glaser\textsuperscript{2} and L.R. Hays\textsuperscript{2}, \textsuperscript{1}Behavioral Science, \textsuperscript{2}Psychiatry, and \textsuperscript{3}Psychology, University of Kentucky, Lexington, KY

11:15 Adolescent nicotine exposure alters the aversive effects of cocaine in adult rats
M. Hutchison and A.L. Riley, American University, Washington, DC

11:30 The effects of CXCL12 on cocaine within the mesolimbic dopamine pathway
J. Trecki\textsuperscript{1,3}, S.M. Rawls\textsuperscript{2,3} and E.M. Unterwald\textsuperscript{1,3}, \textsuperscript{1}Pharmacology, Temple University School of Medicine, \textsuperscript{2}Pharmaceutical Sciences, Temple University School of Pharmacy, and \textsuperscript{3}Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA

11:45 Interaction of serotonin 5-HT2A and 5-HT2C receptors in DOI-elicted head twitch behavior in mice
W.E. Fantegrossi\textsuperscript{1,2,3}, J. Simoneau\textsuperscript{2} and J.H. Woods\textsuperscript{3}, \textsuperscript{1}Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, AR, \textsuperscript{2}Division of Neuroscience, Yerkes National Primate Research Center, Atlanta, GA and \textsuperscript{3}Pharmacology, University of Michigan, Ann Arbor, MI

Workshop

JOURNAL REVIEW LUNCHEON
(Pre-Registrants Only)

Conference 8/9
12:00 - 1:30 PM
Symposium XIII

San Cristobal
1:30 - 3:30 PM

OPIOID ANALGESICS: PROTECTING THEIR USE AND PREVENTING ABUSE

Chairs: Sharon L. Walsh and Sidney H. Schnoll

1:30 Abuse-resistant opioid formulations: Current status
William K. Schmidt, NorthStar Consulting, LLC, Limerick NeuroSciences, Inc., Davis, CA

1:55 Opioid analgesic abuse in patients with chronic non-cancer pain: Project Pain
Deborah L. Haller, St. Luke’s-Roosevelt Hospital Center Behavioral Science Research Unit, New York, NY

2:20 Aberrant drug-taking behaviors in pain management: What do we know?
Steve Passik, Memorial Sloan Kettering Cancer Center, New York, NY

2:45 Abuse and diversion of prescription pain medications: Policy and clinical imperatives
Aaron Gilson, University of Wisconsin-Madison, WHO Collaborating Center, Madison, WI

3:10 Discussant
Sidney Schnoll, Pinney Associates, Inc., Bethesda, MD

Oral Communications 12

San Geronimo A
1:30 - 3:30 PM

ALL MIXED UP: POLYDRUG ABUSE

Chairs: Kristen Anderson and Mary Waldron

1:30 Polydrug use among club-going young adults
C. Grov¹,², B.C. Kelly³, S.A. Golub⁴ and J.T. Parsons¹⁵, CHEST, NDRI, Queens College, and Hunter College, New York, NY and Purdue, West Lafayette, IN

1:45 Treatment of attention-deficit hyperactivity disorder and subsequent cigarette smoking and substance use disorders in adolescent girls
T.E. Wilens¹, J. Adamson¹, M.C. Monuteaux¹, S.V. Faraone², M. Schilling¹, D. Westerberg¹ and J. Biederman¹, Pediatric Psychopharmacology Research, Massachusetts General Hospital, Boston, MA and SUNY Upstate Medical University, Syracuse, NY

2:00 Sexual risk behaviors and use of methamphetamines and other drugs among incarcerated female adolescents with an STD diagnosis
J. Steinberg¹, M. Boudov¹, P. Kerndt¹, C. Grella² and C. Kadnika³, Sexually Transmitted Disease Program, Los Angeles County Department of Public Health, Integrated Substance Abuse Programs, University of California-Los Angeles, and Juvenile Court Health Services, Los Angeles County Department of Health Services, Los Angeles, CA

2:15 10-year use patterns after adolescent SUD treatment: Impact on relationship status in adulthood
K.G. Anderson¹ and S.A. Brown², Psychology, Reed College, Portland, OR Psychology and Psychiatry, University of California, San Diego, La Jolla, CA and VA San Diego Healthcare System, San Diego, CA
2:30  *Cannabis and other illicit drug use predict delayed reproduction in men and women*
   M. Waldron1, A.C. Heath1, M.T. Lynskey1, K.K. Bucholz1, P. Madden1 and N.G. Martin2,
   1Psychiatry, Washington University School of Medicine, St. Louis, MO and 2Genetic
   Epidemiology Unit, Queensland Institute of Medical Research, Brisbane, QLD, Australia

2:45  *Bang costs $50 a bean: Sources of diverted prescription drugs in the Miami club culture*
   J.A. Inciardi, S.P. Kurtz and H.L. Surratt, University of Delaware, Coral Gables, FL

3:00  *Substance use in the Basque region of France: Prevalence estimation and evaluation of the*
   *CSAPA BIZIA-MDM prevention program*
   J. Daulouede1, J.L. Pradeille1, A. Aguerretxe Colina1, V. Beltran34, C. Maitre1, C. Olaizola1,
   M. Auriacombe3 and J. Swendsen2, 1Addiction Clinic Bizia, 2Université Bordeaux 2,
   Bordeaux, and 3Addiction Psychiatry, Université Bordeaux 2, Bordeaux, France

3:15  *Highlights from the 2007 Ontario Student Drug Use and Health Survey*
   B. Brands123, A. Boak2 and E. Adlaf23, 1Office of Research and Surveillance, Health Canada,
   Ottawa, and 2Centre for Addiction and Mental Health, and 3University of Toronto, Toronto,
   ON, Canada

**Oral Communications 13**

**San Geronimo B**

**GETTING UP TO SPEED ON STIMULANT MECHANISMS**

Chairs: Rae Matsumoto and Amy Goodwin

1:30  *Lobeline attenuates METH-induced hyperactivity but does not alter METH-mediated contextual*
   *conditioning in male and female periadolescent rats*
   S. Harrod, I.D. Longacre and A.A. Basilakos, Psychology, University of South Carolina,
   Columbia, SC

1:45  *Attenuation of methamphetamine-induced effects through antagonism of sigma receptors:*
   *Evidence from in vivo and in vitro studies*
   R. Matsumoto1, J. Shaikh1, L.L. Wilson1, S. Vedam1, C.R. McCurdy1 and A. Coop2,
   1University of Mississippi, University, MS and 2University of Maryland, Baltimore, MD

2:00  *The dopamine D3 receptor antagonist SB277011A inhibits methamphetamine self-
   administration and methamphetamine-triggered reinstatement of drug-seeking behavior in rats*
   E.L. Gardner, A. Higley and Z. Xi, Neuropsychopharmacology, National Institute on Drug
   Abuse, Baltimore, MD

2:15  *Enrichment-induced differences in plasma corticosterone: A potential mechanism for*
   *differential responses to amphetamine in rats*
   D.J. Stairs1, M.A. Prendergast2 and M.T. Bardo2, 1Psychology, Creighton University,
   Omaha, NE and 2Psychology, University of Kentucky, Lexington, KY

2:30  *GABAergic modulators fail to attenuate the discriminative stimulus effects of cocaine in*
   *baboons*
   A.K. Goodwin and E.M. Weerts, School of Medicine, Johns Hopkins University,
   Baltimore, MD

2:45  *Ovarian hormones modulate the within-animal relationships between dopamine cell number,*
   *cocaine-stimulated behavior and dopamine release*
   Q.D. Walker, M.L. Johnson, J.M. Caster and C.M. Kuhn, Pharmacology, Duke Medical
   Center, Durham, NC
Oral Communications 14

San Geronoimo C
1:30 - 3:30 PM

EXPRESSION SESSION: GENETICS OF DRUG ABUSE

Chairs: Jamie Mangold and Teresa Franklin

1:30 DNA methylation of CpG dinucleotides in the μ-opioid receptor gene promoter region occurs in vivo and is increased in lymphocytes of Caucasian former severe heroin addicts
D.A. Nielsen\textsuperscript{1}, V. Yuferov\textsuperscript{1}, S. Hamon\textsuperscript{2}, M. Rouault\textsuperscript{1}, C. Jackson\textsuperscript{1}, J. Ott\textsuperscript{1} and M.J. Kreek\textsuperscript{1}, \textsuperscript{1}Laboratory of the Biology of Addictive Diseases, and \textsuperscript{2}Laboratory of Statistical Genetics, The Rockefeller University, New York, NY

1:45 Association of P2RX7 gene with alcohol use in comorbid bipolar patients
U.E. Busto, B. Yasseen, K. Yang, J. Kennedy and L.A. Zawertailo, Neuroscience, Centre for Addiction and Mental Health, Toronto, ON, Canada

2:00 DAT genotype underlies the intensity and direction of corticolimbic activation to smoking cues
T. Franklin\textsuperscript{1}, Z. Wang\textsuperscript{2}, F. Lohoff\textsuperscript{3}, Y. Li\textsuperscript{1}, K. Kampman\textsuperscript{1}, W. Berrettini\textsuperscript{1}, C.P. O'Brien\textsuperscript{1} and A.R. Childress\textsuperscript{1}, \textsuperscript{1}Psychiatry, and \textsuperscript{2}Radiology, University of Pennsylvania, Philadelphia, PA

2:15 Association between cannabis-related behaviors and OPRM1 in the Nicotine Addiction Genetics project
A. Agrawal\textsuperscript{1}, M. Pergadia\textsuperscript{1}, M. Lynskey\textsuperscript{1}, J. Wang\textsuperscript{1}, S. Saccone\textsuperscript{1}, J. Rice\textsuperscript{1}, R. Todd\textsuperscript{1}, A. Heath\textsuperscript{1}, N. Martin\textsuperscript{2}, G. Montgomery\textsuperscript{2}, A. Goate\textsuperscript{1} and P. Madden\textsuperscript{1}, \textsuperscript{1}Washington University School of Medicine, St. Louis, MO and \textsuperscript{2}Queensland Inst. Medical Research, Brisbane, QLD, Australia

2:30 Significant association of bitter taste receptor genes with nicotine dependence in African Americans
J.E. Mangold\textsuperscript{1}, Q. Xu\textsuperscript{1}, G. Chen\textsuperscript{1}, T.J. Payne\textsuperscript{2} and M.D. Li\textsuperscript{1}, \textsuperscript{1}Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, VA and \textsuperscript{2}Otolaryngology, University of Mississippi, Jackson, MS

2:45 Smoking cessation outcomes at end of treatment using nicotine replacement therapy: A candidate gene association study
L.A. Zawertailo\textsuperscript{1,3}, D.S. Lobo\textsuperscript{2}, J.L. Kennedy\textsuperscript{2,3} and P. Selby\textsuperscript{1,3}, \textsuperscript{1}Addictions Program, Centre for Addiction and Mental Health, \textsuperscript{2}Neurogenetics Program, Centre for Addiction and Mental Health, and \textsuperscript{3}Faculty of Medicine, University of Toronto, Toronto, ON, Canada
3:00 Comparison of the prevalence of serotonin 2A receptor (5-HT2AR) polymorphisms in MDMA users versus controls
N. Moukaddam¹, D. Guo², K.A. Cunningham³ and F.G. Moeller¹, ¹Psychiatry, and ²Internal Medicine, University of Texas Health Science Center-Houston, Houston, TX and ³Pharmacology and Toxicology, Center for Addiction Research, University of Texas Medical School, Galveston, TX

3:15 Dopamine transporter 3'-UTR VNTR genotype is associated with behavioral inhibition—a pharmacogenetic study with acute d-amphetamine administration
A. Hamidovic¹, E. Cook² and H. de Wit¹, ¹Psychiatry, The University of Chicago, and ²Psychiatry, University of Illinois at Chicago, Chicago, IL

Oral Communications 15
San Cristobal
3:45 - 4:45 PM
DOPAMINE RECEPTORS/TRANSPORTERS

Chairs: Annette Fleckenstein and Michael Baumann

3:45 Peripheral administration of cocaine, acting via D2 dopamine receptors, causes the release of endogenous opioid peptides that activate mu receptors within the striatum and VTA
A.R. Soderman and E.M. Unterwald, Pharmacology, Temple University School of Medicine, Philadelphia, PA

4:00 Amphetamine and dopamine interfere with dopamine transporter oligomerization and trafficking
M.E. Reith, N. Chen and S.Y. Cheng, Psychiatry, New York University School of Medicine, New York, NY

4:15 Methylphenidate-induced alterations in VMAT-2 function: Role of dopaminergic and muscarinic receptors
A. Fleckenstein¹², T. Volz¹, S. Farnsworth² and G. Hanson¹², ¹Pharmacology and Toxicology, and ²Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, UT

4:30 Evidence that stimulant effects of modafinil in rats involve dopamine transporters
M.H. Baumann¹, D. Zolkowska¹, R. Jain¹, J.S. Partilla¹, T.E. Prisizano² and R.B. Rothman¹, ¹Clinical Psychopharmacology Section, IRP, NIDA, NIH, Baltimore, MD and ²Medicinal and Natural Product Chemistry, University of Iowa, Iowa City, IA

Oral Communications 16
San Geronimo A
3:45 - 4:45 PM
NEUROBIOLOGY

Chairs: Gerald Zernig and Usoa Busto

3:45 Cerebral morphological changes in human MDMA (ecstasy) polydrug users: A voxel-based morphometry study

4:00 Nucleus accumbens core acetylcholine is selectively activated during drug- vs food-reinforcement acquisition
G. Zernig, C.A. Crespo, P. Stöckl, K. Zorn and A. Saria, Psychiatry, Medical University Innsbruck, Innsbruck, Austria
Wednesday, June 18, 2008

4:15 Ethanol increases extracellular glutamate levels in the ventral tegmental area via D1 receptor activation
M.F. Olive and W.C. Griffin, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

4:30 Dysfunctional reward processing in alcohol dependence assessed by functional magnetic resonance imaging in combination with a dopaminergic probe
X.L. Balducci1,2,3, T.W. Schmitz1, B.A. Sproule1,3, E. De Rosa1, N. Herrmann1,2 and U.E. Busto1,3, 1University of Toronto, 2Sunnybrook Health Sciences Centre, and 3Centre for Addiction and Mental Health, Toronto, ON, Canada

Oral Communications 17

SMOKING IN FEMALES

Chairs: Gabriele Fischer

3:45 Impulsivity and cigarette smoking among pregnant women
R. Rogers, S.T. Higgins and C.S. Thomas, University of Vermont, Burlington, VT

4:00 Neonatal tobacco exposure in opioid-maintained pregnant women — Impact and consequences
B. Winklbaur1, A. Baewert1, R. Jagsch2, K. Rohrmeister3, C. Aschbach-Jachman1, K. Thau1 and G. Fischer1, 1Psychiatry and Psychotherapy, 2Neonatology, Medical University of Vienna, and 3Clinical, Biological and Differential Psychology, Faculty of Psychology, Vienna, Austria

4:15 The relationship between cigarette use and maternal and neonatal outcomes among pregnant methadone-maintained patients
M. Chisolm1, M. Tuten2, E. Strain2 and H. Jones2, 1Johns Hopkins Bayview Medical Center, and 2Johns Hopkins University School of Medicine, Baltimore, MD

4:30 Acute effects of progesterone on nicotine self-administration by female nonhuman primates
N.K. Mello, J.L. Newman, I.M. Knudson, M. Kelly and P.A. Fivel, Alcohol and Drug Abuse Research Center, McLean Hospital-Harvard Medical School, Belmont, MA

Symposium XIV

INNOVATIVE APPLICATIONS OF TECHNOLOGY
TO THE PREVENTION AND TREATMENT OF
SUBSTANCE USE DISORDERS

Chairs: Lisa A. Marsch and Kathleen M. Carroll

3:45 Computer-delivery of science-based drug abuse prevention for youth
Lisa A. Marsch, National Development and Research Institutes, Center for Technology and Health, New York, NY

4:05 Technological innovations in behavioral treatments for cigarette smoking
Jesse Dallery, University of Florida, Gainsville, FL and National Development and Research Institutes, Center for Technology and Health, New York, NY

4:25 Effectiveness of computer-based training in cognitive behavioral therapy: Main outcomes from a randomized clinical trial
Kathleen Carroll, Yale University School of Medicine, West Haven, CT
Wednesday, June 18, 2008

CPDD BUSINESS MEETING
San Cristobal
5:00 - 6:00 PM

DINNER AND DANCING
San Geronimo Ballroom
7:30 - 10:30 PM

BADGES MUST BE WORN IN ALL SCIENTIFIC SESSION
POSTER SESSION IV (Breakfast)  

Odd-numbered posters manned first hour;  
Even-numbered, second hour  

Set-up time begins Wednesday 1:00 PM  
Must be removed by Thursday 12:00 NOON  

DRUG INTERACTIONS

1. **Methodology for assessing cocaine's effect on individual and combined actions of endogenous pressor agents**  
   N. Lamarre¹² and R.J. Tallarida¹², ¹Pharmacology, and ²Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA

2. **D-Cycloserine augments extinction learning and delays re-acquisition of cocaine self-administration in squirrel monkeys**  
   C. Achat-Mendes¹, D.M. Platt¹, K.M. Kantak² and R.D. Spealman¹, ¹NEPRC, Harvard Medical School, Southborough, MA and ²Psychology, Boston University, Boston, MA

3. **N-methyl D-aspartate receptor regulation of amphetamine-induced behavioral and molecular activation**  
   R. Hazim¹³, W.L. Sun¹³, L. Zhou¹², V.Q. Jenab¹³ and S. Jenab¹³, ¹Psychology, ²Biological Sciences, and ³Biopsychology/Behavioral Neuroscience Doctoral Subprogram, CUNY Hunter College, and ⁴Psychology Doctoral Program, CUNY Graduate School and University Center, New York, NY

4. **The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine self-administration in the rat**  
   J. Haggkvist¹, S. Lindholm² and J. Franck¹, ¹Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden and ²Safety Pharmacology, AstraZeneca R&D, Södertälje, Sweden

5. **Effects of norBNI on the self-administration of ethanol in cross- and in-fostered Lewis and Fischer female rats**  
   J.A. Rinker¹, K.M. Serafine¹, P.G. Roma¹, K. Cheng², K.C. Rice² and A.L. Riley¹, ¹Psychopharmacology Lab, Psychology, American University, Washington, DC and ²Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD

6. **Effects of norBNI on ethanol-induced conditioned taste aversions in both in- and cross-fostered Lewis and Fischer female rats**  
   K.M. Serafine¹, J.A. Rinker¹, P.G. Roma¹, K. Cheng², K.C. Rice³ and A.L. Riley¹, ¹Psychology- Psychopharmacology Laboratory, American University, Washington, DC and ²Laboratory of Medicinal Chemistry, NIDDK, Bethesda, MD

7. **Disulfiram enhances subjective effects of dextroamphetamine in humans**  
   R.A. Sewell¹, K. Hill¹, J. Poling¹, T.R. Kosten² and M. Sofuoglu¹, ¹Psychiatry, VA Connecticut Healthcare/Yale University School of Medicine, West Haven, CT and ²Psychiatry, Baylor College of Medicine, Houston, TX

8. **Effect of alcohol dependence diagnosis on efficacy of disulfiram in methadone-stabilized cocaine-dependent volunteers**  
   A. Oliveto, M.J. Mancino and Z.L. Feldman, Psychiatry, UAMS, Little Rock, AR
9 Dose effects of triazolam and alcohol on cognitive performance in healthy volunteers
   B.A. Kleykamp, R.R. Griffiths and M.Z. Mintzer, School of Medicine, Johns Hopkins University, Baltimore, MD

10 Acamprosate efficacy in alcohol-dependent patients: Effect of nicotine and illicit substance use on treatment response
   B.J. Mason¹ and P. Lehert², ¹Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA and ²Statistics, University of Mons, FUCAM, Mons, Belgium

11 Comparing behavioral correlates of EEG variations between stimulant users, alcoholics and community controls
   S.J. Nixon¹, R.A. Prather¹ and N.A. Ceballos², ¹Psychiatry, University of Florida, Gainesville, FL and ²Psychology, Texas State University, San Marcos, TX

CLUB DRUGS

12 The acute subjective effects of benzylpiperazine in healthy females
   H. Lee¹, J. Lin¹, N. Bangs¹, H. Hsiao¹, J. Krstik¹, I.J. Kirk² and B.R. Russell¹, ¹School of Pharmacy, and ²Research Centre for Cognitive Neuroscience, Psychology, The University of Auckland, Auckland, New Zealand

13 Acute effects of MDMA on emotional processing
   G. Bedi and H. de Wit, Psychiatry, University of Chicago, Chicago, IL

14 Alpha-1 noradrenergic receptors contribute to psychostimulant-like effects of MDMA in humans
   M. Baggott¹², G.P. Galloway¹, M. Jang¹, R. Didier¹ and J.E. Mendelson¹, ¹California Pacific Medical Center, San Francisco, CA and ²Helen Wills Neuroscience Institute, UC Berkeley, Berkeley, CA

15 Cannabis use disorders affect the psychological consequences of MDMA
   A. Milosevic¹, L. Sander¹, H. Durdle¹, L.H. Lundahl¹, M.E. Tancer¹ and C.E. Johanson², ¹Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, MI and ²Loyola University, Chicago, IL

16 Psychiatric disorders and health characteristics in MDMA users: Results from the NESARC
   N. Niv¹, D. Sarkisyan¹, U. Warda¹, C. Grella¹, A. Moore¹² and M. Karno¹, ¹Integrated Substance Abuse Programs, and ²Division of Geriatrics, University of California-Los Angeles, Los Angeles, CA

17 MDMA (ecstasy) produces withdrawal-like aftereffects in non-dependent users

18 Brief motivational intervention for ecstasy users: A pilot randomized trial
   G. Martin and J. Copeland, NCPIC, UNSW, Sydney, NSW, Australia

19 The Marquis reaction as a harm reduction element in party atmospheres: An assessment of the on-site testing of ecstasy tablets
   J. Pradeille¹, N. Chakroun², V. Beltran¹⁴, A. Aguerrretxe-Colina¹, M. Auriacome³ and J.P. Daulouede¹, ¹Addiction Clinic BIZIA, Bayonne, ²University of Clermont-Ferrand, UMR 6024, National Center for Scientific Research [CNRS], Clermont-Ferrand, and ³Addiction Psychiatry, JE2358, INSERM IFR 99, U. Victor Segalen Bordeaux 2, Bordeaux, France
**BEHAVIOR**

20  *D-serine reduces spatial learning and memory deficits by γ-hydroxybutyric acid in adolescent rat*  
R. Sircar, D. Sircar and L. Wu, Psychiatry, The Zucker Hillside Hospital/Albert Einstein College of Medicine, Glen Oaks, NY

21  *Periadolescent male, but not female rats, acquire METH-induced CTA when the CS-US trace interval is extended beyond two hours*  
R.T. Lacy, I.D. Longacre, L. Ballina and S. Harrod, Psychology, University of South Carolina, Columbia, SC

22  *Repeated methamphetamine produces time-dependent changes in accumbens dopamine and glutamate*  
K.D. Lominac and K.K. Szumlinski, Psychology, University of California at Santa Barbara, Santa Barbara, CA

23  *Pre-exposure to methamphetamine impairs sexual motivation but not sexual performance*  
B.L. Bolin and C.K. Akins, Psychology, University of Kentucky, Lexington, KY

24  *Sex differences in the development of cocaine-induced stereotyped behavior*  
L. Zhou1,2, W.L. Sun1,3, J. Liu2, Y.X. Liang2, M. Timothy2, K. Weierstall1,3, A.C. Minerly1,3, S. Jenab1,2,3 and V. Quinones-Jenab1,2,3, 1Psychology, and 2Biology, Hunter College, and 3Graduate Center of The City University of New York, New York, NY

25  *Potentiation of cue-induced reinstatement of cocaine seeking in female rats by yohimbine*  

26  *Effects of a differential-reinforcement-of-alternative-behavior schedule of alternative nondrug reinforcement on cocaine self-administration in rats*  
M.G. LeSage, 1Medicine, Minneapolis Medical Research Foundation, and 2Medicine, University of Minnesota, Minneapolis, MN

27  *Food restriction affects cocaine-induced priming but not maintained cocaine self-administration in rats*  
V.L. Tsibulsky, W.B. Buesing, M.K. Norman and A.B. Norman, Psychiatry, University of Cincinnati, Cincinnati, OH

28  *Effect of the orexin 1 (hypocretin 1) receptor antagonist SB 334867 on high-fat food self-administration and relapse to food seeking in rats*  
T. Adams-Deustch, S.G. Nair, S.A. Golden and Y. Shaham, Behavioral Neuroscience, NIDA/IRP/NIH/DHHS, Baltimore, MD

29  *Food restriction and high-fat diet differentially affect the behavioral effects of quinpirole and raclopride in rats*  
M. Baladi1 and C.P. France2, 1Pharmacology, and 2Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, TX

30  *The effects of morphine on delay discounting in pigeons*  
A. Acheson1,2 and C.P. France1, 1Pharmacology, and 2Research Imaging Center, University of Texas Health Science Center at San Antonio, San Antonio, TX

31  *Effects of acute and chronic cocaine on self-control behavior*  
K. Dandy1, J. Higa4, G. King3 and M. Gatch2,3, 1Psychology, Texas Christian University, and 2Pharmacology, University of North Texas Health Science Center, Fort Worth, TX, 3University of Hawaii, and 4University of Hawaii-Honolulu Community College, Honolulu, HI
32 **Impulsivity predicts the escalation of cocaine self-administration in female rats**
J.J. Anker¹, J.L. Perry², J.L. Pawlik¹ and M.E. Carroll¹, ¹University of Minnesota, St. Paul, MN and ²University of Kentucky, Lexington, KY

33 **Trait impulsiveness associates with cognitive deficits in non-human primates**
A.S. James³, S.M. Groman¹, E. Seu¹, M.J. Jorgensen², L.A. Fairbanks² and J.D. Jentsch¹,², ¹Psychology, and ²Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, CA

34 **Individual differences in impulsive-like behavior and sensitivity to money as a function of sensation-seeking status**
S. Babalonis¹,² and T.H. Kelly¹,²,³, ¹Behavioral Science, ²Psychology, and ³Psychiatry, University of Kentucky, Lexington, KY

35 **Methylphenidate self-administration in high- and low-impulsive sensation seekers using a progressive-ratio procedure**

36 **Methylphenidate reinforcement in adults with and without Attention Deficit Hyperactivity Disorder**

**SUBSTANCE ABUSE IN ADOLESCENTS III**

37 **The relationship between tobacco and cannabis use among teens in treatment for cannabis use disorders and ADHD**
C. Thurstone¹,², M. deDios³ and P.D. Riggs¹, ¹Denver Health and Hospital Authority, and ²University of Colorado at Denver and Health Sciences Center, Denver, CO and ³Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC

38 **Correlates of ADHD comorbidity among adolescent smokers**
H. Upadhyaya¹, G.E. Gilbert², K.M. Gray¹, M. Carpenter¹, T. Randall¹ and D. Deas¹, ¹Psychiatry and Behavioral Sciences, and ²Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC

39 **Characteristics of psychopathy and delay discounting in adolescent smokers and nonsmokers**
S. Melanko¹,², K. Leraas¹,², C. Collins¹,², M. Patak¹,² and B. Reynolds¹,², ¹The Research Institute at Nationwide Children's Hospital, and ²Pediatrics, Ohio State University, Columbus, OH

40 **Delay discounting in children of smokers and nonsmokers**
C. Collins¹,², K. Leraas¹,², S. Melanko¹,² and B. Reynolds¹,², ¹Pediatrics, Ohio State University, and ²The Research Institute at Nationwide Children's Hospital, Columbus, OH

41 **Delay discounting and self-reported stress in adolescents experimenting with cigarette smoking**
B. Reynolds¹,², C. Collins¹,², M. Patak¹,², K. Leraas¹,², S. Melanko¹,² and R. Penfold¹,², ¹Pediatrics, Ohio State University, and ²The Research Institute at Nationwide Children's Hospital, Columbus, OH

42 **Impulsivity, self-efficacy and coping styles in adolescent tobacco users**
S. Krishnan-Sarin, A.E. Smith, D.A. Cavallo, T.S. Schepis, A. McFetridge and T. Liss, Psychiatry, Yale University School of Medicine, New Haven, CT
43 Risk for preteen substance use from impulsivity, perceived safety, and others’ use
   T.A. Ridenour1,2, J.L. Maggs2, M.T. Greenberg2 and D.B. Clark1, 1Center for Education and
   Drug Abuse Research, University of Pittsburgh, Pittsburgh, PA and 2Prevention Research
   Center, The Pennsylvania State University, State College, PA

44 Adolescents seeking cessation treatment: Level of tobacco dependence and reported morbidity
   S.J. Lo, C.C. Collins and E.T. Moolchan, TTATRC, NIDA IRP, Baltimore, MD

45 Adolescent low-rate smokers desire and attempt to quit as much as heavier smokers
   M.J. Carpenter1, A. Alberg1, K. Cartmell1, C. Vitoc2, S. Biggers2 and H. Upadhyaya1,
   1Medical University of South Carolina, Charleston, SC and 2South Carolina Department of
   Health and Environmental Control, Columbia, SC

46 Factors associated with tobacco smoking in Mexican high school students
   O. Campollo1,2, C. Alvarez-Gonzalez1, M. Bustos Gamiño1, H. Sanchez1 and
   J. Toro Guerrero1, 1Center of Studies on Alcohol and ADdictions, Universidad de Guadalajara,
   and 2Clínica para dejar de fumar, Antiguo Hospital Civil de Guadalajara, Guadalajara, Mexico

47 Physician continuity and treatment outcome in an adolescent smoking cessation study
   A.S. Leinbach, M.J. Carpenter, G.E. Gilbert, E.M. Klintworth, K.M. Gray and
   H.P. Upadhyaya, Medical University of South Carolina, Charleston, SC

48 A Web-based contingency management program with adolescent smokers
   K. Leraas1,2, S. Melanko1,2, C. Collins1,2, J. Dallery3 and B. Reynolds1,2, 1Pediatrics, Ohio State
   University, and 2The Research Institute at Nationwide Children's Hospital, Columbus, OH and
   3University of Florida, Gainesville, FL

49 Does contingency management improve study retention and treatment outcomes in adolescent
   smoking cessation research?
   K.M. Gray1, M.J. Carpenter2,1, G.E. Gilbert3 and H.P. Upadhyaya1, 1Psychiatry and Behavioral
   Sciences, 2Hollings Cancer Center, and 3Biostatistics, Bioinformatics, and Epidemiology,
   Medical University of South Carolina, Charleston, SC

50 Spending habits of adolescents participating in a contingency management-based smoking
   cessation research program
   B.J. Rounsaville and S. Krishnan-Sarin, Psychiatry, Yale University, New Haven, CT

51 Preliminary study of varenicline for adolescent smoking
   D.C. Lott1,2,3 and C. Thurstone4,5, 1Linden Oaks Hospital, Naperville, IL
   University of Illinois at Chicago, and 3University of Colorado at Denver and
   Health Sciences Center, and 4DHHA, Denver, CO

52 Nicotine replacement therapy use and FTND scores in adolescents seeking tobacco cessation
   treatment
   C.E. Wieczorek, C.C. Collins, C.S. Parzynski and E.T. Moolchan, TTATRC, NIDA IRP,
   Baltimore, MD

53 Adolescent weight gain during the treatment phase of a nicotine replacement therapy trial:
   Relationship with medication compliance rates
   C.S. Parzynski, E.D. Thorner, C. Wieczorek, M.J. Gasior, C.C. Collins and E.T. Moolchan,
   TTATRC, NIDA IRP, Baltimore, MD
PSYCHIATRIC COMORBIDITY II

54 Contrasting models of genetic comorbidity for childhood conduct disorder and cannabis involvement
M. Lynskey¹, A. Agrawal¹, K.K. Bucholz¹, P.A. Madden¹, A.C. Heath¹ and N.G. Martin²,
¹Washington University School of Medicine, St. Louis, MO and ²Queensland Institute of Medical Research, Brisbane, QLD, Australia

55 Cannabis abuse and severity of psychotic and affective disorders in psychiatric inpatients
G. Katz, R. Durst, E. Shufman, R. Bar-Hamburger and L. Grunhaus, Jerusalem Mental Health Center - Kfar Shaul Hospital, Jerusalem, Israel

56 The role of anxiety in the treatment of marijuana dependence
J.D. Buckner and K. Carroll, Yale University School of Medicine, New Haven, CT

57 Scaling phenotype and enviromotype for prediction of cannabis use disorder
L. Kirisci, R. Tarter, M. Vanyukov, A. Mezzich, M. Reynolds and T. Ridenour, Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA

58 Increased schizotypal traits and altered affect in young cannabis users
R.K. Minas², R. Cowan¹ and S. Park², ¹Psychiatric Neuroimaging Program, and ²Psychology, Vanderbilt University, Nashville, TN

59 Bupropion plus incentives for smoking reductions in outpatients with schizophrenia
J.W. Tidey¹², D. Rohsenow¹³¹, G. Kaplan³ and R. Swift¹³¹, ¹Center for Alcohol and Addiction Studies, Brown University, and ²Research Service, VA Medical Center, Providence, RI and ³Mental Health Service, VA Boston Healthcare System, Brockton, MA

60 High-dose nicotine and sensorimotor replacement effects on cognition in smokers with schizophrenia
C.G. AhnAllen and J.W. Tidey, Center for Alcohol and Addictions Studies, Brown University, Providence, RI

61 Smoking cues increase caffeine urges in outpatients with schizophrenia
A.B. Adolfo¹, J.W. Tidey¹² and C. Ahnallen¹, ¹Center for Alcohol and Addiction Studies, Brown University, and ²Research Service, VA Medical Center, Providence, RI

62 The Balloon Analogue Risk Task as a measure of impulsivity in alcohol-dependent individuals with bipolar disorder
B.K. Tolliver, A.E. Waldrop and K.T. Brady, Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC

63 Quetiapine versus risperidone: A double-blind, randomized treatment trial in co-occurring bipolar disorder with cocaine or methamphetamine dependence
V.A. Nejtek¹², M. Avila¹, L.A. Chen², A. Podawiltz³, T. Zielinski³, M. Djokovic¹, K. Kaiser¹ and A.J. Rush³, ¹Psychiatry, University of North Texas Health Science Center, Fort Worth, TX and ²Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX and ³Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX

64 The effects of khat and posttraumatic stress on psychotic symptoms: A cross-sectional study in Somali combatants
M. Odenwald¹, H. Hinkel², E. Schauer³⁴, F. Neuner¹, M. Schauer³⁴, B. Rockstroh¹ and T.R. Elbert¹, ¹Psychology, University of Konstanz, Konstanz, Germany, ²Multi-Country Demobilization and Reintegration Program, The World Bank, Goma, Congo, Dem. Rep. and ³Vivo Foundation, Ancona, Italy

65 Lack of efficacy of fluoxetine in depressed cocaine-dependent subjects
E.L. Winstanley, E. Strain and G. Bigelow, Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, Baltimore, MD
Depressive symptoms and nonmedical use of prescription stimulants among college students

C.J. Teter, S.E. McCabe, J.A. Cranford and C.J. Boyd, School of Pharmacy, Northeastern University, Boston, and Alcohol and Drug Abuse Treatment Program, McLean Hospital, Belmont, MA, Substance Abuse Research Center, and Institute for Research on Women and Gender, University of Michigan, Ann Arbor, MI

Impulsivity and cocaine use as risk factors for high-risk sexual behavior in dually diagnosed outpatients

K. Serowik, R.A. Black and M.I. Rosen, Psychiatry, Yale University School of Medicine, New Haven, CT and Psychiatry, VA Connecticut Healthcare System, West Haven, CT

Treatment outcomes of methamphetamine-dependent adults with psychotic disorders

S. Glasner-Edwards, L.J. Mooney, P. Marinelli-Casey, M. Hillhouse, A. Ang and R.A. Rawson, Integrated Substance Abuse Programs, and University of California-Los Angeles, Los Angeles, CA

Cocaine/crack use is frequent among new admissions and predicts early dropout from psychiatric day treatment

J. Spybrook, S. Magura, A. Rosenblum, C. Fong, C. Villano, H. Vogel and T. Betzler, Evaluation Center, Western Michigan University, Kalamazoo, MI, National Development and Research Institutes, and Albert Einstein College of Medicine, NY, NY

Baseline study of problem gambling and co-occurring substance use among students at the University of Iowa

A.H. Skinstad, S. Hansen, K. Montes, M.O. Goransson and K.M. Summers, Community and Behavioral Health, College of Public Health, and Student Health Services, University of Iowa, Iowa City, IA

Assessment and treatment of co-occurring eating disorders in publicly funded addiction treatment programs

S.M. Gordon, A. Johnson, S. Greenfield, L. Cohen, T. Killeen and P. Roman, Seabrook House, Seabrook, NJ, University of Georgia, Athens, GA, Columbia University, New York, NY, Medical University SC, Charleston, SC, Harvard Medical School, Boston, and McLean Hospital, Belmont, MA

Cocaína: Human Studies II

The cocaine selective severity assessment: Self-report vs clinician-rating

A. Umbricht, E.L. Winstanley, M.Z. Mintzer, E.C. Strain and G.E. Bigelow, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, MD

The validity of measures for monitoring cocaine use in outpatient clinical trials

W.V. Lechner, S.L. Hedden, R.J. Malcolm and K. Hartwell, Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, SC and Mental Health, Johns Hopkins Bloomberg School of Medicine, Baltimore, MD

Monitoring daily self-reported cocaine use using Interactive Voice Response technology: Compliance and validation

J. Lindsay, J.M. Schmitz and C.M. Green, University of Texas Health Science Center at Houston, Houston, TX

Zero-inflation in ASI composite scores: Comparisons with concurrent validation measures

K.G. Lynch, J.S. Cacciola and A.I. Alterman, University of Pennsylvania, and Treatment Research Institute, Philadelphia, PA
76 Reactive aggression and proactive aggression in suicidal ideation and attempts
K.R. Conner¹², R.J. Houston¹ and M.T. Swogger¹, Psychiatry, University of Rochester Medical Center, Rochester, NY, ²VA Center of Excellence, Canandaigua, NY and ³Research Institute on Addictions, Buffalo, NY

77 Clinical relationships between cognition, commitment language and behavioral change in cocaine-dependent patients
P. Amrhein¹², E. Aharonovich⁵, D. Hasin², A. Bisaga² and E. Nunes², Psychology, Montclair State University, Montclair, NJ and ³Psychiatry, Columbia University, New York, NY

78 Outpatient cocaine therapies: Pilot study on incentivizing study attendance and retention
T. Polk¹³, T. Gardner¹³, K. McQueen²⁴, M. Sitzer⁵ and T. Kosten¹³, Psychiatry, and ²Medicine, Baylor College of Medicine, ³Michael E DeBakey VA Medical Center, Houston, and ⁴Ben Taub General Hospital, Houston, TX and ⁵Johns Hopkins University School of Medicine, Baltimore, MD

79 Cocaine abstinence in a randomized controlled trial of 3 vs 9 months of voucher-based reinforcement therapy: Year 1 outcomes
C.M. Carpenedo¹, B.E. Versek¹, E. Bresani¹, T.F. Case¹, J.E. Clement¹, M.C. Carter¹, B.J. Rosenwasser¹, K.L. Dugosh¹, K. Lynch³¹ and K.C. Kirby¹², ¹Behavioral Interventions, Treatment Research Institute, and ²University of Pennsylvania, Philadelphia, PA

80 Randomized clinical trial of contingency management among parenting cocaine-dependent African American female recovery house residents
L.E. Durant¹, J.L. Rounds-Bryant² and J. Dutta¹, ¹Duke University Medical Center, and ²Mental Health Solutions, Durham, NC

81 Community Reinforcement Approach plus vouchers for cocaine addicts: Clinical variables outcomes
O. Garcia-Rodriguez¹, R. Secades-Villa², J.R. Fernandez-Hermida² and J.L. Carballo², ¹Clinical Psychology, University of Barcelona, Barcelona, Spain and ²Psychology, University of Oviedo, Oviedo, Spain

82 Cost-effectiveness of a contingency management intervention in a community setting
R. Secades-Villa¹, O. Garcia-Rodriguez², J.R. Fernandez-Hermida¹ and E. Sanchez-Hervas³, ¹Psychology, University of Oviedo, Oviedo, ²Clinical Psychology, University of Barcelona, Barcelona, and ³Valencia State Health Agency, Valencia, Spain

83 Contingency management and CBT in intensive outpatient treatment for cocaine dependence

84 A randomized controlled trial of a money-management-based intervention targeting substance use
M.I. Rosen¹², K.M. Carroll¹², E.A. Stefanovic²¹ and R.A. Rosenheck²¹, ¹Psychiatry, Yale University School of Medicine, New Haven, and ²Psychiatry, VA Connecticut Healthcare System, West Haven, CT

85 A Transtheoretical Model group therapy for cocaine abusers
M.M. Velasquez¹, A.L. Stotts², K.L. von Sternberg¹, C.L. Dodrill² and J.P. Carbonari³, ¹University of Texas-Austin, Austin, ²University of Texas Medical School-Houston, and ³University of Houston, Houston, TX
86 Abstinence during contingency management treatment predicts abstinence at follow-up in three clinical trials with homeless cocaine-dependent persons
R. Vuchinich1, J. Milby1, J. Schumacher1, D. Wallace2, S. Kertesz1 and S. Mennemeyer1,
1University of Alabama at Birmingham, Birmingham, AL and 2RHO Federal Systems
Division, Inc., Chapel Hill, NC

87 Employment-based abstinence reinforcement as a maintenance intervention for the treatment of persistent cocaine use in methadone patients: A molecular analysis
A. DeFulio1, M. Needham1, W.D. Donlin2, C.J. Wong3 and K. Silverman1, 1Johns Hopkins
University School of Medicine, Baltimore, MD, 2University of North Carolina Wilmington,
Wilmington, NC and 3University of Kentucky College of Medicine, Lexington, KY

OPIOIDS: HUMAN STUDIES II

88 Selective GABA reuptake inhibition for methadone induction and early stabilization
G. Gonzalez1,2, M. Romero-Gonzalez1,2, M. Randall1,2, R. Desai1,2, H. Patwa1,2, H. Tokuno1,2,
R. Hart1,2, J. Napoleone1,2 and I. Petrakis1,2, 1Yale University, New Haven, CT and 2VA CT
Healthcare System, West Haven, CT

89 Poor objective sleep among methadone-maintained patients is associated with chronic pain but not with methadone dose
E. Peles1, S. Schreiber1,2, R.B. Hamburger3 and M. Adelson1, 1Dr. Miriam & Sheldon G.
Adelson Clinic for Drug Abuse Treatment and Research, and 3Psychiatry, Tel-Aviv Sourasky
Medical Center, Tel Aviv, and 3Israel National, Anti-Drug Authority, Jerusalem, Israel

90 Is methadone treatment and indication missing from the medical record? A patient safety issue
Medicine, Boston University School of Medicine, Boston, MA

91 Consistent use of methadone maintenance is associated with lower cost to the managed care organization
K. Stoller1, A. Schuster1,2, D.A. Tompkins1, P. Fagan1,2, L. Dunbar2, C. Schmidt1,2 and
R. Brooner1, 1Psychiatry and Behavioral Sciences, Johns Hopkins University School of
Medicine, Baltimore, 2Johns Hopkins HealthCare, LLC, Glen Burnie, and 3Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD

92 Methadone vs. non-methadone patients in a therapeutic community: Test of equivalency
J.L. Sorensen1, S. Andrews2, K.L. Delucchi2, B. Greenberg2, J. Guydish1 and C.L. Masson1,
1Psychiatry, University of California, San Francisco, and 2Walden House Inc.,
San Francisco, CA

93 A therapeutic workplace for the long-term treatment of drug addiction in methadone patients: Eight-year outcomes
W.M. Aklin1, C.J. Wong2, D. Svikis3, M.L. Stitzer1, G.E. Bigelow1 and K. Silverman1,
1Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, 2Psychiatry, University of
Kentucky College of Medicine, Lexington, KY and 3Psychology, Virginia Commonwealth
University, Richmond, VA

94 Predictors of treatment enrollment in syringe exchange participants
V.L. King, J. Peirce, R. Brooner and M. Kidorf, Psychiatry, JOhns HOpkins School of
Medicine, Baltimore, MD

95 One-year-treatment outcomes for patients referred from syringe exchange versus other sources
K.J. Neufeld, M. Cutler, J. Peirce, R. Brooner, V. King and M. Kidorf, Psychiatry, Johns
Hopkins University School of Medicine, Baltimore, MD
96 Predictors of outcomes for opiate IDUs in methadone treatment
K.F. Corsi, W.K. Lehman and R.E. Booth, Psychiatry, University of Colorado Denver Health Sciences Center, Denver, CO

97 Relationship between patient satisfaction and methadone treatment outcomes
S. Kelly1, R.P. Schwartz1, K.E. O’Grady2 and B.S. Brown1,2, 1Friends Research Institute, Baltimore, MD, 2University of Maryland, College Park, MD and 3University of North Carolina, Wilmington, NC

98 Personality factors associated with methadone maintenance dose
H.W. Murray1, R.K. McHugh1, J. Hogan1, E. Behar2, T. Markowitz1 and M.W. Otto1, 1Boston University, Boston, MA and 2University of Illinois at Chicago, Chicago, IL

99 Relation between vulnerable attachment styles and drug abuse among methadone maintenance treatment patients
D. Potik, Y. Abramsohn, E. Peles, S. Schreiber and M. Adelson, The Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse Treatment & Research, Tel-Aviv, Israel

100 Integrated psychiatric services are associated with improved service delivery and better treatment response
R.K. Brooner, V. King, K. Neufeld, K. Stoller, J. Peirce, M. Kidorff, M. Clark and W. Aklin, School of Medicine, Johns Hopkins University, Baltimore, MD

101 Dissolution of a VA harm reduction program for opiate agonist treatment: Impact on substance use and service utilization
B.J. Hartzler1, D. Calsyn1,2, A. Cotton3, R. Guerra4 and N. Gignoux2, 1Alcohol & Drug Abuse Institute, University of Washington, 2Addiction Treatment Center, VA Puget Sound Healthcare System, and 3Psychiatry & Behavioral Sciences, University of Washington, Seattle, WA

102 Using an Internet-based platform to deliver intensified services in treatment seeking opioid-dependent patients
K. Kindbom1, V. King1, K. Stoller1, R. Brooner1, M. Kidorff4, S. Hursh2 and T. Brady3, 1School of Medicine, Johns Hopkins University, and 2Institute for Behavior Resources, Baltimore, MD and 3CRC Health Group, San Jose, CA

103 Mobile telephones: Feasibility for prospective follow-up of injecting-heroin users in Sweden
A. Hakansson, C. Wallin, P. Isendahl and M. Berglund, Lund University, Lund University, Malmö, Sweden

104 Impact of telephone reminder calls on adherence to scheduled counseling sessions in a methadone substitution clinic
M.L. Cutler, R. Brooner, M. Kidorff and K. Neufeld, Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD

105 Abstinence and use of benzodiazepines are major risk factors for fatal opiate overdose: Objective evidence from blood and segmental hair analysis
J.J. Strandberg1, K. Alkass2, F.C. Kugelberg2, I. Nyström2, R. Kronstrand2 and H. Drudi1, 1Forensic Medicine, Karolinska Institutet, Stockholm, Sweden and 2Forensic Genetics and Toxicology, National Board of Forensic Medicine, Linköping, Sweden

106 Potential triggers for overdose among individuals with substance dependence
J.D. Wines1, R. Saitz2, D. Allensworth-Davies3, D.M. Cheng3 and J.H. Samet2, 1Psychiatry, McLean Hospital-Harvard Medical School, Belmont, MA, 2Medicine, Boston Medical Center-Boston University School of Medicine, Boston, MA and 3Data Coordinating Center, Boston University School of Public Health, Boston, MA
107 Risk factors for oxygen desaturation after injection of heroin or methadone: A laboratory model of overdose susceptibility

108 Source of methadone in overdose deaths in rural western Virginia in 2004
   M.J. Wunsch, M. Weimer and K. Nakamoto, Addiction Medicine, Virginia College of Osteopathic Medicine, Blacksburg, VA, Internal Medicine, Oregon Health Sciences Center, Portland, OR and Marketing, Virginia Tech, Blacksburg, VA

GENDER DIFFERENCES

109 Gender differences in mortality among heroin, cocaine and methamphetamine users
   L. Liang, M. Brecht and Y. Hser, Medicine, and Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA

110 Gender differences in problem gambling and comorbid substance use behaviors in the Canadian general population
   L.A. Ghandour, S. Martins and C. Storr, Mental Health, Johns Hopkins University, Baltimore, MD

111 Gender differences in cortisol reactivity among African American polysubstance users
   R.M. Schuster, S. Daughters, M. Sargeant, C. Forst, C. Lejuez and R. Sinha, Psychology, University of Maryland, College Park, MD and Psychiatry, Yale University, New Haven, CT

112 Effects of IM progesterone administration upon responses to acute psychosocial stress
   E. Childs, N.T. Van Dam and H. de Wit, Psychiatry, The University of Chicago, Chicago, IL

113 Gender differences in stress and cue-related adrenergic response in cocaine-dependent patients compared with social-drinking controls
   K. Hong, H. Fox, G. Anderson and R. Sinha, Psychiatry, Yale University, New Haven, CT

   H. Cheng and J.C. Anthony, Michigan State University, East Lansing, MI

115 Alcohol-associated social maladaptation, cannabis use, and male-female differences: A latent class analysis
   M. Radovanovic, J. Posada-Villa, J.C. Anthony, M.E. Medina-Mora and World Mental Health Surveys Consortium, Epidemiology, Michigan State University, East Lansing, MI, Institute of Psychiatry, Ciudad de Mexico, Mexico, Saldarriaga Concha Foundation, Bogota, Colombia and WMHS Consortium, Boston, MA

116 Gender differences in subjective and physiological response to oral THC in cannabis-dependent humans
   L.H. Lundahl, H. Lockhart, M.E. Tancer and C.E. Johanson, Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI and Loyola University, Chicago, IL

117 Gender differences in progression to dependence in non-treatment-seeking adult cannabis users
   M.L. Copersino, K.H. Levin, S.J. Heishman and D.A. Gorelick, McLean Hospital/Harvard Medical School, Belmont, MA and IRP NIDA/NIH/DHHS, Baltimore, MD

118 Gender moderates stereotype threat in cannabis users
   A. Looby and M. Earleywine, Psychology, University at Albany, SUNY, Albany, NY
119 Gender differences in coping motives and substance use disorder severity  
R. McHugh, H.W. Murray, E.M. Pratt, J.B. Hogan, T.C. Rowley and M.W. Otto, Psychology, Boston University, Boston, MA

120 Substance use disorder treatment is associated with lower incidence of traumatic events for women  
J. Peirce, W.M. Aklin, K.B. Stoller, M.S. Kidorf and R.K. Brooner, Johns Hopkins University School of Medicine, Baltimore, MD

121 Gender differences in lifetime experiences of intimate partner violence among heroin users in a 25-year follow-up  
L. Rodriguez and C. Grella, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA

122 Gender differences in the association between victimization history and substance abuse with regard to prevalence and risk factors  
C.K. Danielson\textsuperscript{1}, A. Amstadter\textsuperscript{1}, C.W. Lejuez\textsuperscript{2}, H. Resnick\textsuperscript{1}, B. Saunders\textsuperscript{1} and D. Kilpatrick\textsuperscript{1}, \textsuperscript{1}MUSC, Charleston, SC and \textsuperscript{2}University of MD, College Park, MD

123 Gender differences in the social and support networks of inner-city current and former drug users  
A.S. Buchanan and C.A. Latkin, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD

124 Gender differences in HIV risk: Results from a randomized clinical trial  
M. Wilson\textsuperscript{1}, R.P. Schwartz\textsuperscript{1}, K.E. O'Grady\textsuperscript{2}, D. Highfield\textsuperscript{1} and J.H. Jaffe\textsuperscript{1}, \textsuperscript{1}Friends Research Institute, Baltimore, MD and \textsuperscript{2}University of Maryland, College Park, MD

125 Children as motivation to reduce HIV risk: Gender differences among IDUs in treatment  
M. Copenhaver\textsuperscript{1}, A. Merz\textsuperscript{2} and I. Lee\textsuperscript{3}, \textsuperscript{1}Allied Health Sciences and Psychology, University of Connecticut, Storrs, and \textsuperscript{2}Public Health, University of Connecticut, Farmington, CT and \textsuperscript{3}Psychology, National Chengchi University, Taipei, Taiwan

126 Inclusion of women and minorities in clinical trials of FDA-approved pharmacotherapy for smoking cessation  
D.L. Dickerson\textsuperscript{1}, R.F. Leeman\textsuperscript{2}, C.M. Mazure\textsuperscript{2} and S.S. O'Malley\textsuperscript{2}, \textsuperscript{1}ISAP, University of California-Los Angeles, Long Beach, CA and \textsuperscript{2}Yale University, New Haven, CT

127 Male-female differences in tobacco dependence: Colombia, 2003  
J.E. Salinas\textsuperscript{1}, J. Posada-Villa\textsuperscript{2}, H. Cheng\textsuperscript{1}, J.C. Anthony\textsuperscript{1} and World Mental Health Survey Consortium\textsuperscript{3}, \textsuperscript{1}Epidemiology, MSU, East Lansing, MI, \textsuperscript{2}Saldarriaga Concha Foundation, Bogota, Colombia and \textsuperscript{3}WMHS Consortium, Boston, MA

128 Male-female differences in tobacco dependence: Mexico, 2001-2002  
M.M. Catacora\textsuperscript{1}, M.E. Medina-Mora\textsuperscript{2}, G. Borges\textsuperscript{2}, H. Cheng\textsuperscript{1}, J.C. Anthony\textsuperscript{1} and World Mental Health Survey Consortium\textsuperscript{3}, \textsuperscript{1}Epidemiology, Michigan State University, East Lansing, MI, \textsuperscript{2}National Institute of Psychiatry and Metropolitan Autonomous University, Mexico F.D., Mexico and \textsuperscript{3}WMHS Consortium, Boston, MA

129 Gender differences in prevalence, risk and clinical correlates of smoking comorbidity in schizophrenia in a Chinese population  
X.Y. Zhang\textsuperscript{12}, D.F. Zhou\textsuperscript{2}, G.Y. Wu\textsuperscript{1}, T.A. Kosten\textsuperscript{1} and T.R. Kosten\textsuperscript{1}, \textsuperscript{1}Psychiatry, Baylor College of Medicine, Houston, TX and \textsuperscript{2}Psychiatry, Peking University, Beijing, China

130 Evaluation of gender differences in subjective craving and stress reactions to smoking and stress cues in nicotine-dependent individuals  
M.E. Saladin, H. Upadhyaya, M. Carpenter, S. LaRowe, S. DeSantis and K. Brady, Medical University of South Carolina, Charleston, SC
<table>
<thead>
<tr>
<th>131</th>
<th>Individual differences in stimulant-induced increases in cigarette smoking</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M.M. Poole¹, A.R. Vansickle¹², W.W. Stoops² and C.R. Rush¹²³, ¹Psychology, ²Behavioral Science, and ³Psychiatry, University of Kentucky, Lexington, KY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>132</th>
<th>Male-female differences and risk of developing a dependence syndrome soon after onset of extra-medical use of psychostimulant compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>O.A. Adelaja and J.C. Anthony, Epidemiology, Michigan State University, East Lansing, MI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>133</th>
<th>Gender and sexual relationship power among out-of-treatment methamphetamine users</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D.J. Rinehart, K.F. Corsi and R.E. Booth, University of Colorado at Denver and Health Sciences, Denver, CO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>134</th>
<th>d-Amphetamine self-administration in women and men</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F. Wagner¹, A.R. Vansickle¹², W.W. Stoops¹ and C.R. Rush¹²³, ¹Behavioral Science, ²Psychology, and ³Psychiatry, University of Kentucky, Lexington, KY</td>
</tr>
</tbody>
</table>

**POLICY**

<table>
<thead>
<tr>
<th>135</th>
<th>Drug-endangered children: Parental methamphetamine use and manufacture</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N.P. Messina, R. Rawson and P. Marinelli-Casey, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>136</th>
<th>The impact of a three-hour neuroscience of addiction curriculum on college students' knowledge and attitudes: Preliminary results of the NIDA enters college project</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J.A. Hartje¹, M.S. Berry¹, W.L. Woods¹, A.D. Broadus¹, N.A. Roget¹ and P. Riggs², ¹CASAT, University of Nevada, Reno, NV and ²Health Sciences Center, University of Colorado, Denver, CO</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>137</th>
<th>High-risk offenders in California's Proposition 36</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Y. Hser and E. Evans, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>138</th>
<th>Readiness to change as a predictor of drug-related behaviors in a sample of rural felony probationers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J.L. Duvall, C.B. Oser and C.G. Leukefeld, University of Kentucky, Lexington, KY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>139</th>
<th>National study of Departments of Corrections as purchasers of community-based treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Pimlott Kubiak¹, C.L. Arfken² and E.D. Shifflet Gibson¹, ¹School of Social Work, Michigan State University, East Lansing, and ²Wayne State University, Detroit, MI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>140</th>
<th>Measuring perceptions of coercion in research with addicted offenders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K.L. Dugosh, D.S. Festinger and J.R. Croft, Treatment Research Institute, Philadelphia, PA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>141</th>
<th>Do client perceptions of drug court influence their outcomes?</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>142</th>
<th>Recall of informed consent information: It pays to remember</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>143</th>
<th>Does corrected feedback improve recall of informed consent information?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J.R. Croft, D. Festinger and K. Dugosh, Law and Ethics, Treatment Research Institute, Philadelphia, PA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>144</th>
<th>Preference-based utility values for drug use and drug disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>K.L. Kraemer¹, Q. Dang¹, A. Gordon¹, J. Cornelius¹, M. Roberts¹, R. Saitz², J. Conigliaro³ and L. Settles¹, ¹Medicine, University of Pittsburgh, Pittsburgh, PA, ²Medicine, Boston University, Boston, MA and ³Medicine, University of Kentucky, Lexington, LA</td>
</tr>
</tbody>
</table>
145 Access to substance abuse treatment for people from historically disadvantaged South African communities
  B. Myers, Alcohol and Drug Abuse Research Unit, South African Medical Research Council, Tygerberg, South Africa

146 Work- and health-related disparities for low-income working adults with mental health and/or substance misuse disorders
  T.M. Bohman¹, L. Wallisch¹, E. Nwokeji¹, A. Pittman¹, R.T. Spence¹, B. Ostermeyer² and B. Reed², ¹University of Texas, Austin, and ²Baylor College of Medicine, Houston, TX

147 Distance traveled and cross-state commuting among patients in opioid agonist treatment programs
  M. Parrino², A. Rosenblum¹, C. Fong¹, C. Maxwell² and S. Magura³⁴, ¹National Development and Research Institutes, Inc., and ²American Association for the Treatment of Opioid Dependence, New York, NY and ³Western Michigan University, Kalamazoo, MI

148 Barriers for buprenorphine treatment in the Veterans Health Administration
  J. Liberto¹, G.J. Kavanagh¹, R. Ramgopal², S. Paidisetty² and A.J. Gordon², ¹VA Maryland Health Care System, Baltimore, MD and ²VA Pittsburgh Healthcare System, Pittsburgh, PA

149 Enabling factors for buprenorphine treatment in the Veterans Health Administration
  A.J. Gordon¹, G.J. Kavanagh², R. Ramgopal¹, S. Paidisetty² and J. Liberto², ¹VA Pittsburgh Healthcare System, Pittsburgh, PA and ²VA Maryland Health Care System, Baltimore, MD

150 Opioid pharmacotherapy maintenance: Supply, demand and service system modelling
  A. Ritter and J. Chalmers, Drug Policy Modelling Program, University of New South Wales, Sydney, NSW, Australia

PROGRAM DESCRIPTION II

151 A mosaic and tapestry approach to training drug abuse researchers in the Responsible Conduct of Research
  C.L. Striley, E.L. Murdock and L.B. Cottler, Psychiatry, Washington University, St. Louis, MO

152 Developing models for community-based research: Lessons learned from NIDA studies
  L.B. Cottler, C. Striley and C. Callahan, Psychiatry, Washington University School of Medicine, St. Louis, MO

153 Innovation adoption: Lessons learned from recruiting drug treatment agencies into a randomized control trial
  A. Pulvermacher¹, J.H. Ford¹, A. Quanbeck¹, D. Gustafson¹, D. McCarty², J. McConnel² and K. Hoffman², ¹University of Wisconsin - Madison, Madison, WI and ²Oregon Health and Sciences University, Portland, OR

154 Translating ideas into practice: Implementation of a process improvement RCT for 200 drug treatment agencies
  J.H. Ford¹, A. Quanbeck¹, A. Pulvermacher¹, D. Gustafson¹, D. McCarty², K. Hoffman² and J. McConnel², ¹University of Wisconsin - Madison, Madison, WI and ²Oregon Health Sciences University, Portland, OR

155 National multidisciplinary French training program to improve the quality of treatment for opiate addiction patients and to make a professional's care easier: Objectives and outcome
  D.P. Touzeau¹, C. Bronner², S. Personnic³ and B. Mouret³, ¹Clinique Liberté, Bagneux, ²IRMG, and ³Sante et Public, Paris, France
156 Evaluation of Treatnet—The international network of drug dependence treatment and rehabilitation resource centres
J. Tomas-Rossello¹, E. Saenz-Miranda¹, A. Busse¹, B. Sibanda², B. Torggler², G. Gerra¹ and Treatnet Network¹,¹Division of Operations, Global Challenges Section, Prevention, Treatment and Rehabilitation Unit, and ²Independent Evaluation Unit, United Nations Office on Drugs and Crime, Vienna, Austria

157 Evaluation of a drug treatment program for families engaged in the child welfare system
M.S. Shafer, B. Arthur, M. Mellacheruvu and L. Crone-Koshel, College of Human Services, Arizona State University, Phoenix, AZ

158 Implementing evidence-based practices in a transitional housing program
W. Beauchamp¹, M.S. Shafer¹, R. Rhode¹, N. Jones², B. Arthur¹ and T. Litwicki², ¹Arizona State University, Phoenix, AZ and ²Old Pueblo Community Foundation, Tucson, AZ

159 Access to Recovery: A federal initiative to increase substance abuse treatment capacity
H. Clark, A. Kopstein, D. Avula, N. Lu, J. Stein and R. Kopanda, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD

160 Outcomes monitoring as a clinical intervention
J.S. Cacciola¹², D. Carise¹², J.R. McKay¹² and A.T. McLellan¹², ¹Treatment Research Institute, and ²University of Pennsylvania, Philadelphia, PA

161 The NOBLE Study: Assessing the effectiveness of residential vs. intensive outpatient prison-based treatment and inmates’ views on HIV/AIDS-related behaviors and services
W.M. Burdon, J. St. De Lore and M.L. Prendergast, Integrated Substance Abuse Programs, University of California, Los Angeles, Los Angeles, CA

162 Project BRITE: Developing and implementing a positive behavioral reinforcement intervention to increase treatment engagement in prison-based substance abuse treatment
J. St. De Lore, W.M. Burdon and M.L. Prendergast, Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA

163 An intervention to increase medical assessment of in-treatment socially precarious polydrug users. Impact of a focused group counseling session
A. Van Paemelen², A. Larraburu², C. Denis¹², E. Lavie¹², M. Fatseas¹² and M. Auriacombe¹², ¹Addiction Psychiatry EA4139/INSERM-IFR99, Universite Victor Segalen Bordeaux 2, and ²Addiction Treatment Center, CHCP, CHU, Bordeaux, France

164 Developing a curriculum for conflict resolution education for use by substance abuse counselors with adult substance abusers
R. Oser¹, C. Tuohy², D. Petska¹, S. Libretto¹, H. Wong¹ and J. Hoffman¹, ¹Danya International, Silver Spring, MD and ²NAADAC, Alexandria, VA

165 Teaching medical students to perform screening and brief interventions for unhealthy substance use
D.P. Alford¹, T.W. Kim¹, L. Ellenberg¹, D. Clark², N. Radhakrishnan¹ and M. Brolin³, ¹Medicine, Boston University School of Medicine, and ²Boston Public Health Commission, Boston, and ³Brandeis University, Waltham, MA

166 Screening, brief intervention, and referral to treatment in an undergraduate nursing program
R. Shipley, D. Langer and H. Hagle, Institute for Research, Education and Training in Addictions, Pittsburgh, PA

167 Recent chemical controls in response to deaths attributed to the illicit manufacture of fentanyl
T.L. Boos, D.E. Peters, L.L. Wong, S.M. Carr and C.A. Sannerud, Drug Enforcement Administration, Washington, DC
Symposium XV

PRECLINICAL RESEARCH ON THE DISCOVERY OF GLUTAMATERIC THERAPEUTICS FOR THE TREATMENT OF ADDICTION

Chairs: David A. White and Athina Markou

10:00 Possible glutamatergic targets for the treatment of high-dose substituted amphetamine exposure
   Bryan K. Yamamoto, Boston University School of Medicine, Boston, MA

10:25 The role of NMDA and AMPA receptors in cocaine addiction
   Ainhoa Bilbao, Central Institute of Mental Health, Mannheim, Germany

10:50 mGluR-Homer-P13K signaling mechanisms in addiction-related behaviors
   Karen K. Szumlinski, University of California, Santa Barbara, CA

11:15 Allosteric modulators of mGluRs as a novel approach to treatment of drug abuse and other CNS disorders
   Carrie Jones, Vanderbilt University School of Medicine, Nashville, TN

11:40 Discussant
   Athina Markou, University of California, San Diego, CA

Oral Communications 18

EXTINCTION/REINSTATEMENT: ON AGAIN, OFF AGAIN

Chairs: John Roache and Xiu Liu

10:00 Modulation of the neuroadaptive changes in glutamate and dopamine transporters during the extinction of cocaine self-administration
   E. Ambrosio, M. Miguéns, J.A. Crespo, N. Del Olmo, A. Higuera-Matas, G.L. Montoya and C. García-Lecumberri, Psychobiology, Universidad Nacional de Educación a Distancia [UNED], Madrid, Spain

10:15 Conditioning and extinction of cue-reactivity in cocaine-dependent human subjects
   J.D. Roache¹, C.L. Wallace¹, R.J. Lamb¹, T. Newton², J. Mojsiak³ and A. Elkashef⁴,
   ¹University of Texas Health Science Center, San Antonio, TX, ²University of California-Los Angeles, Los Angeles, CA and ³NIDA, Washington, DC
10:30 Can baclofen and varenicline facilitate extinction of the limbic brain response to brief cocaine cues?
A. Childress1,2, R.N. Ehrman2,1, Z. Wang1, Y. Li1, T. Franklin1, M. Goldman1, J. Suh1,2, A. Fornash1,2, J. Hakun1, W. Jens1, J. Cruz1, J. Plebani1, K. Kampman1 and C.P. O'Brien1,2, 1Psychiatry, University of Pennsylvania School of Medicine, and 2VA VISN 4 MIRECC, Philadelphia VAMC, Philadelphia, PA

10:45 D-Cycloserine and cocaine cue extinction
K.T. Brady, A.L. McRae, M.E. Saladin, M.M. Moran and K.L. Price, Psychiatry, Medical University of South Carolina, Charleston, SC

11:00 Naltrexone attenuates cue-induced reinstatement of nicotine-seeking but does not change nicotine self-administration in rats
X. Liu, A.R. Caggiula, M.I. Palmatier, E.C. Donny and A.F. Sved, University of Pittsburgh, Pittsburgh, PA

11:15 Reinstatement of heroin-seeking in rats is potentiated by infusions of morphine into the substantia nigra
K.M. Banna1, K.L. Blough2, J.L. Rogers1, A.Q. Carnell1 and R.E. See1, 1Neurosciences, Medical University of South Carolina, Charleston, SC and 2Virginia Commonwealth University, Richmond, VA

11:30 Differential sensitivity of the rostral and caudal basolateral amygdala to modulation of cocaine-seeking behavior by the D1 receptor antagonist SCH 23390
Y. Mashhoon, L.A. Tsikitas and K.M. Kantak, Psychology, Boston University, Boston, MA

11:45 Drug cravings following trauma cue exposure among crack/cocaine-dependent patients with and without PTSD
M.J. McDermott1,2, M.T. Tull1,2 and C.W. Lejuez1,2, 1Psychology, University of Maryland, and 2Center for Addictions, Personality, and Emotion Research [CAPER], College Park, MD

Oral Communications 19

San Geronimo C
10:00 AM - 12:00 PM

DEViating FROM THE SCRIPT:
EPIDEMIOLOGY OF Rx DRUG ABUSE

Chairs: Sean McCabe and Jennifer Havens

10:00 Trends in recent-onset extramedical opioid analgesics use in the US from 1990 to 2005
S.S. Martins1, C.L. Storr1, H. Zhou1 and H.D. Chilcoat2, 1Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD and 2GlaxoSmithKline Worldwide Epidemiology, GlaxoSmithKline Research Triangle Park, NC

10:15 Prevalence of non-medical prescription opioids and illegal opioids use in Canada
J. Patra, J. Rehm, S. Popova, S. Mohapatra and B. Fischer, Social, Prevention and Health Policy Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada

10:30 Nonmedical use of prescription opioids and other drug use: What comes first?
S.E. McCabe, B.T. West, J.A. Cranford and C.J. Boyd, University of Michigan, Ann Arbor, MI

10:45 Incidence and persistence of nonmedical use of prescription analgesics among college students
K. Caldeira1, A. Arria1, K. Vincent1, K. O’Grady2 and E. Wish1, 1Center for Substance Abuse Research, and 2Psychology, University of Maryland, College Park, MD

93
11:00 Characterizing opioid analgesic injectors: Results from a national sample
J.R. Havens¹, L.A. Simmons², C.B. Oser³¹ and L.M. Shannon¹, ¹CDAR, ²Family Studies, and
³Sociology, University of Kentucky, Lexington, KY

11:15 A latent class analysis of prescription opioid abuse in the National Addictions Vigilance
Intervention and Prevention Program
T.G. Green² and S.F. Butler¹, ¹Inflexxion, Inc, Newton, MA and ²School of Public Health,
Yale University, New Haven, CT

11:30 Characterization of buprenorphine abuse using RADARS® System Poison Center data
A. Spaeth¹, J.E. Bailey¹ and R.C. Dart¹², ¹Research, Rocky Mountain Poison and Drug Center,
and ²University of Colorado Health Sciences Center, Denver, CO

11:45 Profile of buprenorphine-naloxone injectors in Malaysia: A community survey
M. Mazlan³, V. Balasingam Kasinather², M.C. Chawarski¹ and R.S. Schottenfeld¹,
¹Yale University, New Haven, CT and ²University Sains Malaysia, Pulau Pinang, and
³Substance Abuse Center, Muar, Malaysia

Oral Communications 20

San Cristobal
10:00 AM - 12:00 PM

IMAGING: VIEW FROM THE TOP

Chairs: Edythe London and Mark Greenwald

10:00 Adolescents with substance/conduct problems: Risky decisions and brain activation
T.J. Crowley¹, M. Dalwani¹, S. Mikulich-Gilbertson¹, K. Raymond¹, C. Lejuez² and
M. Banich³, ¹Division of Substance Dependence, Psychiatry, University of Colorado Denver
School of Medicine, Denver, and ²Psychology, University of Colorado, Boulder, CO
³Psychology, University of Maryland, College Park, MD

10:15 Effects of cannabis use on brain reward circuitry in teenagers: An fMRI study
G. Jager¹, R.I. Block², J.M. van Ree¹, M. Luijten¹, C. Fruehling-Wall² and N.F. Ramsey¹,
¹Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht,
Utrecht, Netherlands and ²University of Iowa, Iowa, IA

10:30 Heavy marijuana users show altered neurofunctional activity during decision making and
feedback processing while performing the Iowa Gambling Task
M. Wesley, C. Hanlon, M.D. Miller and L.J. Porrino, Physiology and Pharmacology, Wake
Forest University School of Medicine, Winston Salem, NC

10:45 Women on nicotine replacement therapy show significant brain activity in response to smoking
cues
A.C. Janes¹, B.B. Frederick¹, C. Burbridge¹, S. Richardt¹, A.E. Evins², M. Fava³,
P.F. Renshaw¹ and M.J. Kaufman¹, ¹Brain Imaging Center, McLean Hospital, Belmont,
²Center for Addiction Medicine, Massachusetts General Hospital, and ³Depression Clinical
and Research Program, Massachusetts General Hospital, Boston, MA

11:00 Neural correlates of negative emotion response and regulation in methamphetamine-dependent
and comparison subjects
E.D. London, K. Baicy and J. Monterosso, Psychiatry and Biobehavioral Sciences,
David Geffen School of Medicine, University of California, Los Angeles, CA
11:15  Does chronic cocaine use affect a mother's brain response to baby face cues? A pilot fMRI study  
L. Strathearn\textsuperscript{1,2} and T.R. Kosten\textsuperscript{3,4}; \textsuperscript{1}Pediatrics, \textsuperscript{2}Neuroscience, and \textsuperscript{3}Psychiatry and Behavioral Sciences, Baylor College of Medicine, and \textsuperscript{4}Michael E. DeBakey Veteran Affairs Medical Center, Houston, TX

11:30  Anterior cingulate glutamate measured with high-field, short-TE, single-voxel 1H-MRS is greater during low- vs. high-dose methadone maintenance  
M.K. Greenwald, D. Khatib, M. Keshavan and J. Stanley, Wayne State University, Detroit, MI

11:45  MDMA (ecstasy) use is associated with altered brain activation to word encoding and recall: An fMRI study  

---

**BRUNCH WITH CHAMPIONS**  
(Pre-Registrants Only)  
Las Olas  
12:00 - 1:30 PM

---

**Symposium XVI**  
San Geronimo A  
1:30 - 3:30 PM

**PHARMACOGENETICS OF MEDICATIONS FOR THE TREATMENT OF ADDICTIONS**

Chairs: Ivan D. Montoya and Joni Rutter

1:30  Genetic factors associated with the differential efficacy and side effects of smoking cessation medications  
Caryn Lerman, University of Pennsylvania, Philadelphia, PA

1:55  The role of pharmacogenetics in the evaluation of medications for the treatment of cocaine addiction  
Thomas Kosten, Baylor College of Medicine, Houston, TX

2:20  Genetics of the opioid receptor and response to opioid agonist, partial agonist, and antagonist treatment  
Mary Jeanne Kreek, The Rockefeller University, New York, NY

2:45  Genetic variations in the cannabinoid system and response to pharmacotherapies for marijuana addiction  
Bernard Le Foll, University of Toronto, Toronto, ON, Canada

3:10  Genetics and the outcome of addiction treatments  
George Uhl, NIDA Intramural Research Program, Baltimore, MD
Oral Communications 21
San Geronimo B
1:30 - 3:30 PM

STIMULANT TREATMENT: WHAT’S UP?

Chairs: Steve Shoptaw and Joy Schmitz

1:30 Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
   S. Shoptaw\textsuperscript{1,2}, K.G. Heinzerling\textsuperscript{1}, E. Rotheram-Fuller\textsuperscript{1}, T. Steward\textsuperscript{1}, J. Wang\textsuperscript{1}, A. Swanson\textsuperscript{1}, R. De La Garza\textsuperscript{2}, T. Newton\textsuperscript{2} and W. Ling\textsuperscript{3}, \textsuperscript{1}Family Medicine and \textsuperscript{2}Integrated Substance Abuse Programs, University of California-Los Angeles, Los Angeles, CA

1:45 Randomized placebo-controlled trial of modafinil for methamphetamine withdrawal: Results of an Australian pilot study
   N.K. Lee\textsuperscript{1}, A. Pennay\textsuperscript{1} and R. Hester\textsuperscript{2}, \textsuperscript{1}Clinical Research, Turning Point Alcohol and Drug Centre, Fitzroy, VIC, Australia and \textsuperscript{2}University of Queensland, Brisbane, QLD, Australia

2:00 Acute modafinil treatment does not improve cognitive function in methamphetamine-dependent volunteers
   B. Jackson, A.D. Kalechstein, R. De La Garza II and T.F. Newton, Psychiatry and Biobehavioral Sciences, University of California-Los Angeles, Los Angeles, CA

2:15 High-dose naltrexone therapy for cocaine-alcohol dependence
   J.M. Schmitz\textsuperscript{1}, J. Grabowski\textsuperscript{2}, C. Green\textsuperscript{1}, D. Herin\textsuperscript{1} and J. Lindsay\textsuperscript{1}, \textsuperscript{1}University of Texas-Houston, Houston, TX and \textsuperscript{2}University of Minnesota, Minneapolis, MN

2:30 Preexisting anti-cocaine IgM antibody associated with low antibody responses to cocaine conjugate vaccine
   F.M. Orson\textsuperscript{2,1}, B.M. Kinsey\textsuperscript{2,1}, R.A. Singh\textsuperscript{1}, Y. Wu\textsuperscript{1}, W. Huang\textsuperscript{2,3} and T.R. Kosten\textsuperscript{2,3}, \textsuperscript{2}Medical Service, Veterans Affairs Medical Center, and \textsuperscript{1}Internal Medicine, and \textsuperscript{3}Psychiatry, Baylor College of Medicine, Houston, TX

2:45 The effects of γ-vinyl-γ-aminobutyric acid (GVG, vigabatrin) on the subjective, cardiovascular and reinforcing effects produced by methamphetamine (METH) in METH-dependent volunteers
   T.F. Newton\textsuperscript{1}, R. De La Garza, II\textsuperscript{1}, A. Lee\textsuperscript{1}, R.A. Donovick\textsuperscript{1}, K.G. Heinzerling\textsuperscript{1,2} and S. Shoptaw\textsuperscript{2,1}, \textsuperscript{1}Psychiatry, and \textsuperscript{2}Family Medicine, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA

3:00 Impact of DSM-IV diagnoses on abstinence outcomes for homeless clients undergoing contingency-managed treatment
   J.B. Milby\textsuperscript{1}, J. Schumacher\textsuperscript{1}, D. Wallace\textsuperscript{2}, K. Crouch\textsuperscript{1}, R. Cusimano\textsuperscript{1}, S. Kertesz\textsuperscript{3}, S. Mennemeyer\textsuperscript{1} and R. Vuchinich\textsuperscript{1}, \textsuperscript{1}University of Alabama at Birmingham, and \textsuperscript{3}VAMC, Birmingham, AL, and \textsuperscript{2}RHO Federal Systems Division Inc, Raleigh-Durham, NC

3:15 Continuing care for stimulant recovery: An experimental test of telephone support
   D.J. Farabee, R. Rawson, V.J. Pearce, A. Bellows, J. Hemberg, S.J. Cousins, S. Patel and J. Brummer, ISAP, University of California-Los Angeles, Los Angeles, CA
Thursday, June 19, 2008

Oral Communications 22

San Geronimo C

1:30 - 3:30 PM

IMPULSIVITY—WHAT’S THE RUSH?

Chairs: Marilyn E. Carroll and Jennifer Perry

1:30  A laboratory model of relapse to smoking: Effects of incentives for not smoking and relationship to temporal discounting
      W.K. Bickel¹, B.P. Kowal¹, R. Yi¹, M.L. Sitzer¹² and R.D. Landes¹, ¹Psychiatry, University of Arkansas for Medical Sciences, Little Rock, AR and ²Psychiatry, The Johns Hopkins University - School of Medicine, Baltimore, MD

1:45  Effects of sustained abstinence and impulsivity on the relative reinforcing effects of cigarette smoking

2:00  Evaluating aspects of discounting behavior in adolescent substance users and controls
      S.K. Mikulich-Gilbertson, L.L. Thompson and T.J. Crowley, Division of Substance Dependence, Psychiatry, University of Colorado at Denver School of Medicine, Denver, CO

2:15  Substance abuser impulsivity decreases with a 9-month stay in a therapeutic community
      S.M. Bankston¹, F.G. Moeller², J. Schmitz², S. Cron¹, L.K. Granmayeh¹, D.D. Carroll¹ and M. T. Marcus¹, ¹University of Texas Health Science Center at Houston School of Nursing, and ²University of Texas Health Science Center at Houston Medical School, Houston, TX

2:30  Impulsivity (delay discounting) and drug self-administration in rhesus monkeys
      M.E. Carroll¹, J.L. Mach¹, J.L. Perry² and J.L. Newman³, ¹Psychiatry, and ²Psychology, University of Kentucky, Lexington, KY and ³McLean Hospital, Harvard Medical School, Belmont, MA

2:45  Temporal discounting of saccharin as a reinforcer by rhesus monkeys
      K.B. Freeman and W. Woolverton, Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS

3:00  Stress and behavioral sensitization to nicotine in a rodent model of impulsivity
      K.R. Hamilton, A.K. Starosciak and N.E. Grunberg, Uniformed Services University of the Health Sciences, Bethesda, MD

3:15  Role of dopamine and serotonin receptors in medial prefrontal cortex in impulsive choice
      J.L. Perry¹ and M.T. Bardo², ¹Minneapolis Medical Research Foundation, Minneapolis, MN and ²Psychology, University of Kentucky, Lexington, KY

SWEEPSTAKES DRAWING

San Cristobal

3:35 PM

YOU MUST BE SEATED IN ONE OF THE SESSIONS AT 3:15 PM IN ORDER TO HAVE YOUR BADGE COLLECTED

HAVE A SAFE TRIP HOME
SEE YOU IN RENO, NEVADA, JUNE 20-25, 2009
<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbara, C.</td>
<td>54</td>
</tr>
<tr>
<td>Abdra khmanova, G.</td>
<td>31</td>
</tr>
<tr>
<td>Abrams, L.</td>
<td>8</td>
</tr>
<tr>
<td>Abramson, Y.</td>
<td>40, 86</td>
</tr>
<tr>
<td>Achat-Mendes, C.</td>
<td>77</td>
</tr>
<tr>
<td>Acheson, A.</td>
<td>79</td>
</tr>
<tr>
<td>Acosta, A.</td>
<td>15</td>
</tr>
<tr>
<td>Acosta, M.C.</td>
<td>26, 70</td>
</tr>
<tr>
<td>Adam, T.</td>
<td>57</td>
</tr>
<tr>
<td>Adams-Deustch, T.</td>
<td>79</td>
</tr>
<tr>
<td>Adamson, J.</td>
<td>71</td>
</tr>
<tr>
<td>Addou, S.</td>
<td>13</td>
</tr>
<tr>
<td>Adelaja, O.A.</td>
<td>89</td>
</tr>
<tr>
<td>Acosta, M.C.</td>
<td>26, 70</td>
</tr>
<tr>
<td>Adam, T.</td>
<td>57</td>
</tr>
<tr>
<td>Adams-Deustch, T.</td>
<td>79</td>
</tr>
<tr>
<td>Adamson, J.</td>
<td>71</td>
</tr>
<tr>
<td>Addou, S.</td>
<td>13</td>
</tr>
<tr>
<td>Aguirrextex-Colina, A.</td>
<td>72, 78</td>
</tr>
<tr>
<td>Aigular, V.R.</td>
<td>49</td>
</tr>
<tr>
<td>Agulló, V.</td>
<td>10, 38, 44</td>
</tr>
<tr>
<td>Aharonovich, E.</td>
<td>12, 84</td>
</tr>
<tr>
<td>Ahmed, A.</td>
<td>21</td>
</tr>
<tr>
<td>Ahmed, M.S.</td>
<td>32</td>
</tr>
<tr>
<td>Ahmedani, B.K.</td>
<td>63</td>
</tr>
<tr>
<td>AhnAllen, C.G.</td>
<td>82</td>
</tr>
<tr>
<td>Ainette, M.</td>
<td>62</td>
</tr>
<tr>
<td>Ait-Daoud, N.</td>
<td>60</td>
</tr>
<tr>
<td>Akins, C.K.9</td>
<td>79</td>
</tr>
<tr>
<td>Aklin, W.M.</td>
<td>85, 86, 88</td>
</tr>
<tr>
<td>Alberg, A.</td>
<td>81</td>
</tr>
<tr>
<td>Albert, S.</td>
<td>16</td>
</tr>
<tr>
<td>Albizu-García, C.E.</td>
<td>38, 41</td>
</tr>
<tr>
<td>Alburgeses, M.E.</td>
<td>34</td>
</tr>
<tr>
<td>Aleixandre-Benavent, R.</td>
<td>38, 44</td>
</tr>
<tr>
<td>Alexander, M.</td>
<td>33</td>
</tr>
<tr>
<td>Alford, D.P.</td>
<td>85, 91</td>
</tr>
<tr>
<td>Ali, R.</td>
<td>26, 42</td>
</tr>
<tr>
<td>Alkass, K.</td>
<td>86</td>
</tr>
<tr>
<td>Allen, C.</td>
<td>69</td>
</tr>
<tr>
<td>Allen, N.</td>
<td>46</td>
</tr>
<tr>
<td>Allensworth-Davies, D.</td>
<td>86</td>
</tr>
<tr>
<td>Allsop, S.</td>
<td>67</td>
</tr>
<tr>
<td>Alonso, A.</td>
<td>38</td>
</tr>
<tr>
<td>Alterman, A.I.</td>
<td>19, 83</td>
</tr>
<tr>
<td>Altice, F.</td>
<td>15</td>
</tr>
<tr>
<td>Alvanzo, A.</td>
<td>35, 62</td>
</tr>
<tr>
<td>Alvarado, G.F.</td>
<td>14, 29</td>
</tr>
<tr>
<td>Alvarez, Y.</td>
<td>11</td>
</tr>
<tr>
<td>Alvarez-Gonzalez, C.</td>
<td>81</td>
</tr>
<tr>
<td>Amador, N.J.</td>
<td>8</td>
</tr>
<tr>
<td>Amaechi, O.</td>
<td>15</td>
</tr>
<tr>
<td>Amble, P.</td>
<td>18</td>
</tr>
<tr>
<td>Ambrosio, E.</td>
<td>92</td>
</tr>
<tr>
<td>Ames, S.</td>
<td>59</td>
</tr>
<tr>
<td>Ammann, M.A.</td>
<td>28</td>
</tr>
<tr>
<td>Amodeo, M.</td>
<td>19, 57</td>
</tr>
<tr>
<td>Amadio, K.10</td>
<td>71</td>
</tr>
<tr>
<td>Amrhein, P.</td>
<td>84</td>
</tr>
<tr>
<td>Amstader, A.</td>
<td>88</td>
</tr>
<tr>
<td>Anastasio, N.</td>
<td>31</td>
</tr>
<tr>
<td>Andersen, R.M.</td>
<td>19</td>
</tr>
<tr>
<td>Andersen, V.</td>
<td>11</td>
</tr>
<tr>
<td>Anderson, G.</td>
<td>87</td>
</tr>
<tr>
<td>Anderson, K.G.</td>
<td>71</td>
</tr>
<tr>
<td>Anderson, L.</td>
<td>60</td>
</tr>
<tr>
<td>Andorn, A.C.</td>
<td>61</td>
</tr>
<tr>
<td>Andrews, S.</td>
<td>85</td>
</tr>
<tr>
<td>Anen, S.J.</td>
<td>37</td>
</tr>
<tr>
<td>Ang, A.</td>
<td>83</td>
</tr>
<tr>
<td>Anglin, D.M.</td>
<td>20</td>
</tr>
<tr>
<td>Anker, J.J.</td>
<td>34, 80</td>
</tr>
<tr>
<td>Anokhin, A.P.</td>
<td>59</td>
</tr>
<tr>
<td>Anthony, J.C.</td>
<td>12, 14, 38, 29, 59, 63, 87, 88, 89</td>
</tr>
<tr>
<td>Arabia, P.L.</td>
<td>18, 89</td>
</tr>
<tr>
<td>Arasteh, K.</td>
<td>4</td>
</tr>
<tr>
<td>Arenella, L.</td>
<td>54</td>
</tr>
<tr>
<td>Arfken, C.L.</td>
<td>89</td>
</tr>
<tr>
<td>Arkes, J.</td>
<td>67</td>
</tr>
<tr>
<td>Arnold, S.</td>
<td>63</td>
</tr>
<tr>
<td>Arria, A.</td>
<td>24, 35, 59, 60, 64, 93</td>
</tr>
<tr>
<td>Arribas, M.</td>
<td>7</td>
</tr>
<tr>
<td>Arthur, B.</td>
<td>91</td>
</tr>
<tr>
<td>Ary, A.W.</td>
<td>53</td>
</tr>
<tr>
<td>Aschbach-Jachman, C.</td>
<td>75</td>
</tr>
<tr>
<td>Aston-Jones, G.</td>
<td>5</td>
</tr>
<tr>
<td>Astone-Twerell, J.</td>
<td>41</td>
</tr>
<tr>
<td>Ator, N.A.</td>
<td>23</td>
</tr>
<tr>
<td>Auclair, C.</td>
<td>12, 17</td>
</tr>
<tr>
<td>Augustino, D.K.</td>
<td>17</td>
</tr>
<tr>
<td>Auriacombe, M.</td>
<td>9, 10, 26, 65, 72, 78, 91</td>
</tr>
<tr>
<td>Austin, E.</td>
<td>19</td>
</tr>
<tr>
<td>Authier, N.A.</td>
<td>17</td>
</tr>
<tr>
<td>Avila, M.</td>
<td>82</td>
</tr>
<tr>
<td>Avula, D.</td>
<td>91</td>
</tr>
<tr>
<td>Babaloni, S.</td>
<td>55, 80</td>
</tr>
<tr>
<td>Back, S.</td>
<td>41</td>
</tr>
<tr>
<td>Back, S.E.</td>
<td>11, 50</td>
</tr>
<tr>
<td>Badger, G.J.</td>
<td>58</td>
</tr>
<tr>
<td>Baewert, A.</td>
<td>75</td>
</tr>
<tr>
<td>Baggott, M.J.</td>
<td>55, 56, 78</td>
</tr>
<tr>
<td>Bai, Y.</td>
<td>94</td>
</tr>
<tr>
<td>Bailey, G.</td>
<td>45</td>
</tr>
<tr>
<td>Bailey, J.E.</td>
<td>64, 94</td>
</tr>
<tr>
<td>Baillie, A.</td>
<td>61</td>
</tr>
<tr>
<td>Baker, A.</td>
<td>41, 46, 57</td>
</tr>
<tr>
<td>Baladi, M.</td>
<td>79</td>
</tr>
<tr>
<td>Balasingam Kasinath, V.</td>
<td>94</td>
</tr>
<tr>
<td>Balducci, X.L.</td>
<td>75</td>
</tr>
<tr>
<td>Baldwin, G.C.</td>
<td>3, 42</td>
</tr>
<tr>
<td>Balester Mouret, S.</td>
<td>61</td>
</tr>
<tr>
<td>Ball, S.A.</td>
<td>17, 40, 58</td>
</tr>
<tr>
<td>Battleo, B.W.</td>
<td>5</td>
</tr>
<tr>
<td>Ballina, L.</td>
<td>79</td>
</tr>
<tr>
<td>Bandstra, E.</td>
<td>47</td>
</tr>
<tr>
<td>Bangs, N.</td>
<td>78</td>
</tr>
<tr>
<td>Banich, M.</td>
<td>94</td>
</tr>
<tr>
<td>Bankston, S.M.</td>
<td>97</td>
</tr>
<tr>
<td>Banna, K.M.</td>
<td>93</td>
</tr>
<tr>
<td>Banta-Green, C.J.</td>
<td>26, 64</td>
</tr>
<tr>
<td>Bantchevska, D.</td>
<td>45</td>
</tr>
<tr>
<td>Bar-Hamburger, R.</td>
<td>82</td>
</tr>
<tr>
<td>Barahona, M.</td>
<td>16</td>
</tr>
<tr>
<td>Bardo, M.T.</td>
<td>13, 72, 97</td>
</tr>
<tr>
<td>Barker, M.</td>
<td>16</td>
</tr>
<tr>
<td>Barksdale, W.</td>
<td>38</td>
</tr>
<tr>
<td>Baron, M.</td>
<td>56</td>
</tr>
<tr>
<td>Barrick, C.</td>
<td>67</td>
</tr>
<tr>
<td>Barry, D.T.</td>
<td>26</td>
</tr>
<tr>
<td>Barth, K.</td>
<td>15</td>
</tr>
<tr>
<td>Bartle-Haring, S.</td>
<td>45</td>
</tr>
<tr>
<td>Author Name</td>
<td>Pages</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Barton, D.</td>
<td>3</td>
</tr>
<tr>
<td>Basilakos, A.A.</td>
<td>72</td>
</tr>
<tr>
<td>Batel, P.</td>
<td>61</td>
</tr>
<tr>
<td>Batis, J.</td>
<td>32, 54</td>
</tr>
<tr>
<td>Batki, S.L.</td>
<td>10</td>
</tr>
<tr>
<td>Bauernfeind, A.L.</td>
<td>74, 95</td>
</tr>
<tr>
<td>Baumann, M.H.</td>
<td>74</td>
</tr>
<tr>
<td>Beatty, J.R.</td>
<td>36</td>
</tr>
<tr>
<td>Beauchamp, W.</td>
<td>91</td>
</tr>
<tr>
<td>Becher, J.</td>
<td>42</td>
</tr>
<tr>
<td>Beck, O.</td>
<td>56</td>
</tr>
<tr>
<td>Becker, W.C.</td>
<td>15, 64</td>
</tr>
<tr>
<td>Bedi, G.</td>
<td>78</td>
</tr>
<tr>
<td>Behar, E.</td>
<td>86</td>
</tr>
<tr>
<td>Beitel, M.</td>
<td>26</td>
</tr>
<tr>
<td>Bejjani, A.</td>
<td>54</td>
</tr>
<tr>
<td>Bell, G.H.</td>
<td>34</td>
</tr>
<tr>
<td>Bellows, A.</td>
<td>96</td>
</tr>
<tr>
<td>Beltran, V.</td>
<td>72, 78</td>
</tr>
<tr>
<td>Ben Abdallah, A.</td>
<td>12</td>
</tr>
<tr>
<td>Benamar, K.</td>
<td>13</td>
</tr>
<tr>
<td>Benasutti, K.M.</td>
<td>89</td>
</tr>
<tr>
<td>Bender, R.</td>
<td>48</td>
</tr>
<tr>
<td>Benoit, E.</td>
<td>62</td>
</tr>
<tr>
<td>Bentley, T.</td>
<td>67</td>
</tr>
<tr>
<td>Benyamina, A.</td>
<td>54</td>
</tr>
<tr>
<td>Benzano, D.</td>
<td>61</td>
</tr>
<tr>
<td>Berdah, C.</td>
<td>9</td>
</tr>
<tr>
<td>Berenson, A.B.</td>
<td>40</td>
</tr>
<tr>
<td>Berge, D.</td>
<td>17</td>
</tr>
<tr>
<td>Berger, D.</td>
<td>12</td>
</tr>
<tr>
<td>Berglund, M.</td>
<td>86</td>
</tr>
<tr>
<td>Bergman, J.</td>
<td>60, 69</td>
</tr>
<tr>
<td>Bergquist, K.L.</td>
<td>10, 27, 49</td>
</tr>
<tr>
<td>Beringer, K.</td>
<td>23</td>
</tr>
<tr>
<td>Berko, J.</td>
<td>17</td>
</tr>
<tr>
<td>Berrettini, W.</td>
<td>15, 73</td>
</tr>
<tr>
<td>Berry, M.S.</td>
<td>89</td>
</tr>
<tr>
<td>Berterame, S.</td>
<td>45</td>
</tr>
<tr>
<td>Beseler, C.</td>
<td>12</td>
</tr>
<tr>
<td>Best, A.M.</td>
<td>20</td>
</tr>
<tr>
<td>Betzler, T.</td>
<td>83</td>
</tr>
<tr>
<td>Beveridge, T.J.</td>
<td>55</td>
</tr>
<tr>
<td>Bevins, R.A.</td>
<td>69</td>
</tr>
<tr>
<td>Bian, H.</td>
<td>59</td>
</tr>
<tr>
<td>Bickel, W.K.</td>
<td>37, 58, 97</td>
</tr>
<tr>
<td>Bidlack, J.M.</td>
<td>7</td>
</tr>
<tr>
<td>Biederman, J.</td>
<td>71</td>
</tr>
<tr>
<td>Bierut, L.</td>
<td>58</td>
</tr>
<tr>
<td>Bigelow, G.E.</td>
<td>36, 37, 82, 83, 85</td>
</tr>
<tr>
<td>Biggers, S.</td>
<td>81</td>
</tr>
<tr>
<td>Bilbao, A.</td>
<td>92</td>
</tr>
<tr>
<td>Billa, S.</td>
<td>8</td>
</tr>
<tr>
<td>Binswanger, I.A.</td>
<td>20</td>
</tr>
<tr>
<td>Birk, T.J.</td>
<td>19</td>
</tr>
<tr>
<td>Bisaga, A.</td>
<td>37, 84</td>
</tr>
<tr>
<td>Bjork, J.</td>
<td>25</td>
</tr>
<tr>
<td>Black, R.A.</td>
<td>83</td>
</tr>
<tr>
<td>Blanchette, J.</td>
<td>44</td>
</tr>
<tr>
<td>Blanco, C.</td>
<td>24</td>
</tr>
<tr>
<td>Blank, M.B.</td>
<td>43</td>
</tr>
<tr>
<td>Block, R.I.</td>
<td>94</td>
</tr>
<tr>
<td>Bloom Oquendo, J.</td>
<td>21</td>
</tr>
<tr>
<td>Blough, B.</td>
<td>31</td>
</tr>
<tr>
<td>Blough, K.L.</td>
<td>93</td>
</tr>
<tr>
<td>Boak, A.</td>
<td>72</td>
</tr>
<tr>
<td>Bobashev, G.</td>
<td>43</td>
</tr>
<tr>
<td>Bogenschutz, M.P.</td>
<td>18, 19, 35, 46</td>
</tr>
<tr>
<td>Bohman, T.M.</td>
<td>61, 90</td>
</tr>
<tr>
<td>Bohn, L.M.</td>
<td>31</td>
</tr>
<tr>
<td>Bohnert, K.M.</td>
<td>59</td>
</tr>
<tr>
<td>Bois, F.</td>
<td>54</td>
</tr>
<tr>
<td>Bokarius, A.V.</td>
<td>54</td>
</tr>
<tr>
<td>Bolan, B.</td>
<td>3</td>
</tr>
<tr>
<td>Bolin, B.L.</td>
<td>79</td>
</tr>
<tr>
<td>Bolla, K.I.</td>
<td>78</td>
</tr>
<tr>
<td>Bolo, N.</td>
<td>54</td>
</tr>
<tr>
<td>Bond, A.J.</td>
<td>70</td>
</tr>
<tr>
<td>Bongiovanni, M.J.</td>
<td>79</td>
</tr>
<tr>
<td>Bonhomme-Faivre, L.</td>
<td>54</td>
</tr>
<tr>
<td>Boos, T.L.</td>
<td>6, 91</td>
</tr>
<tr>
<td>Booth, B.M.</td>
<td>11</td>
</tr>
<tr>
<td>Booth, R.E.</td>
<td>20, 42, 43, 86, 89</td>
</tr>
<tr>
<td>Borges, G.</td>
<td>88</td>
</tr>
<tr>
<td>Bornovalova, M.</td>
<td>45</td>
</tr>
<tr>
<td>Bossert, J.M.</td>
<td>8</td>
</tr>
<tr>
<td>Boudov, M.</td>
<td>71</td>
</tr>
<tr>
<td>Boudreau, D.M.</td>
<td>26, 64</td>
</tr>
<tr>
<td>Bourseul, V.</td>
<td>9</td>
</tr>
<tr>
<td>Bowen, S.</td>
<td>32</td>
</tr>
<tr>
<td>Bowers, C.</td>
<td>15</td>
</tr>
<tr>
<td>Boyd, C.J.</td>
<td>64, 65, 83, 93</td>
</tr>
<tr>
<td>Boyé, A.</td>
<td>17</td>
</tr>
<tr>
<td>Brackeen, M.F.</td>
<td>13, 49</td>
</tr>
<tr>
<td>Bradstreet, M.P.</td>
<td>97</td>
</tr>
<tr>
<td>Brady, J.V.</td>
<td>1</td>
</tr>
<tr>
<td>Brady, K.T.</td>
<td>11, 13, 41, 50, 59, 82, 88, 93</td>
</tr>
<tr>
<td>Brady, T.</td>
<td>86</td>
</tr>
<tr>
<td>Branch, M.N.</td>
<td>34</td>
</tr>
<tr>
<td>Brands, B.</td>
<td>40, 70, 72</td>
</tr>
<tr>
<td>Brasel, C.M.</td>
<td>7</td>
</tr>
<tr>
<td>Braskie, M.N.</td>
<td>54</td>
</tr>
<tr>
<td>Brason III, F.W.</td>
<td>16</td>
</tr>
<tr>
<td>Brecht, M.</td>
<td>18, 38, 42, 87</td>
</tr>
<tr>
<td>Breitmeyer, B.G.</td>
<td>62</td>
</tr>
<tr>
<td>Bresani, E.</td>
<td>84</td>
</tr>
<tr>
<td>Breslau, N.</td>
<td>59</td>
</tr>
<tr>
<td>Breslow, J.</td>
<td>9</td>
</tr>
<tr>
<td>Brewer, D.D.</td>
<td>16</td>
</tr>
<tr>
<td>Brewer, J.</td>
<td>55</td>
</tr>
<tr>
<td>Brewster, J.T.</td>
<td>42</td>
</tr>
<tr>
<td>Brim, R.L.</td>
<td>69</td>
</tr>
<tr>
<td>Brimijoin, S.</td>
<td>32</td>
</tr>
<tr>
<td>Britton, P.C.</td>
<td>17</td>
</tr>
<tr>
<td>Broadbear, J.H.</td>
<td>23</td>
</tr>
<tr>
<td>Broadus, A.D.</td>
<td>89</td>
</tr>
<tr>
<td>Brolin, M.</td>
<td>91</td>
</tr>
<tr>
<td>Bronner, C.</td>
<td>90</td>
</tr>
<tr>
<td>Brooks, A.C.</td>
<td>19, 37</td>
</tr>
<tr>
<td>Brooks, D.J.</td>
<td>10, 12, 43</td>
</tr>
<tr>
<td>Brooner, R.K.</td>
<td>19, 85, 86, 88</td>
</tr>
<tr>
<td>Brosch, J.</td>
<td>16</td>
</tr>
<tr>
<td>Brown, A.H.</td>
<td>56, 57</td>
</tr>
<tr>
<td>Brown, B.S.</td>
<td>38, 86</td>
</tr>
<tr>
<td>Brown, C.H.</td>
<td>43, 59</td>
</tr>
<tr>
<td>Brown, L.</td>
<td>2</td>
</tr>
<tr>
<td>Brown, S.A.</td>
<td>46, 53, 71</td>
</tr>
<tr>
<td>Brown, Jr., L.S.</td>
<td>15</td>
</tr>
<tr>
<td>Brownell, K.D.</td>
<td>2</td>
</tr>
<tr>
<td>Brownstein, J.S.</td>
<td>64</td>
</tr>
<tr>
<td>Bruce, R.D.</td>
<td>15</td>
</tr>
<tr>
<td>Brummer, J.</td>
<td>57, 96</td>
</tr>
<tr>
<td>Brundage, P.M.</td>
<td>92</td>
</tr>
<tr>
<td>Bryan, B.R.</td>
<td>43</td>
</tr>
<tr>
<td>Buchanan, A.S.</td>
<td>88</td>
</tr>
<tr>
<td>Buchhalter, A.</td>
<td>37</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Buchman, A.C. 65, 66
Bucholz, K.K. 59, 72, 82
Buckner, J.D. 82
Budman, S.H. 16, 39
Budney, A.J. 47, 58, 59
Bueno, F. 38
Buesing, W.B. 79
Buffalari, D. 69
Bukstein, O.G. 60
Bulbena, A. 17
Bumaguin, D. 62
Burakov, A. 37
Burbridge, C. 94
Burdon, W.M. 91
Burke, C. 17
Burne, K. 17
Burns, L. 36
Burt, M. 38
Bushara, N. 37
Busto, U.E. 14, 73, 75
Bustos Gamiño, M. 81
Butelman, E.R. 8
Butler, S.F. 16, 39, 64, 94
Byrd, E.A. 79
Cabaniss, B. 74
Cacciola, J.S. 19, 83, 91
Cachay, C. 40
Casadonte, P.P. 15, 53
Cain, M.E. 14, 34
Caldeira, K.M. 59, 60, 64, 93
Calderon, S.N. 28
Callahan, C.L. 20, 90
Calsyn, D.A. 9, 26, 43, 64, 86
Cam, I. 11
Cammilleri, A. 19
Campagna, E.J. 64
Campbell, A. 9, 41
Campbell, J.E. 69
Campbell, N.D. 25, 50
Campollo, O. 81
Cañadas, F. 8
Canfield, K.M. 10
Caraballo, G. 38
Carballo, J.L. 84
Carbonari, J.P. 84
Carbonaro, T. 31
Cargile, C. 37, 56
Caris, L.H. 38
Carise, D. 19, 40, 91
Carlezon, W.A. 4
Carlin, J.B. 59
Carlo, G. 18
Carlson, R. 65
Carnell, A.Q. 93
Carpenedo, C.M. 84
Carpenter, K.M. 37
Carpenter, M.J. 13, 80, 81, 88
Carr, S.M. 91, 92
Carroll, F.I. 13, 31
Carroll, K.M. 34, 80, 97
Carroll, S. 46
Carter, C.S. 4
Carter, L.P. 23
Carter, M.C. 84
Carter, R.E. 9, 13
Carter, T. 62
Cartmell, K. 81
Casadonte, P.P. 15, 53
Casarella, J. 62
Case, T.F. 84
Cassidy, T. 16
Castel, S. 40
Castellano, M. 10
Caster, J.M. 72, 73
Castro, F.G. 21
Catarina, M.M. 88
Catania, L. 46
Caulkins, J. 67
Cavallo, D.A. 59, 80, 81
Cavazos-Rehg, P. 58
Ceballos, N.A. 78
Cely, I.C. 5
Cepeich, S.D. 24, 61
Chakrapani, S. 54
Chakroun, N. 78
Chalmers, J. 90
Chan, Y.F. 44
Chang, C. 32
Chang, I. 32
Chang, L.T. 7
Chang, N. 64
Chaplin, T.M. 35
Chapman, C. 16
Chapman, J.E. 16
Chappin, S.R. 39
Chase, S.K. 36
Chatterjee, P. 41
Chaudhry, A.A. 3
Chawarski, M.C. 39, 42, 94
Chen, C. 32, 58
Chen, G. 73
Chen, H. 4
Chen, K.L. 42
Chen, L.A. 82
Chen, N. 74
Chen, T. 43
Chen, W.J. 58
Che, X. 9
Cheng, D.M. 19, 85, 86
Cheng, H. 87, 88
Cheng, K.J. 7, 23, 77
Cheng, S.Y. 74
Cherek, D.R. 20
Cherrier, M. 56
Chhatre, S. 42
Chilcoat, H.D. 3, 4, 61, 93
Childress, A.R. 2, 26, 27, 73, 93
Childs, E. 87
Chisolm, M. 75
Chivers, L.L. 97
Chopra, M.P. 37, 56
Chrisman, A.K. 80
Chu, M. 15, 18
Chuang, L. 60
Chun, J. 63
Cilente, J. 18
Ciskowski, S. 18
Clair, M. 21
Clark, A. 44
Clark, D. 91
Clark, D.B. 58, 60, 81
AUTHOR INDEX

Clark, H. 91
Clark, H.W. 67
Clark, J. 55
Clark, M. 86
Clark, N. 66
Clark, W. 24
Clarke, J. 44
Clatts, M.C. 43
Clayton, T. 60
Clement, J.E. 84
Clements, K. 45
Clerkin, S. 54
Coen, K. 14
Coffey, C. 59
Coffin, L.S. 65
Coffin, P. 64
Cohen, L. 9, 83
Coles, C.D. 35
Collins, C. 80, 81
Collins, C.C. 60, 81
Collins, G.T. 69
Comegys, D. 37
Comer, S.D. 36
Comerford, M. 4, 42
Condon, T.P. 5
Conigliaro, J. 22
Conner, B.T. 21
Conner, K.R. 17, 84
Cook, E. 74
Cook, J.M. 60
Cook, M. 61
Coolon, R.A. 14, 34
Coop, A. 72
Cooper, Z.D. 13, 70
Coors, M.E. 45
Copeland, J. 16, 78
Copenhaver, M. 15, 88
Copersino, M.L. 12, 87
Corbly, C.R. 55
Corley, M. 62
Corley, R. 58
Cornelius, J.R. 40, 48, 60, 89
Cornelius, M.D. 35, 59
Corrigall, W.A. 13
Corsi, K.F. 86, 89
Cortizo, R. 17
Cosgrove, K.P. 54
Costello, M.J. 63
Costenbader, E. 43
Cottler, L.B. 12, 20, 43, 58, 90
Cotton, A. 86
Courty, P. 12, 17
Cousins, S.J. 43, 57, 96
Coviello, D.M. 21, 84
Cowan, R.L. 74, 82, 95
Coyle, J.R. 78
Coyle, M. 24, 35
Cranford, J.A. 65, 83, 93
Crawford, N.D. 43
Crespo, C.A. 74
Crespo, J.A. 92
Crits-Christoph, P. 16, 57
Croft, J.R. 89
Cron, S. 97
Crone-Koshel, L. 91
Crooks, P.A. 13, 14
Croom, C. 33
Cropsey, K.L. 20, 63
Crouch, K. 96
Crowley, T.J. 12, 45, 58, 94, 97
Cruciani, R. 26
Cruz, J. 93
Cruz, V.O. 40
Cui, C.L. 4
Cui, J. 7
Culbertson, C. 56
Cummings, A. 61
Cummins, E. 8
Cunningham, K.A. 33, 68, 69, 74
Curtin, J.J. 61
Cusimano, R. 96
Cutler, M.L. 85, 86
Cutler, S.J. 7
Czoty, P.W. 69
D'Amante, D. 45
Daamen, M. 12
Dabre, Z. 37
Dackis, C. 48, 84
Dakin, L.A. 33
Dakof, G.A. 21, 60
Dallery, J. 14, 34, 62, 63, 75, 81
Dakof, G.A. 64
Danel, M.A. 54
Danielson, C.K. 88
Danulaityte, R. 65
Dart, R.C. 64, 94
Dasgupta, N. 16
Datko, M.C. 53
Daughters, S.B. 11, 38, 40, 42, 87
Daulouede, J.P. 9, 10, 72, 78
Davies, R. 45, 60
Davis, C.M. 7, 8
De Genna, N.M. 59
De La Garza, II, R. 42, 56, 96
de la Torre, R. 53
de Lédinghen, V. 9
De Rosa, E. 75
de Wit, H. 74, 78, 87
Deas, D. 44, 80
DeBon, R. 62
de Dios, M. 80
DeFulio, A. 85
Degenhardt, L. 47, 59
DeGruttola, V. 42
Del Olmo, N. 92
da Cruz, A.M. 33
Delile, J.M. 9
Delucchi, K.L. 63, 85
Dembro, K.A. 26
Denis, C. 9, 10, 26, 65, 91
Dennis, M.L. 17, 18, 29, 44, 46
Denton, W.H. 57
DePaolo, S. 4
Deren, S. 10, 57
Dermens, K.H. 17
Dersch, C.M. 7
Des Jarlais, D.C. 4, 65
Desai, R. 85
DeSantis, S.M. 50, 88
DeSouza, C. 10
Detre, J. 26
Detrick, C. 61
AUTHOR INDEX

DeVane, C.L. 15
Devine, S. 18
Dewey, W.L. 1, 2, 7, 22
Diaz, G. 34
Diaz, S.E. 34
Dick, D.M. 59
Dickerhoof, R.M. 56
Dickerson, D.L. 88
Dickinson, J. 16
DiClemente, C. 59
Didier, R. 78
Dietrich, M.S. , 95
Dillon, P. 67
DiPietro, J.A. 36
DiRocco, D. 38, 60
Djazayeri, S. 69
Djokovic, M. 82
Dodrill, C.L. 84
Doebrick, C. 17
Dominguez, G. 15
Donlin, W.D. 85
Donnini, C. 45
Donny, E.C. 14, 93
Donovick, R.A. 96
Doré, G. 3
Dornelas, E. 79
Douaihy, A.B. 48
Doyele, S.R. 26, 43, 64
Dragonetti, R. 63
Drexler, K. 62
Ducaye, J. 86
Du, J. 4
DuBose-O'Hagan, T. 10
Dubray, C. 17
Ducate, E. 53
Dufault, D.L. 55
Dufka, F. 55
Dugosh, K.L. 18, 84, 89
Duke, A. 32
Dumchev, K. 39, 42
Dunbar, D. 42
Dunbar, L. 85
Duncan, A.E. 59
Dunlap, E. 62, 66
Dunlop, A. 57
Dunn, K.E. 26, 38, 50
Duplinsky, M.S. 45, 58
DuPree, J. 4
Durant, L.E. 84
Durdle, H. 63, 78
Durell, T. 48
Dunham, T.G. 67
Durst, R. 82
Dutta, J. 84
Duvall, J.L. 20, 44, 89
Dvoryak, S. 42
Dwoskin, L.P. 13, 14
Dy, S. 19
Dykstra, L.A. 4, 9, 34
Eachus, S. 43
Eaddy, J.L. 34
Earlywine, M. 87
Easton, C.J. 18, 20
Edmundson, E. 67
Edwards, E.P. 36, 61
Egan, J.E. 37
Egleston, B.L. 63
Egorova, V. 37
Ehrman, R.N. 26, 27, 93
Eibner, C. 67
Eiden, R.D. 35, 36
Eisenberg, M.M. 42, 43
Eisenstein, T.K. 9
Elbert, T.R. 82
Eldridge, G.D. 20
Elkader, A. 70
Elkashef, A. 10, 92
Elkovitch, A. 66
Elko, A. 36
Elkus, Y. 37
Elenberg, L. 91
Elmore, J.G. 20
Elskes, C. 31
English, J. 80
Epstein, D.H. 19
Erickson, S.J. 19, 35
Ertischek, M.E. 66
Eschaler, A. 17
Esterlis, I. 54
Evans, E. 21, 38, 42, 89
Evans, R.J. 12
Evans, S.M. 36
Everly, J.J. 37
Evins, A.E. 62, 94
Fabbri, S. 24, 61
Fagan, P. 19, 85
Fahy, T. 35
Fairbanks, L.A. 80
Fallak, R. 65
Faller, S. 61
Fals-Stewart, W. 11, 17
Fan, C. 4
Fan, J. 54
Fang, S. 32
Fansler, A.C. 61
Fant, R.V. 65, 66
Fantegrossi, W.E. 70
Farabbe, D.J. 96
Faraoone, S.V. 71
Farid araki, K. 14
Farinotti, R. 54
Farnsworth, S. 74
Farnum, S. 17
Farrar, D. 85
Farrar, J. 22
Farre, M. 11, 53
Farrell, L. 24, 61
Fatseas, M. 9, 10, 26, 65, 91
Fava, M. 94
Febo, M. 34
Feldman, Z.L. 50, 77
Feltenstein, M.W. 79
Ferguson, L. 56
Fernandez-Hermida, J.R. 84
Ferris, C. 34
Festinger, D.S. 18, 89
Feussner, G.K. 92
Field, C. 58
Fields, H.L. 8, 54
Fiellin, D.A. 37, 39
Fiestas, F.A. 12
Fingerhood, M. 37
Fiore, D. 42
Fischer, B.D. 4, 9, 34, 93
Fischer, G. 24, 35, 75
Fishback, J.A. 53
**AUTHOR INDEX**

<table>
<thead>
<tr>
<th>Author</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fitzgerald, J.P.</td>
<td>66</td>
</tr>
<tr>
<td>Fitzgerald, T.</td>
<td>9</td>
</tr>
<tr>
<td>Fivel, P.A.</td>
<td>75</td>
</tr>
<tr>
<td>Flaherty, M.</td>
<td>6</td>
</tr>
<tr>
<td>Flannery, D.</td>
<td>66</td>
</tr>
<tr>
<td>Fleckenstein, A.</td>
<td>74</td>
</tr>
<tr>
<td>Flores-Ortega, Y.G.</td>
<td>59</td>
</tr>
<tr>
<td>Flower, K.</td>
<td>56</td>
</tr>
<tr>
<td>Floyd, L.J.</td>
<td>4, 39, 43</td>
</tr>
<tr>
<td>Fokina, V.</td>
<td>32</td>
</tr>
<tr>
<td>Foley, K.</td>
<td>18</td>
</tr>
<tr>
<td>Foltin, R.W.</td>
<td>10, 23, 27, 36, 55</td>
</tr>
<tr>
<td>Fong, C.</td>
<td>83, 90</td>
</tr>
<tr>
<td>Fonseca, F.</td>
<td>11, 17, 53</td>
</tr>
<tr>
<td>Forcehimes, A.A.</td>
<td>18, 46</td>
</tr>
<tr>
<td>Ford, C.L.</td>
<td>66</td>
</tr>
<tr>
<td>Ford, II, J.H.</td>
<td>58, 67, 90</td>
</tr>
<tr>
<td>Foremny, G.</td>
<td>4</td>
</tr>
<tr>
<td>Forasti-Zubaran, K.</td>
<td>32</td>
</tr>
<tr>
<td>Forman, R.</td>
<td>16, 57</td>
</tr>
<tr>
<td>Formash, A.</td>
<td>93</td>
</tr>
<tr>
<td>Forst, C.</td>
<td>87</td>
</tr>
<tr>
<td>Forster, M.J.</td>
<td>31</td>
</tr>
<tr>
<td>Forzisi, L.</td>
<td>87</td>
</tr>
<tr>
<td>Foucher, J.</td>
<td>9</td>
</tr>
<tr>
<td>Fox, H.C.</td>
<td>10, 87</td>
</tr>
<tr>
<td>France, C.P.</td>
<td>5, 23, 79</td>
</tr>
<tr>
<td>Franceschini, P.</td>
<td>32</td>
</tr>
<tr>
<td>Franck, J.</td>
<td>56, 77</td>
</tr>
<tr>
<td>Frank, I.</td>
<td>42</td>
</tr>
<tr>
<td>Franklin, T.</td>
<td>73, 93</td>
</tr>
<tr>
<td>Frasca, J.</td>
<td>69</td>
</tr>
<tr>
<td>Frascella, J.</td>
<td>2</td>
</tr>
<tr>
<td>Frederick, B.B.</td>
<td>94</td>
</tr>
<tr>
<td>Freeman, K.B.</td>
<td>97</td>
</tr>
<tr>
<td>Freeman, R.</td>
<td>17</td>
</tr>
<tr>
<td>Freese, T.</td>
<td>51</td>
</tr>
<tr>
<td>Friedman, E.</td>
<td>41</td>
</tr>
<tr>
<td>Friedman, S.R.</td>
<td>4, 10</td>
</tr>
<tr>
<td>Frisman, L.</td>
<td>43, 44</td>
</tr>
<tr>
<td>Froimowitz, M.</td>
<td>33</td>
</tr>
<tr>
<td>Fruehling-Wall, C.</td>
<td>94</td>
</tr>
<tr>
<td>Fuchs, R.A.</td>
<td>34</td>
</tr>
<tr>
<td>Fulbright, R.K.</td>
<td>49</td>
</tr>
<tr>
<td>Fuller, C.M.</td>
<td>43</td>
</tr>
<tr>
<td>Funk, R.</td>
<td>46</td>
</tr>
<tr>
<td>Furr, E.B.</td>
<td>7</td>
</tr>
<tr>
<td>Gabra, B.H.</td>
<td>7</td>
</tr>
<tr>
<td>Gallagher, R.M.</td>
<td>15, 64</td>
</tr>
<tr>
<td>Gallop, R.</td>
<td>48, 61</td>
</tr>
<tr>
<td>Galloway, G.P.</td>
<td>13</td>
</tr>
<tr>
<td>Galloway, M.P.</td>
<td>55</td>
</tr>
<tr>
<td>Gamal Eddin, I.H.</td>
<td>32</td>
</tr>
<tr>
<td>Gao, Y.</td>
<td>32</td>
</tr>
<tr>
<td>García-Lecumberri, C.</td>
<td>92</td>
</tr>
<tr>
<td>Garcia-Rodriguez, O.</td>
<td>84</td>
</tr>
<tr>
<td>Gardner, E.L.</td>
<td>33, 72</td>
</tr>
<tr>
<td>Gardner, T.</td>
<td>11, 84</td>
</tr>
<tr>
<td>Garner, B.R.</td>
<td>44, 46</td>
</tr>
<tr>
<td>Garnet, B.</td>
<td>26</td>
</tr>
<tr>
<td>Garnier, C.</td>
<td>17</td>
</tr>
<tr>
<td>Garnier, L.</td>
<td>64</td>
</tr>
<tr>
<td>Garrett, N.R.</td>
<td>69</td>
</tr>
<tr>
<td>Garrity, T.F.</td>
<td>11, 58</td>
</tr>
<tr>
<td>Gasior, M.J.</td>
<td>81</td>
</tr>
<tr>
<td>Gass, J.</td>
<td>37</td>
</tr>
<tr>
<td>Gatch, M.B.</td>
<td>31, 79</td>
</tr>
<tr>
<td>Gatchalian, K.M.</td>
<td>37</td>
</tr>
<tr>
<td>Gates, P.</td>
<td>67</td>
</tr>
<tr>
<td>Gauchet, A.</td>
<td>10, 61</td>
</tr>
<tr>
<td>Gaughan, J.P.</td>
<td>9</td>
</tr>
<tr>
<td>Geaghan, T.</td>
<td>17</td>
</tr>
<tr>
<td>Gelberg, L.</td>
<td>19</td>
</tr>
<tr>
<td>Gelhorn, H.L.</td>
<td>58</td>
</tr>
<tr>
<td>Geller, E.B.</td>
<td>9, 13</td>
</tr>
<tr>
<td>Gentilin, S.</td>
<td>15</td>
</tr>
<tr>
<td>Gentry, W.</td>
<td>56</td>
</tr>
<tr>
<td>George, S.R.</td>
<td>48</td>
</tr>
<tr>
<td>Gerak, L.R.</td>
<td>32</td>
</tr>
<tr>
<td>Gerbaut, L.</td>
<td>12</td>
</tr>
<tr>
<td>German, D.</td>
<td>18</td>
</tr>
<tr>
<td>Gerra, G.</td>
<td>45, 91</td>
</tr>
<tr>
<td>Gerstenberger, E.</td>
<td>19, 57</td>
</tr>
<tr>
<td>Gervais, A.</td>
<td>9, 10</td>
</tr>
<tr>
<td>Ghandour, L.A.</td>
<td>87</td>
</tr>
<tr>
<td>Ghodoussi, F.</td>
<td>55</td>
</tr>
<tr>
<td>Ghozland, S.G.</td>
<td>6, 92</td>
</tr>
<tr>
<td>Gifford, E.</td>
<td>16</td>
</tr>
<tr>
<td>Gignoux, N.</td>
<td>86</td>
</tr>
<tr>
<td>Gilbert, G.E.</td>
<td>80, 81</td>
</tr>
<tr>
<td>Gill, M.J.</td>
<td>34</td>
</tr>
<tr>
<td>Gillespie, D.</td>
<td>27</td>
</tr>
<tr>
<td>Gilliam, A.F.</td>
<td>13, 49</td>
</tr>
<tr>
<td>Gillikin, C.</td>
<td>21</td>
</tr>
<tr>
<td>Gilson, A.M.</td>
<td>66, 71</td>
</tr>
<tr>
<td>Gines, J.M.</td>
<td>17</td>
</tr>
<tr>
<td>Gingras, M.</td>
<td>21</td>
</tr>
<tr>
<td>Glaser, P.E.</td>
<td>56, 70</td>
</tr>
<tr>
<td>Glasmacher, C.</td>
<td>12</td>
</tr>
<tr>
<td>Glasmann, A.</td>
<td>24</td>
</tr>
<tr>
<td>Glasner-Edwards, S.</td>
<td>83</td>
</tr>
<tr>
<td>Gleghorn, A.</td>
<td>15</td>
</tr>
<tr>
<td>Glick, A.</td>
<td>20</td>
</tr>
<tr>
<td>Gnegy, M.E.</td>
<td>13</td>
</tr>
<tr>
<td>Goate, A.</td>
<td>73</td>
</tr>
<tr>
<td>Godinez, M.</td>
<td>43</td>
</tr>
<tr>
<td>Godley, M.D.</td>
<td>46</td>
</tr>
<tr>
<td>Godley, S.H.</td>
<td>46</td>
</tr>
<tr>
<td>Goeders, N.E.</td>
<td>5</td>
</tr>
<tr>
<td>Gold, M.</td>
<td>38</td>
</tr>
<tr>
<td>Goldberger, B.</td>
<td>38</td>
</tr>
<tr>
<td>Golden, S.A.</td>
<td>79</td>
</tr>
<tr>
<td>Goldman, M.</td>
<td>26, 27, 93</td>
</tr>
<tr>
<td>Goldsamt, L.A.</td>
<td>43</td>
</tr>
<tr>
<td>Goleviani, N.</td>
<td>54</td>
</tr>
<tr>
<td>Golub, S.A.</td>
<td>71</td>
</tr>
<tr>
<td>Gómez, E.</td>
<td>10, 44</td>
</tr>
<tr>
<td>Gonzales, R.</td>
<td>18, 57</td>
</tr>
<tr>
<td>González, G.</td>
<td>38, 85</td>
</tr>
<tr>
<td>Gonzalez-Perez, J.L.</td>
<td>21</td>
</tr>
<tr>
<td>Goodwin, A.K.</td>
<td>23, 72</td>
</tr>
<tr>
<td>Goransson, M.O.</td>
<td>16, 83</td>
</tr>
<tr>
<td>Gorbach, P.</td>
<td>44</td>
</tr>
<tr>
<td>Gordon, A.J.</td>
<td>38, 89, 90</td>
</tr>
<tr>
<td>Gordon, M.S.</td>
<td>21</td>
</tr>
<tr>
<td>Gordon, S.M.</td>
<td>83</td>
</tr>
<tr>
<td>Gorelick, D.A.</td>
<td>12, 18, 40, 87</td>
</tr>
<tr>
<td>Gorka, S.M.</td>
<td>11, 38, 40</td>
</tr>
<tr>
<td>Gould, R.W.</td>
<td>69</td>
</tr>
<tr>
<td>Goulding, S.P.</td>
<td>54</td>
</tr>
<tr>
<td>Gouraier, L.</td>
<td>9, 10, 61</td>
</tr>
<tr>
<td>Gourevitch, M.N.</td>
<td>38, 60</td>
</tr>
<tr>
<td>Gowin, J.L.</td>
<td>20</td>
</tr>
<tr>
<td>Grabinoski, M.</td>
<td>63</td>
</tr>
<tr>
<td>Grabowski, J.</td>
<td>11, 96</td>
</tr>
<tr>
<td>Grady, J.J.</td>
<td>40</td>
</tr>
<tr>
<td>Author</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Graff, F.</td>
<td>48</td>
</tr>
<tr>
<td>Graham, C.M.</td>
<td>10</td>
</tr>
<tr>
<td>Graham, J.</td>
<td>16</td>
</tr>
<tr>
<td>Graham, N.A.</td>
<td>38</td>
</tr>
<tr>
<td>Granger, D.</td>
<td>35</td>
</tr>
<tr>
<td>Granmayeh, L.K.</td>
<td>97</td>
</tr>
<tr>
<td>Grant, B.</td>
<td>24</td>
</tr>
<tr>
<td>Grant, J.D.</td>
<td>59</td>
</tr>
<tr>
<td>Grant, K.M.</td>
<td>69</td>
</tr>
<tr>
<td>Grasing, K.W.</td>
<td>10</td>
</tr>
<tr>
<td>Gray, K.M.</td>
<td>80, 81</td>
</tr>
<tr>
<td>Green, C.M.</td>
<td>11, 53, 83, 96</td>
</tr>
<tr>
<td>Green, T.G.</td>
<td>94</td>
</tr>
<tr>
<td>Greenbaum, P.E.</td>
<td>60</td>
</tr>
<tr>
<td>Greenberg, A.E.</td>
<td>41</td>
</tr>
<tr>
<td>Greenberg, B.</td>
<td>85</td>
</tr>
<tr>
<td>Greenberg, M.T.</td>
<td>81</td>
</tr>
<tr>
<td>Greene, J.</td>
<td>24</td>
</tr>
<tr>
<td>Greenfield, S.F.</td>
<td>61, 83</td>
</tr>
<tr>
<td>Greenwald, M.K.</td>
<td>15, 36, 38, 63, 95</td>
</tr>
<tr>
<td>Grekin, E.R.</td>
<td>12</td>
</tr>
<tr>
<td>Grella, C.</td>
<td>19, 71, 78, 88</td>
</tr>
<tr>
<td>Grey, J.</td>
<td>13</td>
</tr>
<tr>
<td>Griffin, B.</td>
<td>66</td>
</tr>
<tr>
<td>Griffin, M.</td>
<td>48</td>
</tr>
<tr>
<td>Griffin, W.C.</td>
<td>75</td>
</tr>
<tr>
<td>Griffith, S.</td>
<td>18</td>
</tr>
<tr>
<td>Griffiths, R.R.</td>
<td>23, 31, 78</td>
</tr>
<tr>
<td>Grinenko, A.</td>
<td>37</td>
</tr>
<tr>
<td>Grohman, K.</td>
<td>61</td>
</tr>
<tr>
<td>Groman, S.M.</td>
<td>26, 80</td>
</tr>
<tr>
<td>Grosheider, T.J.</td>
<td>38</td>
</tr>
<tr>
<td>Grossman, E.</td>
<td>38, 60</td>
</tr>
<tr>
<td>Grov, C.</td>
<td>71</td>
</tr>
<tr>
<td>Grunberg, N.E.</td>
<td>97</td>
</tr>
<tr>
<td>Grunhaus, L.</td>
<td>82</td>
</tr>
<tr>
<td>Gu, Y.</td>
<td>33</td>
</tr>
<tr>
<td>Guenthner, G.</td>
<td>63</td>
</tr>
<tr>
<td>Guerra, R.</td>
<td>86</td>
</tr>
<tr>
<td>Gunderson, E.W.</td>
<td>23, 25, 55, 64</td>
</tr>
<tr>
<td>Guo, D.</td>
<td>53, 74</td>
</tr>
<tr>
<td>Gust, S.W.</td>
<td>30</td>
</tr>
<tr>
<td>Gustafson, D.</td>
<td>67, 90</td>
</tr>
<tr>
<td>Gutierrez, S.</td>
<td>36</td>
</tr>
<tr>
<td>Guydish, J.R.</td>
<td>63, 85</td>
</tr>
<tr>
<td>Gyarmathy, A.</td>
<td>43</td>
</tr>
<tr>
<td>Gyarmathy, V.</td>
<td>4</td>
</tr>
<tr>
<td>Habecker, E.</td>
<td>54</td>
</tr>
<tr>
<td>Haber, J.R.</td>
<td>59</td>
</tr>
<tr>
<td>Haddox, J.D.</td>
<td>64, 66</td>
</tr>
<tr>
<td>Hader, S.</td>
<td>41</td>
</tr>
<tr>
<td>Hagan, H.</td>
<td>4, 65</td>
</tr>
<tr>
<td>Haggkvist, J.</td>
<td>77</td>
</tr>
<tr>
<td>Hagle, H.</td>
<td>91</td>
</tr>
<tr>
<td>Hakansson, A.</td>
<td>86</td>
</tr>
<tr>
<td>Hakun, J.</td>
<td>26, 27, 93</td>
</tr>
<tr>
<td>Hall, D.R.</td>
<td>16</td>
</tr>
<tr>
<td>Hall, E.</td>
<td>20</td>
</tr>
<tr>
<td>Haller, D.L.</td>
<td>26, 70, 71</td>
</tr>
<tr>
<td>Hallyburton, M.</td>
<td>80</td>
</tr>
<tr>
<td>Halperin, J.</td>
<td>54</td>
</tr>
<tr>
<td>Halpern, J.H.</td>
<td>31</td>
</tr>
<tr>
<td>Hamann, S.</td>
<td>35</td>
</tr>
<tr>
<td>Hamburger, R.B.</td>
<td>85</td>
</tr>
<tr>
<td>Hamidovic, A.</td>
<td>74</td>
</tr>
<tr>
<td>Hamilton, F.</td>
<td>41</td>
</tr>
<tr>
<td>Hamilton, K.R.</td>
<td>97</td>
</tr>
<tr>
<td>Hamilton, W.</td>
<td>38</td>
</tr>
<tr>
<td>Hammarberg, A.</td>
<td>56</td>
</tr>
<tr>
<td>Hammond, C.</td>
<td>38</td>
</tr>
<tr>
<td>Hamon, S.</td>
<td>73</td>
</tr>
<tr>
<td>Han, D.H.</td>
<td>54, 55</td>
</tr>
<tr>
<td>Han, J.S.</td>
<td>4</td>
</tr>
<tr>
<td>Haney, M.</td>
<td>10, 12, 13, 23, 27, 70</td>
</tr>
<tr>
<td>Hankins, G.</td>
<td>32</td>
</tr>
<tr>
<td>Hanley, K.</td>
<td>60</td>
</tr>
<tr>
<td>Hanlon, C.A.</td>
<td>27, 55, 94</td>
</tr>
<tr>
<td>Hannigan, J.</td>
<td>32</td>
</tr>
<tr>
<td>Hanselka, L.L.</td>
<td>56</td>
</tr>
<tr>
<td>Hansen, S.</td>
<td>83</td>
</tr>
<tr>
<td>Hanson, G.R.</td>
<td>34, 74</td>
</tr>
<tr>
<td>Hao, C.</td>
<td>42</td>
</tr>
<tr>
<td>Hartford, T.</td>
<td>39</td>
</tr>
<tr>
<td>Harper-Castle, S.</td>
<td>60</td>
</tr>
<tr>
<td>Harrand, A.</td>
<td>17</td>
</tr>
<tr>
<td>Harris, A.C.</td>
<td>14</td>
</tr>
<tr>
<td>Harris, E.</td>
<td>36</td>
</tr>
<tr>
<td>Harris, T.R.</td>
<td>58</td>
</tr>
<tr>
<td>Harrod, S.</td>
<td>72, 79</td>
</tr>
<tr>
<td>Hart, C.L.</td>
<td>10, 23, 27, 55</td>
</tr>
<tr>
<td>Hart, R.</td>
<td>85</td>
</tr>
<tr>
<td>Hartje, J.A.</td>
<td>16, 89</td>
</tr>
<tr>
<td>Hartman, C.</td>
<td>58</td>
</tr>
<tr>
<td>Hartwell, K.</td>
<td>11, 83</td>
</tr>
<tr>
<td>Hartzler, B.J.</td>
<td>86</td>
</tr>
<tr>
<td>Harui, A.</td>
<td>3</td>
</tr>
<tr>
<td>Harvey, R.C.</td>
<td>26</td>
</tr>
<tr>
<td>Hashimoto, K.</td>
<td>8</td>
</tr>
<tr>
<td>Hasin, D.S.</td>
<td>12, 24, 39, 84</td>
</tr>
<tr>
<td>Hatch-Maillette, M.A.</td>
<td>15, 43</td>
</tr>
<tr>
<td>Hathazi, D.</td>
<td>44</td>
</tr>
<tr>
<td>Haug, N.</td>
<td>63</td>
</tr>
<tr>
<td>Havens, J.R.</td>
<td>18, 20, 43, 44, 94</td>
</tr>
<tr>
<td>Hawken, A.</td>
<td>20, 21</td>
</tr>
<tr>
<td>Haynes, L.</td>
<td>9</td>
</tr>
<tr>
<td>Hays, L.R.</td>
<td>55, 70</td>
</tr>
<tr>
<td>Hazim, R.</td>
<td>33, 77</td>
</tr>
<tr>
<td>Heath, A.C.</td>
<td>72, 73, 82</td>
</tr>
<tr>
<td>Heckman, C.</td>
<td>63</td>
</tr>
<tr>
<td>Hedden, S.L.</td>
<td>10, 11, 17, 24, 83</td>
</tr>
<tr>
<td>Heil, S.H.</td>
<td>24, 26, 35, 36, 38</td>
</tr>
<tr>
<td>Heimer, R.</td>
<td>27</td>
</tr>
<tr>
<td>Heinz erling, K.G.</td>
<td>56, 96</td>
</tr>
<tr>
<td>Heishman, S.J.</td>
<td>12, 60, 87</td>
</tr>
<tr>
<td>Helmbrecht, T.</td>
<td>63</td>
</tr>
<tr>
<td>Heltshe, S.L.</td>
<td>64</td>
</tr>
<tr>
<td>Hemberg, J.</td>
<td>96</td>
</tr>
<tr>
<td>Henderson, A.R.</td>
<td>79</td>
</tr>
<tr>
<td>Henderson, C.E.</td>
<td>21, 60</td>
</tr>
<tr>
<td>Hengge ler, S.W.</td>
<td>16</td>
</tr>
<tr>
<td>Henningfield, J.E.</td>
<td>1, 65, 66</td>
</tr>
<tr>
<td>Henry, III, F.E.</td>
<td>4, 9, 34</td>
</tr>
<tr>
<td>Herbeck, D.</td>
<td>42</td>
</tr>
<tr>
<td>Herin, D.V.</td>
<td>11, 96</td>
</tr>
<tr>
<td>Hernandez, A.</td>
<td>41</td>
</tr>
<tr>
<td>Hernandez, P.</td>
<td>34</td>
</tr>
<tr>
<td>Herrn tche, T.</td>
<td>41</td>
</tr>
<tr>
<td>Herrin, A.E.</td>
<td>9</td>
</tr>
<tr>
<td>Herrmann, N.</td>
<td>75</td>
</tr>
<tr>
<td>Hersh, D.</td>
<td>15</td>
</tr>
<tr>
<td>Hershberger, J.</td>
<td>20</td>
</tr>
<tr>
<td>Herting, J.</td>
<td>21</td>
</tr>
<tr>
<td>Hester, R.</td>
<td>96</td>
</tr>
<tr>
<td>Hettema, J.E.</td>
<td>19, 58</td>
</tr>
<tr>
<td>Hewitt, J.</td>
<td>58</td>
</tr>
<tr>
<td>Hides, L.</td>
<td>46</td>
</tr>
<tr>
<td>Hien, D.</td>
<td>41</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Higa, J. 79
Higgins, S.T. 1, 24, 26, 36, 38, 67, 75, 97
Higgs, S. 13
Highfield, D. 21, 88
Higley, A. 72
Higuera-Matas, A. 92
Hij, A. 10, 61
Hill, K.P. 11, 77
Hillhouse, M. 42, 83
Hinkel, H. 82
Hirshon, J. 18, 40
Hjelmstad, G.O. 8
Ho, A. 8, 53
Hoffman, I.F. 4
Hoffman, J. 91
Hoffman, K. 90
Hofmann, M. 63
Hogan, J.B. 86, 88
Holzer, C. 40
Homish, D.L. 17
Homish, G.G. 40, 67
Hong, K.A. 37, 49, 87
Hong, K.X. 42
Hopfer, C. 58
Hoppe, M.J. 45
Hopwood, S. 41
Horton, Jr., A.M. 67
Horvatich, P.K. 51
Hossain, M.B. 39
Houston, R.J. 84
Hser, Y.Y. 38, 40, 87, 89
Hsiao, H. 78
Hsin, L.W. 7
Hu, M. 9
Hu, X. 35
Huang, D. 38, 40
Huang, S.L. 58
Huang, W. 33, 54, 96
Huang, Y. 49
Hucks-Ortiz, C. 44
Huebner, K.R. 11
Huizink, A.C. 27, 59
Hulbert, A. 62
Hunter, D. 8
Hunter, J. 18
Huntley, K. 28, 51
Hurd, Y.L. 25
Hurst, S. 86
Hurt, H. 3
Hussain, S. 63
Hutchison, M. 70
Hwang, J. 55
Hyde, E.M. 36, 55
Hyman, S.M. 37
Hyun Rhee, S. 27
Ialongo, N. 43
Icenhower, M. 69
Iguchi, M. 2
Inciardi, J.A. 41, 43, 44, 65, 72
Indarte, M. 49
Indlekofer, F. 12
Ingersoll, K.S. 24, 61
Ingram, B.L. 66
Inoue, T. 8
Inturrisi, C. 22
Iordanou, J.C. 34
Irenkauf, S. 32
Irvine, R.J. 23
Isasi, C. 62
Isendahl, P. 86
Islam, L. 24
Ivanov, I. 54
Ives, M. 44, 46
Izenwasser, S. 25, 49, 50
Jackson, B. 96
Jackson, C. 53, 73
Jackson, D.O. 63
Jackson, L. 37
Jackson Bloom, J. 44
Jacob, T. 59
Jacobs, P. 68
Jacobson, A.E. 7
Jaehne, E.J. 23
Jaffe, C. 56
Jaffe, J.H. 21, 28, 88
Jaffee, W. 45, 48
Jager, G. 94
Jagsch, R. 75
Jagust, W.J. 54
Jain, R. 74
James, A.S. 80
Janes, A.C. 94
Jang, M. 78
Jansson, L.M. 36
Jayaram-Lindstrom, N. 56
Jenab, S. 8, 33, 34, 77, 79
Jenab, V.Q. 77
Jens, W. 26, 27, 93
Jentsch, J.D. 26, 80
Ji, F. 53
Jiang, D. 40
Jiang, H. 37
Johnson, C.E. 78, 87
John-Hull, C. 15
Johnson, A. 83
Johnson, B.A. 60
Johnson, B.D. 66
Johnson, F. 32, 37
Johnson, K.M. 31
Johnson, M.L. 72
Johnson, M.W. 31
Johnson, N. 44
Jones, C. 92
Jones, H.E. 1, 24, 35, 36, 37, 75
Jones, J. 37
Jones, N. 91
Jones, J.B. 32
Jorgensen, M.J. 80
Joseph, H. 20, 26, 38
Joseph, J.E. 55
Joshi, D. 26
Jospitre, T. 18
Jullien, V. 9
Jungman, J. 9
Justus, T. 78
Jutkiewicz, E.M. 13
Kadrnka, C. 71
Kaiser, K. 82
Kalechstein, A.D. 96
Kaltenbach, K. 1, 24, 35, 47
Kaminski, B.J. 23
Kampman, K.M. 48, 50, 73, 93
Kang, S.Y. 10, 57
AUTHOR INDEX

Kantak, K.M.  22, 26, 77, 93
Kapasova, Z.  54
Kaplan, G.  82
Kaprio, J.  59
Karakashian, M.  61
Karjane, N.  60
Karno, M.  19, 78
Kasinather, V.B.  39
Katz, E.C.  38
Katz, G.  82
Katz, H.  12
Kaufman, M.J.  1, 94
Kaushal, N.  33, 49
Kavanagh, G.J.  90
Kay-Lambkin, F.  46
Keith, D.  54
Kellam, S.  43
Kelley, C.J.  33
Kelley, M.L.  11, 17
Kellogg, S.  57
Kelly, B.C.  71
Kelly, M.  75
Kelly, S.  21, 86
Kelly, T.H.  55, 62, 63, 80
Kelly, T.M.  48
Kemp, J.  19
Kennedy, A.  56
Kennedy, J.L.  73
Kerntop, K.A.  49
Kertesz, S.  85, 96
Keshavan, M.  95
Kessler, F.H.  61
Kileas, K.  24
Keyler, D.E.  14, 33
Keyser-Marcus, L.  24
Khan, M.R.  45
Khatib, D.  95
Khazan, B.  18
Khurana, A.  45
Kichko, I.  49
Kidorf, M.  85, 86
Kidorf, M.S.  88
Kielstein, A.  78
Kierster, S.  3
Killeen, T.K.  13, 41, 59, 83
Kilmer, B.  67
Kilpatrick, D.  88
Kilts, C.  55
Kim, T.W.  19, 91
Kindbom, K.  86
King, G.  79
King, S.  38
King, V.L.  85, 86
Kinlock, T.W.  21
Kinsey, B.M.  33, 96
Kippen, T.E.  49
Kirby, K.C.  84
Kirchner, K.  48
Kirillova, G.  45
Kirk, I.J.  23, 78
Kirkpatrick, M.G.  55
Kirser, R.S.  19
Kish, J.  65
Kivlighan, K.T.  36
Kleber, H.D.  25
Klein, C.  45
Klein, H.  39
Kleykamp, B.A.  78
Kline, A.T.  66
Klintworth, E.M.  81
Kloczynski, T.A.  54
Kloth, J.T.  54
Knackstedt, P.T.  5
Knapp, B.I.  7
Knauer, H.  36
Knudsen, H.  43, 44
Knudson, I.M.  75
Ko, M.C.  33
Kobayashi, Y.  4
Koek, W.  23
Kohut, S.J.  49
Kollins, S.H.  80
Koob, G.F.  69
Kopanda, R.  91
Kopstein, A.  91
Korhonen, T.  59
Kosten, T.A.  33, 49, 88
Kosten, T.R.  11, 26, 77, 84, 88, 95, 96
Koutsky, J.R.  17
Kowal, B.P.  97
Kowalczyk, W.J.  36
Kozlov, A.P.  4, 43
Kraen, A.  61
Kraemer, K.L.  89
Kramer, L.A.  26
Kranzler, H.R.  24, 56
Krauss, M.  58
Kreek, M.J.  8, 34, 53, 73, 95
Krishnan-Sarin, S.  54, 59, 80, 81
Kritz, S.A.  15
Kronborg, I.J.  3
Kronstrand, R.  86
Krstik, J.  78
Krueger, P.M.  20
Krupitsky, E.  37
Kubiak, S.P.  63
Kugelberg, F.C.  86
Kuhn, C.M.  72, 73
Kulaga, A.  16, 57
Kuo, I.  41
Kuper, L.  61
Kurahashi, K.  4
Kurtz, S.P.  65, 72
Kushner, R.  46
Kuzumaki, N.  8
Lacadie, C.M.  49
Lacy, R.T.  79
Lam, K.  11
Lam, W.K.  17
Lamarre, N.  77
Lamb, R.J.  10, 92
Landes, R.D.  37, 97
Lanoy, S.D.  20, 26
Lanfranco, M.F.  33
Langer, D.  91
Langhorst, D.  35, 62
Langohr, K.  53
Langston, T.L.  49
Languerand, E.  61
Lanier, R.K.  36
Lankenau, S.E.  44
LaPaglia, D.  40
Laranjeira, R.  62
Larkby, C.  35
AUTHOR INDEX

Larkins, S. 44
LaRowe, S. 62, 88
Larraburu, A. 91
Larson, M.J. 17, 19, 57
Latimer, W.W. 4, 10, 17, 24, 39, 43, 45
Latkin, C.A. 4, 18, 41, 42, 43, 88
Latimer, W.W. 4, 10, 12, 43, 52, 64, 68
Levin, K.H. 12, 87
Levitt, N.A. 10
Levran, O. 53
Levy, A.M. 69
Lewis, B. 35
Li, C. 27
Li, C.R. 49
Li, H. 21
Li, J. 5, 33
Li, L. 42
Li, M.D. 54, 73
Li, N. 4
Li, X. 33
Li, Y. 26, 27, 62, 73, 93
Li, Z. 35
Liang, L. 87
Liang, S. 42
Liang, Y.X. 79
Liautaud, J. 20
Liberto, J. 90
Libretto, S. 16, 91
Licari, A. 16
Licata, S.C. 17
Liddle, H.A. 21, 29, 60
Lieb, R. 12
Lile, J.A. 55, 80
Lim, J. 15
Lin, J. 78
Lin, J.L. 19
Lin, K. 32
Lin, M. 15
Linares Scott, T. 36
Lino, M.F. 61
Lindholm, S. 77
Lindsay, J. 83, 96
Ling, W. 15, 25, 26, 96
Link, T.C. 58
Lintzeris, N. 70, 87
Limy, S. 53
Lioy, K. 16
Liss, T.B. 59, 80, 81
Listerud, J. 37
Little, S. 15
Litwack, T. 91
Liu, C.Y. 58
Liu, H. 4
Liu, J. 79
Liu, R. 1
Liu, X. 93
Liu, Y. 49, 53
Llorca, P. 17
Llorens, N. 38
Llosa, T. 66
Lloyd, J.J. 44
Lo, S.J. 81
Lobo, D.S. 73
LoCastro, J.S. 19
Locy, M. 14
Lockhart, H. 87
Lofwall, M.R. 36
Lohman, M. 45
Lohoff, F. 73
Lomas, L. 9
Lominac, K.D. 79
London, E.D. 26, 28, 54, 56, 94
Londono, D. 53
Long, E. 2
Longacre, I.D. 72, 79
Longshore, D. 21
Looby, A. 17, 87
Lopacinski, S.M. 21
Lopez, C. 32, 44
Lopez, E. 67
Lopez, J.C. 78
Lopez, L.M. 9
Lopez Vargas, E. 21
Lord, S.E. 16, 45
Loree, A. 36
Lorenz, D.I. 64
Lorenzi, F. 67
Lott, D.C. 81
Louie, B. 15
Love, M. 19
Lu, N. 91
Lubman, D.I. 46
Luftman, V. 63
Luijten, M. 94
Lukas, S.E. 13, 17, 60
Lundahl, L.H. 35, 78, 87
Lundgren, L. 9
Luther, J. 38
Ly, T. 24, 61
Lynch, K.G. 19, 48, 59, 84
Lynch, M.E. 35
Lynch, W.J. 14
Lynskey, M.T. 72, 73, 82
Lyoo, I. 54, 55
Ma, J.Z. 54
Ma, Y. 4
Maccarelli, L. 40
Mach, J.L. 97
Mackey, D. 16
Mackey, D.H. 51
Mackey, D.L. 35
MacPherson, L. 45, 58
Maadden, L. 17, 67
Madden, P.A. 72, 73, 82
Madray, C. 15
Madura, J.L. 81
Magidson, J. 42
Magnus, M. 41
Magura, S. 20, 26, 38, 83, 90
Mahony, A. 10
Maidment, N.T. 5
Maitre, C. 72
Malagon, M.A. 17
Malcolm, R.J. 11, 62, 83
Mallet, P. 47
Malte, C.A. 56
Mancha, B.E. 43
Mancino, M.J. 37, 50, 56, 77
Mandell, W. 18
Mangold, J.E. 73
Mangrum, L.M. 6, 57
Manser, K. 10
Manteuffel, B. 58
Manubay, J.M. 25
Marcus, M.T. 97
Mardekin, S.K. 14
Mardikian, P.N. 62
Margolis, E.B. 8
Mariani, J.J. 10, 12, 43
Marinelli-Casey, P. 83, 89
Markou, A. 92
Markowitz, T. 86
Marlowe, D.B. 18, 29, 89
Marsch, L.A. 20, 26, 37, 58, 75
Martell, B. 11
Martin, B.R. 1, 31
Martin, C.A. 55, 62, 63, 80
Martin, C.N. 40
Martin, G. 78
Martin, N.G. 72, 73, 82
Martin, P. 24, 35
Martin, R. 21
Martin-Santos, R. 53
Martinez, D.C. 17
Martins, S. 29, 87, 93
Marusich, J.A. 34
Masalov, D. 37
Mascarella, W.S. 13
Mashhoon, Y. 93
Mason, B.J. 78
Masson, C.L. 15, 85
Masuda, A. 15
Mateu-Gelabert, M. 10
Mateyoke-Scriviner, A. 18
Mathur, D. 10
Matsumoto, R.R. 33, 49, 53, 72
Mattick, R.P. 36
Maurer, M.A. 66
Maxwell, C. 90
Maxwell, J.C. 38, 44
Mayes, L.C. 35
Mayet, S. 87
Mazlan, M. 39, 42, 94
Mazure, C.M. 88
McCabe, S.E. 64, 65, 83, 93
McCaffrey, D.F. 66
McCann, U.D. 31
McCarty, D. 67, 90
McClellon, J. 22
McClure, B. 16, 57
McConnell, J. 67, 90
McCoy, C.B. 4, 42
McCuller, W.J. 21, 57
McCurdy, C.R. 7, 33, 49, 72
McDermott, M.J. 38, 93
McDonald, C.L. 18
McFetridge, A.K. 59, 80, 81
McGaugh, J.D. 56
McHugh, R.K. 86, 88
McKay, J.R. 37, 84, 91
McKetin, R. 57
McKnight, C. 4, 15
McLaren, J.A. 67
McLellan, A.T. 91
McMahon, L. 13
McNees, E. 37
McNeil, J.F. 60
McNicholas, L.F. 26, 37
McQueary, S. 62
McQueen, K. 61, 84
McRae, A.L. 13, 50, 59, 93
Meade, C. 48
Medina-Mora, M. 12
Medina-Mora, M.E. 87, 88
Meissler, J.J. 9
Melanko, S. 80, 81
Melia, D. 53
Melin, P. 61
Mellacheruvu, M. 91
Mello, N.K. 54, 75
Mendelson, J. 55
Mendelson, J.E. 56, 78
Mendez, A. 59
Mennemeyer, S. 85, 96
Mennes, C.E. 12
Meredith, C.W. 56
Mericle, A.A. 40
Merlo, L. 38
Merrill, J.O. 20, 26, 64
Merritt, C. 44
Merrouche, W. 9
Merz, A. 88
Mesangeau, C. 7, 33, 49
Meshberg-Cohen, S. 41
Messina, N.P. 89
Metzger, D.S. 42, 43, 66
Mezzich, A.C. 45, 82
Michaels, M.S. 55
Miele, G. 9
Miguelez, M. 32
Miguéns, M. 92
<table>
<thead>
<tr>
<th>Author Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mikulich-Gilbertson, S.K.</td>
<td>45, 60, 94, 97</td>
</tr>
<tr>
<td>Milby, J.B.</td>
<td>85, 96</td>
</tr>
<tr>
<td>Miles, D.</td>
<td>60</td>
</tr>
<tr>
<td>Miles, J.</td>
<td>18</td>
</tr>
<tr>
<td>Miller, E.K.</td>
<td>62</td>
</tr>
<tr>
<td>Miller, J.</td>
<td>73</td>
</tr>
<tr>
<td>Miller, L.L.</td>
<td>4, 34</td>
</tr>
<tr>
<td>Miller, M.D.</td>
<td>94</td>
</tr>
<tr>
<td>Mills, K.L.</td>
<td>41</td>
</tr>
<tr>
<td>Milner, J.E.</td>
<td>40</td>
</tr>
<tr>
<td>Milosevic, A.</td>
<td>78</td>
</tr>
<tr>
<td>Minas, R.K.</td>
<td>82</td>
</tr>
<tr>
<td>Minerly, A.C.</td>
<td>79</td>
</tr>
<tr>
<td>Minnes, S.</td>
<td>35</td>
</tr>
<tr>
<td>Mino, M.E.</td>
<td>10, 57</td>
</tr>
<tr>
<td>Mintzer, M.Z.</td>
<td>23, 36, 78, 83</td>
</tr>
<tr>
<td>Mitchell, J.M.</td>
<td>8, 15, 54</td>
</tr>
<tr>
<td>Mitchell, M.P.</td>
<td>24</td>
</tr>
<tr>
<td>Mitchell, T.B.</td>
<td>87</td>
</tr>
<tr>
<td>Miyagawa, K.</td>
<td>34</td>
</tr>
<tr>
<td>Miyatake, M.</td>
<td>34</td>
</tr>
<tr>
<td>Mizuo, K.</td>
<td>34</td>
</tr>
<tr>
<td>Moberg, C.A.</td>
<td>61</td>
</tr>
<tr>
<td>Moberg, P.</td>
<td>6</td>
</tr>
<tr>
<td>Moeller, F.G.</td>
<td>20, 26, 53, 74, 97</td>
</tr>
<tr>
<td>Mohapatra, S.</td>
<td>93</td>
</tr>
<tr>
<td>Mojsiak, J.</td>
<td>10, 92</td>
</tr>
<tr>
<td>Molina, S.G.</td>
<td>68</td>
</tr>
<tr>
<td>Monroy, M.A.</td>
<td>9</td>
</tr>
<tr>
<td>Montbach, J.</td>
<td>41</td>
</tr>
<tr>
<td>Montero-Sosco, J.</td>
<td>54, 94</td>
</tr>
<tr>
<td>Montes, K.</td>
<td>83</td>
</tr>
<tr>
<td>Montgomery, G.</td>
<td>73</td>
</tr>
<tr>
<td>Montoya, A.M.</td>
<td>64</td>
</tr>
<tr>
<td>Montoya, G.L.</td>
<td>92</td>
</tr>
<tr>
<td>Montoya, I.D.</td>
<td>52</td>
</tr>
<tr>
<td>Monuteaux, M.C.</td>
<td>71</td>
</tr>
<tr>
<td>Moolchand, E.T.</td>
<td>60, 81</td>
</tr>
<tr>
<td>Mooney, J.</td>
<td>20, 44</td>
</tr>
<tr>
<td>Mooney, L.J.</td>
<td>83</td>
</tr>
<tr>
<td>Moore, A.</td>
<td>19, 78</td>
</tr>
<tr>
<td>Moore, B.A.</td>
<td>37</td>
</tr>
<tr>
<td>Moore, M.</td>
<td>59</td>
</tr>
<tr>
<td>Moore, R.D.</td>
<td>3</td>
</tr>
<tr>
<td>Moore, S.K.</td>
<td>58</td>
</tr>
<tr>
<td>Morales, C.</td>
<td>44</td>
</tr>
<tr>
<td>Morales-Manrique, C.</td>
<td>10</td>
</tr>
<tr>
<td>Moran, M.M.</td>
<td>93</td>
</tr>
<tr>
<td>Moran-Santa Maria, M.</td>
<td>50</td>
</tr>
<tr>
<td>Morgan, D.</td>
<td>4</td>
</tr>
<tr>
<td>Morgelo, S.</td>
<td>53</td>
</tr>
<tr>
<td>Morgen, K.</td>
<td>41</td>
</tr>
<tr>
<td>Moroz-Concepcion, J.</td>
<td>8, 33, 68</td>
</tr>
<tr>
<td>Morral, A.R.</td>
<td>21, 66</td>
</tr>
<tr>
<td>Morris, R.J.</td>
<td>43</td>
</tr>
<tr>
<td>Morrison, D.M.</td>
<td>45</td>
</tr>
<tr>
<td>Morrison, R.</td>
<td>84</td>
</tr>
<tr>
<td>Moukaddam, N.J.</td>
<td>11, 74</td>
</tr>
<tr>
<td>Mountford, A.</td>
<td>11</td>
</tr>
<tr>
<td>Mouret, B.</td>
<td>90</td>
</tr>
<tr>
<td>Moyers, W.</td>
<td>2</td>
</tr>
<tr>
<td>Moyers, W.C.</td>
<td>1</td>
</tr>
<tr>
<td>Mullett, T.</td>
<td>63</td>
</tr>
<tr>
<td>Mumford, G.K.</td>
<td>1</td>
</tr>
<tr>
<td>Murdock, E.L.</td>
<td>90</td>
</tr>
<tr>
<td>Murff, W.L.</td>
<td>10</td>
</tr>
<tr>
<td>Muroff, J.</td>
<td>57</td>
</tr>
<tr>
<td>Murphy, D.</td>
<td>42</td>
</tr>
<tr>
<td>Murray, H.W.</td>
<td>86, 88</td>
</tr>
<tr>
<td>Murray, J.E.</td>
<td>69</td>
</tr>
<tr>
<td>Murray, K.A.</td>
<td>12</td>
</tr>
<tr>
<td>Murtaugh, M.P.</td>
<td>33</td>
</tr>
<tr>
<td>Mustroph, M.L.</td>
<td>34</td>
</tr>
<tr>
<td>Mutebi, M.M.</td>
<td>26</td>
</tr>
<tr>
<td>Myers, B.</td>
<td>90</td>
</tr>
<tr>
<td>Nader, M.A.</td>
<td>3, 28, 55, 69</td>
</tr>
<tr>
<td>Nair, S.G.</td>
<td>79</td>
</tr>
<tr>
<td>Nakamoto, K.</td>
<td>87</td>
</tr>
<tr>
<td>Nakamura, A.</td>
<td>4, 8</td>
</tr>
<tr>
<td>Nakoneznny, P.A.</td>
<td>57</td>
</tr>
<tr>
<td>Nandi, A.</td>
<td>43</td>
</tr>
<tr>
<td>Nanovskaya, T.N.</td>
<td>32</td>
</tr>
<tr>
<td>Napier, T.C.</td>
<td>68</td>
</tr>
<tr>
<td>Napoleone, J.</td>
<td>65</td>
</tr>
<tr>
<td>Narasimhan, D.</td>
<td>33, 69</td>
</tr>
<tr>
<td>Narayana, P.A.</td>
<td>26</td>
</tr>
<tr>
<td>Narayanan, S.</td>
<td>33, 49</td>
</tr>
<tr>
<td>Narita, M.</td>
<td>4, 8, 34</td>
</tr>
<tr>
<td>Nathan, P.</td>
<td>6</td>
</tr>
<tr>
<td>Natividad, L.A.</td>
<td>14</td>
</tr>
<tr>
<td>Navarro, H.A.</td>
<td>49</td>
</tr>
<tr>
<td>Needham, M.</td>
<td>85</td>
</tr>
<tr>
<td>Negro-Vilar, A.</td>
<td>32</td>
</tr>
<tr>
<td>Negus, S.S.</td>
<td>4, 7</td>
</tr>
<tr>
<td>Neisweander, J.L.</td>
<td>25</td>
</tr>
<tr>
<td>Nejtek, V.A.</td>
<td>82</td>
</tr>
<tr>
<td>Netherland, J.</td>
<td>37</td>
</tr>
<tr>
<td>Neufeld, K.J.</td>
<td>85, 86</td>
</tr>
<tr>
<td>Neumark, Y.</td>
<td>32, 44</td>
</tr>
<tr>
<td>Neuner, F.</td>
<td>82</td>
</tr>
<tr>
<td>Newberry, A.M.</td>
<td>65</td>
</tr>
<tr>
<td>Newman, J.L.</td>
<td>54</td>
</tr>
<tr>
<td>Newton, T.F.</td>
<td>42, 56, 92, 96</td>
</tr>
<tr>
<td>Nic Dhonnchadha, B.</td>
<td>69</td>
</tr>
<tr>
<td>Nich, C.</td>
<td>81</td>
</tr>
<tr>
<td>Nielsen, D.A.</td>
<td>53, 73</td>
</tr>
<tr>
<td>Nielsen, S.</td>
<td>70</td>
</tr>
<tr>
<td>Niiikura, K.</td>
<td>4</td>
</tr>
<tr>
<td>Nilson, D.</td>
<td>41</td>
</tr>
<tr>
<td>Niv, N.</td>
<td>19, 78</td>
</tr>
<tr>
<td>Nixon, S.J.</td>
<td>78</td>
</tr>
<tr>
<td>Nolan, T.L.</td>
<td>7, 33</td>
</tr>
<tr>
<td>Nordahl, T.E.</td>
<td>56</td>
</tr>
<tr>
<td>Norman, A.B.</td>
<td>79</td>
</tr>
<tr>
<td>Norman, M.K.</td>
<td>79</td>
</tr>
<tr>
<td>Nunes, E.V.</td>
<td>9, 10, 11, 37, 41, 84</td>
</tr>
<tr>
<td>Nurhidayat, A.</td>
<td>66</td>
</tr>
<tr>
<td>Nuzzo, P.A.</td>
<td>36, 62, 63</td>
</tr>
<tr>
<td>Nwokeji, E.</td>
<td>90</td>
</tr>
<tr>
<td>Nyberg, F.J.</td>
<td>49</td>
</tr>
<tr>
<td>Nyström, I.</td>
<td>86</td>
</tr>
<tr>
<td>O’Brien, C.P.</td>
<td>22, 26, 27, 48, 50, 73, 93</td>
</tr>
<tr>
<td>O'Dell, L.E.</td>
<td>14</td>
</tr>
<tr>
<td>O'Grady, K.E.</td>
<td>21, 24, 35, 59, 60, 64, 86, 88, 93</td>
</tr>
<tr>
<td>O'Hara, K.</td>
<td>53</td>
</tr>
<tr>
<td>O'Malley, S.S.</td>
<td>54, 88</td>
</tr>
<tr>
<td>O'Neill, J.</td>
<td>54</td>
</tr>
<tr>
<td>Obara, I.</td>
<td>54</td>
</tr>
<tr>
<td>Ober, A.</td>
<td>44</td>
</tr>
<tr>
<td>Obot, I.S.</td>
<td>39</td>
</tr>
</tbody>
</table>
AUTHOR INDEX

Odell, T. 16
Odenwald, M. 82
Okitsu, D. 4
Olaizola, C. 72
Olson, M. 24
Olson, M.F. 75
Olivet, A. 50, 56, 77
Olson, D. 54
Olson, G. 6
Oncken, C. 24
Ondersma, S.J. 12, 24, 35, 36, 63
Orson, F.M. 33, 96
Osborne, V. 65
Oser, C.B. 20, 43, 44, 89, 94
Oser, R. 16, 91
Oslin, D.W. 15, 37, 64
Ostrowski, M. 40
Ott, J. 53, 73
Otto, M.W. 86, 88
Ouellet, L. 27
Pacula, R. 67
Paddock, S. 67
Page, K. 13
Pagnoni, G. 55
Paidisetty, S. 90
Pallas, D. 18
Palmatier, M.I. 93
Palmer, C. 17
Palmer, J. 43
Pantin, M. 59
Park, S. 82
Paronis, C.A. 60
Parrino, M. 90
Parrish, A.B. 49
Parsons, J.T. 11, 71
Partilla, J.S. 74
Parzynski, C.S. 60, 81
Pascal, M. 10, 61
Passalacqua, E. 63
Passetti, L.L. 44, 46
Passik, S. 71
Pasternak, G. 22
Pastor, A. 53
Patak, M. 80
Patapis, N.S. 18
Patel, S. 96
Patra, J. 93
Patton, G.C. 59
Patwa, H. 85
Pavlicova, M. 9
Pawlik, J.L. 34, 80
Payne, R. 64
Payne, T.J. 54, 73
Pearce, V.J. 57, 96
Pechansky, F. 61, 62
Pecora, A. 19
Pecorarro, A. 19
Peirce, J. 85, 86, 88
Peles, E. 40, 53, 85, 86
Penberthy, J.K. 24, 61
Penfold, R. 80
Pennay, A. 96
Penetar, D.M. 13, 17, 60
Peli, E. 15
Pereira Do Carmo, G. 4
Perez, A. 7
Perez, A.Y. 23, 55
Pérez de los Cobos, J.C. 10, 38, 44
Pergadia, M. 73
Perlman, D.C. 4, 15, 65
Perrine, S.A. 55
Perry, E. 54
Perry, J.L. 80, 97
Personnic, S. 90
Peters, C.H. 16
Peters, D.E. 91
Peters, E. 17
Peterson, J.A. 41
Petakis, I. 85
Petska, D. 91
Pettinati, H.M. 48, 50
Peyret, E. 61
Pfister, H. 12
Philbrook, M.A. 66
Phillips, T.R. 55
Phipps, L.B. 60
Piazza, M. 62
Picetti, R. 8, 34
Picker, M.J. 4, 9
Piechaczek, M. 12
Pieper, B. 19
Pimlott Kubiak, S. 89
Pinsky, I. 62
Pittenger, S.T. 14
Pittman, A. 61, 90
Pivavarchyk, M. 14
Platt, D.M. 32, 60, 77
Plebani, J.G. 50, 93
Plebani-Lussier, J. 97
Podawiltz, A. 82
Podus, D. 38
Poduska, J. 43
Poldrack, R.A. 54
Polgar, W.E. 7
Poling, J. 11, 77
Polk, T. 84
Pollock, J. 5
Polydorou, S. 64
Poole, M.M. 89
Popova, S. 93
Popuch, R. 61
Porkorny, S. 59
Porrino, L.J. 27, 55, 94
Portenoy, R.K. 26
Portoghese, P.S. 48
Posada-Villa, J. 12, 87, 88
Potenza, M.N. 2, 49, 55
Potik, D. 40, 86
Potter, J.S. 25, 41
Potter, L.B. 41
Poudayal Chhetri, M.B. 12
Poupaert, J.H. 33, 49
Poznyak, V. 66
Pradeille, J.L. 72, 78
Prather, K. 25, 41
Prather, R.A. 78
Pratt, E.M. 88
Prendergast, M.A. 72
Prendergast, M.L. 20, 91
Preston, K.L. 19
Price, K.L. 93
Price, R.K. 39
Prisinzano, T.E. 7, 8, 69, 74
Prochaska, J.J. 62
AUTHOR INDEX

Provost, S. 25
Pulkkinen, L. 59
Pulvermacher, A. 90
Qian, H.Z. 42
Qin, G.M. 42
Quanbeck, A. 67, 90
Quina, K. 21
Quinones-Jenab, V. 8, 33, 34, 79
Quirk, G. 22
Raby, W.N. 10, 11, 37
Radhakrishnan, N. 91
Radovanovic, M.E. 12, 29, 87
Raehal, K.M. 31
Raggi, M.A. 45
Rahmim, A. 33
Raiff, B.R. 14
Raj, V. 95
Rajagopalan, K. 26
Rallapalli, S. 60
Ramchand, R. 21
Ramgopal, R. 38, 90
Ramirez, D.R. 34
Ramo, D. 46
Ramsey, N.F. 94
Randall, M. 85
Randall, T. 80
Randall-Thompson, J.F. 7
Randesi, M. 53
Rataeman, L. 57
Rataeman, S. 57
Raugei, R. 8, 53
Rauhut, A.S. 14
Rawls, A.L. 41
Rawls, S.M. 70
Rawson, R.A. 18, 56, 57, 83, 89, 96
Ray, B. 53
Raymond, K. 16, 94
Raymond, K.M. 45
Reed, B. 90
Rees, J. 37
Rehm, J. 93
Reiber, C. 21
Reichel, C.M. 69
Reid-Quinones, K. 35
Reieller, B. 9
Reiner, S. 16
Reissig, C.J. 23
Reith, M.E. 74
Renshaw, P.F. 17, 54, 55, 94
Resnick, H. 88
Reynaud, M. 54
Reynolds, B. 80, 81
Reynolds, C.R. 67
Reynolds, E.K. 45, 58
Reynolds, M. 82
Rhee, S.H. 58
Rhode, R. 91
Rhodes, G.L. 15
Rice, J. 73
Rice, K.C. 7, 8, 23, 49, 77
Richards, B.D. 31
Richards, J.M. 38
Richards, W.A. 31
Richardson, G.A. 35
Richardson, K.A. 5
Richardt, S. 94
Ridenour, T.A. 45, 81, 82
Riehman, K.S. 58
Riggs, P.D. 45, 60, 68, 80, 89
Riley, A.L. 7, 8, 49, 70, 77
Riley, L.A. 21
Rinehart, D.J. 89
Ring-Kurtz, S. 16, 57
Ringel, J. 67
Rinker, J.A. 77
Rios-Bedoya, C.F. 14, 29, 39
Risk, N. 39
Ritter, A. 90
Roache, J.D. 10, 92
Robbins, G. 80
Roberts, M. 89
Roberts, S.C. 66
Robinson, J. 56
Robinson, R. 80
Rocha, B. 28
Rocha, N.S. 61
Rockstroh, B. 82
Rodolico, J. 17
Rodriguez, L. 88
Rodriguez Orengo, J. 21
Roehrs, T. 36
Roerig, S. 48
Rogers, J.L. 93
Rogers, N. 28, 51
Rogers, R. 75
Roget, N.A. 16, 51, 89
Rohan, M. 54
Rohrmeister, K. 75
Rohsenow, D. 82
Roiko, S.A. 14, 33
Roma, P.G. 77
Romach, M. 37
Roman, P. 83
Romanova, T. 37
Romero-Gonzalez, M. 85
Roscop, N. 65
Rose, R.J. 59
Rosen, M.I. 83, 84
Rosenblum, A. 20, 26, 38, 83, 90
Rosengard, C. 29
Rosenheck, R.A. 84
Rosenwasser, B.J. 84
Ross, C.A. 33
Ross, J. 64
Ross, J.T. 13
Roth, A.L. 27
Roth, M.D. 3
Roth, T. 36
Rotheram-Borus, M.J. 66
Rotheram-Fuller, E. 56, 96
Rothman, R.B. 7, 31, 74
Rotrosen, J. 16, 53, 57, 60
Rouault, M. 73
Rounds-Bryant, J.L. 84
Rounsaville, B.J. 55, 81
Rowe, C.L. 60
Rowlett, J. 32
Rowley, T.C. 88
Roy, J. 18
Ruan, Y.H. 42
Rubin, E. 10
Rudy, E.T. 3
Ruedi-Bettschen, D. 60
Ruglass, L. 65
Rus, S. 8

111
AUTHOR INDEX

Rush, A.J. 82
Rush, B.R. 40
Rush, C.R. 55, 56, 62, 70, 89
Russell, B.R. 23, 78
Rutledge, M. 31
Ruttenber, A.J. 31
Rutter, J. 5
Ryan, E.T. 17, 60
Saavedra, J. 40
Saccone, S. 73
Saenz-Miranda, E. 45, 91
Sage, R.E. 18
Saitz, R. 19, 86, 89
Sakai, J. 39, 58
Saladin, M.E. 50, 88, 93
Salama, C.H. 4, 39, 43
Salem, A. 23
Salinas, J.E. 88
Salles, S. 62
Salloum, I.M. 48, 60
Sally, E.J. 7
Salo, R.E. 56
Samet, J.H. 19, 85, 86
Sananes, M. 9
Sanchez, H. 81
Sanchez, J.P. 39
Sanchez-Hervas, E. 84
Sander, L.M. 35, 78
Sanders, B. 44
Sandoval, M. 10
Sands, B. 18
Sanfilippo, L.C. 11
Sankey, H. 24
Sannerud, C.A. 6, 91, 92
Sannibale, C. 41
Santana, N. 20
Santhanam, P. 35
Santiago, G. 34
Santigo, O.J. 14
Sargeant, M.N. 40, 87
Saria, A. 74
Sarkisyan, D. 78
Sasadeusz, J. 3
Satayathum, S. 35
Saunders, B. 88
Savage, S.R. 26
Sawyer, G.W. 7
Saxon, A.J. 15, 56
Schauer, E. 82
Schauer, M. 82
Schepis, T.S. 59, 80, 81
Scherrer, J.F. 59
Schiller, M.J. 40
Schillinger, M. 71
Schlussman, S.D. 8
Schmid, C.L. 31
Schmitz, T.W. 75
Schmoll, S.H. 65, 66, 71
Schottenfeld, R.S. 26, 37, 39, 42, 94
Schramm Sapyta, N. 25
Schreiber, S. 40, 85, 86
Schorde, K. 4
Schuetze, P. 35, 36
Schuh, L. 48
Schulz, K. 54
Schumacher, J.E. 39, 42, 85, 96
Schurig, M. 58
Schuster, A. 19, 85
Schuster, C.R. 3, 36
Schuster, R.M. 40, 42, 87
Schütz, C.G. 12
Schwartz, R.P. 21, 38, 86, 88
Scott, C.K. 17, 18
Scott, M.C. 20
Scott, T. 24
Scotto di Cesare, E. 9
Secades-Villa, R. 84
Seddig, E.L. 16
See, R.E. 22, 69, 79, 93
Seewald, R. 57
Segarra, A.C. 21, 34
Seibyl, J.P. 54
Seidman, G. 34
Selby, P. 24, 35, 63, 70, 73
Sellers, E. 32, 37
Seltzman, H.H. 13, 49
Selzer, J. 25
Seo, D. 4
Sepulveda, D.R. 65
Serafine, K.M. 77
Serowik, K. 83
Setnik, B. 32, 37
Settles, L. 89
Seu, E. 26, 80
Sevak, R. 55
Severtson, S.G. 17, 24, 41, 45
Sewell, R.A. 77
Shacham, E. 43
Shafer, M.S. 91
Shaffer, J.H. 40
Shaham, Y. 8, 79
Shaikh, J. 33, 49, 53, 72
Shaller, N.S. 60, 69
Shannon, L.M. 18, 94
Shao, Y.M. 42
Sharkoski, T. 48
Sheer, A.J. 18, 40
Sheidow, A.J. 16
Sheikhattari, P. 39
Shelley, D. 13
Shelley, K.D. 41
Shelton, K.L. 32
Sherbin Coffin, L. 65
Sherwood, A.R. 31
Shifflet Gibson, E.D. 89
Shiokawa, M. 8
Shipley, R. 91
Shippenberg, T.S. 68
Shivers, K.Y. 8
Shmueli, D. 62
Shoaib, M. 14
Shoptaw, S. 3, 27, 44, 56, 96
Short, E. 35
Shropshire, C. 20
Shufman, E. 82
Shurtleff, D. 5
Shuster, K. 16
Sibanda, B. 91
Sigmon, S.C. 24, 26, 36, 38, 50
Silverman, K. 3, 37, 85
Simmons, L.A. 94
<table>
<thead>
<tr>
<th>Author</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simoneau, J.</td>
<td>70</td>
</tr>
<tr>
<td>Simpson, D.</td>
<td>7</td>
</tr>
<tr>
<td>Simpson, D.S.</td>
<td>8</td>
</tr>
<tr>
<td>Simpson, S.A.</td>
<td>13</td>
</tr>
<tr>
<td>Singer, L.</td>
<td>35</td>
</tr>
<tr>
<td>Singh, N.</td>
<td>33</td>
</tr>
<tr>
<td>Singh, R.A.</td>
<td>33, 96</td>
</tr>
<tr>
<td>Singleton, E.G.</td>
<td>12, 56</td>
</tr>
<tr>
<td>Sinha, N.</td>
<td>8</td>
</tr>
<tr>
<td>Sinha, R.</td>
<td>5, 10, 27, 35, 37, 49, 87</td>
</tr>
<tr>
<td>Sinitsyna, L.</td>
<td>42</td>
</tr>
<tr>
<td>Sircar, D.</td>
<td>79</td>
</tr>
<tr>
<td>Sircar, R.</td>
<td>79</td>
</tr>
<tr>
<td>Sizemore, G.M.</td>
<td>34</td>
</tr>
<tr>
<td>Skinstad, A.H.</td>
<td>6, 16, 51, 83</td>
</tr>
<tr>
<td>Slade, T.</td>
<td>61</td>
</tr>
<tr>
<td>Slavina, T.</td>
<td>37</td>
</tr>
<tr>
<td>Slawiak, L.</td>
<td>67</td>
</tr>
<tr>
<td>Smith, A.E.</td>
<td>59, 80, 81</td>
</tr>
<tr>
<td>Smith, C.</td>
<td>35, 41</td>
</tr>
<tr>
<td>Smith, F.L.</td>
<td>7</td>
</tr>
<tr>
<td>Smith, H.R.</td>
<td>55</td>
</tr>
<tr>
<td>Smith, M.A.</td>
<td>34</td>
</tr>
<tr>
<td>Smith, M.L.</td>
<td>67</td>
</tr>
<tr>
<td>Smith, M.Y.</td>
<td>64, 65, 66</td>
</tr>
<tr>
<td>Smyth, E.</td>
<td>10</td>
</tr>
<tr>
<td>Sobell, L.C.</td>
<td>61</td>
</tr>
<tr>
<td>Sobell, M.B.</td>
<td>61</td>
</tr>
<tr>
<td>Soderman, A.R.</td>
<td>74</td>
</tr>
<tr>
<td>Sofuoglu, M.</td>
<td>11, 77</td>
</tr>
<tr>
<td>Sokolowska, M.</td>
<td>37</td>
</tr>
<tr>
<td>Solomon, P.</td>
<td>43</td>
</tr>
<tr>
<td>Sonne, S.C.</td>
<td>15</td>
</tr>
<tr>
<td>Sorensen, J.L.</td>
<td>15, 58, 63, 85</td>
</tr>
<tr>
<td>Soto, G.</td>
<td>16</td>
</tr>
<tr>
<td>Spaeth, A.</td>
<td>94</td>
</tr>
<tr>
<td>Spealman, R.D.</td>
<td>77</td>
</tr>
<tr>
<td>Spence, P.B.</td>
<td>9</td>
</tr>
<tr>
<td>Spence, R.T.</td>
<td>61, 90</td>
</tr>
<tr>
<td>Spence, S.</td>
<td>15</td>
</tr>
<tr>
<td>Spiller, H.A.</td>
<td>64</td>
</tr>
<tr>
<td>Spitznagel, E.</td>
<td>58</td>
</tr>
<tr>
<td>Sproule, B.A.</td>
<td>63, 70, 75</td>
</tr>
<tr>
<td>Spybrook, J.</td>
<td>83</td>
</tr>
<tr>
<td>St. De Lore, J.</td>
<td>91</td>
</tr>
<tr>
<td>Stairs, D.J.</td>
<td>72</td>
</tr>
<tr>
<td>Staley, J.K.</td>
<td>54</td>
</tr>
<tr>
<td>Stallings, M.</td>
<td>58</td>
</tr>
<tr>
<td>Standish, K.</td>
<td>43</td>
</tr>
<tr>
<td>Stanger, C.</td>
<td>59</td>
</tr>
<tr>
<td>Stanick, V.</td>
<td>18</td>
</tr>
<tr>
<td>Stanley, J.</td>
<td>95</td>
</tr>
<tr>
<td>Starosciak, A.K.</td>
<td>97</td>
</tr>
<tr>
<td>Staton-Tindall, M.</td>
<td>20, 37, 43, 44</td>
</tr>
<tr>
<td>Stauffer, J.</td>
<td>32</td>
</tr>
<tr>
<td>Staying Safe Valencia, G.</td>
<td>10</td>
</tr>
<tr>
<td>Stefanovics, E.A.</td>
<td>84</td>
</tr>
<tr>
<td>Stefanski, A.</td>
<td>32</td>
</tr>
<tr>
<td>Stein, J.</td>
<td>91</td>
</tr>
<tr>
<td>Stein, L.</td>
<td>21, 29</td>
</tr>
<tr>
<td>Steinberg, J.L.</td>
<td>20, 26, 71</td>
</tr>
<tr>
<td>Steinmiller, C.</td>
<td>38</td>
</tr>
<tr>
<td>Stephens, R.</td>
<td>58</td>
</tr>
<tr>
<td>Stephens, S.L.</td>
<td>36</td>
</tr>
<tr>
<td>Stevens, C.W.</td>
<td>7</td>
</tr>
<tr>
<td>Stevens, D.</td>
<td>60</td>
</tr>
<tr>
<td>Stevenson, G.W.</td>
<td>8</td>
</tr>
<tr>
<td>Steward, T.</td>
<td>96</td>
</tr>
<tr>
<td>Sticht, M.</td>
<td>69</td>
</tr>
<tr>
<td>Stiklus, S.</td>
<td>54</td>
</tr>
<tr>
<td>Stine, S.</td>
<td>24, 35</td>
</tr>
<tr>
<td>Stitzer, M.L.</td>
<td>20, 37, 57, 63, 84, 85, 97</td>
</tr>
<tr>
<td>Stöckl, P.</td>
<td>74</td>
</tr>
<tr>
<td>Stoddard, A.M.</td>
<td>17</td>
</tr>
<tr>
<td>Stoller, K.B.</td>
<td>19, 85, 86, 88</td>
</tr>
<tr>
<td>Stoops, W.W.</td>
<td>55, 56, 62, 70, 89</td>
</tr>
<tr>
<td>Storr, C.L.</td>
<td>58, 87, 93</td>
</tr>
<tr>
<td>Stotts, A.L.</td>
<td>15, 84</td>
</tr>
<tr>
<td>Stovall, D.</td>
<td>60</td>
</tr>
<tr>
<td>Stover, S.K.</td>
<td>45, 60</td>
</tr>
<tr>
<td>Strain, E.C.</td>
<td>26, 36, 52, 75, 82, 83</td>
</tr>
<tr>
<td>Strandberg, J.J.</td>
<td>86</td>
</tr>
<tr>
<td>Strang, J.</td>
<td>87</td>
</tr>
<tr>
<td>Strathearn, L.</td>
<td>95</td>
</tr>
<tr>
<td>Straub, A.</td>
<td>55</td>
</tr>
<tr>
<td>Street, C.</td>
<td>16</td>
</tr>
<tr>
<td>Striley, C.L.</td>
<td>90</td>
</tr>
<tr>
<td>Stutz, S.J.</td>
<td>69</td>
</tr>
<tr>
<td>Su, Z.</td>
<td>34</td>
</tr>
<tr>
<td>Suh, J.J.</td>
<td>26, 27, 93</td>
</tr>
<tr>
<td>Sullivan, L.E.</td>
<td>37, 39</td>
</tr>
<tr>
<td>Sullivan, M.A.</td>
<td>10, 36, 37</td>
</tr>
<tr>
<td>Summers, K.M.</td>
<td>16, 83</td>
</tr>
<tr>
<td>Sumpter, R.</td>
<td>15</td>
</tr>
<tr>
<td>Sun, W.L.</td>
<td>33, 77, 79</td>
</tr>
<tr>
<td>Sunahara, R.K.</td>
<td>33, 69</td>
</tr>
<tr>
<td>Surratt, C.K.</td>
<td>49</td>
</tr>
<tr>
<td>Surratt, H.L.</td>
<td>41, 43, 65, 72</td>
</tr>
<tr>
<td>Suttorp, M.</td>
<td>67</td>
</tr>
<tr>
<td>Suzuki, M.</td>
<td>4, 8</td>
</tr>
<tr>
<td>Suzuki, T.</td>
<td>4, 8, 34</td>
</tr>
<tr>
<td>Sved, A.F.</td>
<td>93</td>
</tr>
<tr>
<td>Svikis, D.S.</td>
<td>18,24, 35, 41, 60, 62, 85</td>
</tr>
<tr>
<td>Swanson, A.</td>
<td>56, 96</td>
</tr>
<tr>
<td>Swetizer, M.M.</td>
<td>14</td>
</tr>
<tr>
<td>Swendsen, J.</td>
<td>72</td>
</tr>
<tr>
<td>Swieter, M.</td>
<td>28, 51</td>
</tr>
<tr>
<td>Swift, R.</td>
<td>82</td>
</tr>
<tr>
<td>Swift, W.</td>
<td>59, 67</td>
</tr>
<tr>
<td>Swogger, M.T.</td>
<td>84</td>
</tr>
<tr>
<td>Sydnor, K.</td>
<td>39</td>
</tr>
<tr>
<td>Szumlinski, K.K.</td>
<td>53, 54, 79, 92</td>
</tr>
<tr>
<td>Tafazoli, S.</td>
<td>54</td>
</tr>
<tr>
<td>Taffe, M.A.</td>
<td>13</td>
</tr>
<tr>
<td>Tai, B.</td>
<td>1</td>
</tr>
<tr>
<td>Tajima, B.</td>
<td>63</td>
</tr>
<tr>
<td>Takeda, K.</td>
<td>34</td>
</tr>
<tr>
<td>Takei, D.</td>
<td>8</td>
</tr>
<tr>
<td>Tallarida, R.J.</td>
<td>77</td>
</tr>
<tr>
<td>Tamagnan, G.D.</td>
<td>54</td>
</tr>
<tr>
<td>Tancer, M.E.</td>
<td>55, 78, 87</td>
</tr>
<tr>
<td>Tapia, E.</td>
<td>62</td>
</tr>
<tr>
<td>Tapp, A.</td>
<td>56</td>
</tr>
<tr>
<td>Tartarini, W.</td>
<td>13</td>
</tr>
<tr>
<td>Tarter, R.</td>
<td>82</td>
</tr>
<tr>
<td>Tashkin, D.P.</td>
<td>3</td>
</tr>
<tr>
<td>Tassini, K.</td>
<td>19</td>
</tr>
<tr>
<td>Tatarsky, A.</td>
<td>57</td>
</tr>
<tr>
<td>Taylor, D.A.</td>
<td>70</td>
</tr>
<tr>
<td>Teesson, M.</td>
<td>41, 61</td>
</tr>
<tr>
<td>Tejeda, H.A.</td>
<td>14</td>
</tr>
<tr>
<td>Tella, S.R.</td>
<td>6, 92</td>
</tr>
<tr>
<td>Author</td>
<td>Page(s)</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>Wallis, A.B.</td>
<td>16</td>
</tr>
<tr>
<td>Wallisch, L.</td>
<td>61, 90</td>
</tr>
<tr>
<td>Walsh, R.</td>
<td>52</td>
</tr>
<tr>
<td>Walsh, S.L.</td>
<td>36</td>
</tr>
<tr>
<td>Wang, D.</td>
<td>4</td>
</tr>
<tr>
<td>Wang, F.L.</td>
<td>45, 58</td>
</tr>
<tr>
<td>Wang, J.</td>
<td>44, 65, 73, 96</td>
</tr>
<tr>
<td>Wang, Y.</td>
<td>35</td>
</tr>
<tr>
<td>Wang, Z.</td>
<td>26, 27, 73, 93</td>
</tr>
<tr>
<td>Ward, S.J.</td>
<td>34</td>
</tr>
<tr>
<td>Warda, U.</td>
<td>19, 20, 78</td>
</tr>
<tr>
<td>Wartella, J.E.</td>
<td>24</td>
</tr>
<tr>
<td>Wasseum, K.</td>
<td>5</td>
</tr>
<tr>
<td>Waters, A.J.</td>
<td>62</td>
</tr>
<tr>
<td>Waters, V.</td>
<td>61</td>
</tr>
<tr>
<td>Watkins, D.J.</td>
<td>49</td>
</tr>
<tr>
<td>Watson, D.W.</td>
<td>21, 57</td>
</tr>
<tr>
<td>Weaver, M.F.</td>
<td>20, 63</td>
</tr>
<tr>
<td>Weaver, M.T.</td>
<td>34</td>
</tr>
<tr>
<td>Webster, J.M.</td>
<td>11, 58</td>
</tr>
<tr>
<td>Wechsberg, W.</td>
<td>35</td>
</tr>
<tr>
<td>Wee, S.</td>
<td>69</td>
</tr>
<tr>
<td>Weed, M.R.</td>
<td>33</td>
</tr>
<tr>
<td>Weeks, K.</td>
<td>19</td>
</tr>
<tr>
<td>Weerts, E.M.</td>
<td>23, 72</td>
</tr>
<tr>
<td>Weierstall, K.</td>
<td>79</td>
</tr>
<tr>
<td>Weimer, M.</td>
<td>87</td>
</tr>
<tr>
<td>Weintraub, D.</td>
<td>2</td>
</tr>
<tr>
<td>Weiss, F.</td>
<td>5</td>
</tr>
<tr>
<td>Weiss, L.</td>
<td>37</td>
</tr>
<tr>
<td>Weiss, R.D.</td>
<td>25, 41, 45, 48</td>
</tr>
<tr>
<td>Welch, C.</td>
<td>20</td>
</tr>
<tr>
<td>Wells, A.</td>
<td>8</td>
</tr>
<tr>
<td>Wells, B.</td>
<td>11</td>
</tr>
<tr>
<td>Weltman, M.</td>
<td>3</td>
</tr>
<tr>
<td>Wente, A.O.</td>
<td>58</td>
</tr>
<tr>
<td>Wenzel, S.L.</td>
<td>18</td>
</tr>
<tr>
<td>Werch, C.C.</td>
<td>59</td>
</tr>
<tr>
<td>Wermeling, D.P.</td>
<td>55</td>
</tr>
<tr>
<td>Wesley, M.J.</td>
<td>27, 55, 94</td>
</tr>
<tr>
<td>Wesnoski, S.A.</td>
<td>21</td>
</tr>
<tr>
<td>West, B.T.</td>
<td>93</td>
</tr>
<tr>
<td>West-Ojo, T.</td>
<td>41</td>
</tr>
<tr>
<td>Westerberg, D.</td>
<td>71</td>
</tr>
<tr>
<td>Whitaker, D.E.</td>
<td>10, 43, 45</td>
</tr>
<tr>
<td>White, M.C.</td>
<td>20</td>
</tr>
<tr>
<td>White, M.K.</td>
<td>46</td>
</tr>
<tr>
<td>White, W.L.</td>
<td>18</td>
</tr>
<tr>
<td>Whittaker, K.</td>
<td>42</td>
</tr>
<tr>
<td>WHO Opioid Substitution Therapy Study Group</td>
<td>42</td>
</tr>
<tr>
<td>Widner, G.</td>
<td>39</td>
</tr>
<tr>
<td>Wieczorek, C.</td>
<td>81</td>
</tr>
<tr>
<td>Wieczorek, C.E.</td>
<td>81</td>
</tr>
<tr>
<td>Wiedemer, N.</td>
<td>15</td>
</tr>
<tr>
<td>Wihbey, K.A.</td>
<td>8</td>
</tr>
<tr>
<td>Wilcox, C.E.</td>
<td>54</td>
</tr>
<tr>
<td>Wilcox, K.M.</td>
<td>33</td>
</tr>
<tr>
<td>Wilens, T.E.</td>
<td>48, 68, 71</td>
</tr>
<tr>
<td>Wilkinson, J.</td>
<td>18</td>
</tr>
<tr>
<td>Williams, A.M.</td>
<td>67</td>
</tr>
<tr>
<td>Willner-Reid, J.</td>
<td>19</td>
</tr>
<tr>
<td>Wills, T.A.</td>
<td>62</td>
</tr>
<tr>
<td>Wilson, K.</td>
<td>15</td>
</tr>
<tr>
<td>Wilson, L.L.</td>
<td>72</td>
</tr>
<tr>
<td>Wilson, M.</td>
<td>21, 88</td>
</tr>
<tr>
<td>Win, S.</td>
<td>38</td>
</tr>
<tr>
<td>Windham, A.M.</td>
<td>43</td>
</tr>
<tr>
<td>Windsor, L.</td>
<td>39, 62</td>
</tr>
<tr>
<td>Wines, Jr., J.D.</td>
<td>17, 86</td>
</tr>
<tr>
<td>Wing, V.C.</td>
<td>14</td>
</tr>
<tr>
<td>Winhusen, T.</td>
<td>35</td>
</tr>
<tr>
<td>Winklbaur, B.</td>
<td>75</td>
</tr>
<tr>
<td>Winstanley, E.L.</td>
<td>82, 83</td>
</tr>
<tr>
<td>Winter, M.</td>
<td>19</td>
</tr>
<tr>
<td>Winters, K.</td>
<td>6, 46</td>
</tr>
<tr>
<td>Wisdom, J.P.</td>
<td>58</td>
</tr>
<tr>
<td>Wise, M.E.</td>
<td>58</td>
</tr>
<tr>
<td>Wish, E.D.</td>
<td>59, 60, 64, 93</td>
</tr>
<tr>
<td>Wisner, K.</td>
<td>47</td>
</tr>
<tr>
<td>Wittchen, H.U.</td>
<td>12</td>
</tr>
<tr>
<td>Wodak, A.</td>
<td>57</td>
</tr>
<tr>
<td>Wolf, M.E.</td>
<td>68</td>
</tr>
<tr>
<td>Wong, C.J.</td>
<td>62, 63, 85</td>
</tr>
<tr>
<td>Wong, D.F.</td>
<td>33</td>
</tr>
<tr>
<td>Wong, H.</td>
<td>16, 91</td>
</tr>
<tr>
<td>Wong, L.L.</td>
<td>91</td>
</tr>
<tr>
<td>Wood, D.S.</td>
<td>60</td>
</tr>
<tr>
<td>Woods, J.H.</td>
<td>13, 33, 69, 70</td>
</tr>
<tr>
<td>Woods, W.L.</td>
<td>16, 89</td>
</tr>
<tr>
<td>Woodward, N.D.</td>
<td>74</td>
</tr>
<tr>
<td>Woody, G.E.</td>
<td>37, 42, 46, 66</td>
</tr>
<tr>
<td>Woolverton, W.</td>
<td>97</td>
</tr>
<tr>
<td>Wooters, T.</td>
<td>13</td>
</tr>
<tr>
<td>Worhunsky, P.</td>
<td>55</td>
</tr>
<tr>
<td>World Mental Health Survey Consortium</td>
<td>12, 88</td>
</tr>
<tr>
<td>World Mental Health Surveys Consortium</td>
<td>87</td>
</tr>
<tr>
<td>Worley, P.F.</td>
<td>53</td>
</tr>
<tr>
<td>Wu, E.</td>
<td>32</td>
</tr>
<tr>
<td>Wu, G.Y.</td>
<td>88</td>
</tr>
<tr>
<td>Wu, H.</td>
<td>5, 40</td>
</tr>
<tr>
<td>Wu, L.</td>
<td>79</td>
</tr>
<tr>
<td>Wu, Y.</td>
<td>33, 96</td>
</tr>
<tr>
<td>Wunsch, M.J.</td>
<td>87</td>
</tr>
<tr>
<td>Wupperman, P.</td>
<td>18, 20</td>
</tr>
<tr>
<td>Xi, Z.X.</td>
<td>33, 72</td>
</tr>
<tr>
<td>Xia, Y.F.</td>
<td>8</td>
</tr>
<tr>
<td>Xie, H.</td>
<td>48</td>
</tr>
<tr>
<td>Xing, H.</td>
<td>42</td>
</tr>
<tr>
<td>Xu, H.</td>
<td>7</td>
</tr>
<tr>
<td>Xu, Q.</td>
<td>73</td>
</tr>
<tr>
<td>Yamamoto, B.K.</td>
<td>92</td>
</tr>
<tr>
<td>Yan, P.</td>
<td>27</td>
</tr>
<tr>
<td>Yanasak, E.</td>
<td>56</td>
</tr>
<tr>
<td>Yang, K.</td>
<td>73</td>
</tr>
<tr>
<td>Yang, M.H.</td>
<td>17</td>
</tr>
<tr>
<td>Yango, E.</td>
<td>25</td>
</tr>
<tr>
<td>Yasseen, B.</td>
<td>73</td>
</tr>
<tr>
<td>Yeatts, S.D.</td>
<td>11</td>
</tr>
<tr>
<td>Yekkirala, A.</td>
<td>48</td>
</tr>
<tr>
<td>Yeung, A.</td>
<td>61</td>
</tr>
<tr>
<td>Yi, R.</td>
<td>97</td>
</tr>
<tr>
<td>Yin, L.</td>
<td>42</td>
</tr>
<tr>
<td>Yoon, J.H.</td>
<td>67, 97</td>
</tr>
<tr>
<td>Yoshihara, M.</td>
<td>3</td>
</tr>
<tr>
<td>Young, J.H.</td>
<td>19</td>
</tr>
<tr>
<td>Young, S.</td>
<td>58</td>
</tr>
<tr>
<td>Yu, S.</td>
<td>4</td>
</tr>
<tr>
<td>Yuan, C.</td>
<td>4</td>
</tr>
<tr>
<td>Yufkerov, V.</td>
<td>53, 73</td>
</tr>
<tr>
<td>Yurgelun-Todd, D.</td>
<td>47</td>
</tr>
<tr>
<td>Zacny, J.P.</td>
<td>36</td>
</tr>
<tr>
<td>Zaharovits, I.</td>
<td>56</td>
</tr>
</tbody>
</table>
Zakharova, E. 49
Zaleski, M. 62
Zammarelli, L. 63
Zanis, D.A. 21
Zavadil, F. 16
Zawertailo, L.A. 63, 73
Zerden, L. 9
Zernig, G. 74
Zezula, J. 7
Zezyulin, O. 39, 42
Zhan, C.G. 69
Zhang, S. 48
Zhang, X.Y. 49, 88
Zhang, Y. 8, 13, 49
Zhang, Z. 13, 14
Zhao, M. 4
Zharikova, O. 32
Zheng, G. 14
Zhou, D.F. 88
Zhou, H. 93
Zhou, L. 33, 77, 79
Zhou, Y. 8, 33
Zhu, J.L. 42
Zhu, S. 39
Zhuo, J. 3, 42
Ziedonis, D. 63
Zielinski, T. 82
Zolkowska, D. 74
Zonana, H. 18
Zorick, T.S. 56
Zorn, K. 74
Zosel, A.E. 64
Zubaran, C. 32
Zule, B. 27
Zule, W. 43
Zvartau, E. 37
Emerging brain, behavioral and genetic data point to substantial overlap in the vulnerabilities for compulsive pursuit of drug and non-drug (e.g., food, sex, and money) rewards. Overlapping vulnerabilities have been linked both to the mesolimbic dopamine reward system and to its failed regulation by frontal regions. Dr. Joe Frascella will review neuroimaging evidence that low dopamine (DA) D2 receptor availability, a feature linked to increased cocaine administration in primates, occurs not only in several drug addictions, but also in obesity. Dr. Lucy Brown will describe activation of the ventral tegmental area (origin of midbrain DA cell bodies) and dorsal striatum (r. caudate, a DA terminal region) in individuals viewing their target of intense, early infatuation. Dr. Marc Potenza will offer several parallels between pathological gambling and drug addiction, noting that frontal regulatory regions are less active when gamblers are engaged by a gambling scenario. Underscoring the role of DA in both drug and non-drug rewards, Dr. Dan Weintraub will describe emergence of problematic sexual, gambling, eating, shopping, repetitive “punding” behaviors, and compulsive medication/drug use, in Parkinsons patients on DA replacement therapy. Following the presentations, Dr. Childress will open an audience discussion on their theoretical, treatment, and nosological implications. For example, by targeting shared vulnerabilities, both prevention and treatment efforts may be able to impact multiple disorders simultaneously (“one-stop shopping”). Our addiction nosology, which has thus far compartmentalized the compulsive pursuit of drug from non-drug rewards, may eventually reflect the rapidly advancing knowledge of shared brain vulnerabilities.

Cocaine dependence and social disadvantage: Evidence from the laboratory, clinic, and community
Chair: Stephen T. Higgins

Cocaine use in the U.S. has followed a pattern that is common with drugs of abuse wherein use is introduced by the more socio-economically affluent and gradually diffuses overtime to the socio-economically disadvantaged. Then as the serious health and other adverse consequences of the drug use are realized, use among the more educated drops off precipitously while use among the less educated and socio-economically disadvantaged persists. The aforementioned pattern has substantial implications for basic and clinical researchers of cocaine and other drug dependence. For example, what basic determinants of cocaine or other drug dependence explain these striking pattern? Can we reconcile what are deemed to be the basic determinants of drug dependence with these epidemiological trends? Do we have to consider potential novel interactions between more molar and molecular determinants to explain these patterns? What implications do these patterns have for the development of effective interventions to prevent and treat cocaine and other drug dependence? This symposium has been organized to address the following three overarching aims: (a) to underscore the importance of the influence of socio-economic disadvantage to understanding and eliminating cocaine and other drug dependence, (b) to illustrate the exciting, cross-disciplinary research that is being conducted on this topic, and (c) to articulate the important scientific, clinical, and policy implications of this research.
SYMPOSIA

Monday, June 16

Addiction liability and pain relief medication: Raymond Houde Memorial Symposium
Chairs: Charles P. O’Brien and Charles Inturrisi

This symposium is dedicated to the memory of Raymond Houde, MD, and will feature up-to-date reviews of the science of opiate analgesics and the methodologies Houde pioneered. Charles Inturrisi will discuss Houde’s contributions to the modern analgesic table and the pharmacological basis of opioid rotation. Gavril Pasternak will review current concepts of multiple opiate receptors and how Houde’s clinical analgesic research impacted on basic science. John Farrar will review the development of measures of analgesic efficacy as pioneered by Houde and Houde’s impact on modern analgesic study design. William Dewey will discuss Houde’s impact on new analgesic drug development and present a perspective on analgesics of the future.

Understanding extinction learning and its translation to drug addiction
Chairs: Paul Schnur and David Shurtleff

Drug addiction is a chronic relapsing disorder characterized by a persistent desire or compulsion to use a drug, loss of control of drug intake, reduction in other important activities, continued use despite knowledge of harm, tolerance, and an abstinence syndrome when the drug is unavailable. Becoming addicted to drugs usually begins with occasional use, which over time gives way to compulsive, uncontrollable use. Alternating cycles of relapse and periods of abstinence are common. Basic research suggests that becoming addicted involves long-term neuroadaptations that underlie learning and memory consolidation. Research further suggests that relapse often follows exposure to drug-related cues and that the motivation to self-administer drugs increases (i.e., incubates) during abstinence. Basic research aimed at understanding extinction mechanisms in order to enhance extinction learning might pave the way for treatment approaches with improved effectiveness. Enhancing extinction of drug seeking is challenging for several reasons: Drugs of abuse, in comparison to natural appetitive rewards, significantly increase neural activity that may lead to exaggerated habit learning and enhanced motivational significance (i.e., salience) of cues associated with drug taking. Moreover, exposure to drugs of abuse may cause epigenetic changes, changes in gene expression, and protein modifications leading to profound neurobiological deficits that may impair cognitive and behavioral abilities such as relearning, inhibitory control, conditioned inhibition or other processes critical for extinction learning. This Symposium will highlight recent research exploring the mechanisms of extinction learning and its translation to therapies for reducing drug seeking. Speakers will focus on the behavioral paradigms employed, the neural circuitry involved in extinction learning and the therapeutic application of extinction procedures to drug addiction.

Adults may be from Mars but adolescents are from Venus
Chairs: Minda R. Lynch and James Bjork

Adolescence is an especially vulnerable period in development that has been associated with enhanced risk taking and a high incidence of drug abuse initiation. There is also evidence that the risk for developing dependence and addiction is greater during this early developmental stage. Researchers using animal models in adolescence are capitalizing on recent developments in genetic, cellular, systems neurobiology and behavioral approaches to understand adolescent responsivity and sensitivity to rewards. Findings from these studies suggest that adolescent exposure to drugs of abuse has enduring effects on the subsequent vulnerability for addiction. Investigations have begun to examine events in brain development that set the stage for altered behavioral sensitivity to reinforcement, stress reactivity, and conditioning to emotionally salient
stimuli along a developmental continuum. Developmental differences are being probed with sensitive behavioral assessments to identify phenotypes and model social or environmental influences that confer enhanced sensitivity to drug rewards during adolescence. This symposium will bring together research from animal models in adolescent stress, emotion and motivation, with perspectives from human neuroimaging research on reward reactivity in adolescents, to discuss how behavioral and neurobiological changes in development might account for an enhanced vulnerability to drug abuse.

Sexual acquisition and transmission of HIV from and among drug-using populations
Chairs: Martin Y. Iguchi and Richard Jenkins

NIDA’s Sexual Acquisition and Transmission of HIV Cooperative Agreement Program (SATHCAP) seeks to better understand the behavioral, biological, and environmental influences on the sexual transmission of HIV/STIs among drug-using populations and the diffusion of infections from drug users (DUs) to non-drug users. To date, over 7,000 DUs, men who have sex with men (MSM), and sexual partners (SPs), have been recruited in four cities by a coordinating center (RAND) and collaborating institutions: Los Angeles (UCLA); Chicago (UIC); Raleigh-Durham (RTI); and St. Petersburg, Russia (Yale and Biomedical Center). Data were collected from all sites using a common sampling approach and data collection instrument. SATHCAP utilized a relatively novel sampling approach, Respondent-Driven Sampling (RDS), with HIV seroincidence estimated from cross-sectional data using the serologic testing algorithm for recent HIV seroconversions (STAHRS). Several unique and important cross-site and site-specific findings are reported. In WAVE 1 (n=3,269), 9%, 11%, and 31% of study participants in Chicago, Raleigh-Durham, and Los Angeles (respectively) were men who reported sex with both men and women (MSMW). Almost all MSMW were African American, not gay identified, and using stimulants (primarily crack). We also report contrasting epidemic features between US sites (varied prevalence and low seroincidence) and our Russian site (high HIV prevalence and incidence), comparisons of rural and urban populations, molecular versus behavioral indicators of HIV transmission, biological and behavioral indications of intervention reach and effectiveness, as well as identification of potential bridge groups and related risk behaviors (e.g. MSMWs engaging in anal sex with women).

The twin design: Studying genes and environment on substance use behaviors
Chairs: Arpana Agrawal and Michael T. Lynskey

The goal of our symposium is to introduce our colleagues to exciting new findings emerging from three independent twin registries (two from the U.S. and one international) that inform the etiology of alcohol, tobacco, cannabis and other illicit drug use behaviors. The twin design can partition individual differences in substance use behaviors into genetic, familial environmental and individual-specific environmental influences and explain the extent to which the co-occurrence of substance-related behaviors is attributable to common genetic liability. Presentations will aim to specify the role of such common genetic and environmental influences on earlier (Huizink) and later (Rhee) stages of drug use. The role of genetic vulnerability to seemingly ‘environmental’ measures will be exemplified through peer group deviance and its relationship with drug use (Gillespie). A long-term goal of this symposium is to allow for enthusiastic dialogue between twin researchers and CPDD attendees and initiate discussions for subsequent workshops and training opportunities in the twin method at CPDD.
SYMPOSIA

Tuesday, June 17

The consequences of chronic cannabis abuse: From neurochemistry to treatment
Chair: Philip Terry

After a period during which cannabis consumption became more socially acceptable in several developed countries, serious concerns are again being expressed about the effects of long-term cannabis use on psychological well-being. Reported rates of cannabis dependence have increased considerably in the USA, the EU, Australia and South Africa over the last 10 years, and the numbers of people entering treatment for problems associated with cannabis have also increased dramatically. For example, over 40% of new clients entering treatment in Germany, Denmark, and Hungary now cite cannabis abuse as their main concern. The aim of the symposium is to provide an overview of our current understanding of how long-term cannabis abuse affects brain and behavior, and to evaluate the implications of recent research for therapeutic intervention. Such an overview is also apposite given the increasing availability of cannabinoid drugs in clinical practice. The symposium will first review recent preclinical studies that have characterized the effects of repeated cannabis use on various neurotransmitter systems, drawing out their functional implications. Next, it will describe the impacts of cannabis use on two aspects of psychological function that have attracted considerable research attention over recent years: cognition and mental health, focusing on the association between cannabis use and psychosis. Recent brain imaging studies will be presented, linking behavioral changes to functional changes in the brain. Often neglected, the significance of these changes for the everyday lives of long-term cannabis users will also be examined. Finally, recent approaches to the treatment of cannabis abuse will be reviewed.

Neonatal responses to maternal substance use
Chairs: Karol Kaltenbach and Loretta Finnegan

In-utero exposure to illicit drugs and/or treatment medications may precipitate abstinence symptoms and other complications in the neonatal period. Common exposures in pregnant women, including opiates/opioids (heroin, oxycodone, methadone, and buprenorphine), cocaine, and antidepressant medications, will be discussed. Infants prenatally exposed to opioids/opiates have a high incidence of neonatal abstinence syndrome (NAS), characterized by predictable symptoms. Considerable controversies exist concerning the choice of treatment medications for NAS and determination of treatment and efficacy of current regimens will be described. Data from prospective studies on growth and neurobehavioral outcomes of neonates exposed in utero to cocaine will be presented. Strengths and limitations of the available clinical research on this topic will be summarized as well as the implications for long-term consequences on the developing child. Early reports of Selective Serotonin Reuptake Inhibitor (SSRI) use during pregnancy in relatively small samples did not identify an increased risk for major malformations; however, as data accrued, other adverse reproductive outcomes were associated with exposure. Research regarding exposure to in utero SSRIs or major depression will be described with regard to 1) minor physical anomalies, 2) maternal weight gain, 3) the rate of premature birth, and 4) neonatal adaptation. Data related to buprenorphine in the treatment of opiate dependence in pregnancy and neonatal outcome data will be summarized and implications presented. Although much has been learned over the past several decades from research of in utero drug exposure, continued evidence-based studies are essential if we are going to determine the intricacies of NAS and the effects upon the newborn. The symposium will provide clear directions as to how to continue to advance the science and improve the treatment of pregnant substance-dependent women and their in utero exposed children.
**SYMPOSIA**

*Functional and clinical relevance of opioid receptor heterodimers*
Chair: Philip S. Portoghese

Opioid receptors are members of the class A group in the superfamily of G Protein-coupled receptors (GPCRs). Over the past decade, there have been numerous reports that opioid receptors and other GPCRs can undergo heterodimerization in cultured cells. Given the potential pharmacological and physiological diversity that may arise from such heterodimerization, an important challenge in opioid research is the development of selective tools for the investigation of opioid receptor heterodimers in vivo. Such tools would be useful for in vivo investigations and would clarify the functional roles of heterodimeric opioid receptors in experimental animals. This may provide a basis for the development of potent analgesics with reduced tolerance, dependence, and other side effects. In this symposium, the first speaker will discuss evidence for opioid receptor heterodimers. The second and third speakers will present results of experiments with ligands that selectively activate opioid heterodimers in experimental animals. Evidence will be presented for the selective activation of opioid receptor heterodimers that are clinically employed as analgesics. The finding that these ligands have little or no tolerance or physical dependence in mice suggest that targeting opioid receptor heterodimers is a viable approach to the development of analgesics that are free of side effects.

**Wednesday, June 18**

*Trafficking signals and addictive processes*
Chairs: Kathryn A. Cunningham and Toni S. Shippenberg

The trajectory from drug use to addiction begins against a background of vulnerability based upon genetic and environmental factors, and progresses as neuronal plasticity in key brain circuits develops. This plasticity is related to both the pharmacological impact of the abused substance as well as the learning and memory processes that associate drugs and environmental cues. The means to reverse neuroplastic events and therapeutically improve function in the addicted brain is an important quest and one ripe for near-term therapeutic potential with positive outcomes. One important advance in understanding the mechanisms underlying plasticity is the characterization of protein trafficking and cellular webs of proteins associated with key neurotransmitter systems in addiction. The present symposium focuses on specific advances in the mechanisms of addiction that may involve trafficking and protein movement within cellular structures.

*Advances in the development of medications for comorbid ADHD and substance use disorders*
Chairs: Petra Jacobs and Frances R. Levin

Studies have shown an epidemiological and clinical association between Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders (SUD). Individuals with ADHD have a high risk of developing SUDs, and conversely, individuals with SUDs often have a history of ADHD symptoms. Furthermore, history or current diagnosis of ADHD can affect the outcome of the treatment of SUDs. Adequate treatment of ADHD appears to reduce the risk of SUDs. The pharmacological treatment of comorbid ADHD and SUD can pose important challenges for the clinician. Some medications for the treatment of ADHD carry a risk of dependence or diversion, and some drugs of abuse can worsen the symptoms of ADHD. However, recent findings about possible shared neurobiological mechanisms between both disorders are offering new opportunities for the development of medications for the treatment of this comorbidity. For example, dopamine dysfunction has been associated with symptoms of inattention and may contribute to the SUD vulnerability in individuals with ADHD, and dopaminergic medications
such as methylphenidate and amphetamines may be promising pharmacological approaches for the treatment of this comorbidity. In addition, new long-acting formulations of stimulant medications to treat ADHD may be a promising approach because they carry a lower risk for misuse or diversion compared with immediate release formulations. The purpose of this symposium is to review the advances in the development of medications, for the treatment of comorbid ADHD and SUDs in both adolescents and adults.

Opioid analgesics: Protecting their use and preventing abuse
Chairs: Sharon L. Walsh and Sidney H. Schnoll

The aim of this symposium is to present current data on the intersection of and balance between providing adequate pain treatment with opioid analgesics while appropriately managing the risks of their abuse and diversion. The approach presented here is translational and will cover the spectrum from pharmacological and formulation strategies to national policy implications. Dr. Schmidt will review current strategies for developing abuse-resistant medications for acute and chronic pain and provide profiles of products in advanced clinical development. Dr. Haller will provide an overview of findings from Project Pain, NIDA’s first treatment development project focusing on opioid analgesic abuse in patients with chronic non-cancer pain. This will include a review of the research protocol and treatment interventions, both behavioral and pharmacological, and the factors found to impact (or not) 4 key treatment outcomes (pain severity, functional interference, opioid adherence and other drug abuse). Dr. Passik will review the concept of aberrant drug taking and the data from empirical/clinical surveys of pain patients. The documentation, differential diagnosis and management of aberrant drug taking will be discussed. Dr. Gilson will describe the Federal policy obligation to prevent the abuse and diversion of prescription pain medications while ensuring their adequate availability for legitimate medical purposes. A conceptual framework will be offered as a means to focus diversion control efforts better so that they do not interfere with clinical practice and patient pain care. Published evidence will demonstrate the need for a variety of safe and effective approaches to stem prescription pain medication abuse and diversion.

Innovative applications of technology to the prevention and treatment of substance use disorders
Chairs: Lisa A. Marsch and Kathleen M. Carroll

Empirically supported technology has the potential to play a critical role in improving community-based substance abuse prevention and treatment interventions in a manner that enables rapid diffusion of science-based interventions and which may be cost-effective. Although informational technology continues to rapidly expand and bring about profound changes in our society in general, it has been infrequently employed in the substance abuse treatment field to date. In this symposium, the scientists’ pioneering research on computer-assisted interventions related to substance use disorders will present results from their research in this area. Dr. Lisa Marsch will present results from a controlled trial evaluating the effectiveness of a multimedia program focused on building up protective factors and reducing risk factors for substance use among elementary school-aged children. Dr. Jesse Dallery will present the latest results from his line of research developing and evaluating an Internet-delivered intervention, grounded in science-based contingency management principles, targeting smoking cessation. Finally, Dr. Kathleen Carroll will present results from a recently completed trial evaluating a computer-based Cognitive Behavior Therapy intervention.
Thursday, June 19

Preclinical research on the discovery of glutamatergic therapeutics for the treatment of addiction

Chairs: David A. White and Athina Markou

As our understanding of the mechanisms mediating addiction-related behaviors has evolved, increased consideration has been given to the importance of glutamatergic neurotransmission in the development and persistence of drug addiction, as well as relapse to drug taking. Further, research has demonstrated that virtually all drugs of abuse interact with glutamatergic systems in the brain. As a result, medications targeting glutamatergic mechanisms show great potential for the treatment of drug addiction. The goal of this symposium is to present current preclinical research involving glutamatergic systems and its significance in the discovery of pharmacotherapies for the treatment of dependence upon drugs of abuse (e.g. nicotine, alcohol, cocaine). Dr. Yamamoto will discuss the impact of exposure to substituted amphetamines on glutamatergic mechanisms and resultant neurotoxicity. Dr. Bilbao will present data on the role of NMDA and AMPA receptors in alcohol and cocaine addiction. Dr. Szumlinski will present findings on mGluR-Homer-PI3K signaling mechanisms and discuss the possible clinical relevance of such drug-induced adaptations. Dr. Jones will discuss allosteric modulation of metabotropic glutamate receptors (GluRs) as a novel approach to treatment of drug abuse and other CNS disorders. Finally, Dr. Markou will discuss and summarize, with input from the audience and the speakers, relevant advances in this area of research and the clinical implications for developing novel treatments for drug addiction.

Pharmacogenetics of medications for the treatment of addictions

Chairs: Ivan D. Montoya and Joni Rutter

Phenotype assessment has provided information about patient characteristics associated with pharmacotherapy response. It has been suggested that much of the individual variability in the safety and efficacy of medications for the treatment of SUDs may be influenced by genetic factors. The area of pharmacogenetics / pharmacogenomics is a relatively new discipline that may help to shed light on the individual mechanisms associated with the safety and efficacy of medications for the treatment of SUDs. Pharmacogenetics involves the study of individual differences in pharmacotherapy responses based upon genetic approaches and it includes the study of genes encoding drug metabolizing enzymes, transporters, receptors and other drug targets. For example, it has been reported that transdermal nicotine is more effective than placebo among smokers who carry the D2 dopamine receptor gene (DRD2) A1 allele, the DBH*A allele, or the OPRM1 Asp40 variant. With regard to bupropion response for smoking treatment, COMT haplotypes at rs737865 and rs165599 may predict a favorable outcome. Genes that code the enzymes involved in the metabolism of opioids may influence the dose and response to agonist treatments for opioid dependence. Although there is no efficacious medication for cocaine and marijuana dependence, genetic variants in the dopamine and cannabinoid systems, respectively, may influence the response to some potential pharmacotherapies for these disorders. The purpose of this symposium is to review the current knowledge about the genetic factors that may account for the differences in the medical safety and treatment response to medications proven effective or under testing for the treatment of addictive disorders. It is the hope that results from pharmacogenetics research will help clinicians to individualize the pharmacological treatment of patients with SUDs and make them safer and more effective by matching the medications to the genetic characteristics of the individual.
WORKSHOPS

Sunday, June 15

Organizing a special interest group on stress and addiction
Chairs: Rajita Sinha and Helen Wu

There is increasing evidence of the role of stress in the development, relapse and compulsive drug-seeking aspects of addictive disorders. Tremendous strides have been made in understanding the basic science that connects stress and the addictions, and epidemiological and population based research emphasizes the role of family and environmental stress factors in the development and maintenance of addictive disorders. Furthermore, evidence from human laboratory and clinical outcome studies reveals that specific stress responses play an important role in compulsive drug seeking and relapse. New therapies to treat addictive disorders are also being developed and tested to address the association between stress and addiction. Findings from these multiple lines of research have been presented in recent CPDD conferences. However, informal discussions among CPDD members revealed a need to organize and provide a forum for interested CPDD members where conceptual and methodological issues pertaining to this area of research may be discussed on an ongoing basis. Thus, the goal of this workshop is to organize and establish a CPDD “Special Interest Group on Stress and Addiction.” In particular, (a) consensus on defining and operationalizing stress, (b) ways to validate and measure it in the experimental and real world context, and (c) the effects of drugs of abuse on stress pathways will be targeted for discussion in the workshop. Additional methodological issues will be solicited from attendees so that these may be addressed in future meetings. As there remain many unanswered questions on the association between stress and addiction, there is a growing consensus that providing such a forum will advance discoveries in this area, and ultimately have a significant impact on both the prevention and treatment development in the field of addiction.

DEA’s drug chemical evaluation section: The scientists behind the badge.
The role of the scientific staff within DEA and resources for CPDD
Chairs: Christine A. Sannerud and Srihari R. Tella

This workshop will illuminate and demystify the scientific and regulatory functions and data collection efforts of DEA’s scientific staff in our efforts to support determinations under the Controlled Substances Act (CSA). DEA will discuss both general and specific information used to determine placement under the CSA, including the substance potential for abuse, and/or dependence liability, medical use and safety. We will also review our role in laboratory data collection for drug and chemical control, and give an overview of other ongoing data collection projects, including the National Forensic Laboratory Information System (NFLIS database). Other issues to be discussed are international treaties obligations and our role in international organization, an overview of the requirements and process for drug quotas, precursor chemical control and exemptions. DEA will also provide an overview of current drug control projects and reviews and the Schedule I researcher registration process. After all, every researcher handling controlled substances and chemicals needs a contact in DEA!
From an acute care model to a recovery managed care model:
What do we know and where do we go from here?
Chairs: Ken Winters and Anne Helene Skinstad

Substance use disorders are chronic progressive disorders that are often treated within an acute care model. With the recent emphasis on recovery-oriented models of care, it is becoming more widely accepted that clients need continued support to change their lifestyle. But how much support do we have for the change in treatment philosophy, and how should recovery be defined? In this symposium, Peter E. Nathan will summarize the status of existing research on long term care for substance use disorders; Laurel M. Mangrum will present data from two recovery managed programs in Texas; Paul Moberg will summarize the results from their NIDA-funded project on the effectiveness of recovery high schools; Gary Olson will present a case study involving the rearrangement of a treatment program to enable it to fit within a recovery managed care system for his long-term clients; and Michael Flaherty will look to the future and present on data from six years of specific efforts to build recovery models of care and over 30 years of clinical and research experience.

Monday, June 16
Challenges for abuse liability testing from drug development to FDA approval
Chairs: Michael A. Nader and Beatriz Rocha

A group consisting of representatives from more than 20 pharmaceutical companies has collaborated and worked through the industry trade association (PhRMA) to organize a one-day "Dialogue Session" with the FDA Controlled Substances Staff (CSS). The purpose of the meeting is to have open discussion about some of the challenges faced by the pharmaceutical industry in developing CNS-active drugs, and to understand the current position and recommendations of the CSS. The meeting was held in February, 2008. The discussion is organized around a series of four hypothetical case studies with the intent of demonstrating some of the complexities in designing preclinical and clinical programs and issues in interpretation of data to assess abuse potential. This session at CPDD will review some of the scenarios discussed at the dialogue session and summarize the key conclusions, recommendations, and areas for potential methodologic refinement. The information obtained from this symposium will be highly informative to CPDD members conducting abuse liability testing.

Academic success and tenure in tight times
Chairs: Kristen Huntley, Nadine Rogers, Eliane Lazar-Wesley and Mark Swieter

This workshop will provide an opportunity to hear about factors used in tenure decisions and other evaluations of success in academic research settings. Senior scientists involved with making these decisions will present their perspectives on what makes an impression, both positive and negative. Each presenter will provide information about the things they look for when making evaluations. Presentations and discussions will be informal and provide an opportunity for substantive audience participation with the panel.
Current meta-analytic findings in adolescent substance abuse research will be reviewed. Speakers with specialty in juvenile and criminal justice settings will then present some of their own work and comment on implications of meta-analytic work to juvenile justice settings (JJS). Links will be made between what the current research indicates is useful in treating adolescents in the JJS, and what is suggested in order to advance the field in future research endeavors. The session concludes with a brief SASATE (see http://www.chestnut.org/li/apss/SASATE/) meeting.

Significance: Advancing the field of substance abuse treatment research for juvenile offenders.

Aim 1: Summarize current cutting-edge research in adolescent substance abuse treatment. Aim 2: Present current substance abuse treatment research in criminal and juvenile justice settings specifically. Aim 3: Develop suggestions for future research in order to advance the field of substance abuse treatment research for juvenile offenders. Aim 4: Moderator, Michael Dennis, will review the discussion generated and then lead us into the SASATE meeting.

The main specific aim of this two-hour workshop is to introduce or to remind workshop attendees of some basic and advanced epidemiological research approaches that are required for correct estimation of point estimates, 95% confidence intervals, and significance tests, when the source of data is a complex multi-stage field survey design, and the research purpose is to shed light on male-female or minority group differences in the NIDA research domains of drug use and drug dependence. To begin, the workshop chairs will provide an overview of the basic concepts, terms of reference, principles, and approaches to be illustrated, and will present some examples of recent field survey discoveries about minority and male-female differences in drug involvement and drug dependence, including some yet-to-be-solved mysteries that require more probing research. During the last 90 minutes, workshop attendees will rotate through small group sessions, led by various speakers listed below, with a brief introduction and then hands-on experience with statistical software tools used for correct estimation (STATA, SAS, MPlus). The speakers will guide the small group through the analysis steps, with the aid of a team of workshop assistants, all of whom are current analysis-experienced fellows in NIDA-supported research training programs (T32, F31, F32, D43) directed by the workshop chair. Four small group sessions will be at the introductory level (i.e., basic models); two will be for advanced users (alternating logistic regressions; IRT and MIMIC modeling).

X
This workshop will be similar to the ones conducted previously by the NIDA International Program, consisting of a poster session presenting drug abuse research being conducted outside of the United States. The primary goal is to provide a venue for CPDD members to meet, exchange ideas, and explore areas of mutual scientific interest with potential collaborators from other countries. Approximately 150 investigators will present research projects from around the globe, and NIDA divisions, offices, and programs will present posters outlining their international priorities and activities. Forging new collaborations among U.S. and foreign investigators is one of the primary goals of the NIDA International Program.

Tuesday, June 17

14th Annual Contingency Management Working Group
Chairs: Stacey Sigmon and Kelly Dunn

The Annual Meeting of the Contingency Management Working Group represents an opportunity each year at CPDD for the dissemination and discussion of current research in the area of contingency management interventions for treating drug abuse. Contingency management procedures have been consistently demonstrated to be efficacious in reducing use of a wide range of drugs across a variety of populations, and the behavioral approach represents one of the most effective interventions for the treatment of substance abuse. At the 14th Annual Meeting of the Contingency Management Working Group in 2008, junior and senior researchers will present preliminary data from ongoing studies.

What’s new at NIDA and NIH: A peek into the black box
Chairs: Nadine Rogers, Eliane Lazar-Wesley, Kristen Huntley and Mark Swieter

This workshop is intended to provide an opportunity for participants to learn about new policies and procedures at NIH and NIDA that are relevant to them. Topics will include new policies for new investigator’s summary statements, changes in the peer review process at NIDA and the Center for Scientific Review (CSR), tips on how to write a good grant application, and ways to get help on application preparation. Other topics and questions of interest to the audience will be addressed. This is very much an interactive, audience-directed activity. We see this workshop as a public service to the CPDD community, with the issues we discuss determined by audience interest. Although we will have a list of topics of interest, as is always the case with these presentations, audience members may ask about the budget, recent Advisory Council Reports, new research directions at NIDA, various NIH mechanisms, or any other subject.

Innovative technology transfer and information dissemination strategies: Results from five ATTC-sponsored initiatives
Chairs: Anne Helen Skinstad and Paula K. Horvatich

According to Miller and colleagues (2005) “…there are sound, scientific, ethical, and compassionate reasons to learn and deliver evidence-based treatments (EBT) …” (p.267). While no one would disagree with this statement, a recent Institute of Medicine report found that less than ten percent of substance use disorder treatments are evidence-based (IOM, 2006). For the past fourteen years, the regional SAMHSA-funded Addiction Technology Transfer Centers
(ATTCs) have served as a bridge between practitioners and researchers by collecting data that identify successful practices and developing strategies to lessen the gap between research and practice. In this workshop, four ATTCs will present the results of five technology transfer projects that have been effective in changing practitioners’ clinical practices, impacting clinical supervisors’ skills and abilities regarding implementing EBPs, improving non-Native counselors’ skills with Native Americans with substance use disorders, disseminating EBPs to an international audience of treatment providers, and determining the best methods for infusing the science of addiction into undergraduate courses. Specifically, Dr. Skinstad will introduce the Toolbox Training program; Dr. Horvatch will report on the successful sequence developed to facilitate technology transfer of MI; Dr. Duane Mackey will introduce South Dakota’s statewide “Native American Cultural Educational Program for Non-Native Counselors; Dr. Freese will discuss the effectiveness of the partnership between PSATTTC/UCLA and the United Nations in developing empirically based treatment training curricula for participants from 20 countries; and Ms. Roget will highlight data from a national addiction educator survey that examined the teaching of the neuroscience of addiction in undergraduate/graduate courses.
The following organizations have generously supported the work of the College on Problems of Drug Dependence during the past year:

American Legacy Foundation
Catalyst Pharmaceutical Partners
Centre de Recherche-Pierre Fabre
CSAT (Center for Substance Abuse Treatment)
Glaxo Smith Kline
Jazz Pharmaceuticals
NIDA (National Institute on Drug Abuse)
Pfizer Inc.
Reckitt Benckiser Pharmaceuticals, Inc.
Shire US Inc.
Society for Research on Nicotine and Tobacco